AMERICAN PSYCHIATRIC ASSOCIATION
2007 ANNUAL MEETING

SAN DIEGO, CA • MAY 19–24, 2007
Seated (left to right): Drs. Worley, Baron (Vice Chairperson), Ruiz (APA President), Guynn (Chairperson), Foulks, Spitz, 2nd Row Standing (left to right): Drs. McCarthy, Merikangas, Matarin, Silk, LeMelle, Scully, Boland, Pandya, Hilty, Licinio, Cheong, Alarcon, Kopelowicz, Mancuso, Rothschild, Pi, Marx, Not Pictured: Drs. Connor, Heath, Stabinsky, Taylor, Vogel Scibilia, Zucker-Goldstein.

May 19, 2007

Dear Colleagues and Guests:

Welcome to the 160th Annual Meeting of the American Psychiatric Association. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care.

This year’s Annual Meeting theme is “Addressing Patient Needs: Access, Parity, and Humane Care.” Many sessions throughout the week will highlight important aspects of the theme. In addition, please make a special effort to attend the Presidential Symposia, from 2:00-5:00 p.m., Monday through Wednesday. An entire track of sessions, presented in collaboration with the National Institute on Drug Abuse has been scheduled throughout the meeting.

I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in San Diego. At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world, and I will present my Presidential Address. I look forward to seeing you there. Please also make sure to attend the Convocation of Distinguished Fellows on Monday night at 5:30 p.m., where we will honor all those being inducted as fellows and distinguished fellows and many receiving awards from APA. The William C. Menninger Memorial lecture will be presented during the Convocation by John F. Nash, Jr., known in popular culture as the subject of the Hollywood movie, A Beautiful Mind, about his mathematical genius and his struggles with schizophrenia.

Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Robert Guynn and the members of the Scientific Program Committee and to the APA staff who work on the Annual Meeting. Welcome to this terrific meeting.

Sincerely,

Pedro Ruiz, M.D.
APA President
May 19, 2007

Dear APA Members and Guests:

Welcome to San Diego, and the 160th Annual Meeting of the American Psychiatric Association. I anticipate that this terrific city, and its fantastic weather, will provide a perfect setting for the scientific presentations we have planned. As you read through the Program Book, you will notice a number of sessions related to the theme "Addressing Patient Needs: Access, Parity, and Humane Care," chosen by our President, Dr. Pedro Ruiz. Let me draw your attention to just a few of the many exciting sessions presented this week, including several Presidential Symposia which will be presented Monday-Wednesday, from 2:00 p.m. - 5:00 p.m.

The Business Meeting and the Opening Session will be held at the San Diego Convention Center on Sunday, May 20. The Convocation of Distinguished Fellows also will be held there, on Monday evening, May 21, 5:30-6:30 p.m. During the Convocation, Nobel laureate John Nash Jr., Ph.D., will present the William C. Menninger Memorial Lecture.

A great way to begin this year's meeting is to attend the "Advances in Series," which will focus on the latest advances in neuropsychiatry and clinical neurosciences, C.L psychiatry and psychosomatic medicine, geriatric psychiatry, and psychiatric disorders. We have also combined the Master Educator Consultations, Discussion Groups, and Research Consultations into Small Interactive Sessions, consisting of 14 clinically-based seminars with outstanding clinician educators. These sessions are held Monday-Wednesday.

This year, we have a special series of sessions which will be presented in collaboration with the National Institute on Drug Abuse. Outstanding leaders in psychiatry and neuroscience research will present across formats from lectures to symposia and workshops. The APA is extremely appreciative of their support of these sessions. For detailed information on the sessions, please consult the separate program on this series, which is included in your registration packet.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year's Annual Meeting. Once again, welcome to San Diego. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

[Signature]

Robert W. Guynn, M.D.
KEY LOCATIONS
SAN DIEGO CONVENTION CENTER

American Journal of Psychiatry and Psychiatric Services
APPI Bookstore, Hall B, Ground Level
APA Communications center
Room 14 A/B, Mezzanine Level
APA Meetings and Conventions Department
Room 16 A, Mezzanine Level
APA Member Center
Hall B, Ground Level
APA Scientific Programs Office
Room 21, Upper Level
A/V Preview Room
Room 15 B, Mezzanine Level
CME Course Enrollment
Hall A, Ground Level
Computerized Evaluation
Lobby d, Ground Level
Daily Bulletin
Room 14 A/B, Mezzanine Level
Exhibit Office/Show Office
Lobby B, Ground Level
Exhibits/Publishers’ Bookfair
Halls B-D, Ground Level
Housing Desk
Lobby A/B, Ground Level
Lost & Found
Room 16 A, Mezzanine Level
Message Center
Lobby, Ground Level
On-Site Job Bank and Placement Center
APA Member Center, Hall B, Ground Level
Registration
Hall A, Ground Level

FIRST AID
Located in Lobby C, Ground Level, San Diego Convention Center. Hours of operation: Tuesday, May 15, through Thursday, May 24, and opens 30 minutes prior to show opening and closes 30 minutes after the last event of the evening.

COURTESY SHUTTLE BUS SERVICE
Service will begin on Saturday, May 19, at approximately 7:00 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule and will conclude on Thursday, May 24, at 6:00 p.m. The San Diego Convention Center will serve as the “hub” for all shuttle bus routes. The Shuttle Bus Desk will be located in Lobby A/B, Ground Level, San Diego Convention Center. A detailed Shuttle Bus Schedule is included in your registration packet and will be posted in the lobbies of participating hotels. Refer to the city map on page XVII-XI for the location of hotels in relation to the Convention Center.

EXHIBITS
Commercial and educational exhibitors will be located in Exhibit Halls B-D, Ground Level, San Diego Convention Center, along with the Publishers’ Bookfair and the APA Member Center. For your convenience, the Publishers’ Bookfair and APA Member Center will be open Saturday, May 19, 10:00 a.m.-5:00 p.m. Educational and commercial exhibit hours are: Sunday, May 20, 10:00 a.m.-4:30 p.m.; Monday, May 21, 10:00 a.m.-5:30 p.m.; Tuesday, May 22, 10:00 a.m.-6:00 p.m.; and the final day, Wednesday, May 23, 10:00 a.m.-3:00 p.m.

MESSAGE CENTER
Located in the Lobby A/B, Ground Level, San Diego Convention Center and open during registration hours (with the exception of Thursday, May 24, when the Center will be open until 5:00 p.m.). Messages can be left and picked up at the Message Center. Ancillary message centers will also be located in Lobby C, Ground Level and Lobby Room 20 A, Upper Level in the San Diego Convention Center. Registrants whose names appear on these monitors should pick up their messages at the Message Center.

APA MEMBER CENTER
Located in Exhibit Hall B, Ground Level, San Diego Convention Center. Hours of operation will be: Saturday, May 19, 10:00 a.m.-5:00 p.m.; Sunday, May 20, 10:00 a.m.-4:30 p.m.; Monday, May 21, 10:00 a.m.-5:30 p.m.; Tuesday, May 22, 10:00 a.m.-6:00 p.m.; and Wednesday, May 23, 10:00 a.m.-3:00 p.m. A few of the many APA activities exhibited include: membership, APAs internet-based programs, continuing medical education, quality improvement, psychiatric services, clinical resources, advocacy tools, career development, practice management, and APA periodicals.

APA JOB BANK
Visit the APA on-site Job Bank at APA 2007! The online APA Job Bank will power the popular on-site Job Bank providing improved tools for both employers and candidates at the APA’s Annual Meeting. Candidates and employers are encouraged to activate their resume and job postings in advance of the meeting for best results. For more information on the Job Bank, visit www.psych.org/jobbank.

APA COMMUNICATIONS OFFICE & PRESS ROOM
Located in Room 14 A/B, Mezzanine Level, San Diego Convention Center. Hours of operation: Saturday, May 19, 11:00 a.m.-5:00 p.m.; Sunday-Wednesday, May 20-23, 8:00 a.m.-6:00 p.m.; and Thursday, May 24, 8:00 a.m.-2:00 p.m. This room is for the use of registered press only and credentialed public relations representatives only.

DAILY BULLETIN
The Daily Bulletin accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Room 14 A/B, Mezzanine Level, by 12 noon prior to the date of publication.

RESIDENTS’ RESOURCE CENTER
Located in the Columbia Rooms, North Tower, Lobby Level, of the Marriott San Diego Hotel & Marina. The Residents’ Resource Center will be open from 7:00 a.m. to 6:00 p.m., Sunday, May 20, through Wednesday, May 23. Daily activities are scheduled for residents (such as the orientation, Residents Only Discussion Groups, and Resident Summits) and medical students. Meet and network with your colleagues and leaders in psychology. Resources specifically for residents and medical students are available here.

AIRPORT AND LUGGAGE CHECK IN
You can now check-in at the San Diego Convention Center and bypass the airport lines! This unique service allows you to check your bags and receive your boarding pass at the Convention Center, leaving you more time to visit the exhibits and attend sessions. It’s safe and secure: The first TSA-approved remote skycap service; All agents are highly trained and credentialed to issue boarding passes and print bag tags on demand; Participating Airlines (Domestic Flights Only): Alaska, American, Continental, Delta, JetBlue, Northwest and United. Rates: $10 per passenger. Normal airline baggage constraints apply. Hours of Operation: Wednesday and Thursday, May 23-24, 8:00 a.m. – 1:00 p.m., in the main lobby of the San Diego Convention Center. Flights may be checked in anytime the
day of departure. Luggage must be checked a minimum of three hours before scheduled flight departure.

TOURS
Stop by the Tour Desk, Lobby A/B, Ground Level to purchase or pick up tickets to local tours.

REGISTRATION
Admission to all sessions by registration badge
Located in Exhibit Hall A, Ground Level, San Diego Convention Center. Hours of operation: Friday, 12 noon-5:00 p.m., Saturday, 7:30 a.m.-5:00 p.m.; Sunday, 7:30 a.m.-5:00 p.m.; Monday, 7:30 a.m.-5:30 p.m.; Tuesday, 7:30 a.m.-6:00 p.m.; Wednesday, 7:30 a.m.-5:00 p.m.; and Thursday, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

**APA MEMBERS**
Full-Time Registration (North American Members).............$295
Full-Time Registration (International Members)...............$295-$520*
Members-in-Training (Member Class MT)........................$ 85
Daily Registration (North American Members)..................$150
Daily Registration (International Members).....................$275
Medical Students ..................................................no charge
*Fee determined by country's gross national income according to the World Bank.

**NONMEMBERS**
Full-Time Registration.............................................$880
Nonmember Residents, Students, Advocacy
Group Members, or Mental Health Chaplains .................$120
Daily Registration (all Nonmember categories) .............$470
Medical Students ..................................................no charge

**GUEST REGISTRATION**
One only per full-time registrant .................................$120
Only one guest is allowed to register with each full-time meeting registrant. The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest!"; they must register as an APA member. ID may be required.
One-Day Exhibit Hall Only Pass (18 and older) ..............20.00
(Only paid registrant can purchase an exhibit hall pass)

On-site fees can be paid by U.S. dollar cash, check, money order, American Express, VISA, or MasterCard. Registration fees are waived only for CME Course Faculty, APA Honorary Fellows (does not include APA Distinguished Fellows/Fellows/Life Fellows/Distinguished Life Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the days they present, except for industry-supported symposium presenters who must pay the fee).

Nonmember psychiatric residents and other full-time students must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book, APA Member Center Guide, and New Research Program and Abstracts Books, and for most categories, a copy of the Syllabus.

REGISTRATION BADGES
Badges are required for all sessions including the Opening Session and exhibit hall. Only an APA member badge will admit you to the Business Meeting.

Badge Color Codes: Blue Members, Yellow-Nonmembers, Silver-Exhibitors, Green-APA Staff, and Clear-Temporary Personnel.
Registered exhibitors will receive red badges, which allow access only to his or her exhibit booth in the exhibit hall and to ride the shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

CME COURSE ENROLLMENT
Ticket purchase required for CME Courses
Located in Exhibit Hall A, Ground Level, San Diego Convention Center. Hours of operation are the same as registration. Tickets not sold in advance will be available online at the onsite fee after April 20, and onsite at the Course Enrollment Area beginning at 12 noon on May 18. You must be registered for the meeting before you can enroll in courses.

APA ART ASSOCIATION
Located in the Lobby D, Ground Level, San Diego Convention Center and open during the commercial exhibit hours, the exhibit includes paintings, photography, ceramics, and crafts created by APA members and/or their significant others. Stop by for information on joining the APA Art Association.

APA ALLIANCE BOOTH
Located in the Lobby A/B, Ground Level San Diego Convention Center. Hours of operation: Saturday, May 19, through Wednesday, May 23, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Alliance's program schedule and information on membership.

APA PERIODICALS
Editorial staff of The American Journal of Psychiatry, Psychiatric Services, Academic Psychiatry, Journal of Neuropsychiatry and Clinical Neurosciences, Psychonomics, and APA's CME journal, Focus will be on hand to demonstrate online access for subscribers, answer questions regarding subscriptions, and show the new state-of-the-art website, www.psychiatryonline.com. Visitors can also purchase or renew subscriptions to all APA/APPI journals at the booth. Complimentary copies of Psychiatric News will be available at stands located throughout the Convention Center. Persons who wish to contact editors or reporters of Psychiatric News are asked to leave a message on the message board in the Annual Meetings Office. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit.
CONTINUING MEDICAL EDUCATION

Educational Objectives: At the conclusion of this meeting, participants will be able to:

- Better understand new research findings in the fields of psychiatry and neuroscience;
- Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
- Identify and remove barriers to the transfer of new knowledge for their practice, including provision of culturally competent care for diverse populations;
- Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and
- Better understand mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 66 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for AMA PRA Category 1 Credit(s)™. Sessions in the following program formats are designated as category 1:
- Advances in... Series, Case Conferences, CME Courses, Focus Live, Forums, Industry-Supported Symposia, Lectures, Presidential Symposia, Scientific and Clinical Reports, Small Interactive Sessions, Symposia, and Workshops. Other scientific sessions not listed may be reported as category 2 (Debates and New Research Poster Sessions). Scientific sessions are open to all Annual Meeting registrants, except for the Case Conferences which are open to APA members only.

PLEASE NOTE: APA MEMBERS ARE REQUIRED TO MAINTAIN THEIR OWN RECORDS OF CME HOURS. REPORTING OF CME CREDIT IS ON AN HONOR BASIS.

To document CME credit earned at the Annual Meeting, participants should maintain a list of sessions they attended. Credit is earned on an hour-for-hour basis. A parchment Certificate of Attendance is also available (see section on evaluation).

The Certificate of Attendance (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 credits of CME activities within a three-year reporting period. At least 60 credits must be in AMA PRA Category 1 Credit(s)™ activities.

CME report forms may be obtained from the Department of CME at the APA or online at www.psych.org. A CME Certificate of Compliance is awarded to APA Members who complete the report. Staff will be available in the APA Member Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year’s Annual Meeting.

You can receive a parchment Certificate of Attendance by returning your completed form (to the Annual Meetings Office, Information Center, or APA Member Center, all located in San Diego Convention Center). A personalized Certificate of Attendance will be available by completing the computerized general evaluation in the Lobby D, Ground Level, San Diego Convention Center. Attendees may also access the web-based evaluation from their own computer during or after the meeting, and the program automatically generates a CME certificate. PLEASE COMPLETE THE GENERAL EVALUATION ONE TIME ONLY.

SESSION CAPACITY

So that all in attendance may benefit, we ask your assistance when overcrowding occurs:
- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

AUDIO RECORDINGS OF SESSIONS

Audiotapes and CDs of most sessions are available shortly after each session concludes and may be purchased at the Mobiltape Booth located in Lobby A, Ground Level, San Diego Convention Center.

SMOKING POLICY

There will be NO SMOKING in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Registrants are welcome to use their own small, portable audiotape recorders to record any session except Case Conferences, unless prohibited by the presenters. Larger, professional tape recorders are not permitted except for use by registered members of the working press in accordance with APA Press Policies. APA has authorized a professional taping firm to audiotape sessions. Badges of personnel representing this firm will clearly identify them. Registrants are not permitted to photograph (including with cell phone cameras) or videotape any session because the intrusive nature of the recording may disrupt the session.
FUTURE APA MEETINGS

APA ANNUAL MEETINGS
2008 May 3-8 Washington, DC
2009 May 16-21 San Francisco, CA
2010 May 22-27 New Orleans, LA
2011 May 14-19 Honolulu, HI

INSTITUTES ON PSYCHIATRIC SERVICES
2007 October 11-14 New Orleans, LA
2008 October 2-5 Chicago, IL
2009 October 8-11 New York, NY
2010 October 14-17 Boston, MA
2011 October 27-30 San Francisco, CA

Preliminary Programs for the 2007 Institute on Psychiatric Services are available in the New Orleans Booth, Ground Level, San Diego Convention Center.

GUIDE TO THE PROGRAM BOOK
Below you will find the table of contents for case in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. NOTE: You can also create your own personal schedule by using the online itinerary planner. Visit APA's homepage www.psych.org and click on the 2007 Annual Meeting link. Then click on the link under the scientific session information heading and follow the instructions.
If you have any questions about this book or the scientific sessions, please feel free to stop by the Scientific Programs Office in Room 21, Upper Level, San Diego Convention Center, and we will be glad to help you. Also, all APA staff will be wearing green badges. Please feel free to direct your questions to them.

TABLE OF CONTENTS

Floor Plans for San Diego Convention Center, Marriott Hotel & Marina, Manchester Grand Hyatt ......................VI-XII
City Map ..................................................................................................................XIII-XIV
Local Information................................................................................................. XV-XVI
Special Acknowledgments .................................................................................... XVII-XIX
Format Descriptions ............................................................................................ XX
Disclosure Information ......................................................................................... XXI-XLII
Audiotape and CD Sales Information ..................................................................XLIII
Saturday Sessions ................................................................................................. 1-4
Sunday Sessions ........................................................................................................5-14
Join the APA Today ................................................................................................. 15
2007 Institute on Psychiatric Service ..................................................................... 16
Monday Sessions ...................................................................................................... 17-40
Tuesday Sessions ................................................................................................. 41-59
District Branch Ad ................................................................................................. 60
Wednesday Sessions ............................................................................................. 61-78
Thursday Sessions ................................................................................................. 79-87
Call for 2008 Annual Meeting Papers .................................................................. 88
Topic Index ............................................................................................................. 89-100
Participant Index .................................................................................................. 101-108
American Psychiatric Foundation Special Events ............................................... 109
American Psychiatric Publishing, Inc. ................................................................. 110-111
APA's Online Library of 2007 Annual Meeting Sessions ................................ 112
Industry-Supported Symposia .............................................................................. 113-128
APA Member Center ............................................................................................ Back Cover

News reports or summaries of APA presentations contained in these program materials may not be published or broadcast before the local time and date of the presentation.

Refer to the APA Exhibits Guide for information on: Exhibits, Publishers’ Bookfair, and Dining Facilities in the San Diego Convention Center.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

©American Psychiatric Association
Marriott Hotel & Marina
333 West Harbor Drive, San Diego, California 92101
619-234-1500

Lobby Level
American Psychiatric Association  
May 19 – 24, 2007

Mission Bay & Beaches (8 miles to SDCC)
1. Hilton San Diego Resort
2. Hyatt Regency Islandia
3. The Dana on Mission Bay

Mission Valley (6 miles to SDCC)
4. Comfort Inn & Suites/Hotel Circle South
5. Comfort Suites Mission Valley
6. DoubleTree Hotel San Diego - Mission Valley
7. Hilton San Diego Mission Valley
8. Holiday Inn San Diego Zoo Area/Hotel Circle
9. Marriott Mission Valley
10. Mission Valley Resort
11. Red Lion Hanalei Hotel
12. Sheraton San Diego Mission Valley
13. Town & Country Resort & Convention Center
Weather
San Diego's "sun-sational" climate makes it the ultimate year-round destination. The average daytime temperature on the Convention Center's outdoor terraces is a pleasant 70 degrees Fahrenheit. The average annual rainfall is less than 10 inches.

Baseball fan? Looking for a fun way to relax? Across the street from the Convention Center is PETCO Park, the new home to Major League Baseball's San Diego Padres.

Downtown San Diego
Downtown San Diego is incredibly compact and convenient. Some of the city's best hotels, restaurants, shopping districts and galleries are all within walking distance, as are incredible views of sparkling San Diego Bay. The Convention Center itself is also very easy to navigate.

Airport Transportation - Arrival
If you need a taxi, there are many companies that provide taxis at the airport. Fares from the airport to the Convention Center range from $10-$12. If you would like to rent a car there are several car rental reservation boards located near the luggage claim areas of Terminals 1 and 2. Use the courtesy phones provided to request shuttle transport to the car rental company of your choice. All car rental agencies are located off-site and car rental shuttles take you to the rental locations. Shuttle vans and buses operated by private companies are also available. You can find shuttle service at the Transportation Plazas across from Terminals 1 and 2, and curbside at the Commuter Terminal. In addition, there are a number of public transportation services available to you at any given time when you need to get to and from the airport.

ETS, APA's shuttle bus provider will provide express shuttle service from the San Diego Convention Center to the San Diego Airport for $9.00 per person. The shuttle will depart every half hour on the hour and the half hour according to the following schedule: Wednesday, May 23 – 10:30 a.m.-4:00 p.m. Thursday, May 24 – 10:30 a.m. -4:00 p.m.

Make reservations at 1-888-447-4387, online at www.orlertours@eventtrans.com or stop by the tour desk onsite at the Convention Center.

What to See and Do
San Diego has nearly perfect weather, 70 miles of beaches and 90 golf courses in the area. Everything about San Diego is easy, which you will see by reading the two pages on local information. There is so much to see and do in San Diego. Just steps away from the Convention Center is the city's hottest dining and entertainment district, the Gaslamp Quarter. San Diego is one of the most family friendly cities in the nation, so plan on spending time with Shamu at SeaWorld San Diego www.seaworld.com or spend a day hanging around Monkey Trails and Forest Tales at the San Diego Zoo's newest exhibit (www.sandiegozoo.org).

At 1,200 acres, lush and green Balboa Park (www.balboapark.org) is one of the nation's largest cultural complexes and home to the largest concentration of museums west of the Mississippi. San Diego also offers its own unique theater scene and world-class opera.

La Jolla and Mission Bay are favorites for groups seeing waterfront gatherings. La Jolla is an older, established neighborhood with many new chefs and restaurants and lovely beaches. It spans across seven miles of coastline and has been dubbed "the Rodeo Drive of San Diego." Mission Bay is another seaside spot, with beaches, restaurants, and nightclubs.

An excellent array of Tours will be offered during the Annual Meeting. Please refer to pages 22-26 in this booklet for complete information. Attendees are encouraged to use the hotel's concierge services to assist with the local information and dinner reservations. Also, refer to the San Diego website: www.meetingsandiego.com/apa/

Airport
San Diego is serviced by the San Diego International Airport and is approximately 10 minutes from downtown San Diego. Almost all major domestic airlines service the airport. For terminal and airlinenformation call (619) 231-2100 or visit www.san.org.

Airport Shuttle Services
Cloud 9 Airport Shuttle Service
You may reserve a one-way or round trip ticket to and from the airport through Cloud 9 Shuttle. To make a reservation, go to www.cloud9shuttle.com and click on "make a reservation" and enter APA2007 in the group code field at the bottom of the page.
Special Discount on Car Rentals

Enterprise Car Rental is offering a special discounted rate to APA attendees. Use the APA discount code 32F3221 and AME for the PIN when making your reservations either online at www.enterprise.com or by calling 1-800-736-8227.

Airport and Luggage Check In

You can now check-in at the San Diego Convention Center and bypass the airport lines! This unique service allows you to check your bags and receive your boarding pass at the Convention Center, leaving you more time to visit the exhibits and attend sessions. It's safe and secure:

- The first TSA approved remote skycap service.
- All agents are highly trained and credentialed to issue boarding passes and print bag tags on demand.
- Proprietary sophisticated technology is used to ensure accurate, safe and secure multi-airline baggage check transport to the airport.


Hours of Operation:

Wednesday and Thursday, May 23-24, 8:00 a.m.–1:00 p.m., in the main lobby of the San Diego Convention Center. Flights may be checked in anytime the day of departure. Luggage must be checked a minimum of three hours before scheduled flight departure.

San Diego Area Transportation

San Diego Metropolitan Transit System, Public Transportation MTS buses, trolleys, and coasters provide convenient transportation throughout San Diego County, including travel to and from the airport, all shopping centers, attractions, beaches, hotels, and Mexico. Bus schedules differ, but most hotels and attractions have service every 15 to 20 minutes. The San Diego Trolley runs every 15 minutes throughout most of the day and every 30 minutes in the evening. The North County Coaster runs 43 miles along the coast with station stops in downtown San Diego, Old Town, Solana Beach, Encinitas, Carlsbad, and Oceanside. You can also get a free trolley transfer that will take you to Tijuana. All MTS buses, trolleys, and coasters are equipped with wheelchair lifts. Call 619-233-3004 for schedule and fare information.

Metropolitan Transit System Flyer Route No. 992 is a bus that travels to and from the San Diego Airport and downtown San Diego. The bus stops between Terminals 1 and 2 and the Commuter Terminal and costs $2.25. The travel time is approximately 10 minutes.

Trolleys operate along two routes. The Blue Line starts near Qualcomm Stadium and runs through Mission/Fashion Valley, Old Town, and Centre City San Diego to the International Border at San Ysidro. The Orange Line runs from Centre City east to El Cajon or Santee. The East line also serves stations on the Bayside extension, at Seaport Village, the San Diego Convention Center, and Gaslamp Quarter.

Taxis from the San Diego International Airport to downtown are approximately $8-$10 one way. Five can ride for the price of one! Taxi cab stands are located at the airport, most hotels, attractions, and shopping centers. Your fare will be displayed on the meter and will include a flag drop charge plus a per-mile and/or a per-hour charge. All cabs leaving the airport charge the same rate.

Child Care Services

Childcare services are available through Marion’s Childcare. This company works independently to provide in-room hotel child care. Advance registrations are required to ensure availability. Please make reservations at least one week in advance for day time care. For rates, further information or to make reservations, please call 1-888-891-5029 (toll free) or 619-305-4379 (Greater San Diego), between 8:30 a.m. and 6:00 p.m. Pacific Time, Monday through Saturday. Feel free to email: amy@hotelchildcare.com, or visit website: www.hotelchildcare.com.

APA does not endorse or guarantee any of the services listed above.
SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

**Abbott Laboratories**: partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 19, 2007, 7:00 p.m.; and support of the Industry-Supported Symposium, “Multiple and Complex Presentations of Bipolar Disorder,” Tuesday, May 23, 7:00 p.m.

**American Academy of Psychiatry and the Law**: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 20, 2:30 p.m.

**American Association of Chairs of Departments of Psychiatry**: support of the APA/AACDP Research Mentorship Award.

**American Association of Psychiatric Administrators**: co-support of the Administrative Psychiatry Award Lecture, Monday, May 22, 9:00 a.m.

**American Psychiatric Association / Hurricane Disaster Relief Fund**: Support of the Disaster Psychiatry Fellowship.

**American Psychiatric Foundation**: support of the APIRE Practice Research Network; Caucus/Committee of Hispanic Psychiatrists’ Forum and Reception, Tuesday, May 22, 5:30 p.m.; Award for Research in Psychiatry, Tuesday, May 22.

**Association of Gay and Lesbian Psychiatrists**: partial support of the John Fryer Award Lecture, Wednesday, May 23, 9:00 a.m.

**Association of Professional Chaplains**: partial support of the Oskar Pfister Award Lecture, Monday, May 21, 11:00 a.m.

**Association of Women Psychiatrists**: support of the joint AWP/APA Women’s Caucus reception and meeting, Monday, May 22, 7:00 p.m.; and co-support of the Alexandra Symonds Award Lecture, Monday, May 22, 11:00 a.m.

**AstraZeneca Pharmaceuticals**: support of the Industry-Supported Symposia, “Rethinking Bipolar Disorder: Implications of Comorbidities”, Sunday, May 20, 1:30 p.m.; “Treating the Spectrum of Bipolar Disorders: An Interactive Case Discussion”, Monday/Tuesday, May 21-22, 7:00 a.m.; “When Endocrinology and Psychiatry Collide: What the Clinician Needs to Know about Antipsychotic-induced Endocrine Disturbances”, Monday, May 21, 7:00 p.m.; support of the APA/AstraZeneca Minority Fellowship, minority fellows poster session and reception, Tuesday, May 22, 7:00 p.m.; the American Psychiatric Foundation “Conversations” event, Tuesday, May 23, 5:30 p.m.; and the APIRE/AstraZeneca Young Minds in Psychiatry Award; Mind Games resident competition, Tuesday May 22, 5:00 p.m.; the George Tarjan Award Lecture, Wednesday, May 24, 9:00 a.m., Resident’s Guide to Surviving Psychiatry Residency

**Boehringer Ingelheim Pharmaceuticals, Inc.**: support of the Industry-Supported Symposium, “Recognition and Management of Restless Legs Syndrome (RLS) in Psychiatric Practice”, Saturday, May 19, 12:30 p.m.

**Bristol-Myers Squibb Company**: support of the Industry-Supported Symposia, “Long-term Treatment Approaches for Schizophrenia: Comparing Maintenance and Recovery Models”, Sunday, May 20, 8:00 a.m.; “Weighing the Risks and Benefits of Atypical Antipsychotics: Can We Have Our Cake and Eat It Too?” Sunday, May 20, 7:00 p.m.; “How do Alprazolam and Antipsychotics Work?: From Receptors to Reality”, Monday/Tuesday, May 21-22, 7:00 a.m.; “Monoamine Oxidase Inhibitors Today: A 21st Century View on the Treatment of Depression”, Tuesday, May 22, 7:00 p.m.; support of the President’s Desert and Reception; and the Solomon Carter Fuller Award Lecture, Monday, May 21, 9:00 a.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; APA Fellowship on Public Psychiatry.

**Bristol-Myers Squibb Sweden**: support of Global Psychiatry: A Session for U.S. and International Residents, Sunday, May 21, 2:00 p.m.

**Center for Mental Health Services**: support of the APIRE Practice Research Network (PRN); and the APA’s HIV-related education programs and materials.

**Center for Substance Abuse Treatment**: support of the APIRE Practice Research Network (PRN); and an audience response system for the course, “Office-Based Buprenorphine Treatment of Opioid-Dependent Patients.”

**Cephalon, Inc.**: support of the Industry-Supported Symposia, “The Alcohol Dependent Patient: Improving Outcomes Through Adherence”, Sunday, May 20, 7:00 p.m.; and co-support if the Industry-Supported Symposia, “Insights from STAR*D: Are Our Patients’ Needs Being Met?”, Saturday, May 19, 6:00 p.m.; “Still Sleepy After All These Cures: Hypersomnia in Psychiatry”, Sunday, May 20, 8:00 a.m.

**Cyberonics, Inc.**: support of the Industry-Supported Symposium, “Caring for Our Most Challenging Patients with Depression: An Interactive Forum on Novel Treatments”, Sunday, May 20, 1:30 p.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.

**Eisai, Inc.**: support of the Industry-Supported Symposium, “Optimizing Outcomes Across the Spectrum of Dementia”, Sunday, May 20, 1:30 p.m.

**Eli Lilly and Company**: support of the Industry-Supported Symposia, “Improving Depression Treatments: Bridging the Gap Between Research and Clinical Practice”, Monday, May 21, 7:00 p.m.; “Understanding the Complexity of Bipolar Mixed Episodes”, Tuesday, May 22, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and the Simon Bolivar Award Lecture, Saturday, May 19, 6:30 p.m.; 11:00 a.m.; support of the Adolf Meyer Award Lecture; the APA/Lilly Psychiatric Research Fellowship; the symposium entitled, “Strengthening of Mental Health Systems in Low and Middle Income Countries,” Monday, May 22, 2006, 7:00 p.m.; and the APA/Lilly Resident Research Awards.

XVII
SPECIAL ACKNOWLEDGMENTS

Estate of Agnes Purcell McGavin: support of the Agnes Purcell McGavin Awards for Distinguished Career Achievement in Child and Adolescent psychiatry, and for Prevention.

Estate of Dorothy C. Kempf: support of APIRE/Kempe Fund Award for Research Development in Psychobiological Psychiatry Awards.

Estate of Frank Rundle, M.D.: partial support for the John Fryer Award Lecture, Wednesday, May 23, 9:00 a.m.

Estate of Judd Marmor, M.D.: support of the Judd Marmor Award Lecture, Wednesday, May 23, 11:00 a.m.

Forest Laboratories, Inc.: support of the Industry-Supported Symposia, “Expert Dialogue on Alzheimer’s Disease: Diagnostic and Referral Issues, Treatment of the Cognitive Deficits, Ameliorating the Behavior Complications, and Comprehensive Multidisciplinary Care”, Saturday, May 19, 12:30 p.m.; “Dark Horizons: Depression and Cognitive Impairment”, Sunday, May 20, 8:00 a.m.; “STAR*D Findings: Implications for Patients, Clinicians, and Other Stakeholders”, Sunday, May 20, 7:00 p.m.; partial support of the American Psychiatric Association Annual Benefit, Saturday, May 20, 7:00 p.m.; and support of the registration portfolios.

Gill Foundation: partial support of the John Fryer Award Lecture, Wednesday, May 23, 9:00 a.m.

GlaxoSmithKline: support of the Industry Supported Symposia, “The Prevaling Predominant Pole of Bipolar Depression”, Saturday, May 19, 6:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; support of the APA/GlaxoSmithKline Fellowship Program and reception.

Harding Foundation: partial support of the Oskar Pfister Award Lecture, Monday, May 21, 11:00 a.m.

Itleson Foundation: support of the Blanche F. Itleson Award for Research in Child Psychiatry.

Janssen Pharmaceutical and Research Foundation: support of the Industry-Supported Symposium, “Planning for Success in Schizophrenia Management”, Sunday, May 20, 2007 1:30 p.m.; “Improving Outcomes in Schizophrenia: Prodrome to Remission”, Monday, May 21, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; the support of the Committee of Asian-American Psychiatrists recruitment reception; and the American Psychiatric Institute for Research and Education/Janssen Resident Psychiatric Research Scholars.


Merck & Co., Inc.: support of the Industry-Supported Symposium, “Insomnia: Primary Diagnosis or Secondary Symptom?”, Saturday, May 19, 6:00 p.m.; support of the APA/Merck & Co., Inc. Early Academic Career Research Award.

National Institute of Mental Health: co-support of the APA/NIMH Vestermark Psychiatry Educator Award Lecture, Tuesday, May 23, 2:00 p.m.; and the Research Colloquium for Junior Investigators; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees; the Program for Minority Research Training in Psychiatry (PMRT); and the Special Annual Meeting Program Track.

National Institute on Alcohol Abuse and Alcoholism (NIAAA): support of annual meeting research track, “Rethinking Alcohol Use Disorders: Science, Diagnosis, Treatment, and Policy”.

Neurocrine Biosciences, Inc.: co-support of the Industry-Supported Symposium, “Insomnia From the Inside Out: From Neuroscience to Clinical Experience to Public Policy,” Sunday, May 21, 7:00 p.m.

Novartis Pharmaceuticals Corporation: support of the daily in-house TV program, “APA TV News.”


Pfizer, Inc.: support of the Industry-Supported Symposia, “Clinical Skills to Clinica Scales: Practical Tools in the Management of Patients with Schizophrenia”, Saturday, May 19, 6:00 p.m.; “Navigating the Complex Maze of Bipolar Disorder”, Monday, May 21, 7:00 p.m.; “Cigarette Smoking, Smoking Cessation and Psychiatric Illness”, Tuesday, May 22, 7:00 p.m.; “Am I a Psychiatrist... or an Endocrinologist? Coping with Metabolic Disturbances During the Treatment of Schizophrenia”, Tuesday, May 22, 7:00 p.m.; “Fibromyalgia: New Insights into the Pathophysiology and Treatment”, Wednesday, May 23, 7:00 p.m.; support of the Psychiatric Services Achievement Awards; the “Abstracts-On-Disk” Program; and the APA Daily Bulletin newspaper; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; the Pfizer Minority Psychiatric Research Fellowship Award; and the APA Daily Bulletin newspaper; and the Simon Bolivar Award Lecture, Saturday, May 19, 6:30 p.m.
SPECIAL ACKNOWLEDGMENTS

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 21, 2:30 p.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and partial support of the Alumni Reception, Tuesday May 22, 6:00 p.m.

Sheppard Pratt Health Services: support of Assembly Warren Williams Speaker’s Awards.

Shire US, Inc.: support of the Industry-Supported Symposia, “Clinical Management of ADHD”, Saturday, May 19, 12:30 p.m.; the Residents’ Session, “Meet the Experts: Sunny-Side Up,” Monday, May 21, 7:00 a.m.; “How Comorbid is ADHD? Results from epidemiological and clinical Studies”, Sunday, May 20, 7:00 p.m.; the Residents’ Session, “Meet the Experts: Sunny-Side Up,” Monday, May 22, 7:00 a.m.; the APA/Shire Child and Adolescent Psychiatry Fellowships; and and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 19, 7:00 p.m.

Solvay Pharmaceuticals Inc.: co-support of the Industry-Supported Symposia, “Am I a Psychiatrist... or an Endocrinologist? Coping with Metabolic Disturbances During the Treatment of Schizophrenia”, Tuesday, May 22, 7:00 p.m.; “The Ongoing Debate Surrounding Atypicals: Are The Benefits Worth the Risks?”, Sunday, May 20, 8:00 a.m.; “Lifting the Burden of Psychiatric Illness: the management of allostatic load, metabolic syndrome, and co-occurring disorders”, Monday/Tuesday, May 21-22,7:00 a.m.; and the support of the coffee service in the exhibit hall.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program.

Takeda Pharmaceuticals North America, Inc.: support of the Industry-Supported Symposium, “Making Every Sheep Count: Evidence-Based Approaches to Treating Insomnia”, Sunday, May 20, 1:30 p.m.; the Internet Village; and the APA Shuttle Bus Service.

University of Nebraska: support of the Frank J. Menolascino Award for Psychiatric Services for persons with Mental Retardation/Developmental Disabilities.

Wyeth Pharmaceuticals: co-support if the Industry-Supported Symposia, “Am I a Psychiatrist... or an Endocrinologist? Coping with Metabolic Disturbances During the Treatment of Schizophrenia”, Tuesday, May 22, 7:00 p.m.; “Lifting the Burden of Psychiatric Illness: the management of allostatic load, metabolic syndrome, and co-occurring disorders”, Monday/Tuesday, May 21-22,7:00 a.m.; “Insights from STAR*D: Are Our Patients’ Needs Being Met?”, Saturday, May 19, 6:00 p.m.; “The Ongoing Debate Surrounding Atypicals: Are The Benefits Worth the Risks?”, Sunday, May 20, 8:00 a.m.; support of the APIRE/Wyeth Pharmaceuticals M.D., Ph.D., Research Fellowship; the Jeanne Sparlock, M.D. Congressional Fellowship; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and co-support of the Alexandra Symonds Award Lecture, Monday, May 22, 11:30 a.m.
FORMAT DESCRIPTIONS

ADVANCES IN.....SERIES
These three-hour and thirty-minute sessions are intended to highlight important new advances occurring in the field of psychiatry involving selected disorders or treatments. The sessions are chaired by editors of recent textbooks published by the American Psychiatric Publishing, Inc (APPI) and feature selected chapter authors from these texts. The books discussed at these sessions may be purchased at the APPI bookstore or online at www.appi.org.

CASE CONFERENCES
During these 90-minute or three-hour sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. Some cases will review the progress of psychotherapy in two successive sessions. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES
Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day), six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Participants must purchase tickets to attend.

DEBATES
Experts in the field, including psychiatrists and nonpsychiatrists will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting, and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

FOCUS LIVE
These 90-minute sessions allow participants to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. ARS sessions can make a group of 300 feel like they are having a small group consultation with an expert clinician. Experts, who serve as guest editors of FOCUS, will lead lively multiple choice question-based discussions, and the audience will enter their answers with hand-held devices. Results are instantly tallied and projected on the screen.

FORUMS
These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES
Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

NEW RESEARCH
This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self-explanatory presentations; Young Investigators' Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators' Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

SCIENTIFIC AND CLINICAL REPORT SESSIONS
Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

SMALL INTERACTIVE SESSIONS
This 90-minute format allows small groups to meet informally with either selected experts in psychiatry to discuss topics chosen by the expert obtain consultations around problems in research from senior researchers; or hear clinically-based seminars presented by outstanding educators. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

SYMPOSIA
Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposia" in this Program Book.

WORKSHOPS
Workshops are 90-minute sessions which typically involve brief presentations from individual panel members, followed by the opportunity to apply to home in small groups, practice new techniques to build skills, and for lively and informative discussion. This format provides for highly interactive audience participation. Media Workshops are three-hour sessions in which a feature-length film is shown and discussed.
# AMERICAN PSYCHIATRIC ASSOCIATION

## CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

Under the ACCME Standards for Commercial Support that were in effect when the 2007 Annual Meeting was planned, the existence of such relationships does not necessarily constitute a conflict of interest; but the prospective audience must be informed of the presenter’s affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The list of presenters below have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter’s name and the company’s name are listed, along with the page number the presenter appears on in this Program Book. The nature of the presenter’s relationship with the disclosed company is indicated by the following code: consultant or advisory board¹, full-time employment², research/grant support³, speakers’ bureau⁴, stock or other financial options⁵, other financial or business relationships⁶. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

The second list of presenters, beginning on page ****, have indicated neither they nor an immediate family member has any significant relationship to disclose. Voting member of the Board of Trustees, Assembly officers, and member of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participating in Industry-Supported Symposia.

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene G. Abel, M.D.</td>
<td>Abel Screening, Inc.⁶</td>
</tr>
<tr>
<td>Hagop S. Akiskal, M.D.</td>
<td>Abbott Laboratories, Inc.;³ AstraZeneca Pharmaceuticals LP;² Bristol-Myers Squibb Company⁵;² Eli Lilly and Company⁴;² GlaxoSmithKline¹;³ Sanofi-Aventis¹;³</td>
</tr>
<tr>
<td>Michael H. Allen, M.D.</td>
<td>Abbott Laboratories, Inc.;¹ AstraZeneca Pharmaceuticals LP;³ Bristol-Myers Squibb Company⁵;² Eli Lilly and Company⁴;³ Janssen Pharmaceutical Products, LP;³ Pfizer Inc.¹³</td>
</tr>
<tr>
<td>Jonathan E. Alpert, M.D.</td>
<td>Abbott Laboratories, Inc.;³ Alkermes, Inc.;³ Aspect Medical Systems⁵; AstraZeneca Pharmaceuticals LP;³ Bristol-Myers Squibb Company⁵;² Cephalon, Inc.;³ Cyberonics, Inc.;² Eli Lilly and Company¹;³ Forest Laboratories, Inc.;³ GlaxoSmithKline¹;³ Johnson &amp; Johnson¹;¹ Johnson and Johnson Pharmaceutical Research and Development²; Lichtwer Pharma GmbH¹; Lorex Pharmaceuticals¹; National Alliance for Research in Schizophrenia and Depression¹; National Institute of Mental Health¹;² Novartis Pharmaceuticals Corporation¹; Organon Pharmaceuticals Inc;³ ParmLab¹;³ Pfizer Inc.¹³; Pharmavite¹;³ Roche Pharmaceuticals¹; Sanofi/Synthelabo¹;³ Sanofi-Aventis¹;³ Solvay Pharmaceuticals, Inc.³; Wyeth-Ayerst Laboratories³</td>
</tr>
<tr>
<td>Lori A. Althshuler, M.D.</td>
<td>Abbott Laboratories, Inc.;³ AstraZeneca Pharmaceuticals LP;² Bristol-Myers Squibb Company¹;³;² Eli Lilly and Company¹;³;² Forest Laboratories, Inc.¹;³;² GlaxoSmithKline¹;³ Pfizer Inc.¹;³;² Wyeth Pharmaceuticals¹</td>
</tr>
<tr>
<td>Sonia Ancoli-Israel, Ph.D.</td>
<td>Acadia Pharmaceuticals Inc;² Cephalon, Inc.¹;³;²;¹ King Pharmaceuticals, Inc.¹;³;² Merck &amp; Co., Inc.¹;² Neurocrine Biosciences Inc.¹;³;² Neuronet Therapeutics¹;² NIH Institute¹;² Pfizer Inc.¹;³;² Sanofi-Aventis¹;³;² Seprocor, Inc.¹;³;² Takeda Pharmaceuticals America, Inc.¹;³</td>
</tr>
<tr>
<td>Raymond F. Anton, M.D.</td>
<td>Alkermes, Inc.¹;³ AstraZeneca Pharmaceuticals LP;² Bristol-Myers Squibb Company¹;³;² Cephalon, Inc.¹;³;² Forest Laboratories, Inc.¹;³;² Ortho-McNeil Pharmaceutical, Inc.¹;³ Pfizer Inc.¹³</td>
</tr>
<tr>
<td>William J. Apfeldorf, M.D.</td>
<td>Abbott Laboratories, Inc.;³ AstraZeneca Pharmaceuticals LP;² Firsal Inc.¹;³ Eli Lilly and Company³;² Forest Laboratories, Inc.¹;³;² Janssen Pharmaceutical Products, LP;² Pfizer Inc.¹;³;² Wyeth Pharmaceuticals¹</td>
</tr>
<tr>
<td>Lesley M. Arnold, M.D.</td>
<td>Cypress Bioscience Inc.¹;³ Eli Lilly and Company¹;³;² Forest Laboratories, Inc.¹;³;² Pfizer Inc.¹;³;² Sanofi-Aventis¹;³;² Seprocor, Inc.¹;³;² Wyeth Pharmaceuticals¹</td>
</tr>
<tr>
<td>Alan Axelson, M.D.</td>
<td>Eli Lilly and Company¹;³;² Novartis Pharmaceuticals Corporation¹;² Shire Pharmaceuticals Group plc.¹</td>
</tr>
<tr>
<td>Marion A. Becker, Ph.D.</td>
<td>Eli Lilly and Company¹</td>
</tr>
<tr>
<td>Julian Beczhold, M.B.Ch.B</td>
<td>AstraZeneca Pharmaceuticals LP;² Bristol-Myers Squibb Company³;² Eli Lilly and Company²;² Janssen-Cilag³</td>
</tr>
<tr>
<td>Bernard D. Beitman, M.D.</td>
<td>Bristol-Myers Squibb Company³</td>
</tr>
<tr>
<td>Ruth M. Benca, M.D.</td>
<td>GlaxoSmithKline¹;³;² Neurocrine Biosciences Inc.¹;³;² Pfizer Inc.¹;³;² Sanofi-Aventis¹;³;² Seprocor, Inc.¹;³;² Takeda Pharmaceuticals America, Inc.¹;³;² Wyeth Pharmaceuticals¹</td>
</tr>
<tr>
<td>Donna S. Bender, Ph.D.</td>
<td>National Institute of Mental Health¹</td>
</tr>
<tr>
<td>Susan R. Bergeson, M.B.A.</td>
<td>Abbott Laboratories, Inc.³</td>
</tr>
</tbody>
</table>

XXI
DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>John L. Beyer, M.D.</td>
<td>Avanir Pharmaceuticals; Bristol-Myers Squibb Company; Liais Inc.; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutical Products; LP; Myriad Generics, Inc.; Pfizer Inc.</td>
</tr>
<tr>
<td>Joseph Biederman, M.D.</td>
<td>Abbott Laboratories, Inc.; Bristol-Myers Squibb Company; Cephalon, Inc.; Eli Lilly and Company; Janssen Pharmaceutical Products; McNeil Consumer Healthcare; National Institute of Child Health and Human Development; National Institute of Mental Health; National Institute on Drug Abuse; Novartis Pharmaceuticals Corporation; NRP; Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc.; Shire Pharmaceuticals Group plc; Stanley Medical Research Institute; UCB Pharma</td>
</tr>
<tr>
<td>Adam Bisaga, M.D.</td>
<td>Forest Laboratories, Inc.; GlaxoSmithKline</td>
</tr>
<tr>
<td>Donald W. Black, M.D.</td>
<td>Forest Laboratories, Inc.; Pfizer Inc.; Scirex Corporation; Shire Pharmaceuticals Group plc</td>
</tr>
<tr>
<td>Carlos Blanco-Jerez, M.D.</td>
<td>Somaxon Pharmaceuticals</td>
</tr>
<tr>
<td>Barton J. Blinder, M.D.</td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Paul B. Bohn, M.D.</td>
<td>Forest Laboratories, Inc.; Pfizer Inc.; Wyeth-Ayerst Laboratories</td>
</tr>
<tr>
<td>Cutley L. Bonds, M.D.</td>
<td>Abbott Laboratories, Inc.; Pfizer Inc.</td>
</tr>
<tr>
<td>Howard E. Book, M.D.</td>
<td>American Psychological Association Press</td>
</tr>
<tr>
<td>Charles L. Bowden, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutical Products; LP; Johnson and Johnson Pharmaceutical Research and Development; National Institute of Mental Health; Parke-Davis; Pfizer Inc.; Stanley Medical Research Institute; UCB Pharma</td>
</tr>
<tr>
<td>Kathleen T. Brady, M.D.</td>
<td>Abbott Laboratories, Inc.; Alkermes, Inc.; Cephalon, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; National Institute on Drug Abuse; Ovation Pharmaceuticals, Inc.; Pfizer Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Ronald Brenner, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company</td>
</tr>
<tr>
<td>Thomas E. Brown, Ph.D.</td>
<td>American Psychiatric Press; Cephalon, Inc.; Eli Lilly and Company; McNeil Consumer Healthcare; Novartis Pharmaceuticals Corporation; Shire Pharmaceuticals Group plc</td>
</tr>
<tr>
<td>Peter F. Buckley, M.D.</td>
<td>Abbott Laboratories, Inc.; Alamo Pharmaceuticals; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceutical Products; LP; Merck &amp; Co., Inc.; National Institute of Mental Health; Pfizer Inc.; Solvay Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Stephen G. Buic, M.D.</td>
<td>Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Oscar G. Bukstein</td>
<td>Cephalon, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceutical, Inc.; Sanofi-Aventis; Shire Pharmaceuticals Group plc</td>
</tr>
<tr>
<td>Harold L. Burke, Ph.D.</td>
<td>EEC Spectrum International, Inc.</td>
</tr>
<tr>
<td>George Bush, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutical Products, LP; Johnson and Johnson Pharmaceutical Research and Development; McNeil Consumer Healthcare; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Shire Pharmaceuticals Group plc</td>
</tr>
<tr>
<td>Daniel J. Buysse, M.D.</td>
<td>Cephalon, Inc.; Eli Lilly and Company; GlaxoSmithKline; Merck &amp; Co., Inc.; Merck, Sharp, and Dohme; Neurocrine Biosciences Inc.; Neurogen Corporation; Pfizer Inc.; Respironics, Inc.; Sanofi-Aventis; Sepracor, Inc.; Servier; Takeda Pharmaceuticals America, Inc.</td>
</tr>
<tr>
<td>Nancy Byatt, D.O.</td>
<td>AstraZeneca Pharmaceuticals LP; Eli Lilly and Company</td>
</tr>
<tr>
<td>Joseph R. Calabrese, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutical Products, LP; Merck &amp; Co., Inc.; Teva Pharmaceutical Industries Ltd.</td>
</tr>
<tr>
<td>William E. Callahan, Jr., M.D.</td>
<td>Bristol-Myers Squibb Company; Otsuka America Pharmaceutical, Inc.</td>
</tr>
<tr>
<td>William H. Campbell, M.D.</td>
<td>Pfizer Inc.; Sanofi-Aventis</td>
</tr>
<tr>
<td>Joseph Cappelleri</td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Stanley N. Carter, M.D.</td>
<td>Bristol-Myers Squibb Company; Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc.</td>
</tr>
<tr>
<td>William T. Carpenter, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon, Inc.; Eli Lilly; National Institute of Mental Health; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Diana Carter, M.B.B.S.</td>
<td>GlaxoSmithKline; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Daniel E. Casey, M.D.</td>
<td>Abbott Laboratories, Inc.; Bristol-Myers Squibb Company; Janssen Pharmaceutical Products, LP; Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Sumitomo Pharmaceuticals Co., Ltd.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>David A. Casey, M.D.</td>
<td>Abbott Laboratories, Inc.; Janssen Pharmaceutical Products, LP; Pfizer Inc.</td>
</tr>
<tr>
<td>Alfonso Cecchini-Nelli, M.D.</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Robert A. Chambers, M.D.</td>
<td>Forest Laboratories, Inc.; National Institute on Drug Abuse</td>
</tr>
<tr>
<td>Kiki D. Chang, M.D.</td>
<td>Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; GlaxoSmithKline; Lilly; Otsuka America Pharmaceutical, Inc.; Shire Pharmaceuticals Group plc</td>
</tr>
</tbody>
</table>

XXII
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph A. Cheong, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Allen Childs, M.D.</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lois W. Choi-Kain, M.D.</td>
<td>National Institute of Mental Health&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Henry Chung, M.D.</td>
<td>National Institute of Mental Health&lt;sup&gt;3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Leslie L. Citrome, M.D.</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;1,6&lt;/sup&gt;; AstraZeneca Pharmaceuticals LP&lt;sup&gt;1,5&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;1,3,5&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3,5&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1,3,5&lt;/sup&gt;; Jansen Pharmaceuticals Products, LP&lt;sup&gt;5&lt;/sup&gt;; Jazz Pharmaceuticals, Inc.&lt;sup&gt;1&lt;/sup&gt;; Johnson and Johnson Pharmaceutical Research and Development&lt;sup&gt;6&lt;/sup&gt;; Merck &amp; Co., Inc.&lt;sup&gt;6&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Daniel J. Clauw, M.D.</td>
<td>Cypress Bioscience Inc.&lt;sup&gt;1,6&lt;/sup&gt;</td>
</tr>
<tr>
<td>Anita L. Clayton, M.D.</td>
<td>Bristol-Myers Squibb Company&lt;sup&gt;1,3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3,5&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;3&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1,3,5&lt;/sup&gt;; Neuropharmaceuticals, Inc.&lt;sup&gt;3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; Sanofi-Aventis&lt;sup&gt;3&lt;/sup&gt;; Vela Pharmaceuticals, Inc.&lt;sup&gt;3&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1,3,5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Emil F. Coccaro, M.D.</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;1,5&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;2&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Judith A. Cohen</td>
<td>Department of Health and Human Services&lt;sup&gt;3&lt;/sup&gt;; Guilford Press&lt;sup&gt;4&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Francesc Colom, Ph.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;5&lt;/sup&gt;; Eli Lilly&lt;sup&gt;5&lt;/sup&gt;; Sanofi-Aventis&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>David O. Conant-Nowell, M.D.</td>
<td>McNeil Consumer Healthcare&lt;sup&gt;5&lt;/sup&gt;; Novartis Pharmaceuticals Corporation&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Daniel F. Connor, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;5&lt;/sup&gt;; Cephalon, Inc.&lt;sup&gt;5&lt;/sup&gt;; Shire Pharmaceuticals Group plc.&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ram Cooppan, M.B.Ch.B.</td>
<td>Bristol-Myers Squibb Company&lt;sup&gt;3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;2&lt;/sup&gt;; Novartis Pharmaceuticals Corporation&lt;sup&gt;5&lt;/sup&gt;; Novo Nordisk Pharmaceuticals, Inc.&lt;sup&gt;2&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;5&lt;/sup&gt;; Sanofi-Aventis&lt;sup&gt;5&lt;/sup&gt;; Takeda Pharmaceuticals America, Inc.&lt;sup&gt;2&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gabriela Cora-Locatelli, M.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;1&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Barbara A. Cornblatt, Ph.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;1&lt;/sup&gt;; Janssen Pharmaceuticals Products, LP&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Maria R. Cortal, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;5&lt;/sup&gt;; Janssen Pharmaceuticals Products, LP&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Christoph U. Correll, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;1,5&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;1,3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3&lt;/sup&gt;; Healthcare Technology Systems, Inc.&lt;sup&gt;1&lt;/sup&gt;; Intra-Cellular Therapeutics&lt;sup&gt;1&lt;/sup&gt;; Janssen Pharmaceuticals Products, LP&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Leslie J. Crofford, M.D.</td>
<td>Allergan Inc.&lt;sup&gt;1&lt;/sup&gt;; Cypress Bioscience Inc.&lt;sup&gt;1&lt;/sup&gt;; Merck, Sharp, and Dohme&lt;sup&gt;1&lt;/sup&gt;; Orphan Medical&lt;sup&gt;1&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1,3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Jeffrey L. Cummings, M.D.</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;1&lt;/sup&gt;; Eisai Inc.&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Daniella David, M.D.</td>
<td>Janssen Pharmaceuticals Products, LP&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Jonathan S. Davinc, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;5&lt;/sup&gt;; Biovail Corporation&lt;sup&gt;5&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lori L. Davis, M.D.</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; AstraZeneca Pharmaceuticals LP&lt;sup&gt;5&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;3&lt;/sup&gt;; Cyberonics, Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Eisai Inc.&lt;sup&gt;5&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;3&lt;/sup&gt;; Janssen Pharmaceuticals Products, LP&lt;sup&gt;5&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Melissa P. DelBello, M.D.</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;1&lt;/sup&gt;; Janssen Pharmaceuticals LP&lt;sup&gt;1,3,5&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;1,3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;3&lt;/sup&gt;; Johnson and Johnson Pharmaceutical Research and Development&lt;sup&gt;1,3&lt;/sup&gt;; Otsuka America Pharmaceutical, Inc.&lt;sup&gt;3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pedro L. Delgado, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;1,5&lt;/sup&gt;; Corcept Therapeutics&lt;sup&gt;1&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,5&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Medtronic, Inc.&lt;sup&gt;3&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;1,5&lt;/sup&gt;; Neurorobics, Inc.&lt;sup&gt;1&lt;/sup&gt;; NIH Institute&lt;sup&gt;1,3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;5&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;3,5&lt;/sup&gt;; Wyeth-Ayerst Laboratories&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Davangere P. Devanand</td>
<td>Eli Lilly and Company&lt;sup&gt;3&lt;/sup&gt;; Pfizer Pharmaceuticals&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>C. Lindsay DeVane, Pharm.D.</td>
<td>Bristol-Myers Squibb Company&lt;sup&gt;5&lt;/sup&gt;; Cyberonics, Inc.&lt;sup&gt;3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1&lt;/sup&gt;; Janssen Pharmaceuticals Products, LP&lt;sup&gt;1,3,5&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;3&lt;/sup&gt;; NovaDel Pharma Inc.&lt;sup&gt;3&lt;/sup&gt;; Novartis Pharmaceuticals Corporation&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Mantosh J. Dewan, M.D.</td>
<td>McNeil Consumer Healthcare&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ronald J. Diamond, M.D.</td>
<td>Bristol-Myers Squibb Company&lt;sup&gt;3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;3&lt;/sup&gt;; Janssen Pharmaceuticals Products, LP&lt;sup&gt;1,3,5&lt;/sup&gt;; Janssen-Cilag&lt;sup&gt;3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Joel Dimsdale, M.D.</td>
<td>Sepracor, Inc.&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lisa Dixon, M.D.</td>
<td>Bristol-Myers Squibb Company&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Robert K. Dolgoff, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;5&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>P. Murali Doriaswamy, M.D.</td>
<td>Eisai Inc.&lt;sup&gt;3&lt;/sup&gt;; Elan Pharmaceuticals, Inc.&lt;sup&gt;3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,5&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;3&lt;/sup&gt;; Myriad Genetics, Inc.&lt;sup&gt;3&lt;/sup&gt;; Searle&lt;sup&gt;5&lt;/sup&gt;; Sanofi-Aventis&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Christoper L. Drake, Ph.D.</td>
<td>Cephalon, Inc.&lt;sup&gt;3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1&lt;/sup&gt;; Sepracor, Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Takeda Pharmaceuticals America, Inc.&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ronald S. Duman, Ph.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;3&lt;/sup&gt;; National Foundation for Mental Health&lt;sup&gt;3&lt;/sup&gt;; Organon Pharmaceuticals Inc.&lt;sup&gt;3&lt;/sup&gt;; Sepracor, Inc.&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Laura B. Dunn, M.D.</td>
<td>National Institute of Mental Health&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>James M. Ellisson, M.D.</td>
<td>Bristol-Myers Squibb Company&lt;sup&gt;5&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;3&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;3,5&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;3&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

XXIII
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raymond A. Faber</td>
<td>Bristol-Myers Squibb Company; Cephalon, Inc; Forest Laboratories, Inc.</td>
</tr>
<tr>
<td>Andrea Fagioliini, M.D.</td>
<td>Bristol-Myers Squibb Company; GlaxoSmithKline; Merck &amp; Co., Inc.; Pfizer Inc.</td>
</tr>
<tr>
<td>Warachal E. Faison, M.D.</td>
<td>Bristol-Myers Squibb Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmacuetica Products, LP; National Institute of Mental Health; National Institute on Aging; Organon Pharmaceuticals Inc; Otsuka America Pharmaceutical, Inc; Pfizer Inc; Shire Pharmaceuticals Group plc</td>
</tr>
<tr>
<td>Stephen V. Faraone, Ph.D.</td>
<td>Cephalon, Inc.; Eli Lilly and Company; McNeil Consumer Healthcare; National Foundation for Mental Health; National Institute of Child Health and Human Development; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute on Drug Abuse; Noven Pharmaceuticals, Inc; Shire Pharmaceuticals Group plc</td>
</tr>
<tr>
<td>Maurizio Fava, M.D.</td>
<td>Abbott Laboratories, Inc.; Alkermes, Inc.; Aspect Medical Systems; AstraZeneca Pharmaceuticals LP; Bayer Corporation; Boehringer-Ingelheim Pharmaceuticals; BrainCells, Inc.; Bristol-Myers Squibb Company; Cephalon, Inc; Compellis Pharmaceuticals; Cypress Bioscience Inc; Cypress Pharmaceuticals; Dov Pharmaceuticals; Eli Lilly and Company; EPIN; Fabre Kramar Pharmaceuticals Inc; Forest Laboratories, Inc; GlaxoSmithKline; Grunenthal GmbH; Janssen Pharmacuetica Products, LP; Jazz Pharmaceuticals, Inc; Johnson and Johnson Pharmaceutical Research and Development; Knoll Pharmaceutical Company; Lichterweh Pharma GmbH; Lorex Pharmaceuticals; Lundbeck; MedAvante, Inc; Neurionics, Inc; Novartis Pharmaceuticals Corporation; Nutrition 21, Inc; Organon Pharmaceuticals Inc; PamiLab; Pfizer Inc; Pharnac &amp; Upjohn; PharmaStur; Pharmavie; Roche Pharmaceuticals; Sanofi-Synthelabo; Sanofi-Aventis; Seprocor, Inc; Solvay Pharmaceuticals, Inc; SomaXen Pharmaceuticals; Somerset Pharmaceuticals Inc; Wyeth Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
</tr>
<tr>
<td>Jan Fawcett, M.D.</td>
<td>Abbott Laboratories, Inc; Eli Lilly and Company; National Institute of Mental Health; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Francisco Fernandez, M.D.</td>
<td>Bristol-Myers Squibb Company; Cyberonics, Inc; Essai-Pfizer; NIH Institute; Pfizer Inc; Sumitomo Pharmaceuticals Co., Ltd; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Robert L. Findling, M.D.</td>
<td>Abbott Laboratories, Inc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc; GlaxoSmithKline; Johnson and Johnson Pharmaceutical Research and Development; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc; Pfizer Inc; Sanofi-Aventis; Shire Pharmaceuticals Group plc; Solvay Pharmaceuticals, Inc; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Naomi A. Fineberg</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon, Inc; GlaxoSmithKline</td>
</tr>
<tr>
<td>David P. Folsom, M.D.</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>Timothy W. Fong, M.D.</td>
<td>Forest Laboratories, Inc; Ortho-McNeil Pharmaceutical, Inc; Reckitt-Benker</td>
</tr>
<tr>
<td>Brent P. Forrester, M.D.</td>
<td>Abbott Laboratories, Inc; AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmacuetica Products, LP; Novartis Pharmaceuticals Corporation; Pfizer Inc</td>
</tr>
<tr>
<td>Philippe Fossati, M.D.</td>
<td>Eli Lilly and Company; Servier</td>
</tr>
<tr>
<td>Ellen Frank, Ph.D.</td>
<td>Eli Lilly and Company; Forest Laboratories, Inc; Forest Research Institute; Guilford Press; Guilford Pharmaceuticals; H. Lundbeck A/S; Guilford Press; Lundbeck; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Pfizer Inc; Servier</td>
</tr>
<tr>
<td>Gordon Franksie, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Fujiwara Pharmaceutical, Co</td>
</tr>
<tr>
<td>Nancy Frasure-Smith, Ph.D.</td>
<td>GlaxoSmithKline; IsodisNatura; Solvay Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Marlene P. Freeman, M.D.</td>
<td>Arizona Disease Control Research Commission; AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Forest Laboratories, Inc; National Institute of Mental Health; Pfizer Inc; Pronova Biocare; Reliant; The Institute for Mental Health Research of Arizona; THFR-X; U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>Fred Frese, M.D.</td>
<td>Abbott Laboratories, Inc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmacuetica Products, LP; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc; Pfizer Inc; Solvay Pharmaceuticals, Inc; Stanley Medical Research Institute; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Robert D. Friedberg, Ph.D.</td>
<td>Guilford Publications</td>
</tr>
<tr>
<td>Joseph L. Friedman, M.D.</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Mark A. Frye, M.D.</td>
<td>Abbott Laboratories, Inc; American Foundation for Suicide Prevention; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon, Inc; Eli Lilly and Company; GlaxoSmithKline; Indeves Pharmaceuticals, Inc; Janssen Pharmacuetica Products, LP; Janssen-Cilag; Johnson and Johnson Pharmaceutical Research and Development; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceutical, Inc; Otsuka America Pharmaceutical, Inc; Pfizer Inc; Solvay Pharmaceuticals, Inc; Stanley Medical Research Institute; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Kenneth D. Gadow, Ph.D.</td>
<td>Checkmate Plus</td>
</tr>
<tr>
<td>Wolfgang Gaebel, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; H. Lundbeck A/S; Janssen-Cilag; Lilly; Lundbeck; Novartis Pharmaceuticals Corporation; Sanofi-Aventis; Wyeth Pharmaceuticals</td>
</tr>
</tbody>
</table>

XXIV
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fred H. Gage, Ph.D.</td>
<td>BrainCells, Inc.; Celgene Corporation; Ceregene, Inc.; Stem Cells Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon, Inc.; Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.</td>
</tr>
<tr>
<td>James E. Galvin, M.D.</td>
<td>Eisai Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; National Institute of Mental Health; National Institute on Aging; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc.</td>
</tr>
<tr>
<td>Keming Gao, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon, Inc.; Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.</td>
</tr>
<tr>
<td>Mark S. George, M.D.</td>
<td>Aventis Pharmaceuticals, Inc.; Biocor Pharmaceuticals, Inc.; Cyberonics, Inc.; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; National Institute of Health; Neurontics, Inc.; NeuroPace, Inc.</td>
</tr>
<tr>
<td>Tony P. George, M.D.</td>
<td>Eli Lilly and Company; National Alliance for Research in Schizophrenia and Depression; National Institute on Drug Abuse; Pfizer Inc.; Targacept, Inc.</td>
</tr>
<tr>
<td>Nassir Ghaemi, M.D.</td>
<td>Abbott Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Pfizer Inc.</td>
</tr>
<tr>
<td>Mona H. Gill, M.D.</td>
<td>Wyeth Pharmaceuticals; Bristol-Myers Squibb Company; Cephalon, Inc.; Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.</td>
</tr>
<tr>
<td>Michael J. Gitlin</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon, Inc.; Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.</td>
</tr>
<tr>
<td>Alexander H. Glassman, M.D.</td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Tasha Glenn, Ph.D.</td>
<td>ChronoCord Association</td>
</tr>
<tr>
<td>Ira D. Glick, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Johnson and Johnson Pharmaceutical Research and Development; Pfizer Inc.; Shire Pharmaceuticals Group plc.; Solvay Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Donald C. Goff, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Pfizer Inc.; Sanofi-Aventis</td>
</tr>
<tr>
<td>Harold W. Goforth, M.D.</td>
<td>Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Pfizer Inc.; Seprocor, Inc.</td>
</tr>
<tr>
<td>Joseph F. Goldberg, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Pfizer Inc.; Sanofi-Aventis; Solvay Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Gabe Goldfeder, M.A.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Janssen Pharmaceutica Products, LP; Myriad Genetics, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Sanofi-Aventis</td>
</tr>
<tr>
<td>Morris B. Goldman, M.D.</td>
<td>National Institute of Mental Health; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.</td>
</tr>
<tr>
<td>Irwin Goldstein</td>
<td>Bayer Corporation; Eli Lilly and Company; Johnson and Johnson Pharmaceutical Research and Development; Pfizer Inc.; Proctor &amp; Gamble Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Frederick K. Goodwin, M.D.</td>
<td>Abbott Laboratories, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Pfizer Inc.; Sanofi-Aventis; Solvay Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Jon F. Grant, M.D.</td>
<td>Forest Laboratories, Inc.; GlaxoSmithKline; Somaxon Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Jack A. Grebbo, M.D.</td>
<td>Bristol-Myers Squibb Company</td>
</tr>
<tr>
<td>George T. Grossberg, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Johnson and Johnson Pharmaceutical Research and Development; Myriad Genetics, Inc.; National Institute on Aging; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Sanofi-Aventis; Sepracor, Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Linda S. Grossman, Ph.D.</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>Heinz Grunze, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; GlaxoSmithKline; Janssen-Cilag; Novartis Pharmaceuticals Corporation; Pfizer Inc.; UCB Pharma</td>
</tr>
<tr>
<td>Sanjay Gupta, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Johnson and Johnson Pharmaceutical Research and Development; Memory Pharmaceuticals; Myriad Genetics, Inc.; Neurochem, Inc.; Ono Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals</td>
</tr>
<tr>
<td>Raquel E. Gur, M.D.</td>
<td>NIH Institute</td>
</tr>
<tr>
<td>Robert E. Hales</td>
<td>Bristol-Myers Squibb Company</td>
</tr>
<tr>
<td>Martin Harrow, Ph.D.</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>Philip D. Harvey, Ph.D.</td>
<td>Solvay Pharmaceuticals, Inc., Pfizer Inc.</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>David Healy, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP^3; Teva Pharmaceutical Industries Ltd.</td>
</tr>
<tr>
<td>David J. Hellerstein, M.D.</td>
<td>Bristol-Myers Squibb Company^2; Eli Lilly and Company^3; Forest Laboratories, Inc.; GlaxoSmithKline^5</td>
</tr>
<tr>
<td>David C. Henderson, M.D.</td>
<td>Bristol-Myers Squibb Company^1,3; Eli Lilly and Company^1; Pfizer Inc.</td>
</tr>
<tr>
<td>Charles H. Hennekens, M.D.</td>
<td>Amgen, Inc.; AstraZeneca Pharmaceuticals LP^1,3; Bayer Corporation; Biovail Corporation; Bristol-Myers</td>
</tr>
<tr>
<td></td>
<td>Squibb Company^1,2; GlaxoSmithKline^2; McNeil Consumer Healthcare; Merck &amp; Co., Inc.; Novartis</td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals Corporation; Pfizer Inc. ; Solvay Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Jacqueline Henschke, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP^3</td>
</tr>
<tr>
<td>Paula L. Hensley, M.D.</td>
<td>Amgen, Inc.; Pfizer Inc.</td>
</tr>
<tr>
<td>Barry K. Herman, M.D.</td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Napoleon B. Higgins, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP^5; GlaxoSmithKline^5; Janssen Pharmaceutical Products, LP^3; McNeil</td>
</tr>
<tr>
<td></td>
<td>Consumer Healthcare; Novartis Pharmaceuticals Corporation; Shire Pharmaceuticals Group plc.</td>
</tr>
<tr>
<td>Marynell Hinton, M.A.</td>
<td>Professional Risk Management Services, Inc.</td>
</tr>
<tr>
<td>Max Hirshkowitz, Ph.D.</td>
<td>Aventis Pharmaceuticals, Inc.; Cephalon, Inc.; GlaxoSmithKline; Landbeck; Merck, Sharp, and Dohme;</td>
</tr>
<tr>
<td></td>
<td>National Institute of Health; Neurocrine Biosciences Inc.; Respironics, Inc.; Sanofi-Aventis^1,3,5;</td>
</tr>
<tr>
<td></td>
<td>Takeda Pharmaceuticals America, Inc.</td>
</tr>
<tr>
<td>Eric Hollander, M.D.</td>
<td>Abbott Laboratories, Inc.; Lilly; National Institute of Mental Health; National Institute of Neurological</td>
</tr>
<tr>
<td></td>
<td>Disorders and Stroke; National Institute on Drug Abuse; Neuropharm^1,2; Ortho-McNeil Pharmaceutical,</td>
</tr>
<tr>
<td></td>
<td>Inc.; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals^5; U.S. Food and Drug Administration^5;</td>
</tr>
<tr>
<td></td>
<td>UCB Pharma^5</td>
</tr>
<tr>
<td>Ray C. Hsiao, M.D.</td>
<td>Bristol-Myers Squibb Company; Pfizer Inc.</td>
</tr>
<tr>
<td>Rona Hu, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP^1,3; Bristol-Myers Squibb Company^1,3; Eli Lilly and Company; Forest</td>
</tr>
<tr>
<td></td>
<td>Laboratories, Inc.; Janssen Pharmaceutical Products, LP^3; Pfizer Inc.</td>
</tr>
<tr>
<td>Michael Y. Hwang, M.D.</td>
<td>Janssen Pharmaceutical Products, LP^1,5</td>
</tr>
<tr>
<td>Dan V. Iosifescu, M.D.</td>
<td>Aspect Medical Systems^1,3; Cephalon, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen</td>
</tr>
<tr>
<td></td>
<td>Pharmaceutical Products, LP^3; Pfizer Inc.</td>
</tr>
<tr>
<td>Naveed Iqbal, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP^1,3; Bristol-Myers Squibb Company^1,3; Forest Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td></td>
<td>Janssen Pharmaceutical Products, LP^1,3,5; Myriad Genetics, Inc.; Otsuka America Pharmaceutical, Inc.</td>
</tr>
<tr>
<td></td>
<td>Pfizer Inc.; Sanofi-Aventis</td>
</tr>
<tr>
<td>Philip G. Janicak, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP^1,3; Bristol-Myers Squibb Company^1,3;</td>
</tr>
<tr>
<td></td>
<td>Janssen Pharmaceutical Products, LP^1,3,5; Neuronetics, Inc.; Pfizer Inc.; Solvay Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Geetha Jayaram, M.D.</td>
<td>Bristol-Myers Squibb Company; Cephalon, Inc.; GlaxoSmithKline; Janssen Pharmaceutical Products,</td>
</tr>
<tr>
<td></td>
<td>LP^1; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>James W. Jefferson, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP^3; Bristol-Myers Squibb Company^3,6; Eli</td>
</tr>
<tr>
<td></td>
<td>Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Healthcare Technology Systems, Inc.;</td>
</tr>
<tr>
<td></td>
<td>Novartis Pharmaceuticals Corporation; Pfizer Inc.; Schwartz Pharma; Shire Pharmaceuticals Group plc.;</td>
</tr>
<tr>
<td></td>
<td>Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Dilip V. Jeste, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP^1,3; Bristol-Myers Squibb Company^1,3; Eli Lilly and Company; Janssen</td>
</tr>
<tr>
<td></td>
<td>Pharmaceutical Products, LP^1,3,4; National Institute of Mental Health; Otsuka America Pharmaceutical,</td>
</tr>
<tr>
<td></td>
<td>Inc.; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Hadine Joffe, M.D.</td>
<td>Berlex Inc.; Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.; Sanofi-Aventis; Sepracor, Inc.;</td>
</tr>
<tr>
<td></td>
<td>Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Bankole Johnson, M.D.</td>
<td>Alkermes, Inc.; Forest Laboratories, Inc.; GlaxoSmithKline; Intranasal Therapeutics, Inc.; Johnson and</td>
</tr>
<tr>
<td></td>
<td>Johnson Pharmaceutical Research and Development; Ortho-McNeil Pharmaceutical, Inc.; Sanofi-Aventis;</td>
</tr>
<tr>
<td></td>
<td>TransOraPharmaceuticals, Inc</td>
</tr>
<tr>
<td>Bradley R. Johnson, M.D.</td>
<td>Forest Laboratories, Inc.</td>
</tr>
<tr>
<td>Joel P. Johnson, M.D.</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Rene Kahn</td>
<td>AstraZeneca Pharmaceuticals LP^1,3; Bristol-Myers Squibb Company^1,3; Eli Lilly and Company^1,5;</td>
</tr>
<tr>
<td></td>
<td>GlaxoSmithKline; Johnson and Johnson Pharmaceutical Research and Development; Merck, Sharp, and</td>
</tr>
<tr>
<td></td>
<td>Dohme^1,3; Organon Pharmaceuticals Inc.; Pfizer Inc.; Sanofi-Aventis</td>
</tr>
<tr>
<td>Thomas A. Kaleita, Ph.D.</td>
<td>Cephalon, Inc.</td>
</tr>
<tr>
<td>Ronald L. Kamm, M.D.</td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Kyle M. Kampman, M.D.</td>
<td>Alkermes, Inc.; Cephalon, Inc.; Forest Laboratories, Inc.</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------</td>
</tr>
<tr>
<td>John M. Kane, M.D.</td>
<td>Abbott Laboratories, Inc.⁷; AstraZeneca Pharmaceuticals LP¹; Bristol-Myers Squibb Company¹⁵; Eli Lilly and Company⁷; Janssen Pharmaceuticals, Inc.¹⁵; Janssen-Cilag¹⁵; Johnson and Johnson Pharmaceutical Research and Development¹; Landbeck¹; MDS Pharma Services¹; MedAvante⁶; Pfizer Inc.¹⁵; Roche Pharmaceuticals¹; Solvay Pharmaceuticals, Inc.¹; Wyeth-Ayerst Laboratories¹</td>
</tr>
<tr>
<td>Shimi Kang, M.D.</td>
<td>Alkermes, Inc.¹; AstraZeneca Pharmaceuticals LP; Cephalon, Inc.²; Eli Lilly and Company⁵; Janssen Pharmaceutical Products, LP</td>
</tr>
<tr>
<td>Shitij Kapur</td>
<td>Forest Laboratories, Inc.³; Schwartz Pharma³</td>
</tr>
<tr>
<td>Wayne J. Katon, M.D.</td>
<td>Eli Lilly and Company⁶; Forest Laboratories, Inc.⁴; GlaxoSmithKline⁵; John A Hartford Foundation⁵; National Institute of Mental Health⁴; Wyeth-Ayerst Laboratories⁴</td>
</tr>
<tr>
<td>David J. Katzenick, M.D.</td>
<td>Abbott Laboratories, Inc.¹; AstraZeneca Pharmaceuticals LP; Forest Laboratories, Inc.⁵; GlaxoSmithKline⁵; Johnson and Johnson Pharmaceutical Research and Development⁶; Lilly⁷; Merck &amp; Co., Inc.¹³; Novartis Pharmaceuticals Corporation⁵; Organon Pharmaceuticals Inc.; Pfizer Inc.¹³; Pharmacia &amp; Upjohn⁵; Robert Wood Johnson Foundation⁶; Solvay Pharmaceuticals, Inc.³; Wyeth Pharmaceuticals¹</td>
</tr>
<tr>
<td>Paul E. Keck, M.D.</td>
<td>Abbott Laboratories, Inc.¹; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company¹; Eli Lilly and Company¹; GlaxoSmithKline¹; Janssen Pharmaceutical Products, LP; Memory Pharmaceuticals; Merck &amp; Co., Inc.³; National Institute of Mental Health; National Institute on Drug Abuse; Neurocrine Biosciences Inc.; Organon Pharmaceuticals Inc.; Ortho-McNeil Pharmaceutical, Inc.¹²; Pfizer Inc.¹³; Shire Pharmaceuticals Group plc.; Stanley Medical Research Institute; UCB Pharma⁶</td>
</tr>
<tr>
<td>George A. Keepers, M.D.</td>
<td>Eli Lilly and Company⁵</td>
</tr>
<tr>
<td>Samuel J. Keith, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company¹; Cyberonics, Inc.³; Eli Lilly and Company⁴; Forest Laboratories, Inc.³; GlaxoSmithKline⁶; Janssen-Cilag¹⁵; Merck, Sharp, and Dohme; Novartis Pharmaceuticals Corporation¹²; Pfizer Inc.¹³; Pharmacia &amp; Upjohn⁵; Wyeth Pharmaceuticals¹</td>
</tr>
<tr>
<td>John R. Kelsoe, M.D.</td>
<td>GlaxoSmithKline⁵; Psynomics, Inc.⁴</td>
</tr>
<tr>
<td>Ronald C. Kessler, Ph.D.</td>
<td>Bristol-Myers Squibb Company²; Eli Lilly and Company¹³; GlaxoSmithKline¹; Ortho-McNeil Pharmaceutical, Inc.³; Pfizer Inc.¹³; Wyeth-Ayerst Laboratories¹</td>
</tr>
<tr>
<td>Terence A. Ketter, M.D.</td>
<td>Abbott Laboratories, Inc.¹; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company¹; Cephalon, Inc.¹; Concept Therapeutics¹; Eisai Inc.¹; Eli Lilly and Company¹; Forest Laboratories, Inc.¹; GlaxoSmithKline¹; Janssen Pharmaceutical Products, LP; Jazz Pharmaceuticals, Inc.; Merck &amp; Co., Inc.¹; Novartis Pharmaceuticals Corporation¹; Pfizer Inc.¹; Shire Pharmaceuticals Group plc.¹; Solvay Pharmaceuticals, Inc.¹; UCB Pharma; Wyeth Pharmaceuticals¹</td>
</tr>
<tr>
<td>Sabrina J. Khan, M.D.</td>
<td>Eli Lilly and Company⁴; Merck &amp; Co., Inc.⁶; Pfizer Inc.⁶; Schering-Plough Corporation⁶</td>
</tr>
<tr>
<td>Clinton D. Kilts, Ph.D.</td>
<td>Forest Laboratories, Inc.¹; H. Lundbeck A/S; Janssen Pharmaceutical Products, LP; National Institute of Mental Health; National Institute on Drug Abuse; Solvay Pharmaceuticals, Inc.¹</td>
</tr>
<tr>
<td>David G. Kingdon, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company²; Eli Lilly and Company⁴; Guilford Press¹; Janssen-Cilag²; Pfizer Inc.³</td>
</tr>
<tr>
<td>Herbert D. Kleber, M.D.</td>
<td>Alkermes, Inc.¹; Reckitt Benkiser¹³</td>
</tr>
<tr>
<td>Harold W. Koening, M.D.</td>
<td>Janssen Pharmaceuticals Products, LP³</td>
</tr>
<tr>
<td>George F. Koob, Ph.D.</td>
<td>Addex Pharmaceuticals¹; Alkermes, Inc.¹; Forest Pharmaceuticals, Inc.¹; Hythiam Inc.¹</td>
</tr>
<tr>
<td>Lorin M. Koran, M.D.</td>
<td>Cypress Bioscience Inc.¹; Eli Lilly and Company⁴; Forest Laboratories, Inc.¹; Jazz Pharmaceuticals, Inc.¹; Ortho-McNeil Pharmaceutical, Inc.¹; Somaxon Pharmaceuticals³</td>
</tr>
<tr>
<td>Thomas R. Kosten, M.D.</td>
<td>Alkermes, Inc.¹; Bristol-Myers Squibb Company¹; Cephalon, Inc.²; Gerson Lehman Group¹; Johnson and Johnson Pharmaceutical Research and Development¹; Merck, Sharp, and Dohme; National Institute of Mental Health; National Institute on Drug Abuse; Novartis Pharmaceuticals Corporation¹; Pfizer Inc.¹</td>
</tr>
<tr>
<td>Christopher J. Kraoehvil, M.D.</td>
<td>Abbott Laboratories, Inc.¹; AstraZeneca Pharmaceuticals LP; Boehringer-Ingelheim Pharmaceuticals¹; Cephalon, Inc.¹; Eli Lilly and Company¹; McNeil Consumer Healthcare¹; National Institute of Mental Health¹; Organon Pharmaceuticals Inc.; Pfizer Inc.¹; Shire Pharmaceuticals Group plc.¹</td>
</tr>
<tr>
<td>K Ranga Krishnan, M.D.</td>
<td>Abbott Laboratories, Inc.¹; Amgen, Inc.¹; Bristol-Myers Squibb Company²; CeNeRx²; Cyberonics, Inc.¹; Eli Lilly and Company¹; GlaxoSmithKline¹; H. Lundbeck A/S¹; Johnson and Johnson Pharmaceutical Research and Development¹; Merck &amp; Co., Inc.¹; Novartis Pharmaceuticals Corporation¹; NPS Pharmaceuticals; Organon Pharmaceuticals Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.¹; Sepracor, Inc.¹; Somerset Pharmaceuticals Inc.; Vela Pharmaceuticals, Inc.; Wyeth Pharmaceuticals¹</td>
</tr>
<tr>
<td>Meir H. Kryger, M.D.</td>
<td>Cephalon, Inc.¹; National Institute of Health; Takeda Pharmaceuticals America, Inc.¹</td>
</tr>
<tr>
<td>Andrew D. Krystal, M.D.</td>
<td>King Pharmaceuticals, Inc.¹; Merck &amp; Co., Inc.¹; Neurocrine Biosciences Inc.¹; Neurogen Corporation¹; Pfizer Inc.¹; Resonics, Inc.¹; Sanofi-Aventis¹; Sepracor, Inc.¹; Somaxon Pharmaceuticals¹; Takeda Pharmaceuticals America, Inc.¹</td>
</tr>
</tbody>
</table>

XXVII
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>John H. Krystal, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc; GlaxoSmithKline; Janssen Research Foundation; Merck Pharmaceuticals; Organon Pharmaceuticals Inc; Pfizer Inc; Takeda Industries</td>
</tr>
<tr>
<td>Jayashri Kulkarni, M.B.B.S.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceuticals Products, LP; Janssen-Cilag; National Alliance for Research in Schizophrenia and Depression; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc; SanoFy; Synthelabo; Sanofi-Aventis; Servier; Stanley Medical Research Institute</td>
</tr>
<tr>
<td>Elisabeth J. S. Kunkel, M.D.</td>
<td>Forest Laboratories, Inc.</td>
</tr>
<tr>
<td>Helen H. Kyomen, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bayer Corporation; AstraZeneca Pharmaceuticals LP; Bayer Corporation; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; John A Hartford Foundation; Merck &amp; Co., Inc; Merck &amp; Co; National Institute on Aging; NIH Institute; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche Pharmaceuticals; The John A. Hartford Foundation; UCB Pharma; Veterans Administration; Wyeth-Ayerst Laboratories</td>
</tr>
<tr>
<td>Samuel J. Langer</td>
<td>Bristol-Myers Squibb Company</td>
</tr>
<tr>
<td>Alan Langleib, M.D.</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>John Lauriello, M.D.</td>
<td>Abel Screening, Inc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceuticals Products, LP; Janssen-Cilag; Pfizer Inc</td>
</tr>
<tr>
<td>William B. Lawson, M.D.</td>
<td>Abbott Laboratories, Inc; Bristol-Myers Squibb Company; Janssen Pharmaceuticals Products, LP; Pfizer Inc</td>
</tr>
<tr>
<td>Arthur L. Lazarus, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP</td>
</tr>
<tr>
<td>Hochang B. Lee, M.D.</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Steven J. Lee, M.D.</td>
<td>Cephalon, Inc; Forest Laboratories, Inc</td>
</tr>
<tr>
<td>Andrew C. Leon, Ph.D.</td>
<td>Cortex Pharmaceuticals, Inc; Cyberonics, Inc; MedAvante; Pfizer Inc; Vanda Pharmaceuticals</td>
</tr>
<tr>
<td>François Lespérance, M.D.</td>
<td>GlaxoSmithKline; IsodisNatura; Lundbeck; Servier; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Stefan Leucht, M.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; H. Lundbeck A/S; Janssen Pharmaceuticals Products; Lundbeck; Pfizer Inc; Sanofi-Aventis</td>
</tr>
<tr>
<td>James L. Levenson, M.D.</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Frances R. Levin, M.D.</td>
<td>Alkermes, Inc; AstraZeneca Pharmaceuticals LP; Cephalon, Inc; Eli Lilly and Company; Ortho-McNeil Pharmaceutical, Inc; Shire Pharmaceuticals Group plc; UCB Pharma</td>
</tr>
<tr>
<td>Petros Levounis, M.D.</td>
<td>Alkermes, Inc; AstraZeneca Pharmaceuticals LP; Cephalon, Inc; Forest Laboratories, Inc; Reckitt-Benkie; Takeda Pharmaceuticals America</td>
</tr>
<tr>
<td>Roberto Lewis-Fernandez, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; National Institute of Mental Health; Pfizer Inc</td>
</tr>
<tr>
<td>Jeffrey A. Lieberman, M.D.</td>
<td>Acadia Pharmaceuticals Inc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceuticals Products, LP; Johnson and Johnson Pharmaceutical Research and Development; Merck, Sharp, and Dohme; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc; Pfizer Inc; Replegen; Sanofi-Aventis</td>
</tr>
<tr>
<td>Russell F. Lim, M.D.</td>
<td>Abbott Laboratories, Inc; AstraZeneca Pharmaceuticals LP</td>
</tr>
<tr>
<td>Jean-Pierre Lindenmayer, M.D.</td>
<td>Alamo Pharmaceuticals; AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen Pharmaceuticals Products, LP; Lundbeck; Sanofi-Aventis; National Institute of Mental Health; Pfizer Inc</td>
</tr>
<tr>
<td>Maria D. Ilorente, M.D.</td>
<td>Abbott Laboratories, Inc; Bristol-Myers Squibb Company; Veterans Administration</td>
</tr>
<tr>
<td>Sheila M. Loboprabhu, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP</td>
</tr>
<tr>
<td>Leslie P. Lundt, M.D.</td>
<td>Cephalon, Inc; Eli Lilly and Company; Forest Laboratories, Inc; GlaxoSmithKline; Merck &amp; Co., Inc; Merck, Sharp, and Dohme; Pfizer Inc; Sanofi-Aventis; Sepneor, Inc; Shire Pharmaceuticals Group plc; Takeda Pharmaceuticals America; Targacept; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Shari L. Luskin, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Robert B. Lydiard, M.D.</td>
<td>Abbott Laboratories, Inc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon, Inc; Eli Lilly and Company; Forest Laboratories, Inc; McNeil Consumer Healthcare; Novartis Pharmaceuticals Corporation; Roche Pharmaceuticals; Sanofi-Aventis; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Constantine G. Lyketsos, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Eisai Inc; Forest Laboratories, Inc; GlaxoSmithKline; H. Lundbeck A/S; National Institute of Health; Novartis Pharmaceuticals Corporation; Pfizer Inc</td>
</tr>
<tr>
<td>Kathryn J. Macdonald, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP</td>
</tr>
<tr>
<td>Sean Mackey, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc</td>
</tr>
<tr>
<td>Vishal Madaan, MD</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Alan S. Maisel, M.D.</td>
<td>Abbott Laboratories, Inc.; Bayer Corporation; Johnson and Johnson Pharmaceutical Research and Development; AstraZeneca Pharmaceuticals LP; Cephalon, Inc.; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceuticals LP; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Pfizer Inc.</td>
</tr>
<tr>
<td>Catherine L. Mancini, M.D.</td>
<td>Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals LP; Aspect Medical Systems; Bristol-Myers Squibb Company; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Medtronics, Inc.; National Institute of Health; Neurotactics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Stanley Medical Research Institute.</td>
</tr>
<tr>
<td>Christina Mangurian, M.D.</td>
<td>Bristol-Myers Squibb Company; GlaxoSmithKline; Merck, Sharp, and Dohme; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Solvay Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Lauren B. Marangell, M.D.</td>
<td>National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health</td>
</tr>
<tr>
<td>Robert W. Marvin, M.D.</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>Prakash S. Masand, M.D.</td>
<td>Abbott Laboratories, Inc.; Alkermes, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; Janssen Pharmaceuticals LP; McNeil Pharmaceutical, Inc.; Organo Pharm Inc.; Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc.; Tagasco, Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Thomas L. Matthews, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Shire Pharmaceuticals Group plc.</td>
</tr>
<tr>
<td>Helen S. Mayberg, M.D.</td>
<td>Advanced Neuromodulation Systems, Inc.; Cyberonics, Inc.</td>
</tr>
<tr>
<td>Linda C. Hayes, M.D.</td>
<td>National Institute of Health</td>
</tr>
<tr>
<td>Thomas H. McGlashan, M.D.</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Keith McBurnett, Ph.D.</td>
<td>Cephalon, Inc.; McNeil Consumer Healthcare; NRP; Shire Pharmaceuticals Group plc.</td>
</tr>
<tr>
<td>Susan L. McElroy, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eisai Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals Products; LP; Johnson and Johnson Pharmaceutical Research and Development; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi-Aventis; Somaxon Pharmaceuticals; Stanley Medical Research Institute; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Joseph P. McEvoy, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen-Cilag; Organon Pharmaceuticals Inc; Otsuka America Pharmaceutical, Inc.; Pharmaceutical Product Development, Inc.</td>
</tr>
<tr>
<td>Patrick D. McGorry, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Janssen-Cilag; Janssen-Cilag</td>
</tr>
<tr>
<td>Roger S. McIntyre, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Biovail Corporation; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; H. Lundbeck A/S; Janssen Pharmaceuticals Products; McNeil Consumer Healthcare; Pfizer Inc.; Merck &amp; Co., Inc.; Merck, Sharp, and Dohme; Organon Pharmaceuticals Inc; Oryx Pharmaceuticals, Inc; Pfizer Inc.; Prestwick Pharmaceuticals, Inc; Servier; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Jacqueline M. Melonas, J.D.</td>
<td>Professional Risk Management Services, Inc.</td>
</tr>
<tr>
<td>Samantha E. Meitzer-Brody, M.D.</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Matthew A. Menza, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; Sanofi-Aventis; Sepacor, Inc; Takeda Pharmaceuticals America, Inc; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Jonathan M. Meyer, M.D.</td>
<td>Bristol-Myers Squibb Company; Janssen Pharmaceuticals Products, LP; McNeil Consumer Healthcare; Shire Pharmaceuticals Group plc.</td>
</tr>
<tr>
<td>Eric Mick</td>
<td>McNeil Consumer Healthcare; National Institute of Mental Health; Shire Pharmaceuticals Group plc.</td>
</tr>
<tr>
<td>Roumen V. Miley, Ph.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Biovail Corporation; Eli Lilly and Company; H. Lundbeck A/S; Wyeth Pharmaceuticals; Wyeth-Ayerst Laboratories.</td>
</tr>
<tr>
<td>Alexander L. Miller, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; InforMedix, Inc; Janssen Pharmaceuticals Products, LP; Organon Pharmaceuticals Inc; Pfizer Inc.</td>
</tr>
<tr>
<td>William R. Miller, Ph.D.</td>
<td>National Institute of Health; National Institute on Drug Abuse</td>
</tr>
<tr>
<td>Jacobo E. Mintzer, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Capital Research Companies; Eisai Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Johnson and Johnson Pharmaceutical Research and Development; Mitsubishi pharmaceutical Corporation; National Institute of Health; National Institute of Mental Health; National Institute on Aging; Nihon Kohden, Inc.; NIH Institute; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Predix Pharmaceuticals; Sanofi-Aventis; Voyager Pharmaceutical Corp.</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Asha S. Mishra, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP⁶; Bristol-Myers Squibb Company⁵</td>
</tr>
<tr>
<td>Shaila Misri, F.R.C.P.C.</td>
<td>AstraZeneca Pharmaceuticals LP¹,²,³; Biovail Corporation²; GlaxoSmithKline¹,³; H. Landbeck A/S¹,³,⁴; Janssen Pharmacuetica Products, LP⁵; Wyeth Pharmaceuticals¹,³,⁵</td>
</tr>
<tr>
<td>Ramin Mojtahedi, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP³; Bristol-Myers Squibb Company¹,³</td>
</tr>
<tr>
<td>Jacques Montplaisir, M.D.</td>
<td>Boehringer-Ingelheim Pharmaceuticals¹; GlaxoSmithKline³; Jazz Pharmaceuticals, Inc.³; Servier¹</td>
</tr>
<tr>
<td>Quinton E. Moss, M.D.</td>
<td>National Institute of Mental Health²; Pfizer Inc.⁵</td>
</tr>
<tr>
<td>David A. Maziek, M.D.</td>
<td>AssurRx⁶</td>
</tr>
<tr>
<td>Rodrigo A. Munoz, M.D.</td>
<td>Eli Lilly and Company³</td>
</tr>
<tr>
<td>Philip R. Muskin, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP⁵; Bristol-Myers Squibb Company¹,³,⁵; Cephalon, Inc.¹,⁵; Eli Lilly and Company²; Forest Laboratories, Inc.⁵; GlaxoSmithKline⁵; Janssen Pharmacuetica Products, LP⁵; National Institute of Mental Health¹; Otsuka America Pharmaceutical, Inc.³; Pfizer Inc.¹,⁵</td>
</tr>
<tr>
<td>Hugh Myrick, M.D.</td>
<td>Abbott Laboratories, Inc.⁵; AstraZeneca Pharmaceuticals LP⁵; Bristol-Myers Squibb Company³,⁵; Forest Laboratories, Inc.³,⁵; National Institute of Alcohol Abuse and Alcoholism³; National Institute on Drug Abuse³; Ortho-McNeil Pharmaceutical, Inc.³; Pfizer Inc.³</td>
</tr>
<tr>
<td>David K. Nace, M.D.</td>
<td>McKesson Corporation²; McKesson Corporation²</td>
</tr>
<tr>
<td>Ziad H. Nahas, M.D.</td>
<td>Cyberonics, Inc.¹,³; Neuronecits, Inc.¹,³</td>
</tr>
<tr>
<td>Joseph C. Napoli, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP⁵; GlaxoSmithKline³; Pfizer Inc.⁵</td>
</tr>
<tr>
<td>Meera Narasimhan, M.D.</td>
<td>Abbott Laboratories, Inc.¹; AstraZeneca Pharmaceuticals LP⁵; Bristol-Myers Squibb Company¹,³,⁵; Eli Lilly and Company¹,³; Forest Laboratories, Inc.²; Janssen Pharmacuetica Products, LP³,⁵; National Institute of Health³; National Institute on Drug Abuse³,⁵; Pfizer Inc.³</td>
</tr>
<tr>
<td>Kenneth C. Nash, M.D.</td>
<td>Eli Lilly and Company³; Novartis Pharmaceuticals Corporation⁵</td>
</tr>
<tr>
<td>Henry A. Nastrallah, M.D.</td>
<td>Abbott Laboratories, Inc.¹,³; AstraZeneca Pharmaceuticals LP³,⁵; Eli Lilly and Company³; Janssen Pharmacuetica Products, LP³,⁵; Pfizer Inc.¹,³,⁵; Shire Pharmaceuticals Group plc.¹,³</td>
</tr>
<tr>
<td>Randy J. Nelson</td>
<td>Merck &amp; Co., Inc.¹; National Institute of Mental Health³</td>
</tr>
<tr>
<td>Charles B. Nemeroff, M.D.</td>
<td>Abbott Laboratories, Inc.¹,³; Acadia Pharmaceuticals Inc.¹; AstraZeneca Pharmaceuticals LP³; Bristol-Myers Squibb Company¹,³,⁵; CeNeRx³; Cyberonics, Inc.¹; Cypress BioScience Inc.¹,³; Eli Lilly and Company¹; Forest Laboratories, Inc.¹,³; GlaxoSmithKline¹,³; Janssen Pharmacuetica Products, LP¹,³,⁵; National Alliance for Research in Schizophrenia and Depression³; National Institute of Mental Health³; NovaDel Pharma Inc.⁶; Otsuka America Pharmaceutical, Inc.¹; Pfizer Inc.¹,³,⁵; Reexva³; UCB Pharma³; Wyeth Pharmaceuticals¹,³,⁵</td>
</tr>
<tr>
<td>David N. Neubauer, M.D.</td>
<td>Neurocrine Biosciences Inc.¹; Pfizer Inc.¹; Sanofi-Aventis¹,³; Takeda Pharmaceuticals America, Inc.¹,³</td>
</tr>
<tr>
<td>John W. Newcomer, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP⁵; Bristol-Myers Squibb Company¹,³; Compact Clinicals³; GlaxoSmithKline¹; Janssen Pharmacuetica Products, LP¹,³; National Alliance for Research in Schizophrenia and Depression³; National Institute of Mental Health³; Organon Pharmaceuticals Inc.¹; Pfizer Inc.¹,³; Sidney R. Baer Foundation³; Solvay Pharmaceuticals, Inc.¹; Wyeth Pharmaceuticals¹</td>
</tr>
<tr>
<td>D. Jeffrey Newport, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP⁵; Eli Lilly and Company³,⁵; GlaxoSmithKline³,⁵; Janssen Pharmacuetica Products, LP³; Pfizer Inc.³; Wyeth Pharmaceuticals³</td>
</tr>
<tr>
<td>Anthony T. Ng, M.D.</td>
<td>Eli Lilly and Company³; Pfizer Inc.³; Substance Abuse and Mental Health Services Administration/ Center for Substance Abuse Treatment¹,³</td>
</tr>
<tr>
<td>Andrew A. Nierenberg, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP³; Bristol-Myers Squibb Company¹,³,³; Cederroth International³; Cyberonics, Inc.¹,³; Eli Lilly and Company¹,³,³; Forest Laboratories, Inc.¹,³; Genaissance Pharmaceuticals¹; GlaxoSmithKline¹,³,³; Innnapharma, Inc.¹; Janssen-Cilag¹; Lichtwer Pharma GmbH¹; Millenium Pharmaceuticals, Inc.¹; National Alliance for Research in Schizophrenia and Depression³; National Institute of Mental Health³; Neuronecits, Inc.¹; Novartis Pharmaceuticals Corporation¹; Organon Pharmaceuticals Inc.¹,³,³; Pfizer Inc.¹,³; Sepracor, Inc.¹; Shire Pharmaceuticals Group plc.¹; Somerset Pharmaceuticals Inc.¹; Stanley Medical Research Institute²; Sumitomo Pharmaceuticals Co., Ltd.¹; Wyeth Pharmaceuticals¹,³,⁵</td>
</tr>
<tr>
<td>Andrei Novac, M.D.</td>
<td>Forest Laboratories, Inc.³; GlaxoSmithKline³; Pfizer Inc.³</td>
</tr>
<tr>
<td>Keith H. Nuechterlein, Ph.D.</td>
<td>Janssen Pharmacuetica Products, LP³; National Institute of Mental Health, Janssen Pharmacuetica Products, LP³</td>
</tr>
<tr>
<td>Edward V. Nunes, M.D.</td>
<td>Alkermes, Inc.¹,³; Cephalon, Inc.³</td>
</tr>
<tr>
<td>H. George Nurnberg, M.D.</td>
<td>Abbott Laboratories, Inc.¹,³; Bristol-Myers Squibb Company¹,³,³; Eli Lilly and Company¹,³,³; GlaxoSmithKline¹,³; Lipha Pharma³; Parke-Davis³; Pfizer Inc.¹,³,³; Wyeth Pharmaceuticals¹,³,³</td>
</tr>
</tbody>
</table>

XXX
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>David J. Nutt, D.M.</td>
<td>Asahi; Cephalon, Inc.; Cypress Bioscience Inc.; Eli Lilly and Company; Esteve; GlaxoSmithKline; Janssen Pharmaceuticals Products; Lundbeck; MDS Pharma Services; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc; Passion for Life; Pfizer Inc.; Pharmacia &amp; Upjohn; Reckitt-Benckiser; Servier; Takeda Pharmaceuticals America; Therasci; Wyeth Pharmaceuticals; Yamanouchi</td>
</tr>
<tr>
<td>Mary B. O'Malley, M.D.</td>
<td>Cephalon, Inc.; GlaxoSmithKline; Merck &amp; Co., Inc.; Neurocrine Biosciences Inc.; Pfizer Inc.; Sepracor, Inc.</td>
</tr>
<tr>
<td>Stephanie O'Malley, Ph.D.</td>
<td>Alkermes, Inc.</td>
</tr>
<tr>
<td>Cheryl A. Oncken, M.D.</td>
<td>National Institute on Drug Abuse; Pfizer Inc.</td>
</tr>
<tr>
<td>Lewis A. Opler, M.D.</td>
<td>Multi-Health Systems, Inc.</td>
</tr>
<tr>
<td>Urban p. Ösby, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; National Alliance for Research in Schizophrenia and Depression; Pfizer Inc.</td>
</tr>
<tr>
<td>David W. Oslin, M.D.</td>
<td>NIH Institute; Robert Wood Johnson Foundation</td>
</tr>
<tr>
<td>Michael J. Ostacher, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceutical Products; Pfizer Inc.</td>
</tr>
<tr>
<td>Sagar V. Parikh, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Biovail Corporation; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutical Products; Wyeth Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>Lawrence T. Park, M.D.</td>
<td>Abbott Laboratories, Inc.; Bristol-Myers Squibb Company; Janssen Pharmaceutical Products, LP</td>
</tr>
<tr>
<td>Joseph J. Parks</td>
<td>Abbott Laboratories, Inc.; Comprehensive Neurosciences Incorporated; Medical Letters and Sciences</td>
</tr>
<tr>
<td>Amita R. Patel, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Sanofi-Aventis; Takeda Pharmaceuticals America; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Martin P. Paulus, M.D.</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Roy H. Perlis, Ph.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.</td>
</tr>
<tr>
<td>Eric D. Peselow, M.D.</td>
<td>Forest Laboratories, Inc.; GlaxoSmithKline; Pfizer Inc.</td>
</tr>
<tr>
<td>Francois C. Petitjean, M.D.</td>
<td>Bristol-Myers Squibb Company; Janssen-Cilag; Sanofi-Aventis</td>
</tr>
<tr>
<td>Barbara A. Phillips, M.D.</td>
<td>Boehringer-Ingelheim Pharmaceuticals; GlaxoSmithKline</td>
</tr>
<tr>
<td>Katharine A. Phillips, M.D.</td>
<td>American Psychiatric Press; Forest Laboratories, Inc.; National Institute of Mental Health; UCB Pharma</td>
</tr>
<tr>
<td>Edmond H. Pi, M.D.</td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Harold A. Pincus, M.D.</td>
<td>Academy of Managed Care Pharmacy (AMCP) Horizons, LLC; American Psychiatric Press; Atlantic Philanthropies; Bimark Medical Education; Cardinal Health, Inc.; Cisco Systems; Columbia University; Community Care Behavioral Health Organization/UPMC Health Plan; Comprehensive Neuroscience, Inc.; Medical Information Technologies; Current Opinion in Psychiatry/Lipinski, William and Wilkins; National Institute of Child Health and Human Development; National Institute of Mental Health; National Institute on Drug Abuse; New York Presbyterian Hospital; RAND Corporation; Raymond John Wean Foundation; Substance Abuse and Mental Health Services Administration/Center for Substance Abuse Treatment; The Heinz Endowments; The John A. Hartford Foundation; The Robert Wood Johnson Foundation; Veterans Administration</td>
</tr>
<tr>
<td>Mark H. Pollack, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutical Products; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; National Institute on Drug Abuse; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi-Aventis; Sepracor, Inc.; UCB Pharma; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Bruce G. Pollock, M.D.</td>
<td>Forest Laboratories, Inc.; Janssen Pharmaceutical Products, LP; Lundbeck; National Institute of Mental Health</td>
</tr>
<tr>
<td>Marc N. Potenza, M.D.</td>
<td>Gerson Lehman Group; GlaxoSmithKline; National Institute of Alcohol Abuse and Alcoholism; National Institute of Child Health and Human Development; National Institute of Neurological Disorders and Stroke; National Institute on Drug Abuse; NIH Institute; Somaxon Pharmaceuticals</td>
</tr>
<tr>
<td>Annelle B. Primm, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Pfizer Inc.</td>
</tr>
<tr>
<td>Andres J. Purnatiega, M.D.</td>
<td>Eli Lilly and Company; Forest Laboratories, Inc.</td>
</tr>
<tr>
<td>Paul M. Ramirez, Ph.D.</td>
<td>Multi-Health Systems, Inc.</td>
</tr>
</tbody>
</table>

XXXI
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark H. Rapaport, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; BrainCells, Inc.; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutical Products, LP; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; National Institute on Drug Abuse; Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmacia &amp; Upjohn; Roche Pharmaceuticals; Sanofi-Aventis; Solvay Pharmaceuticals, Inc.; Stanley Medical Research Institute; Sumitomo Pharmaceuticals Co., Ltd; UCB Pharma; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Natalia L. Rasgon, M.Ed.</td>
<td>Abbott Laboratories, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Lawrence P. Reagan, Ph.D.</td>
<td>Servier</td>
</tr>
<tr>
<td>John A. Renner, M.D.</td>
<td>Alkermes, Inc.; Cephalon, Inc.; Johnson &amp; Johnson; Reckitt-Benckiser; Shire Pharmaceuticals Group plc.</td>
</tr>
<tr>
<td>Perry F. Renshaw, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Kyowa Hakko; Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>Roy O. Resnikoff, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Pfizer Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Victor I. Reus, M.D.</td>
<td>Nabi Pharmaceuticals</td>
</tr>
<tr>
<td>Charles F. Reynolds, M.D.</td>
<td>Forest Laboratories, Inc.</td>
</tr>
<tr>
<td>Michelle B. Riba, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.</td>
</tr>
<tr>
<td>Steven Richeimer, M.D.</td>
<td>Merek &amp; Co., Inc.; Pfizer Inc.; Purdue Pharma LP</td>
</tr>
<tr>
<td>Elliott Richelson, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutical Products, LP; Neurontics, Inc.; Pfizer Inc.; Sanofi-Aventis; Somax Pharmaceuticals</td>
</tr>
<tr>
<td>Paula D. Riggs, M.D.</td>
<td>Eli Lilly and Company; McNeil Consumer Healthcare; National Institute on Drug Abuse; Shire Pharmaceuticals Group plc.</td>
</tr>
<tr>
<td>Trevor Robbins, Ph.D.</td>
<td>CeNeS Pharmaceuticals; Cephalon, Inc.; Cortex Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.; Roche Pharmaceuticals</td>
</tr>
<tr>
<td>Delbert G. Robinson, M.D.</td>
<td>Bristol-Myers Squibb Company; Janssen Pharmaceutical Products, LP</td>
</tr>
<tr>
<td>Robert G. Robinson, M.D.</td>
<td>Avanir Pharmaceuticals</td>
</tr>
<tr>
<td>Steven P. Roose, M.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Jerrold F. Rosenbaum</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc.; Pfizer Inc.; Roche Pharmaceuticals; Sanofi-Aventis; Sepacor, Inc.</td>
</tr>
<tr>
<td>Cherise Rosen, Ph.D.</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>Robert Rosenheck, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Janssen Pharmaceutical Products, LP; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>A. John Rush, M.D.</td>
<td>Advanced Neuromodulation Systems, Inc.; Best Practice Project Management, Inc.; Bristol-Myers Squibb Company; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; Gerson Lehman Group; GlaxoSmithKline; Guilford Publications; Healthcare Technology Systems, Inc.; Jazz Pharmaceuticals, Inc.; Merek &amp; Co., Inc.; National Institute of Mental Health; Neurontics, Inc.; NIH Institute; Novartis Pharmaceuticals Corporation; Ono Pharmaceuticals, Inc.; Organon Pharmaceuticals Inc.; Personality Disorder Research Corporation; Pfizer Inc.; Robert Wood Johnson Foundation; Stanley Medical Research Institute; Urban Institute; Wyeth Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
</tr>
<tr>
<td>Deirdre M. Ryan, F.R.C.P.C.</td>
<td>Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Abe M. Rychlik, J.D.</td>
<td>Professional Risk Management Services, Inc.</td>
</tr>
<tr>
<td>Perminder Sachdev, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Pfizer Inc.</td>
</tr>
<tr>
<td>Gary S. Sachs, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutical Products, LP; Memory Pharmaceuticals; Merek &amp; Co., Inc.; Merck, Sharp, and Dohme; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Sanofi-Aventis; Shire Pharmaceuticals Group plc.; Stanley Medical Research Institute; Wyeth Pharmaceuticals; Alkermes, Inc.; AstraZeneca Pharmaceuticals LP; Cephalon, Inc.; Drug Abuse Sciences, Inc.; Forest Laboratories, Inc.; Lipha Pharma; Ortho-McNeil Pharmaceutical, Inc.; Oy Contra Pharma</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Jitendar Sareen, M.D.</td>
<td>GlaxoSmithKline&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Norman H. Sartorius, M.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;1,3&lt;/sup&gt;; Janssen-Cilag&lt;sup&gt;1&lt;/sup&gt;; Lilly&lt;sup&gt;1&lt;/sup&gt;; Lundbeck&lt;sup&gt;1&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ayal Schaffer, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;1,2,5&lt;/sup&gt;; Biovail Corporation&lt;sup&gt;2&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,2,5&lt;/sup&gt;; H. Lundbeck A/S&lt;sup&gt;5&lt;/sup&gt;; Sanofi-Aventis&lt;sup&gt;5&lt;/sup&gt;; Servier&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Alan F. Schatzberg, M.D.</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;1&lt;/sup&gt;; Aventis Pharmaceuticals, Inc.&lt;sup&gt;1&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;1,2&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,2,3&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;2,5&lt;/sup&gt;; Innapharma, Inc.&lt;sup&gt;1&lt;/sup&gt;; Janssen Pharmaceutica Products, LP&lt;sup&gt;1,3&lt;/sup&gt;; Neurones, Inc.&lt;sup&gt;1&lt;/sup&gt;; Organon Pharmaceuticals Inc.&lt;sup&gt;1&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,5&lt;/sup&gt;; Somaxon Pharmaceuticals&lt;sup&gt;1,3&lt;/sup&gt;; Somerset Pharmaceuticals Inc.&lt;sup&gt;1,2&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1,3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Thomas Schlaper</td>
<td>Cyberonics, Inc.&lt;sup&gt;1&lt;/sup&gt;; Medtronics, Inc.&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lon S. Schneider, M.D.</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; AstraZeneca Pharmaceuticals LP&lt;sup&gt;1,2,5&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;1,2&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3,5&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1,2&lt;/sup&gt;; Johnson and Johnson Pharmaceutical Research and Development&lt;sup&gt;1,5&lt;/sup&gt;; Lundbeck&lt;sup&gt;1&lt;/sup&gt;; Myriad Genetics, Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Novartis Pharmaceuticals Corporation&lt;sup&gt;1,2&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,5&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Nina R. Schooler, Ph.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;1&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;1,3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1&lt;/sup&gt;; Janssen Pharmaceutica Products, LP&lt;sup&gt;1,3&lt;/sup&gt;; Merck &amp; Co., Inc.&lt;sup&gt;1&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;1&lt;/sup&gt;; National Institute on Drug Abuse&lt;sup&gt;1&lt;/sup&gt;; Organon Pharmaceuticals Inc.&lt;sup&gt;1&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,5&lt;/sup&gt;; Vanda Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>S. Charles Schulz, M.D.</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;3&lt;/sup&gt;; AstraZeneca Pharmaceuticals LP&lt;sup&gt;1,3,5&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3,5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gary J. Schummer, Ph.D.</td>
<td>A.D.D. Treatment Centers&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Michael A. Schwartz, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;1,3,5&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;1,3,5&lt;/sup&gt;; Cephalon, Inc.&lt;sup&gt;3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3,5&lt;/sup&gt;; Janssen Pharmaceutica Products, LP&lt;sup&gt;1,3&lt;/sup&gt;; Johnson and Johnson Pharmaceutical Research and Development&lt;sup&gt;1&lt;/sup&gt;; Takeda Pharmaceuticals America, Inc.&lt;sup&gt;3&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Thomas L. Schwartz, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;3&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;1,3,5&lt;/sup&gt;; Cephalon, Inc.&lt;sup&gt;3,5&lt;/sup&gt;; Cyberonics, Inc.&lt;sup&gt;3,5&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;3&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;3,5&lt;/sup&gt;; Jazz Pharmaceuticals, Inc.&lt;sup&gt;3,5&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;3,5&lt;/sup&gt;; Sanofi-Aventis&lt;sup&gt;5&lt;/sup&gt;; Takeda Pharmaceuticals America, Inc.&lt;sup&gt;3&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;3,5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Jan L. Scott, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;3,5&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;3,5&lt;/sup&gt;; Janssen-Cilag&lt;sup&gt;3&lt;/sup&gt;; Otsuka America Pharmaceutical, Inc.&lt;sup&gt;3&lt;/sup&gt;; Sanofi-Aventis&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>David S. Shannahoff-Khalsa</td>
<td>W.W. Norton &amp; Co., Inc.&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Zafar Sharif, M.D.</td>
<td>Bristol-Myers Squibb Company&lt;sup&gt;5&lt;/sup&gt;; Janssen Pharmaceutica Products, LP&lt;sup&gt;5&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;5&lt;/sup&gt;; Janssen Pharmaceutica Products, LP&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>M. Katherine Shear, M.D.</td>
<td>Forest Laboratories, Inc.&lt;sup&gt;3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>David V. Sheehan, M.D.</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; Alexza MDC&lt;sup&gt;1&lt;/sup&gt;; AstraZeneca Pharmaceuticals LP&lt;sup&gt;1,3,5&lt;/sup&gt;; Avera Pharmaceuticals, Inc.&lt;sup&gt;1&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;1,3,5&lt;/sup&gt;; Cephalon, Inc.&lt;sup&gt;3&lt;/sup&gt;; Cortex Pharmaceuticals, Inc.&lt;sup&gt;1&lt;/sup&gt;; Cypress Bioscience Inc.&lt;sup&gt;1&lt;/sup&gt;; Eisai Inc.&lt;sup&gt;1&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3,5&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1,3,5&lt;/sup&gt;; Janssen Pharmaceutica Products, LP&lt;sup&gt;1,3,5&lt;/sup&gt;; Jazz Pharmaceuticals, Inc.&lt;sup&gt;1&lt;/sup&gt;; Layton Biosciences, Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; Mead Johnson&lt;sup&gt;1,3,5&lt;/sup&gt;; Medical Outcome Systems, Inc.&lt;sup&gt;3&lt;/sup&gt;; Merck &amp; Co., Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; Novartis Pharmaceuticals Corporation&lt;sup&gt;2&lt;/sup&gt;; Novo Nordisk Pharmaceuticals, Inc.&lt;sup&gt;3,5&lt;/sup&gt;; Organon Pharmaceuticals Inc.&lt;sup&gt;1,5&lt;/sup&gt;; Ortho-McNeil Pharmaceutical, Inc.&lt;sup&gt;5&lt;/sup&gt;; Parke-Davis&lt;sup&gt;3,5&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; Pharmacia &amp; Upjohn&lt;sup&gt;1,5&lt;/sup&gt;; Roche Pharmaceuticals&lt;sup&gt;1,3,5&lt;/sup&gt;; Sanofi-Aventis&lt;sup&gt;1&lt;/sup&gt;; Schering Plough Corporation&lt;sup&gt;3&lt;/sup&gt;; Shire Pharmaceuticals Group plc.&lt;sup&gt;3&lt;/sup&gt;; Solvay Pharmaceuticals, Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; TAP Pharmaceuticals, Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; Warner Chilcott PLC&lt;sup&gt;3,5&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;3,5&lt;/sup&gt;; ZARS Pharma&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Richard C. Shelton</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;3,5&lt;/sup&gt;; AstraZeneca Pharmaceuticals LP&lt;sup&gt;3&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;5&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;3,5&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;3,5&lt;/sup&gt;; Janssen Pharmaceutica Products, LP&lt;sup&gt;1,3,5&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; Sanofi-Aventis&lt;sup&gt;3,5&lt;/sup&gt;; Solvay Pharmaceuticals, Inc.&lt;sup&gt;1,3,5&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;3,5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Larry J. Siever, M.Ed.</td>
<td>Eli Lilly and Company&lt;sup&gt;1,3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Daphne Simeon, M.D.</td>
<td>National Institute of Health&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gregory E. Simon, M.D.</td>
<td>Bristol-Myers Squibb Company&lt;sup&gt;1&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Naomi M. Simon, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;3&lt;/sup&gt;; Cephalon, Inc.&lt;sup&gt;3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;3&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;3&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;3&lt;/sup&gt;; Janssen Pharmaceutica Products, LP&lt;sup&gt;3&lt;/sup&gt;; National Alliance for Research in Schizophrenia and Depression&lt;sup&gt;3&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;3,5&lt;/sup&gt;; Sepcator, Inc.&lt;sup&gt;3&lt;/sup&gt;; UCB Pharma&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Kelly H. Skelton, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;5&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Andrew E. Skodol, M.D.</td>
<td>National Institute of Mental Health&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gary W. Small</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;1,5&lt;/sup&gt;; Brainstorming Co.&lt;sup&gt;1&lt;/sup&gt;; Dakim&lt;sup&gt;1,5&lt;/sup&gt;; Eisai Inc.&lt;sup&gt;1,5&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1,5&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;5&lt;/sup&gt;; Memory Fitness Institute&lt;sup&gt;1,5&lt;/sup&gt;; Myriad Genetics, Inc.&lt;sup&gt;1,5&lt;/sup&gt;; Novartis Pharmaceuticals Corporation&lt;sup&gt;1,5&lt;/sup&gt;; Ortho-McNeil Pharmaceutical, Inc.&lt;sup&gt;1,5&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,5&lt;/sup&gt;; Siemens&lt;sup&gt;1,4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Thomas E. Smith, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;5&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3&lt;/sup&gt;; Janssen Pharmaceutica Products, LP&lt;sup&gt;1,5&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Joyce C. West, Ph.D.</td>
<td>AstraZeneca Pharmaceuticals LP²; Bristol-Myers Squibb Company³; Eli Lilly and Company³; Janssen Pharmacy Products, LP³; National Institute of Mental Health³; Substance Abuse and Mental Health Services Administration / Center for Substance Abuse Treatment³; Wyeth Pharmaceuticals³</td>
</tr>
<tr>
<td>Timothy E. Wilens, M.D.</td>
<td>Abbott Laboratories, Inc.¹; Eli Lilly and Company⁵; GlaxoSmithKline¹; Janssen Pharmaceutical Products, LP¹; National Institute of Mental Health¹; National Institute on Drug Abuse¹; NeuroSearch A/S¹; Novartis Pharmaceuticals Corporation¹; Ortho-McNeil Pharmaceutical, Inc.²; Pfizer Inc.¹; Saegis¹; Sanofi-Aventis¹; Shire Pharmaceuticals Group plc.¹,²,³,⁵</td>
</tr>
<tr>
<td>Jeffery N. Wilkins, M.D.</td>
<td>Alkermes, Inc.¹;²; CME LLC¹; Forest Laboratories, Inc.¹; Hythiam Inc.¹,²</td>
</tr>
<tr>
<td>Janet B.W. Williams, D.S.W.</td>
<td>American Psychiatric Press¹; Columbia University²; MedAvante, Inc.¹</td>
</tr>
<tr>
<td>Solomon S. Williams, M.D.</td>
<td>Boehringer-Ingelheim Pharmaceuticals²</td>
</tr>
<tr>
<td>M.E. Jan Wise, M.B.Ch.B.</td>
<td>Bristol-Myers Squibb Company⁵; Eli Lilly and Company⁵</td>
</tr>
<tr>
<td>Thomas N. Wise, M.D.</td>
<td>Eli Lilly and Company⁵</td>
</tr>
<tr>
<td>Jesse H. Wright III, M.D.</td>
<td>Mindstreet⁴; Pfizer, GlaxoSmithKline⁵</td>
</tr>
<tr>
<td>Aysegul Yildiz-Yesiloglu, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP¹; GlaxoSmithKline¹; Janssen-Cilag¹; Pfizer Inc.³</td>
</tr>
<tr>
<td>Monique Yohonan, M.D.</td>
<td>Elan Pharmaceuticals, Inc.⁴; Johnson and Johnson Pharmaceutical Research and Development⁶</td>
</tr>
<tr>
<td>M. Scott Young, Ph.D.</td>
<td>Eli Lilly and Company³</td>
</tr>
<tr>
<td>Mary C. Zanarini, Ed.D.</td>
<td>Eli Lilly and Company¹,²</td>
</tr>
<tr>
<td>Phyllis C. Zee, M.D.</td>
<td>Kyowa Pharmaceuticals⁴; Neurocrine Biosciences Inc.¹; Pfizer Inc.¹; Sanofi-Aventis¹; Takeda Pharmaceuticals America, Inc.¹,²,³</td>
</tr>
<tr>
<td>Mark Zimmerman, M.D.</td>
<td>Bristol-Myers Squibb Company³; GlaxoSmithKline³; Wyeth Pharmaceuticals³</td>
</tr>
<tr>
<td>Sidney Zisook, M.D.</td>
<td>Aspect Medical Systems²; Forest Laboratories, Inc.²; GlaxoSmithKline¹,²; National Alliance for Research in Schizophrenia and Depression³; National Institute of Health³; National Institute of Mental Health³; PamLab³</td>
</tr>
<tr>
<td>Joseph Zohar, M.D.</td>
<td>Lundbeck³; Pfizer Inc.³</td>
</tr>
<tr>
<td>Edward Zuzarte, M.D.</td>
<td>Pfizer Inc.⁵</td>
</tr>
</tbody>
</table>
DISCLOSURE INDEX

Pascale Abadie, M.D.
Amina Abhalla, M.D.
Karen M. Abrams, M.D.
Beth L. Abramson, M.D.
Ronald Abramson, M.D.
Neal H. Adams, M.D.
Dominick Addario, M.D.
Lawrence W. Adler, M.D.
Leonard A. Adler, M.D.
Anna M. Agoston, B.A.
Sergio Aguilar-Gaxiolo, M.D.
Abdulhaghi Ahmad, Ph.D.
Isqabal Ahmad, M.D.
Dov Aizenberg, M.D.
Dhatt Ajinder, M.D.
Tsuyoshi Akiyama, M.D.
Soren Akselsen, M.D.
Faouri Alam, M.D.
Renato D. Alarcon, M.D.
Ian E. Alger, M.D.
Yesne Alici-Evitsmen, M.D.
Farhana Ali, M.A.
Andrea Allen, Ph.D.
Hanan Alraeesi
Mona H. Al-Sawaf, M.D.
Sharon L.A. Mozian, M.D.
Steven I. Altschuler, M.D.
Evdokia Anagnostou, M.D.
Allan A. Anderson, M.D.
Naleen N. Andrade, M.D.
Nancy C. Andreasen, M.D.
Linda B. Andrews, M.D.
Jason Andrus, M.D.
Luiz M. Anrea, Psy.D.
Emily Ansell, Ph.D.
Francesca C. Antognini, Ph.D.
Joan M. Anzua, M.D.
Paul S. Appelbaum, M.D.
Alan Apter, M.D.
Gisele Ayser, M.D.
Julio E. Arboleda-Flores, Ph.D.
Britton A. Arey, M.D.
Albert J. Arias, M.D.
Amnon Aronstam, M.D.
Sanjay Arora, Ph.D.
William Arroyo, M.D.
Nadja Arslan, M.D.
Lori Ascherfi, Psy.D.
Kenneth Ashley, M.D.
Peter Ash, M.D.
Anu Asmaani
Robert W. Atkins, M.D.
R. Robert Auger, M.D.
Lana I. August, M.D.
Ron Aviram, Ph.D.
Mary Anne Badaczko, M.D.
Ursula F. Baker, M.D.
Rahn K. Bailey, M.D.
Sue Bailey, M.D.
Brian Baker, M.D.
Mina Bal, M.D.
Anton van Balkom, Ph.D.
Bruce Ballon, M.D.
Axviza O. Bankole, M.D.
Yoram Barak, M.D.
Howard E. Barbee, Ph.D.
Russell Barlow, Ph.D.
Nigel Barlow, M.D.
Sergio Baroni, Ph.D.
Christina S. Barrett, Ph.D.
Ellen F. Barz, L.S.C.W.
Thomas B. Basset, M.D.
Ruth A. Barton, M.D.
Declan Barry, Ph.D.
Selena Bartlett, Ph.D.
Jennifer Barz, Ph.D.
Yehuda Baruch, M.D.
Monica R. Basco, Ph.D.
Anthony Barenman, M.D.
Dorothy Bates, M.D.
Eraka Bath, M.D.
Mark S. Bauer, M.D.
Michael Bauer, M.D.
Antonia L. Baum, M.D.
Elizabeth A. Baxter, M.D.
Andreas Bechholm, M.D.
Daniel F. Becker, M.D.
Deborah R. Becker, M.A.
Judith V. Becker, Ph.D.
Judith S. Beck, Ph.D.
Alan R. Beecher, M.D.
Denis B. Becdile, M.D.
Aarjan T.F. Beekman
Leo Beem
Edgard Belfort, M.D.
Aysenel Belger
Morris D. Bell, Ph.D.
James D. Bellazzini, Ph.D.
Elissa P. Beneceik, M.D.
Michael Berkt
Heather Berlin, Ph.D.
Jason Bernek, M.D.
Silvia Bernardi, M.D.
Carol A. Bernstein, M.D.
David P. Bernstein, Ph.D.
Shyam K. Bhat, M.D.
Anjan Bhattacharyya, M.D.
Sarath Bellavite
O. Joseph Bienvenu, M.D.
Gretchin Biesecker, Ph.D.
Stephen B. Billick, M.D.
Renee L. Binder, M.D.
Aurelia N. Bizanter, M.D.
Paul Bizouard
Jeff E. Black, M.D.
John L. Black, M.D.
Karen Blatik, M.D.
Mel Blaustein, M.D.
Dan Blazer, M.D.
Avi Bleich, M.D.
Hy Bloom, M.D.
Michael Blumenfeld, M.D.
Nannce Blum, M.S.W.
Daniel J. Bober, D.O.
Daniel A. Boonsie, M.D.
Kimberley Bogan
Radiniga Bogulnisch, M.A.
Olivera J. Bogunovic, M.D.
Martin Bohus, M.D.
Vladimir Bokalis, M.D., Ph.D.
Robert J. Boland, M.D.
Nicolas R. Boloo, Ph.D.
Antonello Bonci, M.D.
Dorret J. Bongers, Ph.D.
Andrew Borys, M.D.
Nicolete Borel, Ph.D.
Ninnaat N. Bouros, M.D.
Kimberly A. Bouwer, M.D.
Thetan C. Bowles, Jr., M.D.
John M. Bradford, F.R.C.P.C.
Douglas Brau-Harvey, M.A.
Parrell H. Brazil, M.D.
Joel Brogman, M.D.
David H. Brendel, M.D.
Adam M. Brenner, M.D.
Jessica L. Broadway, M.D.
Thomas M. Brod, M.D.
Elizabeth Bromeley, M.D.
Beth A. Brooks, M.D.
Richard P. Brown, M.D.
Travis O. Bruce, M.D.
William Bruce
Nancy B. Wallis, Ph.D.
Richard Buccigross
Alec Buchanan, M.D.
Gary T. Buckholz, M.D.
Peter J. Buckley, M.D.
Dinesh Bughra, Ph.D.
Viet Bui, M.D.
Ed T. Bulimore, M.D.
Clayton M. Bullock, M.D.
Ronald M. Burd, M.D.
Tracee Burroughs, M.D.
Harold J. Bursztajn, M.D.
Rami T. Bustami, Ph.D.
Fran Butler-Cohen, M.D.
Jeremy R. Butler, M.D.
Mirrat G. Butt, M.D.
Sarah Byford, Ph.D.
Robert P. Cabaj, M.D.
Claudio O. Cabrejos
Consuelo C. Cagande, M.D.
John Caine, Ph.D.
Norana Caiwano, M.D.
Charles F. Caley, Ph.D.
Eve Caligor, M.D.
Alvaro Camacho, M.D.
Enrique R. Camarena, M.D.
Herbert L. Campbell, M.D.
Niakia N. Campbell, M.D.
Ania E. Camo, M.D.
Olivier J. Caneel, Psy.D.
Angel A. Canale, M.D.
Robert Caudill, M.D.
Alex A. Cardoni, M.S.
Daniel J. Carlet, M.D.
Vladimir Carli, M.D.
Ian Carroll, M.D.
Matthew P. Carrillo, M.D.
Cameron Carter, M.D.
Bradly G. Case, M.D.
B.J. Carey, Ph.D.
Daniel Castellanos, M.D.
Mario Catena, M.D.
Samuel Chamberlain, Ph.D.
Frances A. Champagne, Ph.D.
Carlisle H. Chan, M.D.
Redmona K. Chandler, Ph.D.
Jacequyn Chang, M.D.
Daniel P. Chapman, Ph.D.
Dana Charles, B.A.
Irene Chatour, M.D.
Haroon R. Chaudhry, M.D.
Allison Chauser, Ph.D.
Iwana Chelminski, Ph.D.
H. Chen
Tai-Jui Chen, M.D.
Xianning Chen, Ph.D.
Amy H. Cheung, M.D.
Jeffrey Childers, M.D.
Anna R. Childress, Ph.D.
Austina Cho, M.D.
Wendy S. Chow, M.S.W.
Yujuan Choy, M.D.
Paul S. Ciechanowski, M.D.
Connie Clark, L.P.C.
David Clark, M.D.
Jennifer G. Clark, M.D.
John F. Clarkin, Ph.D.
Timothy F. Cloughesy, Ray E. Clouse, M.D.
Crisistn M. Coonee, M.D.
C. Edward Coffey, M.D.
Cari I. Cohen, M.D.
Lee S. Cohen, M.D.
Mary Ann Cohen, M.D.
Christopher C. Colenda, M.D.
Nora Cole, M.Ed.
Pamela Y. Collins, M.D.
Theodore M. Collins, Ph.D.
Wilson M. Compton, M.D.
Timothy Condon, Ph.D.
Robert R. Conley, M.D.
Kathryn Connor, M.D.
Kevin P. Conway, M.D.
Jana Cook
Andrew Cooper, B.S.C.
Arnold Cooper, M.D.
Gabriela Cera-Locatelli, M.D.
Cheryl M. Corcoran, M.D.
Jay Corcoran, M.D.
Maurice Corcos, M.D.
Vladimir Cortic, M.D.
Jack R. Connell, M.D.
Eduardo A. Correa, M.D.
Sara Corya, M.D.
Joan Cottier, M.S.W.
Francine Coumos, M.D.
Keith Courney, M.D.
Kathleen A. Crapanzano, M.D.
M. Cornelia Cremons, M.D.
Brian Crowley, M.D.
Bernadette Cullen, M.D.
Jennifer Cummings, M.D.
Dina Daskos, M.D.
Alain Dougé, M.D.

XXXVII
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven A. Epstein, M.D.</td>
<td></td>
</tr>
<tr>
<td>Monique Emes, M.D.</td>
<td></td>
</tr>
<tr>
<td>Javier I. Escolar, M.D.</td>
<td></td>
</tr>
<tr>
<td>Kimberly A. Espy, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Susan M. Essock, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Spencer Eth, M.D.</td>
<td></td>
</tr>
<tr>
<td>Amir E. Etnekal, M.D.</td>
<td></td>
</tr>
<tr>
<td>Karleton C. Evans, M.D.</td>
<td></td>
</tr>
<tr>
<td>William D. Evans, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Hanan Eweimeen, M.D.</td>
<td></td>
</tr>
<tr>
<td>George Everly, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Kelvin Exum, M.D.</td>
<td></td>
</tr>
<tr>
<td>Anthony Fabio, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Michele Fabrizio, M.D.</td>
<td></td>
</tr>
<tr>
<td>Nima A. Fahtian, M.D.</td>
<td></td>
</tr>
<tr>
<td>Rodolfo D. Fahrer, M.D.</td>
<td></td>
</tr>
<tr>
<td>Tatiana Falcone, M.D.</td>
<td></td>
</tr>
<tr>
<td>Bruno Falassard, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Jin Fan, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Ming-Yu Fan, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Amy H. Farabah, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Larry R. Faulkner, M.D.</td>
<td></td>
</tr>
<tr>
<td>Robert Faull, B.S.</td>
<td></td>
</tr>
<tr>
<td>Jan A. Fawcett, M.D.</td>
<td></td>
</tr>
<tr>
<td>John Fayad, M.D.</td>
<td></td>
</tr>
<tr>
<td>Jamie Feldman, M.D.</td>
<td></td>
</tr>
<tr>
<td>Theodore Feldmann, M.D.</td>
<td></td>
</tr>
<tr>
<td>Annyon Fernandez, M.D.</td>
<td></td>
</tr>
<tr>
<td>Stephen Ferrando</td>
<td></td>
</tr>
<tr>
<td>Frank D. Ferris, M.D.</td>
<td></td>
</tr>
<tr>
<td>Donald C. Fidler, M.D.</td>
<td></td>
</tr>
<tr>
<td>Robert Fish, M.D.</td>
<td></td>
</tr>
<tr>
<td>Michael B. First, M.D.</td>
<td></td>
</tr>
<tr>
<td>Lauren Fisher, B.A.</td>
<td></td>
</tr>
<tr>
<td>Joanna Finadon, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Paul Fitzgerald</td>
<td></td>
</tr>
<tr>
<td>Candace A. Fleming, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Heather L. Flett, M.D.</td>
<td></td>
</tr>
<tr>
<td>Chris Flood, M.S.C.</td>
<td></td>
</tr>
<tr>
<td>Julianna Flynn, M.D.</td>
<td></td>
</tr>
<tr>
<td>Laura J. Fochmann, M.D.</td>
<td></td>
</tr>
<tr>
<td>Perer Forany, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>William W. Foote, M.D.</td>
<td></td>
</tr>
<tr>
<td>Charles V. Ford, M.D.</td>
<td></td>
</tr>
<tr>
<td>Julian D. Ford, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Peter F. Fore, M.D.</td>
<td></td>
</tr>
<tr>
<td>Marshall Forstein, M.D.</td>
<td></td>
</tr>
<tr>
<td>Edward F. Foulks, M.D.</td>
<td></td>
</tr>
<tr>
<td>Joanna S. Fowler, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Andrew J. Francis, M.D.</td>
<td></td>
</tr>
<tr>
<td>Frances R. Frankenburg, M.D.</td>
<td></td>
</tr>
<tr>
<td>Ryan Franke, M.D.</td>
<td></td>
</tr>
<tr>
<td>Guido K. Frank, M.D.</td>
<td></td>
</tr>
<tr>
<td>Debra L. Franko, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Joseph Frascella, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Lisa Freedman, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Kenneth E. Freedland, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Rafael C. Freire, M.D.</td>
<td></td>
</tr>
<tr>
<td>Kenneth Freundlich, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Larry Fricks, M.D.</td>
<td></td>
</tr>
<tr>
<td>Peter D. Friedmann, M.D.</td>
<td></td>
</tr>
<tr>
<td>Rohn S. Friedman, M.D.</td>
<td></td>
</tr>
<tr>
<td>Susan H. Friedman, M.D.</td>
<td></td>
</tr>
<tr>
<td>Ronna Fried, M.D.</td>
<td></td>
</tr>
<tr>
<td>René Frydman, M.D.</td>
<td></td>
</tr>
<tr>
<td>Glen O. Gabbard, M.D.</td>
<td></td>
</tr>
<tr>
<td>Geoffrey M. Gabriel, M.D.</td>
<td></td>
</tr>
<tr>
<td>William F. Gabrielli Jr, M.D.</td>
<td></td>
</tr>
<tr>
<td>Wolfgang Gaeble, M.D.</td>
<td></td>
</tr>
<tr>
<td>Cheryl Gagne, Sc.D.</td>
<td></td>
</tr>
<tr>
<td>Marc Galanter, M.D.</td>
<td></td>
</tr>
<tr>
<td>Igor L. Galynker, M.D.</td>
<td></td>
</tr>
<tr>
<td>Krauz Ganadjian</td>
<td></td>
</tr>
<tr>
<td>B.N. Gangadhar, M.D.</td>
<td></td>
</tr>
<tr>
<td>Rohan Ganguli, M.D.</td>
<td></td>
</tr>
<tr>
<td>Stephen J. Ganoczy, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Daniel Garza, M.D.</td>
<td></td>
</tr>
<tr>
<td>Tanara L. Gay, M.D.</td>
<td></td>
</tr>
<tr>
<td>Jeffrey L. Geller, M.D.</td>
<td></td>
</tr>
<tr>
<td>Patricia L. Gerbarg, M.D.</td>
<td></td>
</tr>
<tr>
<td>John A. Gerzen, M.D.</td>
<td></td>
</tr>
<tr>
<td>Elizabeth V. Getter, M.D.</td>
<td></td>
</tr>
<tr>
<td>Kayhan Ghazvani, M.D.</td>
<td></td>
</tr>
<tr>
<td>Hamid Ghodse, M.D.</td>
<td></td>
</tr>
<tr>
<td>Ludovic Gieopec, M.D.</td>
<td></td>
</tr>
<tr>
<td>David A. Gilder, M.D.</td>
<td></td>
</tr>
<tr>
<td>David F. Gitlin, M.D.</td>
<td></td>
</tr>
<tr>
<td>Penny Glass, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Eric Glessner, L.C.S.W.</td>
<td></td>
</tr>
<tr>
<td>William Gnaim, M.D.</td>
<td></td>
</tr>
<tr>
<td>John Godsjeaun, R.N.</td>
<td></td>
</tr>
<tr>
<td>James Goertzen, M.D.</td>
<td></td>
</tr>
<tr>
<td>John W. Goethe, M.D.</td>
<td></td>
</tr>
<tr>
<td>R. Rago Goginitni, M.D.</td>
<td></td>
</tr>
<tr>
<td>Jessica Goen, M.D.</td>
<td></td>
</tr>
<tr>
<td>Robert M. Goldstein, M.D.</td>
<td></td>
</tr>
<tr>
<td>David A. Goldberg, M.D.</td>
<td></td>
</tr>
<tr>
<td>Lisa H. Gold, M.D.</td>
<td></td>
</tr>
<tr>
<td>Michael Goldstein, M.D.</td>
<td></td>
</tr>
<tr>
<td>Joni J. Gonzales, M.D.</td>
<td></td>
</tr>
<tr>
<td>Jose L. Gonzalez de Rivera, M.D.</td>
<td></td>
</tr>
<tr>
<td>Gerardo Gonzalez, M.D.</td>
<td></td>
</tr>
<tr>
<td>Jodi M. Gonzalez, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Francisco Gonzalez-Lima, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Karl Goodkin, M.D.</td>
<td></td>
</tr>
<tr>
<td>Marianne S. Goodman, M.D.</td>
<td></td>
</tr>
<tr>
<td>Mary Jo Good, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Randy B. Goosen, F.R.C.P.C.</td>
<td></td>
</tr>
<tr>
<td>Edward Gordon, M.D.</td>
<td></td>
</tr>
<tr>
<td>Tracy R. Gordy, M.D.</td>
<td></td>
</tr>
<tr>
<td>Bonnie Gosseck</td>
<td></td>
</tr>
<tr>
<td>Diane B. Gottlieb, M.D.</td>
<td></td>
</tr>
<tr>
<td>Marco Grados, M.D.</td>
<td></td>
</tr>
<tr>
<td>Tana A. Grady-Welkly, M.D.</td>
<td></td>
</tr>
<tr>
<td>Robert P. Granacher, M.D.</td>
<td></td>
</tr>
<tr>
<td>Steven J. Grant, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Kevin F. Gray, M.D.</td>
<td></td>
</tr>
<tr>
<td>Laureen Gray, M.S.N.</td>
<td></td>
</tr>
<tr>
<td>Roger P. Greenberg, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Melva I. Green, M.D.</td>
<td></td>
</tr>
<tr>
<td>Michael F. Green, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Stephen A. Green, M.D.</td>
<td></td>
</tr>
<tr>
<td>Carl B. Greiner, M.D.</td>
<td></td>
</tr>
<tr>
<td>Denise Grethen-Doory, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Seena S. Grewel, M.D.</td>
<td></td>
</tr>
<tr>
<td>Daula A. Griffin, M.D.</td>
<td></td>
</tr>
<tr>
<td>Edmund Griffin, M.D.</td>
<td></td>
</tr>
<tr>
<td>James L. Griffith, M.D.</td>
<td></td>
</tr>
<tr>
<td>Roland R. Griffiths, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Carlos M. Grilo, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Charles S. Grob, M.D.</td>
<td></td>
</tr>
<tr>
<td>Bernadette M. Grosjean, M.D.</td>
<td></td>
</tr>
<tr>
<td>Cornelius T. Gross, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Theresa Guarnini, R.N.</td>
<td></td>
</tr>
<tr>
<td>Jon F. Godeman, M.D.</td>
<td></td>
</tr>
<tr>
<td>Rachel G. Guererro, M.S.W.</td>
<td></td>
</tr>
<tr>
<td>Marie-Claued Guerin</td>
<td></td>
</tr>
<tr>
<td>Salvador M. Guinjoa, M.D.</td>
<td></td>
</tr>
<tr>
<td>John G. Gundezen, M.D.</td>
<td></td>
</tr>
<tr>
<td>Dipak K. Gupta, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Nitin Gupta, M.D.</td>
<td></td>
</tr>
<tr>
<td>Thomas G. Gutheil, M.D.</td>
<td></td>
</tr>
<tr>
<td>Sheila H. Gray, M.D.</td>
<td></td>
</tr>
<tr>
<td>John M. Haggarty, M.D.</td>
<td></td>
</tr>
<tr>
<td>Deborah J. Hailes, M.D.</td>
<td></td>
</tr>
<tr>
<td>Gen R. Hall, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Katherine A. Halni, M.D.</td>
<td></td>
</tr>
<tr>
<td>James P. Halper, M.D.</td>
<td></td>
</tr>
<tr>
<td>Scott D. Haltman</td>
<td></td>
</tr>
<tr>
<td>Stephanie Hammarman, M.D.</td>
<td></td>
</tr>
<tr>
<td>Ann Hamer, Pharm.D.</td>
<td></td>
</tr>
<tr>
<td>Roy H. Hamilton, M.D.</td>
<td></td>
</tr>
<tr>
<td>Tom Hamilton, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Paul G. Hammersness, M.D.</td>
<td></td>
</tr>
<tr>
<td>Judith Hampel, R.N.</td>
<td></td>
</tr>
<tr>
<td>Edward Harin, M.D.</td>
<td></td>
</tr>
<tr>
<td>William F. Harlee (II), M.D.</td>
<td></td>
</tr>
<tr>
<td>Richard K. Harding, M.D.</td>
<td></td>
</tr>
<tr>
<td>Larry J. Harmon, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Ausa M. Hazou, M.D.</td>
<td></td>
</tr>
<tr>
<td>Elizabeth Harre, M.D.</td>
<td></td>
</tr>
<tr>
<td>Alexandria M. Harrison, M.D.</td>
<td></td>
</tr>
<tr>
<td>Toi B. Harris, M.D.</td>
<td></td>
</tr>
<tr>
<td>David E. Harrman, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Lawrence Harmann, M.D.</td>
<td></td>
</tr>
<tr>
<td>Nael M. Hassan, M.B.Ch.B</td>
<td></td>
</tr>
<tr>
<td>Susan J. Harners-Friedman, M.D.</td>
<td></td>
</tr>
<tr>
<td>Shikumurti S. Hari, M.D.</td>
<td></td>
</tr>
<tr>
<td>Dan Haupt, M.D.</td>
<td></td>
</tr>
<tr>
<td>Peter Hausel, M.D.</td>
<td></td>
</tr>
<tr>
<td>Rochelle Head-Dunham, M.D.</td>
<td></td>
</tr>
<tr>
<td>Timothy Heerten, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Markus Heilig, M.D.</td>
<td></td>
</tr>
<tr>
<td>Claire Henderson, M.D.</td>
<td></td>
</tr>
<tr>
<td>Grace Hennessy, M.D.</td>
<td></td>
</tr>
<tr>
<td>Brian M. Hepburn, M.D.</td>
<td></td>
</tr>
<tr>
<td>Laurel H. Herbst, M.D.</td>
<td></td>
</tr>
<tr>
<td>Alison M. Heru, M.D.</td>
<td></td>
</tr>
<tr>
<td>Alfred Herzog, M.D.</td>
<td></td>
</tr>
<tr>
<td>David B. Herzog</td>
<td></td>
</tr>
<tr>
<td>Victor Hesseltock, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Rosario Hidalgo</td>
<td></td>
</tr>
<tr>
<td>Napoleon B. Higgins Jr, M.D.</td>
<td></td>
</tr>
<tr>
<td>Mike Hill</td>
<td></td>
</tr>
<tr>
<td>Donald M. Hilty, M.D.</td>
<td></td>
</tr>
<tr>
<td>John Kevin Hines</td>
<td></td>
</tr>
<tr>
<td>Alan R. Hirsch, M.D.</td>
<td></td>
</tr>
<tr>
<td>Hans W. Hoek, M.D.</td>
<td></td>
</tr>
<tr>
<td>Steven K. Hoge, M.D.</td>
<td></td>
</tr>
<tr>
<td>Gavi Hollander, D.O.</td>
<td></td>
</tr>
<tr>
<td>Sheila C. Hollins, M.B.</td>
<td></td>
</tr>
</tbody>
</table>
DISCLOSE INDEX

Yantao Ma, M.D.
Richard Mayeux, M.D.
Bernard Mazoyer, M.D.
Patrick S. Mbaya
Benton McFarland, M.D.
Thomas W. McAllister
Una D. McCaon
Tracey H. McCarthy, M.D.
Diane McDermid
David M. McDowell
Shunda McGhee, M.D.
Michael D. McGee, M.D.
Paul R. McGrath, M.D.
J.M. McIntosh
Jack S. McIntyre, M.D.
Tammy F. McKinnon, M.S.W.
Alexandra B. McLean, M.D.
Shelley McMain, Ph.D.
Nancy L. McNaughton, Ed.M.
Laura McNicholas
Roger L. McRoberts
Maria E. Medina-Mora
Sarnoff Mednick, Ph.D.
David Mee-Lee, M.D.
Nadine Melhem, Ph.D.
Cesar Mella Mejias
Lisa Meller, M.D.
J. Reid Meloy, Ph.D.
Reid Meloy, Ph.D.
Carolyn C. Melzer, M.D.
Cathy Melvin, Ph.D.
W. Finnur Mencel, Ph.D.
Anita Menon, R.N.
Lara Menzies
Michael Menger, Pharm.D.
Philip Mendelsohn, M.D.
Kathleen R. Merikangas, Ph.D.
Joseph P. Meltzer, M.D.
Robert O. Messing, M.D.
Donald J. Meyer, M.D.
Andreas Meyer-Lindenberg, M.D.
Adam L. Meyers
Marco A. Mezzasalma, M.D.
Danni Michaeli, M.D.
Thomas Mick, M.D.
Christel M. Mikkedorp, M.D.
Jouko Miettunen, Ph.D.
Brian P. Mika, M.D.
Eva Mikklehe, Ph.D.
Roseann Milad, B.S.C.
Gary E. Miller, M.D.
Brian P. Miller
Helen E. Miller, M.B.Ch.B.
Paul R. Miller, M.D.
Richard D. Milone
Lucinda I. Miner, Ph.D.
David L. Mintz, M.D.
David Mishoulon, M.D.
James E. Mitchell, M.D.
Zeina Mniehri, M.P.H.
David Mobley
Irmà Molianen, M.D.
Rachel C. Molander, M.D.
Victor A. Molinari, Ph.D.
Catherine Monk, Ph.D.
Reid P. Montague, Ph.D.
Palmiero Monteleone, M.D.
Roger M. Montenegro, M.D.
Richard A. Montgomery, M.D.
William Montgomery
Ivan D. Moota
Mike Monuteaux
Francisco A. Moreno, M.D.
Yannick Moryan, Psy.D.
Payal Mouaffak, M.D.
Dass Mouasavui, M.D.
Khalid A. Mutif, M.D.
Loretta Mulcare, B.S.
Franz Mülener-Pahn, M.D.
Cheryl C. Munday, Ph.D.
Silam Muntasser, M.D.
Graham Murray, M.D.
Irwin L. Muszynski
Mark G. Myers, Ph.D.
Michael F. Myers, M.D.
Wade C. Myers, M.D.
David D. Myran, M.Ed.
Carol C. Nadelson, M.D.
Bonzia Nathaus-Haros, Ph.D.
Arnino Nakayama, M.D.
Gen C. Nakajima, M.D.
Sundar N. Saind, M.D.
Syed K. Naqvi, M.D.
Antonio E. Narhi, M.D.
William F. Narlow, M.D.
Isabella Nascimento, M.D.
John Nasr Jr., M.D.
Vcmon I. Nathaniel, M.D.
Johannes C. Ndlobo, M.D.
Ali Nemat, M.D.
Gerald Nestadt, M.D.
Laura Nevill, MS.N
Antonia S. New, M.Div.
Cassandra F. Newkirk, M.D.
Thomas S. Newman, M.D.
Jason Newsom, Ph.D.
Warren Y.K. Ng, M.D.
Sama Niazi, M.D.
Unaiza Niazi, M.D.
Alphonso F. Nichols, M.D.
Fitzrabeth J. Nickell, M.A.
Isabelle Nicolas
Fokko Nienhuis, M.A.
Caroline M. Nievergelt, Ph.D.
Jessica R. Nitter, M.D.
Billy D. Nix
Frank G. Njenga, M.B.Ch.B.
Richard L. Noel, M.D.
Leo O. Noragbon, M.D.
Grayson S. Norequest
Donna M. Norris, M.D.
Georg Northing
Malkah T. Norman, M.D.
Richard J. Nunes, M.D.
Jeri Oberstar, M.D.
Charles P. O'Brien, M.D.
Kevin Ochsner, Ph.D.
Thomas O'Connor, Ph.D.
Ahmed M. Okasha, M.D.
Tarek A. Okasha, M.D.
Violet A. Okech, M.Med.
John M. Oldham, M.D.
Dost Onur
Désirée Oosterbaan, Ph.D.
Steven Oppenheimer, M.D.
Maria A. Osende, M.D.
Patricia I. Ondorica, M.D.
Barbara Orlowsky, Ph.D.
Alfredo O. Fragola, M.D.
Candice A. Osborn
Urban P. Osby, M.D.
Thomas O. Osinowo, M.D.
Ossaama T. Osman, M.D.
Howard Osofsky, Ph.D.
Joy Osofsky, Ph.D.
David N. Oyor, M.D.
Claes-Goran Östenson, M.D.
Britta Ostertag
Michael W. Oto, Ph.D.
Eugene A. Oulvey, Ph.D.
R Kait Ouzahar, M.D.
Ousayt Ozurku, M.D.
Sharon Parker, D.D.
Tannever Parker, M.D.
Maria E. Pagano, Ph.D.
Clare Pain, M.D.
Serifano Palladini, M.D.
Regina Palley, M.D.
Ilenna Pampapali
Aruna Pandya, M.D.
Rajesh M. Parikh, M.D.
Manuel Paris, Psy.D.
S. L. Parker, M.D.
Suzanne Parker
Grant V.S. Part, M.D.
Irene Pastelets-Siotis, M.D.
Michèle T. Patoc, M.D.
Beth Patterson, B.S.N.
Robindra K. Paul, M.D.
Rodrigo D. Paz, M.D.
Roger Peeler, M.D.
Anna Pejler
Jennifer D. Pender, M.D.
MariBeth Pender, Ph.D.
Elisabeth C. Pennic, Ph.D.
Diane Pennesi
Vincenzo H. Perkins, M.D.
Daniel P. Perl
Claire Perrin
John R. Peter, M.D.
Allan D. Peterkin
Timothy J. Percsens, Ph.D.
Roger H. Peters, Ph.D.
Berty Pfeiferbaum, M.D.
Steven E. Pharr, M.D.
Bruce M. Pfohl, M.D.
Alexandra Phipps-Scott
Melissa P. Piascik
Emmano P. Piccinini, M.D.
Kate Pickertt, Ph.D.
Claire Pierre, M.D.
Debra A. Pinals, M.D.
Daniel Pine, M.D.
Emil R. Pita, M.D.
Anthony Pinto, Ph.D.
Scott Pizzarello
Erik M. Plaunu, M.D.
Robert M. Plovrick, M.D.
David A. Pollack, Ph.D.
Jonathan D. Pollock, Ph.D.
Michael Possnuk, M.D.
David E. Post, M.D.
Michael A. Posternak, M.D.
Jerrold M. Post, M.D.
Alejandra Postlethwaite, M.D.
Robert M. Post, M.D.
Anne M. Pot
William Z. Potter, Ph.D.
Seth Powson, M.D.
Michael Poyurovsky
Aparva Prakash, M.D.
Xavier A. Prud'Homme, M.D.
Julie C. Price, Ph.D.
Marvelin Price, M.D.
Stefan Prithe, M.D.
Christina M. Puchalski, M.D.
Derek Puddy.
Kenitra A. Pugh, Ph.D.
Tarn M. Purdiah, M.D.
Katherine Putnam, Ph.D.
Robert S. Pynoos, M.D.
Adam Quastel, M.D.
Alan Q. Radke, M.D.
Donald S. Rae
Saliq Rahimi, Ph.D.
Ummr S. Rahim, M.D.
Charles J. Rainey
Dilip Ramchandani, M.D.
Luiz F. Ramirez, Ph.D.
Terri L. Randall, M.D.
Sonja Randle
Leah Ramsey, Ph.D.
John Rausen, Ph.D.
Paula Ratnakalloy, M.D.
Nyapati Rao, M.D.
Shanya Rathod, M.D.
Varnish Rathore, M.D.
Paola Ravitz, M.D.
Nancy C. Raymond, M.D.
Annick Razaafandimby, Ph.D.
Maryam Razavi, M.D.
Patricia R. Recupereto, M.D.
Joan Y. Reede, M.D.
Darrel A. Regier, M.D.
D. Bradford Reich, M.D.
James H. Reich, M.D.
Michele Reid, M.D.
William H. Reid, M.D.
Burton V. Reifler, M.D.
James L. Reilly, Ph.D.
Shauna P. Reinsblatt, M.D.
James S. Reinhar, M.D.
Aaron Relford, M.D.
Peter L. Remijnse
David Scott S. Resch, M.D.
Cynthia I. Resendez, M.D.
DISCLOSURE INDEX

Phillip J. Resnick, M.D.
Pa Natalya Reyes, M.D.
Raymond M. Reyes, M.D.
Signy Reynisdottir, M.D.
Karen H. Rhea, M.D.
Greg Richardson
William A. Richards
Josiah D. Rich, M.D.
Mark A. Riddle, M.D.
Muhamad Aly Rifai
Marie-Claude Rigaud, M.D.
Silvana Riggo, M.D.
Helcea Ring, M.D.
Carleen A. Riselli, M.S.N.
Candace B. Risen
Karen A. Ritchie, Ph.D.
Eva C. Rivio, M.D.
Guillermo C.R. Arroyo, Ph.D.
Michael J. Brink, M.D.
Dias Rizk, M.D.
Marion Robin, M.D.
Carolyn B. Robinowitz, M.D.
Beatrice E. Robinson, Ph.D.
David J. Robinson
Gail E. Robinson, M.D.
Jacqueline A. Robinson, M.D.
Michael J. Robinson
Charlotte A.L. Rocker, B.S.
Patricia F. Rockman
Gary Rodin, M.D.
Manuel J. Rodriguez-Abain, Ph.D.
Mercedes M. Rodriquez, M.D.
Jamison E. Rogers, M.D.
Lodi Rohrer, M.P.H.
Stephen J. Rojcewicz, M.D.
John S. Rolland, M.D.
Sarah F. Romas
Emilio F. Romero
Jason G. Roof, M.D.
Mozelleh Rooseoegor, M.D.
Erik Roskes, M.D.
Marc Rothman, M.D.
David A. Rothstein, M.D.
Alec Roy, M.D.
C. Nathaniel Roybal
Guadlberto Ruano, M.D.
Mariza Rubio-Sticp, M.D.
Christian Rück, M.D.
Stephen Ruedrich
Alicia Ruelas, M.D.
Carilo J. Ruggiero, Ph.D.
Stephan Ruhrmann, M.D.
Amanda Ruiz
Katherine G. Ruiz-Mellon, M.D.
Pedro Ruiz, M.D.
Rachel R. Rosenberg, M.A.
L. Mark Russakoff, M.D.
James Russell, M.D.
Bret R. Rutherford, M.D.
Carolyn Rutter, Ph.D.
Jo-Ellyn M. Ryall, M.D.
Suyan Sabri, Ph.D.
Joel Sadavoy, M.H.S.C.
Sy A. Saeed, M.D.
Steven A. Safrao, Ph.D.
Barbara Sahakian, Ph.D.
Fabian M. Saleh
Jack F. Samad, Ph.D.
Francis M. Schon, M.D.
Charles A. Sanislow, Ph.D.
George D. Santos, M.D.
Marco Sarniapiere, M.D.
Vedan Sar, M.D.
Ryoko Sato, M.D.
Erika Saunders, M.D.
Satyajit Saxena, M.D.
Andrew J. Saxon, M.D.
Keshal Sayer, M.D.
Martin Schalling, M.D.
Stephen C. Schelber, M.D.
Neil Scheuclinic, M.D.
Randolph B. Schiffer
Steven C. Schlozman, M.D.
Christian Schmaeh
Chaster W. Schmidt, Jr, M.D.
Ulleke Schmidt, M.D.
Barbara S. Schmeidler, M.D.
Michael Schoenbaum, Ph.D.
Gary R. Schoenmer, M.A.
Robert A. Schoevers, Ph.D.
Nicholas J. Schork, Ph.D.
Agnes Schrner
James Q. Schuhmehl, M.D.
Gunter Schumann, M.D.
Ken Schwartz, M.D.
Robert P. Schwartz, M.D.
Andres Scioilla
Charles L. Scott, M.D.
Marcis Scott, M.D.
William C. Scott, B.S.W.
James H. Scully,Jr, M.D.
Deborah E. Seale, M.A.
Michael Sears, M.D.
Harry Sekhon
Roslyn Seligman, M.D.
Mark J. Sengi, Ph.D.
Andrea L. Serran, M.D.
Daniel Sowell, M.D.
Sandra B. Sesson, M.D.
Amara Shabir
David Shaffer, M.D.
Amal Shamsan, M.D.
Stephen B. Shantfield, M.D.
Edward R. Shapiro, M.D.
Steven S. Sharfstein, M.D.
Suntiv Sharma, M.D.
Saenall Sharma, M.D.
Burr Shap, M.D.
Carla Sharp, Ph.D.
T. Tracie Shea, Ph.D.
Shawn C. Shee, M.D.
Hong Shen, M.D.
Ramakrishnan Sheny, M.D.
Miyuki Shida, M.S.W.
Al Shinkunas, Ph.D.
Ruth S. Shiam, M.D.
Ezra Z. Shomers, M.D.
Patrick Shout, Ph.D.
Denz Shuasel, M.D.
Yin Shupart, Ph.D.
Kenneth L. Shultman, M.D.
David Shurtlett, Ph.D.
Lawrence A. Siegel, M.D.
Richard L. Siegel, M.D.
Kenneth R. Silk, M.D.
Ivan Silver, M.D.
Richard A. Silverman, M.D.
Suzanne Silverstein, M.D.
Stuart B. Silver, M.D.
Asher Simon, M.D.
Robert I. Simon, M.D.
Bruce S. Singh, M.D.
Meets Singh, M.D.
Vrech Singh, M.D.
Pinkhas Sirota, M.D.
E. Yossuf Sivrigulu, M.D.
Elaine Slagboom
James P. Slater, M.D.
Marcia J. Slattery, M.D.
William H. Sledge, M.D.
Theodore A. Slokkin, Ph.D.
Dana M. Small, Ph.D.
Patrick Smallwood, M.D.
Meg Smith, M.D.
Marina Smith, M.D.
Hugo A. Soari, M.D.
Paul H. Solomon, M.D.
Stephen M. Soiysa, M.D.
Shamsia S. Sorawalla, M.D.
Laiba Sooyu, Ph.D.
Eliot Sorel, M.D.
Joanette A. Sorkin, M.D.
Renee M. Sorrentino, M.D.
Elizabeth R. Sowell, Ph.D.
Jana Spalding
Edgar Spicer, Ph.D.
Scan Spence
Jacobs Elliot Sperber, M.D.
Deborah Spitz, M.D.
Jorge C. Srebnstein, M.D.
Jagannath Srinivasragha, M.D.
Apisamit Srinangson, M.D.
Harvey Stainsky, M.D.
Susan Stainsky, M.D.
Jessica Stacer
Laurence R. Stanford, Ph.D.
Joy E. Stankowsksi, M.D.
Barbara H. Stanley, M.D.
Sergio Starkstein, M.D.
Amy B. Staub, M.B.A.
Otto Steenfeldt-Foss, M.D.
Marvin Steinberg, Ph.D.
Harriet C. Stern, M.D.
Hanna E. Stevens, M.D.
Lisa Stevenson, Ph.D.
Andrea Stolar, M.D.
Alan A. Stone, M.D.
Nada I. Stolland, M.D.
Robert L. Stout, Ph.D.
Norman L. Stovner, M.D.
Stephen M. Strakowski, M.D.
Joshua L. Strauss, M.D.
David Streiner, Ph.D.
Meg I. Striepiel, Ph.D.
T. Scott Stroop, M.D.
Heather Stuart, Ph.D.
Kenneth L. Subotnik, Ph.D.
Li-Min Su, M.D.
Ann Marie T. Sullivan, M.D.
Mary A. Sullivan, M.D.
Patrick F. Sullivan, M.D.
Trey Sunderland, M.D.
Young H. Sung, M.D.
Stephen J. Suomi, Ph.D.
Jillian Susman, M.D.
Marina Swartz-Vesnek, M.D.
John A. Sweeney, Ph.D.
Ammika Sweerholm, M.S.W.
John Robert Swenson, M.D.
Ralph W. Swindell
Bonnie S. Szarek, R.N.
Eva M. Szajeghy, M.D.
George Szmukler, M.B.B.S.
Anja Taanila, M.A.
Caroline C. Tabe, M.A.
Kaviya Tahilani, B.S.
Zebulon T. Tanor, M.D.
Jatinor Takbar, M.D.
John A. Talbott, M.D.
Mahmoud S. Taman, M.D.
Tuja Tammelin, M.A.
Rajesh T. Tampi, M.B.B.S.
Yoko Tanaka, Ph.D.
Pietrski Tanskanen, M.D.
Allan Tasman, M.D.
Faye S. Tasmian, Ph.D.
Craig B. Taylor, M.D.
Lyn E. Taylor, M.D.
Valerie Taylor, M.D.
Rolfen ten Doesschate, M.D.
Mughla E. Thakur, M.D.
Ole J. Thenen, M.D.
Graham Thornicroft, M.B.B.S.
Maria L.A. Tiamon-Kassab, M.D.
Jane G. Tillman, Ph.D.
Aung Tint, M.D.
Kay H. Tilghen, S.P.H.R.
Anthony Tomassini, D.M.A.
Lowell D. Tong, M.D.
Jennifer Toomey, R.P.N.
Sari Tommanen
Alfonso Tortorella, M.D.
Wilma L. Townsend, M.S.W.
Brian C. Trainer, Ph.D.
Michael R. Trimbble
Nhu-Ha T. Trinh, M.D.
Carol L. Tripodi, M.D.
Susan Tross, Ph.D.
Manuel Trujillo, M.D.
Quynh Trzaskonski, M.S.
Kuan-yi Tsi, M.D.
Werner Tschun, M.D.
Kuei-Yuan Tseng, Ph.D.
Debbie Tsung
John W. Tsung, M.D.
American Psychiatric Association

CDs and Audiotapes
Recorded Live!

High Quality Continues for
the 2007 Annual Meeting...

Live recordings will be available
for most of the following:

• Lectures • Advances in... Series
  • Presidential Symposia •
• Scientific and Clinical Reports • Symposia
• Small Interactive Sessions
• Advances in Medicine

CDs and tapes may be purchased/ordered on site
at Mobiltape's booth at the San Diego Convention Center

Mobiltape Company, Incorporated
24730 Avenue Tibbits, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 • (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com
SATURDAY, MAY 19, 2007

160TH ANNUAL MEETING

8:00 a.m. Sessions

COURSES 1-4

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 1 8:00 a.m.-12:00 noon
Room 25 B, Upper Level, San Diego Convention Center

DYNAMIC PSYCHOTHERAPY FOR CANCER PATIENTS AND THEIR SPOUSES

Director: Norman L. Straker, M.D.

COURSE 2 8:00 a.m.-12:00 noon
Room 25 C, Upper Level, San Diego Convention Center

DSM-IV-TR CULTURAL FORMULATIONS: DIAGNOSIS AND TREATMENT

Director: Russell F. Lim, M.D.
Faculty: Candace Fleming, Ph.D., Roberto Lewis-Fernandez, M.D., Johannes C. Nellera, M.D., Francis G. Lu, M.D., David C. Henderson, M.D.

COURSE 3 8:00 a.m.-12:00 noon
Room 26 A/B, Upper Level, San Diego Convention Center

THE EVALUATION, IDENTIFICATION, AND TREATMENT OF THE MAJOR DEMENTIAS

Co-Directors: Raymond A. Faber, M.D., Kevin F. Gray, M.D.
Faculty: Randolph B. Schiffer, M.D.

COURSE 4 8:00 a.m.-12:00 noon
Room 29 C, Upper Level, San Diego Convention Center

PSYCHIATRIC INTERVENTIONS IN DISASTER AND PUBLIC HEALTH EMERGENCIES: THEORY TO PRACTICE

Co-Directors: Anthony T. Ng, M.D., Phebe M. Tucker, M.D.
Faculty: Judith A. Cohen, M.D.

9:00 a.m. Sessions

COURSES 5-9

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 5 9:00 a.m.-4:00 p.m.
Room 25 A, Upper Level, San Diego Convention Center

A PRACTICAL APPROACH TO RISK ASSESSMENT

Director: William H. Campbell, M.D.

COURSE 6 9:00 a.m.-4:00 p.m.
Room 28 D, Upper Level, San Diego Convention Center

UPDATES IN GERIATRIC PSYCHIATRY 2007

Co-Directors: Rajesh R. Tampi, M.B.B.S., Kirsten M. Wilkins, M.D.
Faculty: Karin Kerfoot, M.D., Solomon S. Williams, M.D., Matthew T. Malone, D.O.

COURSE 7 9:00 a.m.-4:00 p.m.
Room 29 B, Upper Level, San Diego Convention Center

THE CONCEPTUAL BASIS OF PSYCHIATRY

Co-Directors: Nassir Ghaemi, M.D., David H. Brendel, M.D.

COURSE 8 9:00 a.m.-4:00 p.m.
Room 29 D, Upper Level, San Diego Convention Center

BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY I: THEORY, HUMAN RESOURCES, AND FISCAL MANAGEMENT

Co-Directors: Shiv Kumar S. Hatti, M.D., Arthur L. Lazarus, M.D.
Faculty: Barry K. Herman, M.D., Stuart B. Silver, M.D., Sy A. Saeed, M.D., L. Mark Russakoff, M.D.

COURSE 9 9:00 a.m.-4:00 p.m.
Room 30 A, Upper Level, San Diego Convention Center

NEUROANATOMY OF EMOTIONS: FROM BRAIN TO CLINICAL PRACTICE

Director: Ricardo M. Vela, M.D.
Faculty: Francisco Gonzalez-Lima, Ph.D.
12:30 p.m. Sessions

INDUSTRY SUPPORTED SYMPOSIUM 1
12:30 p.m.-3:30 p.m.
Marina Ballroom, South Tower, Level Three, Marriott

CLINICAL MANAGEMENT OF ADHD
Supported by Shire US, Inc.

Chp: Timothy E. Wilens, M.D.

A Office-Based Diagnosis
Keith McMurrin, Ph.D.

B Effective Psychotherapies for Adults With ADHD
Mary Solanto, Ph.D.

C Addressing Comorbidity in ADHD
Paul G. Hammerness, M.D.

D Addressing Treatment in Special Groups
Christopher J. Kratochvil, M.D.

E Managing Hypertension, Cardiovascular Issues, and SUD in ADHD
Timothy E. Wilens, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 2
12:30 p.m.-3:30 p.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

EXPERT DIALOGUE ON ALZHEIMER'S DISEASE:
DIAGNOSTIC AND REFERRAL ISSUES, TREATMENT
OF THE COGNITIVE DEFICITS, AMELIORATING
THE BEHAVIOR COMPLICATIONS, AND
COMPREHENSIVE MULTIDISCIPLINARY CARE
Supported by Forest Laboratories, Inc.

Chp: George T. Grossberg, M.D.

A Diagnostic and Referral Issues
William E. Reichman, M.D.

B Treating Cognitive Deficits in Patients With Alzheimer's Disease
Pierre N. Tariot, M.D.

C Ameliorating the Behavioral Complications in Patients With Alzheimer's Disease
Jacob E. Mintzer, M.D.

D Comprehensive Multidisciplinary Care
Warachal E. Paison, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 3
12:30 p.m.-3:30 p.m.
Manchester Ballroom, Second Level, Manchester Grand Hyatt

RECOGNITION AND MANAGEMENT OF RESTLESS LEGS SYNDROME IN PSYCHIATRIC PRACTICE
Supported by Boehringer Ingelheim Pharmaceuticals, Inc.

Chp: John W. Winkelman, M.D.

A Understanding RLS: Epidemiology and Clinical Features
Barbara A. Phillips, M.D.

B RLS-Associated Psychiatric Symptoms
Ho chang B. Lee, M.D.

C Treatment Options for RLS
Jacques Montplaisir, M.D.

D The Psychiatrist's Role in Managing RLS
Jed E. Black, M.D.

E Clinical Pathways
John W. Winkelman, M.D.

1:00 p.m. Sessions

COURSES 10-13
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 10 1:00 p.m.-5:00 p.m.
Room 26 A/B, Upper Level, San Diego Convention Center

MANAGEMENT OF PSYCHIATRIC DISORDERS IN PREGNANT AND POSTPARTUM WOMEN

Co-Directors: Shaila Misri, F.R.C.P.C., Diana Carter, M.B.B.S.
Faculty: Shari L. Luskin, M.D., Maria R. Corral, M.D.,
Deirdre M. Ryan, F.R.C.P.C.

COURSE 11 1:00 p.m.-5:00 p.m.
Room 28 E, Upper Level, San Diego Convention Center

INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION

Director: Ziad H. Nahas, M.D.
Faculty: Mark Demitrack, M.D., Frank A. Kozel, M.D., John O'Reardon, M.D., Shirlene Sampson, M.D.

COURSE 12 1:00 p.m.-5:00 p.m.
Room 29 A, Upper Level, San Diego Convention Center

MELATONIN AND LIGHT TREATMENT OF SAD,
SLEEP, AND OTHER BODY CLOCK DISORDERS
Director: Alfred J. Lewy, M.D.
COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS

Co-Directors: Jesse H. Wright, M.D., Michael E. Thase, M.D.
Faculty: Monica R. Basco, Ph.D.

6:00 p.m. Sessions

LECTURE 1

6:00 p.m.-7:30 p.m.
San Diego Ballroom B,
North Tower, Lobby Level, Marriott

APA'S SIMON BOLIVAR AWARD LECTURE

Francisco Fernandez, M.D.

Hispanics and AIDS

Chp: Andres J. Pumariaga, M.D.

Dr. Fernandez' clinical practice consists of consulting on patients with neurobehavioral disorders, psychiatric complications of cancer and AIDS, psychological factors affecting medical illness and end of life decision making, psychopharmacology, pain management, somatoform disorders, attention deficit disorder, memory dysfunction, Alzheimer's disease and other cognitive disorders. Detailing the psychiatric complications of medical illness such as HIV/AIDS, cancer, and end-stage organ disease requiring organ transplant. His main focus has been to assess effective treatment strategies for HIV-Minor Cognitive-Motor Disorder and HIV-Associated Dementia. Another area of research and clinical interest is that of Thanatology. Dr. Fernandez received his M.D. degree from Tufts University School of Medicine and completed his psychiatry training at the Massachusetts General Hospital. Nationally, Dr. Fernandez is Chair of the American Psychiatric Association's Committee on AIDS and serves on the Steering Committee of the American Psychiatric Association's-CMHS funded AIDS Education Project. He has served on the American College of Psychiatrists PRITE Editorial Board since 1995 and was Editor-in-Chief from 2000-2005. He now serves on the Board of Regents for the American College of Psychiatrists. Prior to serving as Chair of Psychiatry and Behavioral Medicine at the University of South Florida, from 1997-2002 he was the Chair of the Department of Psychiatry and Behavioral Neurosciences at Loyola University Chicago, Stritch School of Medicine.

THIS SESSION WILL BE AUDIOTAPE.
INDUSTRY SUPPORTED SYMPOSIUM 6
6:00 p.m.-9:00 p.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

CLINICAL SKILLS TO CLINICAL SCALES:
PRACTICAL TOOLS IN THE MANAGEMENT OF
PATIENTS WITH SCHIZOPHRENIA
Supported by Pfizer Inc.

Chp: John M. Kane, M.D.

A Monitoring Physical Health
   Stephen R. Marder, M.D.

B Measuring and Managing Agitation
   Michael H. Allen, M.D.

C Measuring Cognitive and Functional Outcomes in
   Schizophrenia: A Practical Guide for Clinicians
   Rona Hu, M.D.

D Measurement-Based Clinical Decision-Making in
   Patients With Schizophrenia
   John M. Kane, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 7
6:00 p.m.-9:00 p.m.
Manchester Ballroom, Second Level, Manchester Grand Hyatt

THE PREVAILING PREDOMINANT POLE OF
BIPOLAR DEPRESSION
Supported by GlaxoSmithKline

Chp: Mark A. Frye, M.D.

A Neurobiology of Bipolar Depression: Implications for
   Treatment
   Robert M. Post, M.D.

B New Treatment Options for Bipolar Depression
   Marcia L. Verduin, M.D.

C Clinical Correlates Associated With Treatment-
   Emergent Mania
   Mark A. Frye, M.D.

D The Clinical Interface Between Obesity and Bipolar
   Depression
   Susan L. McElroy, M.D.

E Clinical Challenges of Diagnosing and Treating
   Adolescents With Bipolar Depression
   Kiki D. Chang, M.D.
SUNDAY, MAY 20, 2007

160TH ANNUAL MEETING

8:00 a.m. Sessions

COURSES 14-19
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 14  8:00 a.m.-12:00 noon
Room 23 A/B/C, Upper Level, San Diego Convention Center

ADD IN ADULTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 15  8:00 a.m.-12:00 noon
Room 25 C, Upper Level, San Diego Convention Center

USING BOUNDARY CROSSINGS AS CREATIVE THERAPY INSTEAD OF SLIPPERY SLOPES

Director: Gail E. Robinson, M.D.
Faculty: Howard E. Book, M.D., Gary R. Schoener, M.A., Linda M. Jorgenson, M.A.

COURSE 16  8:00 a.m.-12:00 noon
Room 29 A, Upper Level, San Diego Convention Center

HOW TO GIVE A MORE EFFECTIVE LECTURE: PUNCH, PASSION, AND POLISH

Director: Phillip J. Resnick, M.D.

COURSE 17  8:00 a.m.-12:00 noon
Room 29 B, Upper Level, San Diego Convention Center

PSYCHIATRIC CONSULTATION IN LONG TERM CARE: BASIC

Co-Directors: Abhilash K. Desai, M.D., George T. Grossberg, M.D.

COURSE 18  8:00 a.m.-12:00 noon
Room 29 C, Upper Level, San Diego Convention Center

INTERPERSONAL PSYCHOTHERAPY

Director: John C. Markowitz, M.D.

COURSE 19  8:00 a.m.-12:00 noon
Room 30 B, Upper Level, San Diego Convention Center

IMPROVING CLINICAL OUTCOMES: A PRACTICAL GUIDE TO EVIDENCE-BASED EMPLOYMENT AND RECOVERY PRACTICES

Co-Directors: Eugene A. Oulvey, Ph.D., Karen L. Lee, M.A.
Faculty: Connie Clark, L.P.C., Michael J. Martin, M.D., Shyam K. Bhat, M.D., Vivek Jain, M.D.

INDUSTRY SUPPORTED SYMPOSIA 8-12

INDUSTRY SUPPORTED SYMPOSIUM 8
8:00 a.m.-11:00 a.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

THE ONGOING DEBATE SURROUNDING ATYPICALS: ARE THE BENEFITS WORTH THE RISKS?
Supported by Solvay Pharmaceuticals and Wyeth Pharmaceuticals

Chp.: Stephen R. Marder, M.D.

A  Balancing Between Efficacy and Side Effects
   Samuel J. Keith, M.D.

B  The Effect of Atypicals on Health Outcomes in Light of Pre-Existing Medical Risks
   Henry A. Nasrallah, M.D.

C  The Risk/Benefit Ratio of Atypical Antipsychotics in Early Phase Schizophrenia
   Elizabeth Bronsley, M.D.

D  New Mechanisms and Innovative Pharmacological Strategies
   Stephen R. Marder, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 9
8:00 a.m.-11:00 a.m.
Marina Ballroom, South Tower, Level Three, Marriott

STILL SLEEPY AFTER ALL THESE CURES: HYPERSOMNIA IN PSYCHIATRY
Supported by Cephalon, Inc.

Chp.: Stephen M. Stahl, M.D.

A  The Neurobiology of Hypersomnia
   Stephen M. Stahl, M.D.

B  The Clinical Spectrum of Hypersomnia
   Daniel J. Buysse, M.D.

C  Measurement of Hypersomnia
   Meeta Singh, M.D.

D  Strategies for the Management of Hypersomnia
   Leslie P. Lundt, M.D.

E  Prevalence and Consequences of Hypersomnia
   Christopher L. Drake, Ph.D.
INDUSTRY SUPPORTED SYMPOSIUM 10
8:00 a.m.-11:00 a.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

DECONSTRUCTING ATTENTION AND COGNITION IN ADHD: NEW UNDERSTANDINGS FOR IMPROVED MANAGEMENT
Supported by McNeil Pediatrics and Otsuka America Pharmaceuticals, Inc.

Chp.: Thomas J. Spencer, M.D.

A Overview of ADHD
Thomas J. Spencer, M.D.

B Neurocircuity in ADHD
George Bush, M.D.

C Neuropsychology in ADHD
Ronna Fried, M.D.

D Understanding Cognitive and Behavioral Approaches to Treating ADHD in Adults
Steven A. Safren, Ph.D.

E Pharmacological Treatment of ADHD: Focus on Attention
Timothy E. Wilens, M.D.

F Postactivity Measurement
Thomas J. Spencer, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 12
8:00 a.m.-11:00 a.m.
Manchester Ballroom, Second Level, Manchester Grand Hyatt

DARK HORIZONS: DEPRESSION AND COGNITIVE IMPAIRMENT
Supported by Forest Laboratories, Inc.

Chp.: Steven P. Roose, M.D.

A The Epidemiology of genetic Studies of Depression and Memory
Richard Mayeux, M.D.

C The Biology of Depression and Dementia
Gary W. Small, M.D.

D Vascular Depression and Vascular Dementia
K Ranga R. Krishnan, M.B.

E The Course of Treatment for Patients With Questionable Dementia
Davangere P. Devanand, M.D.

F The Course of Treatment of Patients with Depression and Mild Cognitive Impairment
Roy H. Hamilton, M.D.

9:00 a.m. Sessions

COURSES 20-25

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 20 9:00 a.m.-4:00 p.m.
Room 25 A, Upper Level, San Diego Convention Center

SEEING THE FOREST AND THE TREES: A BIOPSYCHOSOCIAL APPROACH TO THE ORAL BOARD EXAMINATION

Director: William H. Campbell, M.D.

COURSE 21 9:00 a.m.-4:00 p.m.
Room 25 B, Upper Level, San Diego Convention Center

THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES

Director: David C. Jimerson, M.D.
Faculty: Katherine A. Halmi, M.D., James E. Mitchell, M.D., Denise Wilfley, Ph.D., Joe Yager, M.D.
KUNDALINI YOGA MEDITATION TECHNIQUES FOR MENTAL HEALTH

Director: David S. Shannahoff-Khalsa, B.A.

ACHIEVING PSYCHOTHERAPY EFFECTIVENESS: PRACTICAL APPROACHES FOR CLINICIANS

Co-Directors: Paula Ravitz, M.D., Mlyn Leszcz, M.D.
Faculty: Nancy L. McNaughton, Ed.M., Allan D. Peterkin, M.D.,
Clare Pain, M.D., Jon Hunter, M.D.

BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY II

Co-Directors: Shivkumar S. Hatti, M.D., Arthur L. Lazans, M.D.
Faculty: William H. Reid, M.D., Robert W. Atkins, M.D.

INTRODUCTION TO COGNITIVE-BEHAVIORAL THERAPY

Co-Directors: Robert M. Goisman, M.D., Philip G.
Levendusky, Ph.D.

BUSINESS MEETING
(Voting Members Only*)

12:30 p.m.-1:30 p.m.
Ballroom 6 A, Upper Level, San Diego Convention Center

CALL TO ORDER
Pedro Ruiz, M.D., President

MEMORIAL TO DECEASED MEMBERS

ANNOUNCEMENT OF ELECTION RESULTS
Billy E. Jones, M.D., Chairperson, Committee of Tellers

REPORTS TO THE MEMBERSHIP
Secretary-Treasurer: Donna M. Norris, M.D.
Speaker, Assembly: Michael Blumenfield, M.D.
Speaker-Elect, Assembly: Jeffrey Akaka, M.D.
Chairperson, Committee on Bylaws: Ramaswamy Viswanathan, M.D.

Chairperson, Elections Committee: Maria T. Lynberis, M.D.
Chairperson, Membership Committee: Joseph E.V. Rubin, M.D.
Medical Director and CEO: James H. Scully, Jr., M.D.
Chairpersons of Councils (Written Reports Only)

ANNUAL FORUM

ADJOURNMENT

*Members-in-Training, General Members, Distinguished Fellows, Fellows, Life Fellows, Distinguished Life Fellows, and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.

1:00 p.m. Sessions

COURSES 26-32
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

SLEEP MEDICINE REVIEW AND UPDATE FOR PSYCHIATRISTS

Director: Thomas D. Hurwitz, M.D.
Faculty: Max Hirshkowitz, Ph.D., Lois E. Krahn, M.D.

EEG IN CLINICAL PRACTICE: INDICATIONS AND LIMITATIONS

Co-Directors: Nasser N. Boutros, M.D., Silvana Riggio, M.D.

VAGUS NERVE STIMULATION

Director: Ziad H. Nahas, M.D.
Faculty: Linda Carpenter, M.D., Bob Howland, M.D.,
Mitchell King, M.D., Mustafa Husain, M.D.

CLINICIAN ADMINISTERED RATING SCALES FOR MOOD AND ANXIETY DISORDERS

Co-Directors: Sagar V. Patilkh, M.D., Vytas Velyvis, M.A.
COURSE 30 1:00 p.m.-5:00 p.m.
Room 29 B, Upper Level, San Diego Convention Center

BIOETHICS 2007
Director: Edmund G. Howe, M.D.

COURSE 31 1:00 p.m.-5:00 p.m.
Room 29 C, Upper Level, San Diego Convention Center

COGNITIVE THERAPY FOR SCHIZOPHRENIA
Director: Jesse H. Wright, M.D.
Faculty: David Kingdon, M.D., Douglas Turkington M.D.

COURSE 32 1:00 p.m.-5:00 p.m.
Room 30 B, Upper Level, San Diego Convention Center

WEB-BASED CADI, BEHAVIORAL HEALTHCARE, AND CMHCS
Director: Paul R. Miller, M.D., Karen H. Rhea, M.D.
Faculty: Charles Chiu, M.D., Linda Rosenberg, M.S.W., Tom Doub, Ph.D., Charles Johnson, Ph.D.

1:30 p.m. Sessions

INDUSTRY SUPPORTED SYMPOSIA 13-17

INDUSTRY SUPPORTED SYMPOSIUM 13
1:30 p.m.-4:30 p.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

PLANNING FOR SUCCESS IN SCHIZOPHRENIA MANAGEMENT
Supported by Janssen Pharmaceutica and Research Foundation
Chp.: Dilip V. Jeste, M.D.

A Why Do Patients With Schizophrenia Take Their Medication? Adherence Models for First-Episode Patients
Peter J. Weiden, M.D.

B Strategies for Assessing and Managing Adherence
Dilip V. Jeste, M.D.

C Schizophrenia Treatment Planning: Guidelines, Medication Algorithms, and Psychosocial Strategies
Dawn L. Velligan, Ph.D.

D Case Presentations of Adherence Dilemmas
David P. Folsom, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 14
1:30 p.m.-4:30 p.m.
Marina Ballroom, South Tower, Level Three, Marriott

MAKING EVERY SHEEP COUNT: EVIDENCE-BASED APPROACHES TO TREATING INSOMNIA
Supported by Takeda Pharmaceuticals North America, Inc.
Chp.: Daniel J. Buysse, M.D.

A The Clinical Neuroscience of Sleep and Insomnia
Daniel J. Buysse, M.D.

B Comorbidity Between Insomnia and Psychiatric Illness
Meera Narashimhan, M.D.

C Novel Pharmacological Targets for the Management of Insomnia
Ruth M. Benca, M.D.

D Innovative Behavioral Approaches for Treating Insomnia and Comorbid Psychiatric Illness
Karl Doghramji, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 15
1:30 p.m.-4:30 p.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

OPTIMIZING OUTCOMES ACROSS THE SPECTRUM OF DEMENTIA
Supported by Eisai, Inc.
Chp.: Pierre N. Tariot, M.D.

A Blending Science and Best Practice Banner Across the Dementia Spectrum
Pierre N. Tariot, M.D.

B An Office-Based Approach to Early and Accurate Diagnosis
Roy Ysari, M.D.

C Normal Aging, Amnestic MCI, or AD: Managing and Treating Across the Whole Spectrum
Pierre N. Tariot, M.D.

D Management of Behavioral Disturbances in Alzheimer’s Disease
Jeffrey L. Cummings, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 16
1:30 p.m.-4:30 p.m.
Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

RETHINKING BIPOLAR DISORDER: IMPLICATIONS OF COMORBIDITIES
Supported by AstraZeneca Pharmaceuticals
Chp.: Gary S. Sachs, M.D.

A Medical Comorbidities With Bipolar Disorder
Gary S. Sachs, M.D.

B Comorbid Substance Abuse in Bipolar Disorder
Michael J. Ostacher, M.D.

C Suicidality as a Component of Bipolar Disorder
Lauren Marangell, M.D.

D PTSD and Bipolar Disorder: Critical Overlaps and Possible Links in Pathology and Treatment
Lori L. Davis, M.D.

E Neuroimaging of Dual Diagnoses
Stephen M. Strakowski, M.D.
INDUSTRY SUPPORTED SYMPOSIUM 16
1:30 p.m.-4:30 p.m.
Manchester Ballroom, Second Level, Manchester Grand Hyatt

CARING FOR OUR MOST CHALLENGING PATIENTS WITH DEPRESSION: AN INTERACTIVE FORUM ON NOVEL TREATMENTS
Supported by Cyberonics, Inc.

Chp.: Charles B. Nemeroff, M.D.

A Mechanism of Action of Vagus Nerve Stimulation
Charles B. Nemeroff, M.D.

B Assessing the Efficacy of Vagus Nerve Stimulation in Patients With Treatment Resistant Depression
Paul Holtzheimer, M.D.

C Efficacy of Repetitive Transcranial Magnetic Stimulation and Magnetic Seizure Therapy
Thomas Schlaepfer, M.D.

D Mechanism of Action and Efficacy of Deep Brain Stimulation
Helen Mayberg, M.D.

2:30 p.m. Session

LECTURE 2
2:30 p.m.-4:00 p.m.
Room 33 A/B/C, Upper Level, San Diego Convention Center

AAPL/APA'S MANFRED GUTTMACHER AWARD LECTURE

Carl P. Malmquist, M.D.

Adolescent Parricide

Chp.: Patricia R. Recupero, M.D.

Carl P. Malmquist, M.D., M.S., is a psychiatrist, board-certified in Adult Psychiatry, Child and Adolescent Psychiatry, Forensic Psychiatry, and with added qualification in Forensic Psychiatry. He is a Professor of Social Psychiatry at the University of Minnesota, and has also taught in areas of criminology and law. He has also done consultation work for district courts and private law firms.

THIS SESSION WILL BE AUDIOTAPED.

5:00 p.m. Session

OFFICIAL OPENING SESSION
5:00 p.m.-6:30 p.m.
Ballroom 20, Upper Level, San Diego Convention Center

CALL TO ORDER
Pedro Ruiz, M.D., President

INTRODUCTION OF STAGE GUESTS
INTRODUCTION OF CHAIRPERSON OF THE SCIENTIFIC PROGRAM COMMITTEE
Robert W. Guynn, M.D.
Chairperson, Annual Meeting Scientific Program Committee

INTRODUCTION OF VISITING DIGNITARIES (Please refer to pages 11-14 for a listing of the presidents of allied organizations.)

PRESIDENTIAL ADDRESS
Pedro Ruiz M.D
To be introduced by Jack S. McIntyre, M.D.

RESPONSE OF THE PRESIDENT-ELECT
Carolyn B. Robinowitz, M.D.
To be introduced by James H. Scully Jr., M.D.

ADJOURNMENT

7:00 p.m. Sessions

INDUSTRY SUPPORTED SYMPOSIA 18-21

INDUSTRY SUPPORTED SYMPOSIUM 18
7:00 p.m.-10:00 p.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

HOW COMORBID IS ADHD? RESULTS FROM EPIDEMIOLOGICAL AND CLINICAL STUDIES
Supported by Shire US, Inc.

Chp.: Joseph Biederman, M.D.

A Patterns of Comorbidity in Longitudinal Sample of Boys and Girls with ADHD
Joseph Biederman, M.D.

C Patterns of Comorbidity in a Clinical Sample of Adults with ADHD
Thomas J. Spencer, M.D.

D Patterns of Comorbidity in a Community Sample of Adults with ADHD: Results from the National Comorbidity Survey
Ronald C. Kessler, M.D.

(Continued next page)
E  Morphometric Findings in Adults With ADHD With and Without Comorbid Bipolar Disorder
   Mike Monuteaux, Sc.D.

F  Spectroscopic Findings in Children and Comorbid Bipolar Disorder
   Constance M. Moore, Ph.D.

INDUSTRY SUPPORTED SYMPOSIUM 19
7:00 p.m.-10:00 p.m.
Marina Ballroom, South Tower, Level Three, Marriott

THE ALCOHOL DEPENDENT PATIENT: IMPROVING OUTCOMES THROUGH ADHERENCE
Supported by Cephalon, Inc. and Alkermes

Chp.: Robert M. Swift, M.D.

A  Patient Adherence in the Treatment of Alcohol Dependence: The Journey of Recovery
   Roger D. Weiss, M.D.

B  Pharmacotherapeutic Options for the Management of Alcohol Dependence: Importance of Adherence
   Robert M. Swift, M.D.

C  Patient Readiness: Implications for Adherence and Management of Alcohol Dependence
   Carlo C. DiClemente, Ph.D.

D  Implementing Adherence-Enhancing Strategies in Clinical Practice: Negotiating Within the Therapeutic Alliance
   Albert J. Arias, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 20
7:00 p.m.-10:00 p.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

WEIGHING THE RISKS AND BENEFITS OF ATYPICAL ANTI精神病ICHTHICANS: CAN WE HAVE OUR CAKE AND EAT IT TOO?
Supported by Bristol-Myers Squibb Company

Chp.: Henry A. Nasrallah, M.D.

A  High Morbidity and Mortality in Schizophrenia and Bipolar Disorder: What, Why, and How?
   Quinton F. Moss, M.D.

B  Metabolic Complications in the Context of Antipsychotic Effectiveness: Lessons from the CATIE Schizophrenia Trial
   Donald C. Goff, M.D.

C  The Dual Health Jeopardy in Schizophrenia: Highly Prevalent Metabolic Disorders and Low Access to Medical Treatment
   Henry A. Nasrallah, M.D.

D  Lessons from ATPIII, the ADA, and the APA Workgroup on Antipsychotics and Metabolic Risk
   John W. Newcomer, M.D.

E  Patient, Provider, and System Level Approaches to Reducing Risk of Poor Health Outcomes in Patients Receiving Antipsychotics
   Lisa B. Dixon, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 21
7:00 p.m.-10:00 p.m.
Manchester Ballroom, Second Level, Manchester Grand Hyatt

STAR*D FINDINGS: IMPLICATIONS FOR PATIENTS, CLINICIANS, AND OTHER STAKEHOLDERS
Supported by Forest Laboratories, Inc.

Chp.: Grayson S. Norquist, M.D.

A  Clinical Methods and Procedures to Enhance Acute and Long-Term Outcomes
   Junius J. Gonzales, M.D.

B  STAR*D: Selecting Among First and Second Step Acute Treatments: Level One and Level Two
   Marlene P. Freeman, M.D.

C  Treatments After the First Two Steps Including Follow-Up: Level Three and Level Four
   A. John Rush, M.D.

D  The Role of Other Treatment Options in Managing Depression
   K Ranga R. Krishnan, M.B.
2007 Presidents of Allied Organizations

Academy of Organizational and Occupational Psychiatry
Steven E. Pflanz, M.D.

Academy of Cognitive Therapy
Robert Leahy, Ph.D.

Algerian Psychiatric Association
Farid Kacha, M.D.

American Academy of Addiction Psychiatry
Michael H. Gendel, M.D.

American Academy of Child and Adolescent Psychiatry
Thomas F. Anders, M.D.

American Academy of Family Physicians
Rick Kellerman, M.D.

American Academy of Neurology
Stephen M. Sergy, M.B.

American Academy of Psychiatry and the Law
Alan R. Felthous, M.D.

American Academy of Psychoanalysis and Dynamic Psychiatry
Sherry P. Katz-Bearnot, M.D.

American Association for Emergency Psychiatry
Avrom B. Fishbein, M.D.

American Association for Social Psychiatry
Steven S. Sharfstein, M.D.

American Association for the Advancement of Science
David Baltimore, Ph.D.

American Association of Chairs of Departments of Psychiatry
Peter F. Buckley, M.D.

American Association of Community Psychiatrists
Wesley Sowers, M.D.

American Association of Directors of Psychiatric Residency Training
Mark Seris, M.D.

American Association of Practicing Psychiatrists
Janis G. Chester, M.D.

American Association on Mental Retardation
Hank Bersani, Ph.D.

American Board of Psychiatry and Neurology, Inc.
Michael V. Johnston, M.D.

American College of Emergency Physicians
Brian F. Keaton, M.D.

American College of Mental Health Administration
Eric N. Goplen, Ph.D.

American College of Obstetricians and Gynecologists
Douglas E. Lambe, M.D.

American College of Physicians-American Society of Internal Medicine
David C. Dale, M.D.

American College of Psychiatrists
Fawzy I. Fawzy, M.D.

American College of Psychoanalysis
Harriet Wolfe, M.D.

American College of Surgeons
Edward M. Copeland III M.D.

American Group Psychotherapy Association
Elizabeth Knight, M.D.

American Medical Association
William G. Pleeted III, M.D.

American Medical Women's Association
Susan Inuy, M.D.

American Neurological Association
Stephen Hauser, M.D.

American Neuropsychiatric Association
Fred Osiew, M.D.

American Nurses Association
Rebecca Patton, M.S.N

American Orthopsychiatric Association
Diane Willis, M.D.

American Psychiatric Association Alliance
Kay Brada

American Psychoanalytic Association
K. Lynne Moritz, M.D.

American Psychological Association
Sharon Stephens Breon, Ph.D.

American Psychosomatic Society
William Lorrado, Ph.D.

American Society for Adolescent Psychiatry
Mohan Nair, M.D.

American Society of Addiction Medicine
Michael M. Miller, M.D.

American Society of Clinical Psychopharmacology, Inc.
John M. Kanes, M.D.

American Society of Hispanic Psychiatrists
Manuel Trujillo, M.D.

Arab American Psychiatric Association
Abdel F. Amin, M.D.

Arab Gulf Psychiatric Association
Professor Mohamed K. Al-Haddad

Argentinean Association of Psychiatrists
Nisot F. Marchant, M.D.

Amenyan Association of Psychiatrists and Narcologists
Professor Marietta Melik-Pashayan

Asociacion Espanola de Neuropsiquiatria
Alberto Fernandez Luria

Association for Academic Psychiatry
Patrick O'Neill, M.D.

Association for Behavioral and Cognitive Therapies
Raymond DiGuiseppe, Ph.D.
2007 Presidents of Allied Organizations

Association of American Medical Colleges
Darrel Kirch, M.D.

Association of Chinese American Psychiatrists
Edmond H. Pi, M.D.

Association of Directors of Medical Student Education in Psychiatry
Theodore B. Yeldman, M.D.

Association of Free Psychiatrists of Romania
Professor Aurel Ramila

Association of Gay and Lesbian Psychiatrists
Dan H. Karasik, M.D.

Association of Korean American Psychiatrists
Tai Pyung Yoo, M.D.

Association of Psychiatrists in Nigeria
Professor Oye Gureje

Association of Psychiatrists of Tajikistan
Abdavakhid Baibakov, M.D.

Association of Psychiatrists of Uzbekistan
Ulugbek Alimov

Association of Reformers in Psychiatry
Professor Toma Tomov

Association of Women Psychiatrists
Mary Kay Smith, M.D.

Austrian Association for Psychiatry and Psychotherapy
Christoph Stupperich

Bangladesh Association of Psychiatrists
A.K.M. Nazimuddowla Chowdhury

Barbados Association of Psychiatrists
Gajapathy Asokan, M.D.

Black Psychiatrists of America
Cassandra Newkirk, M.D.

Bolivian Society of Psychiatry
Everiberto Montano Yepes, M.D.

Brazilian Association of Psychiatry
Josimar M.F. Franca

Bulgarian Psychiatric Association
Vladimir Velkov, M.D.

Byelorussian Psychiatric Association
Professor Roman A. Evesgueev

Canadian Psychiatric Association
Manon Charbonneau, M.D.

Caribbean Psychiatric Association
Jacqueline Sharpe, M.D.

Chinese Society of Psychiatry
Professor Dongfeng Zhou

Colombian Psychiatric Association
Carlos A. Felizgola Donado, M.D.

Costa Rican Psychiatric Association
Rigoberto Castro Rojas, M.D.

Council of Medical Specialty Societies
Carol Berkowitz, M.D.

Croatian Psychiatric Association
Ljubomir Hotujac

Cyprus Psychiatric Association
Argyris Argyriou, M.D.

Czech Psychiatric Association
Jiri Raboch

Danish Psychiatric Association
Dorte Seisbø, M.D.

Depression and Bipolar Support Alliance
Susan R. Bergson, M.D.

Dominican Society of Psychiatry
Martha Diaz, M.D.

Ecuadorian Association of Psychiatry
Fabrizio Delgado Campodonico, M.D.

Egyptian Psychiatric Association
Professor Ahmed Okasha

Estonian Psychiatric Association
Andres Lehmets, M.D.

Ethiopian Psychiatric Association
Mesfin Arezza, M.D.

Finnish Psychiatric Association
Professor Matti Joukkamaa

Flemish Neurologists and Psychiatrists
J. Peurkens, M.D.

Foundation for Interdisciplinary Investigation of Communication
Professor Miguel Angel Materazzi

Francophone Int’l Federation of Psychiatry
Francois Caro, M.D.

French Association of Psychiatrists in Private Practice
Jean-Jacques Labontiere

French Association of Psychiatry
Professor Christian C. Vassier

French Psychiatric Information Society
Nicole Garret-Gloanec, M.D.

Ghana Psychiatric Association
Sammy Hene, M.D.

Group for the Advancement of Psychiatry
Lois Flaherty, M.D.

Guatemalan Psychiatric Association
Edgar R. Vasquez Trujillo, M.D.

Hellenic Psychiatric Association
Nikolaos Tsavaras

Hellenic Society of Neurology and Psychiatry
Professor Costas Stefanis

Honduran Society of Psychiatry
Sara Maria Murillo Antunez, M.D.

Hong Kong College of Psychiatrists
Chun Wai Lo, M.D.

Hungarian Psychiatric Association
Ferenc Turi

Icelandic Psychiatric Association
Kristofer Portefoss, M.D.
2007 Presidents of Allied Organizations

Independent Psychiatric Association of Russia
Professor Yury Savenko

Indian Association for Social Psychiatry
Professor Anil Malhotra

Indo-American Psychiatric Association
Asha S. Mathra, M.D.

Indonesian Psychiatric Association
H.M. Syamsulbadi

International Association for Cognitive Psychotherapy
Robert Leaby, Ph.D.

International Society of Psychopathology of Expression
Gay Ross, M.D.

Iranian Psychiatric Association
Professor Ahmad Jafati

Iraqi Psychiatric Association
Mohammed R. Lafta, M.B.B.S.

Irish College of Psychiatrists
Kathleen Ganter, M.D.

Israeli Psychiatric Association
Avi Bleich

Italian Association for Research in Schizophrenia
Professor Carlo L. Cazullo

Italian Psychiatric Association
Professor Eugenio Anghele

Italian Psychiatric Society
Mario Maj, M.D.

Ivory Coast Association of Psychiatry
Professor Joseph Delafosse

Jamaican Psychiatric Association
G. Leveridge, M.D.

Japanese Society of Psychiatry and Neurology
Takuya Kojima

Jordan Association of Psychiatrists
Taufik Daradkeh, M.D.

Kazakh Association of Psychiatrists and Narcologists
Professor Boris Dubinin

Kenya Psychiatric Association
Frank G. Nyenga, M.D.

Korean Neuropsychiatric Association
Young Cho Chung

Kuwait Psychiatric Association
Essam A. Al-Ansari

Kyrgyz Science and Practical Comm of Psychiatrists
Professor Valery Sokoljenkin

Latin American Psychiatric Association
Rafael Navarro, M.D.

Latvian Psychiatric Association/ Medical Academy of Latvia
Raisa Andreeze

League of Mental Health from Republic of Moldova
Mihai Heitineanu, M.D.

Lebanese Psychiatric Society
Charles Baddoura

Lithuanian Psychiatric Association
Algirdas Dembinkas

Luxembourgian Society of Psychology, Neurology and Psychotherapy
Christien Jacoby, M.D.

Malaysian Psychiatric Association
Professor Maniam Thambu

Mauritian Psychiatric Association
Parmaman Nagamuth, M.D.

Medical Psychological Society
Professor J.G. Veyrat

Mexican Psychiatric Association
Jesus Del Bosque Garza

Mexican Society of Neurology Psychiatry
Juan Ignacio Rosales, M.D.

Mongolian Mental Health Association
Bayankhun Aynshjav, M.D.

Moroccan Society of Psychiatry
Nedia Kaadri

National Alliance For Research on Schizophrenia and Depression
Constance E. Liefert, M.D.

National Alliance on Mental Illness
Suzanne Vogel-Sabatka, M.D.

National Association of Psychiatric Health Systems
Diana L. Ramsey, M.D.

National Association of Social Workers, Inc.
Esther Craig de Sibua, D.S.W.

National Council for Community Behavioral Healthcare
Linda Rosenberg, M.S.W.

National Institute of Mental Health
Thomas R. Insel, M.D.

National Institute on Drug Abuse
Nora D. Volkow, M.D.

National Mental Health Association
David L. Shein, Ph.D.

Netherlands Psychiatric Association
Professor R.S. Kohn

Nicaraguan Psychiatric Association
Luis Almeida Neyra, M.D.

Norwegian Psychiatric Association
Gerd-Ragnhild Rholth Thorsen, M.D.

Palestinian Psychiatric Association
Bassam Al Ashhab, M.D.

Panamanian Society of Psychosis
Jesse Calderon, M.D.

Papua New Guinea Psychiatric Association
Monica Hagah, M.D.

Paraguayan Society of Psychiatry
Manuel A. Fresco, M.D.

Peruvian Psychiatric Association
Marta Rondon

Philippine Psychiatrists in America
Nector Riel, M.D.
<table>
<thead>
<tr>
<th>Organization</th>
<th>Country</th>
<th>Representative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philippines Psychiatric Association</td>
<td></td>
<td>Purita Trinidad-Onate, M.D.</td>
</tr>
<tr>
<td>Polish Psychiatric Association</td>
<td></td>
<td>Professor Jacek Wistorka</td>
</tr>
<tr>
<td>Portugese Association of Psychiatry Jost C. Dias Cordeiro, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portuguese Association of Psychiatry and Mental Health</td>
<td></td>
<td>Professor Adriano Vaz-Serra</td>
</tr>
<tr>
<td>Psychiatric Association of Macedonia</td>
<td></td>
<td>Professor Predrag Kirovski</td>
</tr>
<tr>
<td>Psychiatric Association for East Europe and the Balkans</td>
<td></td>
<td>George Christodoulou</td>
</tr>
<tr>
<td>Psychiatric Association of Bosnia-Herzegovina</td>
<td></td>
<td>Narrisa Pojsic</td>
</tr>
<tr>
<td>Psychiatric Association of Guatemala</td>
<td></td>
<td>Ismeal Salatarz, M.D.</td>
</tr>
<tr>
<td>Psychiatric Association of Rio de Janeiro State</td>
<td></td>
<td>Marost A. Gehara Muraro, M.D.</td>
</tr>
<tr>
<td>Psychiatric Association of Serbia and Montenegro</td>
<td></td>
<td>Svetlana Dregic Vujez</td>
</tr>
<tr>
<td>Psychiatric Association of Slovenia</td>
<td></td>
<td>Professor Slavko Ziber</td>
</tr>
<tr>
<td>Psychiatric Association of Thailand</td>
<td></td>
<td>Professor Pichet Udomrast</td>
</tr>
<tr>
<td>Psychiatric Association of Turkey</td>
<td></td>
<td>Haluk Ozbay</td>
</tr>
<tr>
<td>Psychiatric Association of Zimbabwe</td>
<td></td>
<td>S.M. Nnhwawitwa, M.D.</td>
</tr>
<tr>
<td>Psychiatrists Association of Nepal</td>
<td></td>
<td>Devk Raj Bahadur Kenwar, M.D.</td>
</tr>
<tr>
<td>Romanian Psychiatric Association</td>
<td></td>
<td>Professor Tudor Udristeian</td>
</tr>
<tr>
<td>Royal Society of Mental Medicine of Belgium</td>
<td>Belgium</td>
<td>Professor Jean Bertrand</td>
</tr>
<tr>
<td>Russian Society of Psychiatrists</td>
<td></td>
<td>Professor Valery Kraivov</td>
</tr>
<tr>
<td>Salvadoran Association of Psychiatry Francisco A. Paniagua Osogueta, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singapore Psychiatric Association</td>
<td></td>
<td>Hong Choon Chea, M.D.</td>
</tr>
<tr>
<td>Slovak Psychiatric Association</td>
<td></td>
<td>Lixa Varrusova</td>
</tr>
<tr>
<td>Society of Flemish Neurologists and Psychiatrists</td>
<td></td>
<td>Bernard Sabbe</td>
</tr>
<tr>
<td>Society of Georgian Psychiatrists</td>
<td>Georgia</td>
<td>George Nameishvili, M.D.</td>
</tr>
<tr>
<td>Society of Psychiatry of Rio Grande do Sul</td>
<td>Brazil</td>
<td>Lais Kajnik, M.D.</td>
</tr>
<tr>
<td>Society of Psychiatry of Uruguay</td>
<td>Uruguay</td>
<td>Angel Valmaggi, M.D.</td>
</tr>
<tr>
<td>Society Settlement of Physically and Mentally Disabled</td>
<td></td>
<td>Professor Daniel Larbi</td>
</tr>
<tr>
<td>South African Society of Psychiatrists</td>
<td></td>
<td>Merryl Vorster</td>
</tr>
<tr>
<td>Spanish Society of Psychiatry</td>
<td></td>
<td>Enrique Baca Baldomero</td>
</tr>
<tr>
<td>Sri Lanka College of Psychiatrists</td>
<td></td>
<td>Jayan Mendis, M.D.</td>
</tr>
<tr>
<td>Sudanese Association of Psychiatrists</td>
<td></td>
<td>Abdullah Abdelrahman, M.D.</td>
</tr>
<tr>
<td>Swedish Psychiatric Association</td>
<td></td>
<td>Anna-Maria af Sadeberg, M.D.</td>
</tr>
<tr>
<td>Swiss Society of Psychiatry</td>
<td></td>
<td>Hans Kurt, M.D.</td>
</tr>
<tr>
<td>Syrian Arab Association of Psychiatrists</td>
<td></td>
<td>Mohamed Adib Essali</td>
</tr>
<tr>
<td>Taiwanese Society of Psychiatry</td>
<td></td>
<td>Chiua-Chy Chen</td>
</tr>
<tr>
<td>The Psychiatric Evolution</td>
<td></td>
<td>Yves Thoret, M.D.</td>
</tr>
<tr>
<td>The Royal Australian and New Zealand College of Psychiatrists</td>
<td></td>
<td>Ken Kirby, M.D.</td>
</tr>
<tr>
<td>The Royal College of Psychiatrists</td>
<td></td>
<td>Sheila Hollins, M.D.</td>
</tr>
<tr>
<td>Tunisian Society of Psychiatry</td>
<td></td>
<td>Professor Saida Douki Dedieu</td>
</tr>
<tr>
<td>Turkish American Neuropsychiatric Association</td>
<td></td>
<td>Erol Uzer, M.D.</td>
</tr>
<tr>
<td>Turkish Neuro-Psychiatric Association</td>
<td></td>
<td>Professor R. Pykhan Gokalp</td>
</tr>
<tr>
<td>Ukraine Scientific Society of Neurologists, Psychiatrists, and Narcologists</td>
<td>Ukraine</td>
<td>Petro V. Voloshyn</td>
</tr>
<tr>
<td>Ukrainian Psychiatric Association</td>
<td></td>
<td>Professor Victor Shumidyansky</td>
</tr>
<tr>
<td>University Hospital Center-Tirana</td>
<td></td>
<td>Professor Anastas Suli</td>
</tr>
<tr>
<td>Venezuelean Society of Psychiatry</td>
<td></td>
<td>Professor Guillermo Ginnari Antich</td>
</tr>
<tr>
<td>World Association for Dynamic Psychiatry</td>
<td></td>
<td>Nikolay Neznanov</td>
</tr>
<tr>
<td>Yemen Psychiatrists and Neurologists Association</td>
<td></td>
<td>Professor Abdelmagid S. Al-Khulaidi</td>
</tr>
<tr>
<td>YUCO- Association of Psychiatric Institutions of Serbia and Montenegro</td>
<td></td>
<td>Jonan Maric</td>
</tr>
<tr>
<td>Yugoslav Psychiatric Association</td>
<td></td>
<td>Professor Mirko Pajovic</td>
</tr>
</tbody>
</table>
Join APA at The Annual Meeting and Qualify for a Rebate

How Do I Qualify?

You may qualify if you:

1. Are a psychiatrist residing in the U.S. or Canada and:

2. Have paid the full-time registration fees at the Annual meeting ($895; January, $980; March)

How Do I Apply?

1. Stop by one of the Membership booths either in the Registration area (near the Registrar) or in the APA Member Center (Exhibit Hall B) to fill out an APA Membership Application. The application must be submitted onsite during the meeting at one of these locations.

2. Additional documentation (proof of ACGME, AOA, or RCPs/C-approved psychiatry residency training and a current, valid medical license) must be received by APA no later than June 30, 2007.

How Does The Rebate Work?

1. Your local psychiatric district branch must approve the application no later than September 30, 2007.

2. The difference between the member and non-member rate will be applied toward your pro-rated 2007 national and local dues. The remaining balance of the rebate amount will be sent directly to you or if you choose, we can apply the remaining balance to your 2008 dues. It’s up to you!

Why Should I Join?

Please stop by one of the Membership booths to learn more about the many benefits and privileges of APA membership.

*Outstanding dues from previous years may be deducted in some cases.
Save the date now to attend the American Psychiatric Association's 59th Institute on Psychiatric Services, APA's leading educational conference on clinical issues and community mental health to meet the service needs of people with severe mental illness. Check out our website at www.psych.org/IPS2007.

This four-day event will feature more than 100 exhibits that complement the educational program, popular networking events, and over 200 expertly-led educational sessions on topics including: Violence, Trauma, and Victimization; Social and Community Psychiatry; Psychopharmacology; Resident and Medical Student Concerns; Disorders; Cross-Cultural and Minority Issues; Psychiatric Administration and Services; Treatment Techniques and Outcome Studies; Cognitive Disorders; Health Service Research; Mood Disorders; Schizophrenia and Other Psychotic Disorders; and much more...

Who Should Attend?
• All APA Members
• Psychiatrists and mental health professionals in community practice or the public sector including state and Veterans Affairs hospitals, community clinics, and jails and prisons
• Psychiatric Administrators
• Mental health professionals interested in social issues that have an impact on patients and their families
• Minority psychiatrists and International Medical Graduates
• Psychiatric Residents (only $60 for advance registration)
• Nonmember Residents and Advocacy Group Members (only $85 for advance registration)
• Medical Students (free registration)

Why Should You Attend?
• This activity has been approved for AMA PRA category 1 credit and CEU credit
• Receive a 40% discount on APA member registration fees
• Network with colleagues at receptions and other events
• Industry-supported lunch and dinner symposia
• Valuable exhibit hall prizes drawn each day

How Will You Benefit?
• Learn about the latest updates and acquire new skills in clinical psychiatry, that can be utilized to improve patient care;
• Acquire a deeper understanding of how the current health care system affects patient care;
• Demonstrate and apply new skills useful in clinical and public psychiatry settings;
• Recognize and improve mental health disparities in the community; and
• Understand all aspects of recovery and how this affects families and the community.

Preliminary Program
The Preliminary Program, which includes registration, housing, and travel information will be available in May at www.psych.org/IPS2007 or call 1-888-35-PSYCH and request a copy. Online registration will begin on June 1.

For more information, please contact:
American Psychiatric Association
1000 Wilson Blvd., Suite 1825
Arlington, VA 22209-3901
Phone: 1-888-35-PSYCH or (703) 907-7300
Fax: (703) 907-1090
E-mail: apa@psych.org
Web: www.psych.org/IPS2007
MONDAY, MAY 21, 2007

160TH ANNUAL MEETING

7:00 a.m. Sessions

PART 1 OF INDUSTRY SUPPORTED BREAKFAST SYMPOSIA 22-24

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 22, PART 1
7:00 a.m.-8:30 a.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

LIFTING THE BURDEN OF PSYCHIATRIC ILLNESS: THE MANAGEMENT OF ALLOSTATIC LOAD, METABOLIC SYNDROME, AND CO-OCCURRING DISORDERS
Supported by Solvay Pharmaceuticals-Wyeth Pharmaceuticals

Chp.: Mark H. Rapaport, M.D.

A The Heart of the Matter: Allostatic Load and Psychiatric Disorders
Robert B. Lydaier, M.D.

B Co-occurring Disorders: The Complex Interplay Between Psychiatric Syndromes, Substance Use, and Health
Kathleen T. Brady, M.D.

C Psychotropic Medications, Psychiatric Illness, and Weight Gain
Rohan Ganguli, M.D.

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 23, PART 1
7:00 a.m.-8:30 a.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

HOW DO ATYPICALS AND ANTIPSYCHOTICS WORK?: FROM RECEPTORS TO REALITY
Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Mechanisms of Antipsychotic Efficacy: Linking Pharmacology to Phenomenology
Shitij Kapur, M.D.

B Neurobiology of Schizophrenia: From Basic Science to Clinical Practice
Gordon Frankel, M.D.

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 24, PART 1
7:00 a.m.-8:30 a.m.
Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

TREATING THE SPECTRUM OF BIPOLAR DISORDERS: AN INTERACTIVE CASE DISCUSSION
Supported by AstraZeneca Pharmaceuticals

Chp.: Michael E. Thase, M.D.

A Psychotherapy and Bipolar Depression
Holly Swartz

B Antidepressants in Bipolar Depression: A Two-Sided Story
Michael E. Thase, M.D.

RESIDENTS’ SESSION
7:00 a.m.-8:30 a.m.
San Diego Ballroom A, North Tower, Lobby Level, Marriott

MEET THE EXPERTS: SUNNY-SIDE UP

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Carolyn B. Robinowitz, M.D.

At this breakfast, nationally-recognized experts will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include: Academic Psychiatry, Addiction Psychiatry, Administrative Psychiatry, Child and Adolescent Psychiatry, Cultural Competency, Ethics, Forensic Psychiatry, Geriatric Psychiatry, Leadership, Neuropsychiatry, Psychodynamic Psychotherapy, Psychosomatic Medicine, Public and Community Psychiatry, Research, and Women’s Mental Health.

8:00 a.m. Sessions

COURSES 33-41

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 33 8:00 a.m.-12 noon
Elizabeth Ballroom F, Second Level, Manchester Grand Hyatt

ADD IN CHILDREN AND ADOLESCENTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 34 8:00 a.m.-12 noon
Edward Room A/B, Second Level, Manchester Grand Hyatt

ENGAGING RESISTANT AND DIFFICULT-TO-TREAT PATIENTS IN COLLABORATIVE TREATMENT

Director: David Mee-Lee, M.D.
MONDAY

COURSE 35 8:00 a.m.-12 noon
Molly Room A/B, Second Level, Manchester Grand Hyatt

FAMILY SKILLS FOR THE GENERAL PSYCHIATRIST

Director: Alison M. Heru, M.D.
Faculty: Laura M. Drury, M.S.W.

COURSE 36 8:00 a.m.-12 noon
Ford Room A/B/C, Third Level, Manchester Grand Hyatt

TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!

Director: Steven E. Hyler, M.D.
Faculty: Jeremy R. Butler, M.D., Michael B. First, M.D.,
Carol A. Bernstein, M.D.

COURSE 37 8:00 a.m.-12 noon
Madeleine Room C/D, Third Level, Manchester Grand Hyatt

BEHAVIORAL NEUROANATOMY: AN INTRODUCTION

Director: Nashaat N. Boutros, M.D.
Faculty: Edward C. Lauterbach, M.D., David Clark, M.D.

COURSE 38 8:00 a.m.-12 noon
Mohsen Room A/B, Third Level, Manchester Grand Hyatt

THE EVALUATION AND TREATMENT OF PHYSICIANS INVOLVED IN SEXUAL MISCONDUCT AND/OR SEXUAL HARASSMENT

Co-Directors: Gene G. Abel, M.D., Tracey I. Marks, M.D.
Faculty: Richard B. Krueger, M.D.

COURSE 39 8:00 a.m.-12 noon
Emma Room A/B/C, Third Level, Manchester Grand Hyatt

THE DETECTION OF MALINGERED MENTAL ILLNESS

Director: Phillip J. Resnick, M.D.

COURSE 40 8:00 a.m.-12 noon
Windsor Room, Third Level, Manchester Grand Hyatt

FAMILIES COPING WITH MEDICAL ILLNESS: A TREATMENT APPROACH FOR PSYCHIATRY

Director: John S. Rolland, M.D.

COURSE 41 8:00 a.m.-5:00 p.m.
Elizabeth Ballroom G, Second Level, Manchester Grand Hyatt

OFFICE-BASED BUPRENORPHINE TREATMENT OF OPIOID-DEPENDENT PATIENTS

Co-Directors: Gerardo Gonzalez, M.D., Laura McNicholas, M.D.
Faculty: Andrew J. Saxon, M.D., Eric C. Strain, M.D.

9:00 a.m. Sessions

CASE CONFERENCE 1
9:00 a.m.-10:30 a.m.
Room 23 A/B, Upper Level, San Diego Convention Center

PSYCHODYNAMIC PSYCHOTHERAPY OF BPD

Moderator: Glen O. Gabbard, M.D.
Presenters: John G. Gunderson, M.D., Lois W. Choi-Kain, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 42-48

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 42 9:00 a.m.-4:00 p.m.
Elizabeth Ballroom H, Second Level, Manchester Grand Hyatt

ADVANCES IN NEUROPSYCHIATRY

Co-Directors: C. Edward Coffey, M.D., Jeffrey L. Cummings, M.D.
Faculty: Thomas W. McAllister, M.D., Michael R. Trimble, M.D.,
Matthew A. Menza, M.D., Mark S. George, M.D.

COURSE 43 9:00 a.m.-4:00 p.m.
Edward Room C/D, Second Level, Manchester Grand Hyatt

PERSONALITY AND POLITICAL BEHAVIOR

Director: Jerrold M. Post, M.D.

COURSE 44 9:00 a.m.-4:00 p.m.
Gregory Room A/B, Second Level, Manchester Grand Hyatt

TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT

Director: Robert P. Granacher, Jr., M.D.

COURSE 45 - WITHDRAWN

COURSE 46 9:00 a.m.-4:00 p.m.
Del Mar Room A/B, Third Level, Manchester Grand Hyatt

COGNITIVE THERAPY ON THE FLY

Co-Directors: Ari E. Zaritsky, F.R.C.P.C., Mark Fefergrad, M.D.
COURSE 47
9:00 a.m.-4:00 p.m.
Annie Room A/B, Third Level, Manchester Grand Hyatt

DAVANLOO’S INTENSIVE SHORT-TERM DYNAMIC
PSYCHOTHERAPY IN CLINICAL PRACTICE

Co-Directors: James Q. Schubmehl, M.D., Alan R. Beeber, M.D.

COURSE 48
9:00 a.m.-4:00 p.m.
Randle Ballroom A, Fourth Level, Manchester Grand Hyatt

LOVE, DESIRE, INTIMACY, AND INFIDELITY

Director: Stephen B. Levine, M.D.

MONDAY

FOCUS LIVE SESSION 1
9:00 a.m.-10:30 a.m.
Room 1 A/B, Upper Level, San Diego Convention Center

PSYCHOPHARMACOLOGY

Moderators: Mark H. Rapaport, M.D., Deborah J. Hales, M.D.
Presenter: Stephen M. Stahl, M.D.

Expert clinicians, who served as the guest editors of the first two issues of Focus, will lead lively multiple-choice, question-based discussions. This session covers Psychopharmacology, the second session at 11:00 a.m. covers Substance Related Disorders, and the third session at 2:00 p.m. covers Genetics and Psychiatry. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 3-5

LECTURE 3
9:00 a.m.-10:30 a.m.
Ballroom 6 B, Upper Level,
San Diego Convention Center

APA’S SOLOMON CARTER FULLER
AWARD LECTURE

David C. Henderson, M.D.

From Psychopharmacology to
Ethnopsychopharmacology and Back to
Psychopharmacology

Chp.: Michele Reid, M.D.

David C. Henderson, M.D., is Associate Professor of Psychiatry at Harvard Medical School and Director of the Schizophrenia, Diabetes and Weight Reduction Research at Massachusetts General Hospital, both in Boston, Massachusetts. He is the Director of the Clozapine Program at the Erich Lindemann Mental Health Center, and Associate Director of the Schizophrenia Clinical and Research Program and Associate Director, Division of International Psychiatry at Massachusetts General Hospital, Massachusetts General Hospital. He also served as Medical Director for the Harvard Program in Refugee Trauma at Harvard Medical School. Dr. Henderson received his undergraduate degree at Tufts University in Massachusetts and received his medical degree at the University of Massachusetts Medical School. Following his internship at St. Elizabeth’s Hospital in Boston, he completed his residency at Massachusetts General Hospital and trained as Chief Resident and Research Fellow of the Freedom Trail Clinic at the Erich Lindemann Mental Health Center, also in Boston. Dr. Henderson’s main research interests focus on psychopharmacological and antipsychotic agents in the treatment of schizophrenia, impacts of antipsychotic agents on metabolic anomalies and glucose metabolism, and ethnic and cultural impacts on psychiatry. He also studies the impact of trauma in areas of mass violence and develops programs to assist vulnerable populations which include projects in Rwanda, Cambodia, East Timor, Bosnia, Peru, New Orleans, and New York City. Dr. Henderson has lectured extensively throughout the United States and internationally on schizophrenia, treatment-resistant schizophrenia, metabolic disorders and schizophrenia, psychopharmacology, ethnopsychopharmacology, trauma, and cultural psychiatry. He has published numerous peer review articles, chapters, and reviews including in journals such as the Archives of General Psychiatry, American Journal of Psychiatry, and Biological Psychiatry.

THIS SESSION WILL BE AUDIOTAPED.
Lecture 4
9:00 a.m.-10:30 a.m.
Ballroom 6 C/D/E/F, Upper Level,
San Diego Convention Center

Congressman Patrick J. Kennedy

The Road to Equity: Marching Toward a Just
Treatment of Mental Illness and Addiction in America
Collaborative Session With the National Institute on Drug Abuse

Chp.: James H. Scully Jr., M.D.
Co-Chp.: Nora Volkow, M.D.

Congressman Patrick J. Kennedy has made mental health reform one of the highest priorities of his legislative career. Congressman Kennedy is the lead Democratic House cosponsor of the Paul Wellstone Equitable Treatment Act, which would end insurance discrimination against mental illness. Working with both Democratic and Republican colleagues, he has built a bipartisan majority in favor of the bill three Congresses in a row. He has authored numerous other pieces of mental health legislation, including the Child Healthcare Crisis Relief Act to help alleviate the critical shortage of child mental health providers and the Positive Aging Act to improve mental health services for seniors. Congressman Kennedy and a bipartisan group of colleagues wrote the Keeping Families Together Act to end the abominable practice of states conditioning mental health care for seriously emotionally disturbed children on their parents' relinquishment of custody. In 2004, he co-founded the House Addiction Treatment and Recovery Caucus, which he co-chairs. Since taking his seat on the Appropriations Committee in 2001, Congressman Kennedy has been the leading proponent for mental health funding on the Labor-Health-Education and Science-State-Commerce-Justice Subcommittees. From that position, he has successfully advocated for funding of mental health programs, including increases in the mental health block grant, creation of a new initiative to promote mental health among seniors, and appropriations for a new jail diversion program. Most recently, in 2006, a Kennedy amendment to the Higher Education Act to provide loan forgiveness for child and adolescent mental health professionals passed the House with 373 votes. Kennedy also worked with Democratic and Republican members of the Education and Workforce Committee to add provisions aimed at improving mental health care for seniors to the Older Americans Act. Kennedy speaks frequently on mental health issues and serves on the Advisory Board of the University of Michigan's Depression Center and is an Honorary Board Member of the Mental Health Association of Rhode Island.

This session will be audiotaaped.

Lecture 5
9:00 a.m.-10:30 a.m.
Room 33 A/B/C, Upper Level,
San Diego Convention Center

Ronald S. Duman, Ph.D.

A Neurotrophic Hypothesis of Depressions and Antidepressant Response

Chp.: Kathryn Connor, M.D.

Dr. Duman is Professor of Psychiatry and Pharmacology and Director of the Abraham Ribicoff Research Facilities at the Yale University School of Medicine. He received his Ph.D. from the University of Texas Medical School in Neuropharmacology and joined the Yale faculty in 1988. He became tenured in 1997 and was named the Elizabeth Mears and House Jameson Professor of Psychiatry in 2000. Dr. Duman has received several prestigious awards for his work on depression including the Anna-Monika Prize (2001), the Nola Maddox Falcone Prize (2002), the Janssen Prize for Research in Psychopharmacology (2003), a NIMH MERIT Award (2005), a NARSAD Distinguished Investigator Award (2005), and the College of International Neuropsychopharmacology (CINP) Basic Research Award (2006). He is author of over 225 original articles, reviews and chapters and has given over 150 invited lectures. Studies from Dr. Duman's laboratory have contributed to the characterization of the molecular and cellular actions of antidepressants and stress, providing the basis for a neurotrophic hypothesis of depression. This hypothesis is based on work from Dr. Duman's laboratory demonstrating that chronic antidepressant treatment increases the expression of neurotrophic factors, and increases the proliferation of new neurons in the adult brain. Up-regulation of these neurotrophic factors and neurogenesis counteract the atrophy and cell loss that is caused by stress and that is thought to underlie, in part, the pathophysiology of depression. Dr. Duman's work has demonstrated that increased neurotrophic factor expression and neurogenesis contribute to the actions of antidepressant treatment. These findings represent major advances in our understanding of the effects of antidepressants and provide a framework for the development of novel therapeutic agents.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPE.
NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 1
9:00 a.m.-10:30 a.m.
Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research submissions, please refer to the New Research Program Book included in your registration packet.

SMALL INTERACTIVE SESSIONS 1-4
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Joel Yager, M.D., on APA Practice Guidelines on the Treatment of Patients With Eating Disorders and Forthcoming Clinical Manual on Eating Disorders (Meet the Authors)</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 27 B, Upper Level, San Diego Convention Center</td>
</tr>
<tr>
<td>2</td>
<td>Lisa Mellman, M.D., on Teaching Psychotherapy: How Relevant Are Psychoanalytic Concepts</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 29 A/B, Upper Level, San Diego Convention Center</td>
</tr>
<tr>
<td>3</td>
<td>Russell F. Lim, M.D., on What Does Cultural Competence Mean in the Real World?</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 31 C, Upper Level, San Diego Convention Center</td>
</tr>
<tr>
<td>4</td>
<td>Iqbal Ahmed, M.D., on Issues in Geriatric Psychiatry</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 32 B, Upper Level, San Diego Convention Center</td>
</tr>
</tbody>
</table>

WORKSHOPS

COMPONENTS 1-12

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 1</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 2, Upper Level, San Diego Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>A MODEL CURRICULUM FOR TEACHING THE WORKING ALLIANCE AS A CORE PROCESS ACROSS PSYCHOTHERAPIES APA Committee on Psychotherapy by Psychiatrists</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 2, Upper Level, San Diego Convention Center</td>
</tr>
<tr>
<td>Chp.: Eric M. Plakun, M.D.</td>
<td>Participants: Donna M. Sudak, M.D., Bernard D. Buitman, M.D., David A. Goldberg, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 2</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 2, Upper Level, San Diego Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>REENTRY AFTER PRISON: REJOINING THE COMMUNITY APA Corresponding Committee on Jails and Prisons</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 2, Upper Level, San Diego Convention Center</td>
</tr>
<tr>
<td>Chp.: Henry C. Weinstein, M.D.</td>
<td>Participants: William Arroyo, M.D., Erik Roskes, M.D., H. Richard Lamb, M.D., Cassandra F. Newkirk, M.D., Tom Hamilton, Ph.D.</td>
<td></td>
</tr>
</tbody>
</table>

| COMPONENT WORKSHOP 3 | 9:00 a.m.-10:30 a.m. | Room 4, Upper Level, San Diego Convention Center |
| COMMITTING OCCUPATIONAL SUICIDE: A PSYCHIATRIC EMERGENCY APA Corresponding Committees on Psychiatry in the Workplace | 9:00 a.m.-10:30 a.m. | Room 5 A, Upper Level, San Diego Convention Center |
| Chp.: Andrea Stolar, M.D. | Participants: Marcia Scott, M.D., Marie-Claude Rigaud, M.D., Marilyn Price, M.D., Aron S. Wolf, M.D., Steven E. Pfiznan, M.D. |

| COMPONENT WORKSHOP 4 | 9:00 a.m.-10:30 a.m. | Room 5 B, Upper Level, San Diego Convention Center |
| PROVIDING OPTIMUM CARE FOR PATIENTS WITH MENTAL RETARDATION AND DEVELOPMENTAL DISABILITIES IN THE PSYCHIATRIC EMERGENCY ROOM APA Committee on Developmental Disabilities | 9:00 a.m.-10:30 a.m. | Room 5 B, Upper Level, San Diego Convention Center |
| Chp.: Katherine A. Stratigos, M.D. | Participants: Joel Bregman, M.D., Stephanie Hamarman, M.D., John de Figueiredo, M.D., Ramakrishnan Shenoy, M.D. |

| COMPONENT WORKSHOP 5 | 9:00 a.m.-10:30 a.m. | Room 5 B, Upper Level, San Diego Convention Center |
| OBESITY IN OUR YOUTH: THE WEIGHT OF MENTAL ILLNESS APA/SAMHSA Minority Fellowship Selection and Program Corresponding Committee | 9:00 a.m.-10:30 a.m. | Room 5 B, Upper Level, San Diego Convention Center |

| COMPONENT WORKSHOP 6 | 9:00 a.m.-10:30 a.m. | Ballroom 6 E, Upper Level, San Diego Convention Center |
| HOW TO BECOME A MORE CREATIVE TEACHER: WINNING STRATEGIES FOR RESIDENTS AND FACULTY APA Council on Medical Education and Lifelong Learning | 9:00 a.m.-10:30 a.m. | Ballroom 6 E, Upper Level, San Diego Convention Center |
| Chp.: Joan M. Anzia, M.D., Lowell D. Tong, M.D. | Participants: Margo Lauterbach, M.D., Jerald Kay, M.D., Theodore Feldman, M.D., Rachel C. Molander, M.D. |

| COMPONENT WORKSHOP 7 | 9:00 a.m.-10:30 a.m. | Room 7 A, Upper Level, San Diego Convention Center |
| BEYOND POWERPOINT: HOW TECHNOLOGY CAN IMPROVE MENTAL HEALTH TRAINING APA Ad Hoc Work Group on Information Systems | 9:00 a.m.-10:30 a.m. | Room 7 A, Upper Level, San Diego Convention Center |
| Co-Chps.: Seth Powsner, M.D., Sharon Packer, M.D. | Participants: Thomas J. Kim, M.D., Willadene Walker-Schmacker, M.D. |
MONDAY

COMPONENT WORKSHOP 8  9:00 a.m.-10:30 a.m.  
Room 7 B, Upper Level, San Diego Convention Center

MENTAL HEALTH TRANSFORMATION: IS IT FOR REAL?  
*APA Committee on Psychiatric Administration and Management*

Chp.: I. Mark Russakoff, M.D.
Participants: Sy A. Saeed, M.D., Brian M. Hepburn, M.D., Lydia E. Weisser, D.O.

COMPONENT WORKSHOP 9  9:00 a.m.-10:30 a.m.  
Room 9, Upper Level, San Diego Convention Center

MENTAL HEALTH AND MEN WHO HAVE SEX WITH MEN IN THE AFRICAN-AMERICAN COMMUNITY: CONTROVERSIES ABOUT THE DOWN LOW  
*APA Committee on Gay, Lesbian, and Bisexual Issues and the APA Committee of Black Psychiatrists*

Co-Chps.: Loudes M. Dominguez, M.D., Napoleon B. Higgins Jr., M.D.
Participants: Kelvin Exum, M.D., Sandra C. Walker, M.D., Saundra A. Maass-Robinson, M.D.

COMPONENT WORKSHOP 10  9:00 a.m.-10:30 a.m.  
Room 11 B, Upper Level, San Diego Convention Center

GENDER AND CULTURE IN ACADEMIC LEADERSHIP: IMPROVING THE CURRENT STATE FOR WOMEN  
*APA Women Psychiatrists*

Chp.: Roslyn Seligman, M.D.
Participants: Vivian Reznik, M.D., Robert Freedman, M.D., Ming T. Tsuang, M.D.

COMPONENT WORKSHOP 11  9:00 a.m.-10:30 a.m.  
Room 24 B, Upper Level, San Diego Convention Center

OPTIMIZING DEPRESSION TREATMENT: CLINICAL APPLICATIONS OF MEASUREMENT-BASED CARE  
*APA American Psychiatric Institute For Research And Education*

Co-Chps.: Farifitch F. Duffy, Ph.D., Jack S. McIntyre, M.D.
Participants: David J. Katzelnick, M.D., Henry Chung, M.D., Madhukar H. Trivedi, M.D., Darrel A. Regier, M.D.

COMPONENT WORKSHOP 12  9:00 a.m.-10:30 a.m.  
Room 32 A, Upper Level, San Diego Convention Center

REACHING OUT: APPROACHES TO SUICIDE AMONGST THE PHYSICIAN POPULATION  
*APA Corresponding Committee on Physician Health, Illness, and Impairment*

Chp.: Malkah T. Nortman, M.D.
Participants: Derek Puddester, M.D., Penelope P. Ziegler, M.D., Michael F. Myers, M.D.

ISSUES 1-16

ISSUE WORKSHOP 1  9:00 a.m.-10:30 a.m.  
Room 23 C, Upper Level, San Diego Convention Center

HEADSPACE THEATRE: AN INNOVATIVE METHOD FOR EXPERIENTIAL LEARNING OF PSYCHIATRIC SYMPTOMATOLOGY USING MODIFIED ROLE-PLAYING AND IMPROVISATIONAL THEATRE TECHNIQUES ASSOCIATION FOR ACADEMIC PSYCHIATRY

Chp.: Bruce Ballon, M.D.
Participants: Ivan Silver, M.D., Donald C. Fidler, M.D.

ISSUE WORKSHOP 2  9:00 a.m.-10:30 a.m.  
Room 24 A, Upper Level, San Diego Convention Center

RISK MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE

Co-Chps.: Jacqueline M. Melonas, J.D., Martin G. Tracy, J.D.
Participants: Marynell Hinton, M.A., Donna Vanderpool, J.D.

ISSUE WORKSHOP 3  9:00 a.m.-10:30 a.m.  
Room 24 C, Upper Level, San Diego Convention Center

CHILDREN OF PSYCHIATRISTS

Co-Chps.: Michelle B. Risa, M.D., Leah J. Dickstein, M.D.
Participants: Jessica Goin, Stephanie A. Zisook, M.D., Jessica L. Worley

ISSUE WORKSHOP 4  9:00 a.m.-10:30 a.m.  
Room 25 A, Upper Level, San Diego Convention Center

PSYCHIATRY AND THE MEDICAL HUMANITIES

Co-Chps.: Bret R. Rutherford, M.D., David J. Hellerstein, M.D.
Participant: Kay R. Jamison, M.D.

ISSUE WORKSHOP 5  9:00 a.m.-10:30 a.m.  
Room 25 C, Upper Level, San Diego Convention Center

LESSONS FROM TEACHING INTERVIEWING TO INTERNATIONAL RESIDENTS: INTEGRATING CULTURAL COMPETENCY FROM THE START OF TRAINING

Chp.: Jacob Sperber, M.D.
Participants: Nyapat Rho, M.D., Milton Kramer, M.D.

ISSUE WORKSHOP 6  9:00 a.m.-10:30 a.m.  
Room 26 A/B, Upper Level, San Diego Convention Center

GRANTWRITING WORKSHOP: RESEARCH FUNDING OPPORTUNITIES FROM THE Collaborative Session With the National Institute on Drug Abuse

Chp.: Lucinda L. Miner, Ph.D.
Participants: Joseph Frascella, Ph.D., Teresa Levitin, Ph.D.
ISSUE WORKSHOP 7 9:00 a.m.-10:30 a.m.  
Room 27 A, Upper Level, San Diego Convention Center

GENE ENVIRONMENT DEVELOPMENT  
INTERACTIONS: IMPLICATIONS FOR PSYCHIATRIC AND SUBSTANCE ABUSE DISORDERS

Collaborative Session With the National Institute on Drug Abuse

Chp.: Julia Kim-Cohen, Ph.D.  
Participants: Jonathan D. Pollock, Ph.D., Stephen J. Suomi, Ph.D.,  
Cornelius T. Gross, Ph.D., Frances A. Champagne, Ph.D.,  
Kathleen R. Merikangas, Ph.D.

ISSUE WORKSHOP 8 9:00 a.m.-10:30 a.m.  
Room 28 A, Upper Level, San Diego Convention Center

ASSESSMENT OF CAPACITY: A MULTIMEDIA APPROACH TO ENHANCING CLINICAL SKILLS IN DIFFERENT CULTURAL AND LEGAL SETTINGS

Collaborative Session With the National Institute on Drug Abuse

Co-Chps.: M.E. Jan Wise, M.B.Ch.B., Julian Beechhold, M.B.Ch.B.

ISSUE WORKSHOP 9 9:00 a.m.-10:30 a.m.  
Room 28 C, Upper Level, San Diego Convention Center

PREVENTION OF BURDEN AND BURNOUT IN CAREGIVERS AT HOME AND HEALTHCARE WORKERS IN LONG-TERM CARE SETTINGS

Chp.: Sanjay M. Vaswani, M.D.  
Participants: Anita R. Patel, M.D., Chuck Wall, Ph.D.

ISSUE WORKSHOP 10 9:00 a.m.-10:30 a.m.  
Room 28 D/E, Upper Level, San Diego Convention Center

GOING TO THE HEART OF THE MATTER IN PATIENT INTERVIEWS: A FURTHER EXPLORATION

Chp.: Harold J. Bursztajn, M.D.  
Participants: Max Day, M.D., Thomas G. Guthiel, M.D., Robindra K. Paul, M.D., Beata A. Zolovska, M.D., David Mobley, M.D.

ISSUE WORKSHOP 11 9:00 a.m.-10:30 a.m.  
Room 30 A, Upper Level, San Diego Convention Center

PRACTICAL PHARMACOTHERAPY FOR THE TREATMENT OF ALCOHOL DEPENDENCE

Chp.: Robert M. Swift, M.D.  
Participants: Roger D. Weiss, M.D., Allen Zweben, D.S.W.

ISSUE WORKSHOP 12 9:00 a.m.-10:30 a.m.  
Room 30 B, Upper Level, San Diego Convention Center

THE TRAUMA OF WAR: UNDERSTANDING INTERVENTIONS IN A DEVELOPMENTAL CONTEXT

Chp.: Steven M. Weine, M.D.  
Participants: Lynn M. Jones, M.D., Christopher M. Laync, Ph.D.,  
Patricia Lester, M.D., Alisa J. Land, M.D.

ISSUE WORKSHOP 13 9:00 a.m.-10:30 a.m.  
Room 30 C, Upper Level, San Diego Convention Center

METABOLIC SCREENING OF PATIENTS ON ANTIPSYCHOTIC MEDICATIONS: IMPLEMENTATION OF A QUALITY IMPROVEMENT PROGRAM IN AN URBAN TRAINING CLINIC

Co-Chps.: Diane B. Gottlieb, M.D., Aurelia N. Bizamecer, M.D.  
Participants: Chioma Inegwara, D.O., April S. Ladavac, M.D.,  
Shaneek Johnson, M.D., Kathleen Diller, M.D., Jiean Kim, M.D.

ISSUE WORKSHOP 14 9:00 a.m.-10:30 a.m.  
Room 30 D/E, Upper Level, San Diego Convention Center

INTERNET CHILD PORNOGRAPHY AND MENTAL ILLNESS: THE PSYCHIATRIST'S ROLE

Chp.: Humberto Temporini, M.D.  
Participants: Charles L. Scott, M.D., Vladimir Coric, M.D.

ISSUE WORKSHOP 15 9:00 a.m.-10:30 a.m.  
Room 31 A, Upper Level, San Diego Convention Center

CHALLENGING THE STATUS QUO: CENTRALIZED ASSESSMENTS IN PSYCHIATRIC CLINICAL TRIALS

Chp.: John M. Kane, M.D.  
Participants: Janet B.W. Williams, D.S.W., Maurizio Fava, M.D.,  
William Z. Potter, Ph.D., Jack A. Grebb, M.D., Andrew C. Leon, Ph.D.

ISSUE WORKSHOP 16 9:00 a.m.-10:30 a.m.  
Room 31 B, Upper Level, San Diego Convention Center

ACHIEVING MEDICATION ADHERENCE BY UNDERSTANDING

Chp.: Stephen N. Wilson, M.D.

MEDIA 1-2

MEDIA WORKSHOP 1 9:00 a.m.-12 noon  
Room 10, Upper Level, San Diego Convention Center

PERSONAL TRANSFORMATION THROUGH AN ENCOUNTER WITH DEATH: AKIRA KUROSAWA'S IKIRU

Chp.: Francis G. Lu, M.D.

MEDIA WORKSHOP 2 9:00 a.m.-12 noon  
Room 11 A, Upper Level, San Diego Convention Center

BROKEBACK MOUNTAIN: THE MYTH, THE REALITY, AND THE CONTROVERSY

APA New York County District Branch's Committee on Gay and Lesbian Issues

Chp.: Kenneth Ashley, M.D.  
Participants: Dann Michaeli, M.D., Daniel Garza, M.D.,  
Steven J. Lee, M.D.
MONDAY

10:30 a.m. Session

ADVANCES IN RESEARCH
10:30 a.m.-12:30 p.m.
Ballroom 6A, Upper Level, San Diego Convention Center

RESEARCH ADVANCES IN PSYCHIATRY

Chp.: Herbert Pardes, M.D.
Co-Chp.: Robert W. Guynn, M.D.
Presenters: Jeffrey A. Lieberman, M.D., Karen D. Wagner, M.D., Susan G. Koran, M.D., Barnett S Meyers, M.D.
THIS SESSION WILL BE AUDIOTAPE.

11:00 a.m. Sessions

ADVANCES IN MEDICINE 1
11:00 a.m.-12:30 p.m.
Room 2, Upper Level, San Diego Convention Center

NEW INTEGRATIVE TREATMENTS FOR PTSD AND CHRONIC FATIGUE, DISORDERS OF AUTONOMIC FUNCTION

Chp.: Patricia L. Gerberg, M.D.
Participants: Richard P. Brown, M.D.
THIS SESSION WILL BE AUDIOTAPE.

FOCUS LIVE SESSION 2
11:00 a.m.-12:30 p.m.
Room 1 A/B, Upper Level, San Diego Convention Center

SUBSTANCE RELATED DISORDERS

Moderators: Mark H. Rapaport, M.D., Deborah J. Hales, M.D.
Presenter: Thomas R. Kosten, M.D.

Expert clinicians, who served as the guest editors of the first two issues of Focus, will lead lively multiple-choice, question-based discussions. This session covers Substance Related Disorders, the first session at 9:00 a.m. covered Psychopharmacology, and the third session at 2:00 p.m. will cover Genetics and Psychiatry. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 6-7

LECTURE 6
11:00 a.m.-12:30 p.m.
Ballroom 6 B, Upper Level, San Diego Convention Center

APA'S OSKAR PFISTER AWARD LECTURE

William R. Miller, Ph.D.

Spiritus Contra Spiritum: The Strange Case of Spirituality and Addiction

Chp.: John R. Peteet, M.D.

Dr. William R. Miller is Emeritus Distinguished Professor of Psychology and Psychiatry at the University of New Mexico, where he joined the faculty in 1976 after receiving his Ph.D. in clinical psychology from the University of Oregon. He served as Director of Clinical Training for UNM's APA-approved doctoral program in clinical psychology and as Co-Director of UNM's Center on Alcoholism, Substance Abuse and Addictions (CASAA). Dr. Miller's publications include 35 books and over 400 articles and chapters. Fundamentally interested in the psychology of change, he has focused in particular on the development, testing, and dissemination of behavioral treatments for addictions. He served as principal investigator for numerous research grants and contracts, founded a private practice group, and served as a consultant to many organizations including the United States Senate, the World Health Organization, the National Academy of Sciences, and the National Institutes of Health. In recognition of his research contributions, Dr. Miller is a recipient of the international Jellinek Memorial Award, a career achievement award from the American Psychological Association, and an Innovators in Combating Substance Abuse award from the Robert Wood Johnson Foundation. He maintains an active interest in pastoral counseling and the integration of spirituality and psychology. The Institute for Scientific Information lists him as one of the world's most cited scientists.

THIS SESSION WILL BE AUDIOTAPE.

LECTURE 7
11:00 a.m.-12:30 p.m.
Ballroom 6 C/D/E/F, Upper Level, San Diego Convention Center

APA'S ADMINISTRATIVE PSYCHIATRY AWARD LECTURE

Jon E. Gudeman, M.D.

Chp.: L. Mark Russakoff, M.D.

Jon E. Gudeman, M.D., is Director of the Center for Psychotherapy at Columbia-St. Mary's Hospital and Professor of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin in Milwaukee. Dr. Gudeman earned his bachelor's and medical degrees at Harvard University. After a medical internship at the University of Chicago Hospitals and Clinic, he did his psychiatric residency at the Massachusetts Mental Health Center (Chief Resident 1966-67) and trained at the Boston Psychoanalytic Institute. On behalf of the Massachusetts Menta Health Center he received the Gold Award from the Hospital & Community Psychiatry Division of the American Psychiatric Association. He also received the "Citation for Outstanding Performance" for the Commonwealth of Massachusetts in 1984 and the Hospital Research Award from the APA and Psychiatric Institutes of America. For many years he
served as Center Director at the Massachusetts Mental Health Center and Associate Professor of Psychiatry at Harvard Medical School. In addition to clinical practice and teaching, Dr. Gudeman's major research interests are in depression, psychotherapy and the care and treatment of serious mental illness in the hospital and community. He developed and studied the Day Hospital/Inn model of care and has written extensively on this program. He has authored or coauthored articles on these and related topics including the follow books: Origins of Alcoholism, Staffing the Mental Health Center and The Use of Psychiatry in Smaller General Hospitals. Dr. Gudeman has served in a variety of professional organizations and leadership positions including President of the Massachusetts Psychiatric Society, Chair of the Joint Information Service (1977), and Chairman of the Continuing Medical Committee (1984-85) of the American Psychiatric Association. He is currently on the Medical Examining Board of Wisconsin.

**THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 8**

11:00 a.m.-12:30 p.m.
Room 33 A/B/C, Upper Level,
San Diego Convention Center

Mary J. Kreek, M.D.

**Stress Responsivity, Gene Variants, and the Persistence of Addictions**

*Collaborative Session with the National Institute on Drug Abuse*

Chp.: Edward M. Foulks, M.D.

Dr. Kreek was part of the original three-member 1964 Rockefeller University team of Drs. Dole, Nyswander, and Kreek that developed methadone maintenance treatment for heroin addiction. In 1983-1984, in collaboration with Dr. Don Des Jarlais, Dr. Kreek identified the problem of HIV infection and AIDS in parenteral drug abusers, as well as the protective value of effective methadone maintenance treatment in opiate addicts. Dr. Kreek has done extensive research with resultant publications on the pharmacology of short-acting versus long-acting opiate drugs, on the changing medical status of addicts in opioid agonist treatment with methadone, and also the major concurrent diseases of hepatitis B, hepatitis C, and HIV-AIDS. For the past twenty years, her research has focused on the molecular and clinical neurobiological, and the molecular genetic bases of specific addictive diseases, as well as other biological correlates of addictive diseases and diseases afflicting the parenteral drug abuser.

**Frontiers of Science Lecture Series**

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-9**

**SCIENTIFIC AND CLINICAL REPORT SESSION 1**

11:00 a.m.-12:30 p.m.
Room 3, Upper Level, San Diego Convention Center

**PRESIDENT'S THEME: "ADDRESSING PATIENT NEEDS: ACCESS, PARITY, AND HUMANE CARE"**

Chp.: Saul Levine, M.D.
Co-Chp.: Amanda Ruiz, M.D.

11:00 a.m.

2 The Discourse of Health Care Economics
David A. Rothstein, M.D.

11:30 a.m.

3 Medicare Part D Prescription Drug Benefits: Impact on Medication Access and Continuity Among Dual Eligible Patients With Psychiatric Conditions
Joyce C. West, Joshua E. Wilk, Irvin L. Muszynski, Donald S. Rae, William E. Narrow, M.D., Dartel A. Regier, M.D.

12 noon

4 Dealing With Disaster Mental Health
Russell F. D'Souza, Sr., M.D., Pedro Ruiz, Jr., M.D.,
Kenneth Kirkby II, M.D., Bruce Singh II, M.D., Jack S. McIntyre, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 2**

11:00 a.m.-12:30 p.m.
Room 4, Upper Level, San Diego Convention Center

**COMPULSIVE AND ADDICTIVE BEHAVIORS**

Chp.: Igor Koutsenok, M.D.
Co-Chp.: Meera Vaswani, Ph.D

11:00 a.m.

5 Association of Cannabis Use With Prodromal Features of Psychosis and Behavioral Problems in Adolescents

11:30 a.m.

6 Paternal Alcoholism Predicts Alcohol Dependence But Not Recovery After 40 Years
Joachim Knop, M.D., Elizabeth C. Penick, Ph.D., Elizabeth J. Nickel, M.A., Per Jensen, M.D., Ann M. Manzardo, Ph.D.,
Samoff Mednick, Ph.D., William F. Gabrielli, Jr., M.D.

12 noon

7 Self-Loathing and Perfectionism: Linking Eating Disorders and Compulsive Exercise
Alayne Yates, M.D., Jason Andrus, M.D., John H. Draeger, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**
SCIENTIFIC AND CLINICAL REPORT SESSION 3
11:00 a.m.-12:30 p.m.
Room 5 A, Upper Level, San Diego Convention Center

OCD

Chp.: Donatella Marazziti, M.D.
Co-Chp.: Krauz Ganadjian, M.D.

11:00 a.m.
8 Capsulotomy in Refractory OCD: Long-Term Outcome in 25 Patients
Christian Rück, M.D.

11:30 a.m.
9 Trichotillomania in Youth: A Naturalistic Outcome Study
Catherine L. Mancini, M.D., Michael A. Van Ameringen, M.D.,
Beth Patterson, B.S.N., Roseann Milad, B.S.C.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 5
11:00 a.m.-12:30 p.m.
Room 9, Upper Level, San Diego Convention Center

LEGAL ISSUES IN PSYCHIATRY
Chp.: Dominick Addario, M.D.
Co-Chp.: Jason R. Kornberg, M.D.

11:00 a.m.
14 Understanding Filicide
Sara G. West, M.D.

11:30 a.m.
15 Testimonies of APA and ANA Presidents in the Harry Thaw "Brain Storm" Defense: Temporary Insanity One Hundred Years Ago in 1907
Emil R. Pinta, M.D.

12 noon
16 Correctional Mental Health Care in a Large, Urban Jail: Challenges and Opportunities
Amina Abdulla, M.D., Michael Searls, M.D., Robert Simon, Jr., M.Psy., Sandra Markle, R.N., John Godejahaun, R.N.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 6
11:00 a.m.-12:30 p.m.
Room 11 B, Upper Level, San Diego Convention Center

METABOLIC DISORDERS AND PSYCHOSIS

Chp.: Mitchel A. A. Kling, M.D.
Co-Chp.: Igor Elman, M.D.

11:00 a.m.
11 Second-Generation Antipsychotics and Diabetes Mellitus: Risk, Number Needed to Harm, and Clinical Impact
Leslie L. Citrome, M.D.

11:30 a.m.
12 Metabolic Risks of Psychosis in Sweden
Urban P. Ösby, M.D., Sören Akselsson, M.D., Anna Löthman, M.D., Helena Ring, M.D., Signy Reynisdottir, M.D., Martin Schalling, M.D., Claes-Göran Östensson, M.D.

12 noon
13 Effect of Body Weight and Metabolic Complications on Health Related Quality of Life in Swedish Outpatients With Schizophrenia
Signy Reynisdottir, M.D., Anna Pejlare, Soren Akselsson, Deanne Mannelid, Helena Ring, Birtgita Lindebus, Urban P. Ösby, M.D.

THIS SESSION WILL BE AUDIOTAPED.

ANXIETY DISORDERS

Chp.: Susan Stabinsky, M.D.
Co-Chp.: Harvey Stabinsky, M.D.

11:00 a.m.
17 Treatment Outcome of Panic Disorder and Agoraphobia in a Naturalistic Clinical Setting
John K. Larn-Po-Tang, M.B.B.S.

11:30 a.m.
18 Panic Disorder With Social Anxiety Disorder Comorbidity: Difference of Response to Low Versus High Doses of Clonazepam
Antonio E. Nardi, M.D., Alexandre M. Valença, M.D., Isabella Nascimento, M.D., Fabiana L. Lopes, M.D., Rafael C. Freire, Valfrido L. de-Melo-Neto, M.D., Marco A. Mezzasalma, M.D.

12 noon
19 The Relationship Between Functional Outcomes and Treatment of Anxious and Painful Somatic Symptoms in Patients With GAD
David V. Sheehan, M.D., Adam Meyers, Apurva Prakash, Michael J. Robinson, Ralph W. Swindle, James Russell, Craig H. Mallinckrodt

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 7
11:00 a.m.-12:30 p.m.
Room 24 C, Upper Level, San Diego Convention Center

ATTENTION SPECTRUM DISORDERS

Chp.: Sanjay Vaswani, M.D.
Co-Chp.: Vishal Madaan, M.D.

11:00 a.m.
20 Circadian Rhythm Disturbances in ADHD
George A. Keepers, M.D., Robert D. Levitan, M.D., Kyle P. Johnson, M.D., Alfred J. Levy, M.D.

11:30 a.m.
21 Is Comorbid Adult ADHD Prevalent in Psychiatric Outpatients?
John A. Gergen, M.D.

This session will be audiotaped.

SCIENTIFIC AND CLINICAL REPORT SESSION 8
11:00 a.m.-12:30 p.m.
Room 25 A, Upper Level, San Diego Convention Center

CHILD AND ADOLESCENT PSYCHIATRY

Chp.: Sonja L. Randle, M.D.
Co-Chp.: Richard I. Buccigross, M.D.

11:00 a.m.
23 Quality of Care for Children and Adolescents: Access to Psychotherapy
Faritha F. Duffy, Ph.D., Joyce C. West, Ph.D., Donald S. Rac, William F. Narrow, M.D., Darrel A. Regier, M.D.

11:30 a.m.
24 Adolescent Depression and Its Relationship to School Dropouts and Accidents on University Campuses
Chih-Wei Yang, M.D., Yi-Hsin Yang, Ph.D., Mei-Chu Yen Jean, M.D., Tai-Jui Chen, M.D., Li-Min Su, M.A.

12 noon
25 Insulin Resistance in Adolescent Subjects at Risk for Psychosis

This session will be audiotaped.

SCIENTIFIC AND CLINICAL REPORT SESSION 9
11:00 a.m.-12:30 p.m.
Room 27 A, Upper Level, San Diego Convention Center

PSYCHIATRIC IMPACT OF MEDICAL CONDITIONS

Chp.: Nitin Gupta, M.D.
Co-Chp.: Mustafa M. Husain, M.D.

11:00 a.m.
26 Severe Headaches and the Risk of Subsequent Suicidal Thoughts or Behaviors
Stephen B. Woolley, D.Sc., John W. Goethe, M.D., Lisa Fredman, Ph.D., Alisa Lincoln, Ph.D., Timothy Heeren, Ph.D.

11:30 a.m.
27 Modafinil Improves Behavioral Alertness in Patients With Residual Excessive Sleepiness Following Nasal Continuous Positive Airway Pressure (nCPAP)-Treated Obstructive Sleep Apnea
David F. Dingess, Ph.D., Max Hirshkowitz, Ph.D., Sanjay Arora, Ph.D., Jed E. Black

This session will be audiotaped.

SMALL INTERACTIVE SESSIONS 5-7
11:00 a.m.-12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

5 Arnold Cooper, M.D., on American Psychoanalysis
Today (Meet the Author)
Room 27 B, Upper Level, San Diego Convention Center

6 Sandra Jacobson, M.D., on Treatment of Dementia With Behavioral Disturbance If Not an Antipsychotic, Then What?
Room 31 C, Upper Level, San Diego Convention Center

7 Otto F. Kernberg, M.D., on Sexuality in the Transference
Room 32 B, Upper Level, San Diego Convention Center
MONDAY

WORKSHOPS

COMPONENTS 13-22

COMPONENT WORKSHOP 13  11:00 a.m.-12:30 p.m.
Room 5 B, Upper Level, San Diego Convention Center

ADVOCACY TRAINING FOR EARLY CAREER PSYCHIATRISTS WITH A FOCUS ON PARITY LEGISLATION
APA Assembly Committee of Early Career Psychiatrists

Chp.: Carol L. Tripitelli, M.D.
Participants: Bob Kearley, M.D., Jason Young, M.D.

COMPONENT WORKSHOP 14  11:00 a.m.-12:30 p.m.
Room 7 A, Upper Level, San Diego Convention Center

UNCOVERING THE SECRET: INTIMATE PARTNER VIOLENCE AMONG ASIAN-AMERICANS
APA Asian-American Psychiatrists

Chp.: Surinder S. Nand, M.D.
Participants: Mina Bak, M.D., Jacquelyn Chang, M.D., Yujuan Choy, M.D., Mona H. Gill, M.D., Eugene Lee, M.D.

COMPONENT WORKSHOP 15  11:00 a.m.-12:30 p.m.
Room 7 B, Upper Level, San Diego Convention Center

CONTROVERSIES IN THE MANAGEMENT OF BEHAVIORAL DISTURBANCE IN DEMENTIA
APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly

Chp.: David A. Casey, M.D.
Participants: Mercedes M. Rodriguez, M.D., Keith R. Stowell, M.D.

COMPONENT WORKSHOP 16  11:00 a.m.-12:30 p.m.
Room 8, Upper Level, San Diego Convention Center

MULTINATIONAL PERSPECTIVES OF PSYCHIATRIC ETHICS
APA Ethics Appeal Board

Co-Chps.: Donna M. Norris, M.D., Driss Moussaoui, M.D.
Participants: Wade C. Myers, M.D. William Arroyo, M.D.

COMPONENT WORKSHOP 17  11:00 a.m.-12:30 p.m.
Room 23 C, Upper Level, San Diego Convention Center

HOW TO TEACH CULTURAL COMPETENCE IN GERIATRIC PSYCHIATRY: ADDRESSING UNMET PATIENT NEEDS
APA Committee on Ethnic Minority Elderly

Co-Chps.: Maria D. Llorente, M.D., Warachal E. Faison, M.D.
Participants: Moises Martinez, M.D., Shundra McGahee, M.D., Vernon I. Nathaniel, M.D., Cynthia I. Resendez, M.D.

COMPONENT WORKSHOP 18  11:00 a.m.-12:30 p.m.
Room 24 A, Upper Level, San Diego Convention Center

PROVIDING SERVICES TO MENTALLY ILL INMATES RETURNING TO THE COMMUNITY
APA Task Force on Forensic Outpatient Services

Chp.: Steven K. Hoge, M.D.
Participants: Alec Buchanan, M.D., Beatrice Kovaszny, M.D.

COMPONENT WORKSHOP 19  11:00 a.m.-12:30 p.m.
Room 25 C, Upper Level, San Diego Convention Center

BOOT CAMP FOR BURNOUT
APA Representatives of Minority Underrepresented Groups

Co-Chps.: Gail F. Robinson, M.D., Altha J. Stewart, M.D.
Participants: Nade L. Storland, M.D., Tana A. Grady-Weliky, M.D., Melva I. Green, M.D., Eva M. Szegedy, M.D.

COMPONENT WORKSHOP 20  11:00 a.m.-12:30 p.m.
Room 28 A, Upper Level, San Diego Convention Center

THE IMPACT OF VIOLENCE IN LATINO COMMUNITIES
APA Committee of Hispanic Psychiatrists

Co-Chp.: Andres J. Pumariega, M.D., Daniel Castellanos, M.D.
Participants: Esperanza Diaz, M.D., Tatiana Falcone, M.D., Natalie Weder, M.D., Rene J. Valles, M.D.

COMPONENT WORKSHOP 21  11:00 a.m.-12:30 p.m.
Room 28 C, Upper Level, San Diego Convention Center

CONCEPTUALIZING ACCESS TO PSYCHIATRIC CARE
APA Access to Care Work Group

Co-Chps.: Eliot Sorel, M.D., Roger Peele, M.D.

COMPONENT WORKSHOP 22  11:00 a.m.-12:30 p.m.
Room 30 A, Upper Level, San Diego Convention Center

PEARLS AND PITFALLS IN NEGOTIATING YOUR FIRST JOB
APA Committee of Residents and Fellows

Co-Chps.: Justin B. Hunt, M.D., Lea E. DeFrancisci Lis, M.D.
Participant: William H. Campbell, M.D.

ISSUES 17-27

ISSUE WORKSHOP 17  11:00 a.m.-12:30 p.m.
Room 23 A/B, Upper Level, San Diego Convention Center

THE DILEMMA OF WOMEN'S PROFESSIONAL GARMENTS AND PROFESSIONALISM
Co-Chps.: Katharine A. Stratigos, M.D., Leah J. Dickstein, M.D.
Participants: Stephanie Le Melle, M.D., Christina Mangunian, M.D., Lisa Mellman, M.D., Asher Simon, M.D.
ISSUE WORKSHOP 18  11:00 a.m.-12:30 p.m.
Room 24 B, Upper Level, San Diego Convention Center

DYNAMIC THERAPY WITH SELF-DESTRUCTIVE BORDERLINES

Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 19  11:00 a.m.-12:30 p.m.
Room 28 B, Upper Level, San Diego Convention Center

FIRST EPISODE MOOD DISORDERS: WHAT HAVE WE LEARNED AND WHERE DO WE GO FROM HERE?

Chp.: Kathryn J. MacDonald, M.D.
Participants: Kaan Yucel, M.D., Valerie Taylor, M.D.

ISSUE WORKSHOP 20  11:00 a.m.-12:30 p.m.
Room 28 D/E, Upper Level, San Diego Convention Center

TEACHING COGNITIVE BEHAVIOR THERAPY TO CHILD AND ADULT RESIDENTS

Chp.: Judith S. Beck, Ph.D.
Participants: Donna M. Sudak, M.D., Jesse H. Wright III M.D., Robert D. Fiedberg, Ph.D.

ISSUE WORKSHOP 21  11:00 a.m.-12:30 p.m.
Room 30 A, Upper Level, San Diego Convention Center

AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY UPDATE: CERTIFICATION AND MAINTENANCE OF CERTIFICATION IN PSYCHIATRY AND ITS SUBSPECIALTIES

Chp.: Larry R. Faulkner, M.D.
Participants: Daniel K. Winstead, M.D., Naline N. Andrade, M.D., Beth Ann Brooks, M.D., David A. Mrazek, M.D., Burton V. Reifler, M.D.

ISSUE WORKSHOP 22  11:00 a.m.-12:30 p.m.
Room 30 B, Upper Level, San Diego Convention Center

ASSESSING CAPACITY TO DRIVE: A PRACTICAL APPROACH TO THE PSYCHIATRIST'S ROLE AND RESPONSIBILITIES

Chp.: Dimitri D. Markov, M.D.
Participants: Clarence Watson Jr, M.D., Marc Rothman, M.D., Elisabeth J.S. Kunkel, M.D.

ISSUE WORKSHOP 23  11:00 a.m.-12:30 p.m.
Room 30 C, Upper Level, San Diego Convention Center

IMPLEMENTING A TELEPSYCHIATRY PROGRAM IN THE KERN COUNTY MENTAL HEALTH SYSTEM IN RURAL CALIFORNIA

Chp.: Tai P. Yoo, M.D.
Participant: Salvador R. del Rosario Jr., M.D.

ISSUE WORKSHOP 24  11:00 a.m.-12:30 p.m.
Room 30 D/E, Upper Level, San Diego Convention Center

WOMEN RESIDENTS AND THEIR NEEDS DURING PSYCHIATRIC TRAINING

Chp.: Anu A. Matorin, M.D.
Participants: Lina M. Lopez, M.D., Toi B. Harris, M.D., Deborah Spitz, M.D., Sandra B. Sexson, M.D.

ISSUE WORKSHOP 25  11:00 a.m.-12:30 p.m.
Room 31 A, Upper Level, San Diego Convention Center

THE EARLIEST ENVIRONMENT: PREGNATAL STRESS, ANXIETY, AND DEPRESSION AND CHILD OUTCOME

Chp.: Hanna E. Stevens, M.D.
Participants: Catherine Mosek, Ph.D., Thomas O'Connor, Ph.D., Zachary N. Stowe, M.D., Pathik D. Wadhwa, M.D.

ISSUE WORKSHOP 26  11:00 a.m.-12:30 p.m.
Room 31 B, Upper Level, San Diego Convention Center

DETECTION OF MALINGERING

Chp.: Alan R. Hirsch, M.D.
Participants: Carl M. Wahlstrom, Jr, M.D., David E. Harman, Ph.D.

ISSUE WORKSHOP 27  11:00 a.m.-12:30 p.m.
Room 32 A, Upper Level, San Diego Convention Center

MUSIC AS A MEANS OF SURVIVAL: THE SIGNIFICANCE OF MUSIC IN SURVIVING THE HOLOCAUST

Chp.: Andrei Novac, M.D.
Participant: Bonita Nahoum-Jaros VIII, Ph.D.

12 noon Sessions

FORUMS 1-5

FORUM 1  12 noon-1:30 p.m.
Ballroom 6 E, Upper Level, San Diego Convention Center

RESEARCH PLANNING FOR DSM-V

Chp.: Darrel A. Regier, M.D.
Participants: David J. Kupfer, M.D., Eric Hollander, M.D., Helena C. Knaer, M.D., Joel Dinsdale, M.D., David Shaffer, M.D., Norman Sartorius, M.D.
1:00 p.m. Sessions

COURSES 49-54

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 49  1:00 p.m.-5:00 p.m.
Edward Room A/B, Second Level, Manchester Grand Hyatt
SPIRITUALITY AND WORLDVIEW IN CLINICAL PRACTICE

Director: Allan M. Josephson, M.D.
Faculty: James L. Griffith, M.D., John R. Petect, M.D.

COURSE 50  1:00 p.m.-5:00 p.m.
Molly Room A/B, Second Level, Manchester Grand Hyatt
CURRENT CPT CODING AND DOCUMENTATION REQUIREMENTS

Co-Directors: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.
Faculty: Allan A. Anderson, M.D., David K. Nace, M.D., Ronald M. Burd, M.D.

COURSE 51  1:00 p.m.-5:00 p.m.
Ford Room A/B/C, Third Level, Manchester Grand Hyatt
STREET DRUGS AND MENTAL DISORDERS: OVERVIEW AND TREATMENT

Director: John W. Tsuang, M.D.
Faculty: Karen Miotto, M.D., Timothy W. Fong, M.D., Stephen Ross, M.D.

COURSE 52  1:00 p.m.-5:00 p.m.
Madeleine Room C/D, Third Level, Manchester Grand Hyatt
ASSESSING POSITIVE AND NEGATIVE SYMPTOMS WITH THE POSITIVE AND NEGATIVE SYNDROME SCALE

Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

COURSE 53  1:00 p.m.-5:00 p.m.
Mohsen Room A/B, Third Level, Manchester Grand Hyatt
PSYCHIATRIC CONSULTATION IN LONG TERM CARE: ADVANCED

Co-Directors: Abhilash K. Desai, M.D., George T. Grossberg, M.D.

COURSE 54  1:00 p.m.-5:00 p.m.
Emma Room A/B/C, Third Level, Manchester Grand Hyatt
THE PSYCHIATRIST AS EXPERT WITNESS

Director: Phillip J. Resnick, M.D.
2:00 p.m. Sessions

FOCUS LIVE SESSION 3
2:00 p.m.-3:30 p.m.
Room 1 A/B, Upper Level, San Diego Convention Center

GENETICS AND PSYCHIATRY

Moderators: Mark H. Rapaport, M.D., Deborah J. Hales, M.D.
Presenter: John Kelsoe, M.D.

Expert clinicians, who served as the guest editors of the first two issues of Focus, will lead lively multiple-choice, question-based discussions. This session covers Genetics and Psychiatry, the first session at 9:00 a.m. covered Psychopharmacology, and the second session at 11:00 a.m. covered Substance Related Disorders. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 9-11

LECTURE 9
2:00 p.m.-3:30 p.m.
Ballroom 6 B, Upper Level,
San Diego Convention Center

APA/NIMH VESTERMARK PSYCHIATRY EDUCATOR AWARD LECTURE

Stephen C. Scheiber, M.D.

The American Board of Psychiatry and Neurology Impact on Psychiatric Education: Past, Present and Future

Chp.: Kailie Shaw, M.D.

Stephen C. Scheiber, M.D. completed 20 1/2 years as the chief executive officer of the American Board of Psychiatry and Neurology (ABPN) on June 30th 2006. He continues his professorial teaching appointments at Northwestern University Feinbstein School of Medicine and at the Medical College of Wisconsin. He received one of the Inaugural Life Fellowship Awards from the Association for Academic Psychiatry in September 2006, the Distinguished Psychiatrist Service Award from the American College of Psychiatrists in February, 2007 and the Distinguished Service Award from the American Board of Medical Specialties in March, 2007. He also was the recipient of the Distinguished Life and Career Achievement Award from the Medical Alumni Association of the University of Buffalo and the Lifetime Educator Award from the Association for Academic Psychiatry. He has served as an officer in five national psychiatric organizations. He was on the University of Arizona Medical School faculty from 1970 to 1988 where he was the founding residency training director. Scheiber served as an officer of the USPHS. He was assigned to Sierra Leone in West Africa as a Peace Corps general physician. This deployment occurred after his internship at the Mary Fletcher Hospital in Burlington, Vermont. Upon returning from Africa, he completed a psychiatry residency at the Strong Memorial Hospital in Rochester, New York. He obtained his undergraduate degree at Columbia College in New York City and his M.D. at the State University of Buffalo in Buffalo, N.Y.

THIS SESSION WILL BE AUDIOTAPE.

LECTURE 10
2:00 p.m.-3:30 p.m.
Ballroom 6 C/D/E/F, Upper Level,
San Diego Convention Center

Dolores Malaspina, M.D.

Advancing Paternal Age and Offspring Risks for Psychiatric Disorders: A Translational Perspective

Chp.: Joseph A. Cheung, M.D.

Dolores Malaspina M.D., became the Chairman of Psychiatry at New York University Medical Center in September 2006. She was previously Professor of Clinical Psychiatry at Columbia University Medical Center and a Research Psychiatrist at New York State Psychiatric Institute, where she also completed her postgraduate medical education, a fellowship in clinical research, and an M.P.H. in Epidemiology. She was the founding Unit Chief for its Schizophrenia Research Unit and she later established its prodromal schizophrenia research clinic. Her academic career encompasses a strong focus on the mentoring and career development of beginning clinical investigators, and she has also mentored over a dozen research scientists now engaged in psychiatric research careers, including psychiatrists, obstetricians-gynecologists, psychologists and social workers. She is now in her seventh of ten years of funding by NIMH to mentor young scientists who are beginning clinical research careers. Dr. Malaspina has received numerous awards for her research, including the American Psychiatric Institute for Research and Education Kempf Fund Award for Research and Mentoring in Psychobiological Psychiatry (in 2006), the Exemplary Psychiatric Award from the National Alliance of the Mentally Ill, the National Alliance for Research in Schizophrenia and Affective Disorders Ritter Award, and the annual Research Award from the New York State Office of Mental Health. She was chosen to be a Chief Resident and received the Alumni Association’s Horowitz Award for clinical excellence as a resident. She is now a fellow of the American College of Neuropsychopharmacology and is a Distinguished Fellow of the American Psychiatric Association.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPE.
LECTURE 11
2:00 p.m.-3:30 p.m.
Room 33 A/B/C, Upper Level,
San Diego Convention Center
Kitty Dukakis and Larry Tye

The Healing Power of ECT

Chp.: Richard Weiner, M.D.
Co-Chp.: Sarah Lisanby, M.D.

Kitty Dukakis, the wife of former Massachusetts governor and 1988 Democratic presidential nominee Michael Dukakis, is a social worker, a founding member of the United States Holocaust Memorial Museum, and an advocate for programs to battle homelessness and promote refugee rights. She revealed her ongoing struggle to overcome depression and her accompanying addictions to alcohol and diet pills in her 1990 memoir, *Now You Know*. Her new book, written with Larry Tye, *Shocks: The Healing Power of Electroconvulsive Therapy*, tells the story of her successful treatment with electroconvulsive therapy along with Mr. Tye's meticulous research into the history and evolution of ECT, over 100 interviews with patients who have had the treatment, and detailed descriptions of the treatment in its modern from and when and under what circumstances it is appropriate.

THIS SESSION WILL BE AUDIOTAPE.

PRESIDENTIAL SYMPOSIUMS 1-2

PRESIDENTIAL SYMPOSIUM 1
2:00 p.m.-5:00 p.m.
Ballroom 6 D, Upper Level, San Diego Convention Center

THE ROLE OF ETHICS IN WORLD PSYCHIATRY
*APA Council on Global Psychiatry*

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Darrel A. Regier, M.D.

A Conflicts of Interest in Psychiatric Practice and Research
Mario Maj, M.D.

B Ethics in the Mediterranean Countries
Juan J. Lopez-Ibor Jr., M.D.

C From Ethical Mantras to Living Ethics in Psychiatry
Julio Arboleda-Flores, M.D.

Discussions: Alan A. Stone, M.D.

THIS SESSION WILL BE AUDIOTAPE.

PRESIDENTIAL SYMPOSIUM 2
2:00 p.m.-5:00 p.m.
Ballroom 6 E, Upper Level, San Diego Convention Center

WOMEN LEADERS IN THE APA AND BEYOND
*APA Committee on Women*

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Donna M. Norris, M.D.

A Women Leaders of the APA and Beyond: The Contribution of International Medical Graduates
Geetha Jayaram, M.D.

B Women in Leadership: Issues and Challenges
Ann Marie T. Sullivan, M.D.

C No Crystal Stair
Anelle B. Primm, M.D.

D Getting to the Inner Circle: The Long Hard Trail
Jo-Ellyn M. Ryall, M.D.

E Lessons in Leadership: Mentoring our Future Women Leaders
Patricia I. Ordonica, M.D.

Discussions: Althea J. Stewart, M.D., Mary Jane England M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIA 1-26

SYMPOSIUM 1
2:00 p.m.-5:00 p.m.
Room 2, Upper Level, San Diego Convention Center

SCHIZOPHRENIA WITH COMORBID CONDITIONS: CLINICAL ISSUES

Chp.: Michael Y. Hwang, M.D.

A Diagnostic Issues and Treatment Strategy in Schizophrenia With Depression
Siegfried Kasper, M.D., Dietmar Winkler, M.D.

B Schizophrenia With Obsessive-Compulsive and Panic Symptoms: Treatment Issues
Michael Y. Hwang, M.D.

C Eating Disorder Comorbidity in Schizophrenia: Clinical Implications for Managing Obesity and Metabolic Disorders
Sun Y Yum, M.D., Michael Y. Hwang, M.D.

D Recent Increments in Knowledge About Suicidality in Schizophrenia
Alec Roy, M.D., Marco Sarchiapone, M.D., Vladimir Carl, M.D., Michael Hwang, M.D.

THIS SESSION WILL BE AUDIOTAPE.
MONDAY

SYMPOSIUM 2 2:00 p.m.-5:00 p.m.
Room 3, Upper Level, San Diego Convention Center

BIOLICAL FOUNDATIONS OF BIPOLAR DISORDER: NEW INSIGHTS AND PROSPECTS FOR TREATMENT

Cp.: Aysegul Yildiz-Yesiloglu, M.D.
Co-Cp.: Eduard Viceta, M.D.

A Cognition, Neuroplasticity, and Treatment, of Bipolar Disorder
Eduard Viceta, M.D.

B Is the Protein Kinase C Inhibition a Keystone in Treatment of Bipolar Disorder?
Aysegul Yildiz-Yesiloglu, M.D.

C Glial Cell Dysfunction in the Pathophysiology of Bipolar Disorder
Dost Ongur, M.D.

D Genetics of Bipolar Disorder: Recent Advances and Coming Attractions
Jordan W. Smoller, M.D.

THIS SESSION WILL BE AUDIOTAPE

SYMPOSIUM 3 2:00 p.m.-5:00 p.m.
Room 4, Upper Level, San Diego Convention Center

PHYSICAL ILLNESS IN PEOPLE WITH SEVERE MENTAL DISORDERS

Cp.: Norman H. Sartorius, M.D.
Co-Cp.: Mario Maj, M.D.

A Physical Illness and Mental Disorder: Neglected Facts
Norman H. Sartorius, M.D.

B Physical Illness and Schizophrenia: Extensive Review of the Literature
Stefan Leucht, M.D.

C Diabetes and Mental Disorders: What Do We Know About Risks and Linkages?
Michelle B. Riba, M.D.

D Physical Illness in Patients With Mental Disorders Seen in Anambar, Nigeria
Richard Uwakwe, M.B.B.S.

THIS SESSION WILL BE AUDIOTAPE

SYMPOSIUM 4 2:00 p.m.-5:00 p.m.
Room 5 A, Upper Level, San Diego Convention Center

SUICIDE ACROSS THE LIFE CYCLE: A SPANISH LANGUAGE UPDATE (MANEJO Y TRATAMIENTO DEL PACIENTE SUICIDA EN LAS DISTINTAS ETAPAS DE LA VIDA)

Cp.: Gabriel Kaplan, M.D.
Co-Cp.: Javier I. Escobar, M.D.

A Neurobiological Correlates of Suicide
Pedro L. Delgado, M.D.

B Youth Suicide (Suicidio Infantojuvenil)
Gabriel Kaplan, M.D.

C Suicidal Behavior in Adults
Maria A. Oquendo, M.D.

D Suicidal Behavior in Late Life
Jacobo E. Mintzer, M.D.

E Suicide in the Medically Ill
Humberto Marín, M.D.

Discussant: Javier I. Escobar, M.D.
THIS SESSION WILL BE AUDIOTAPE

SYMPOSIUM 5 2:00 p.m.-5:00 p.m.
Room 5 B, Upper Level, San Diego Convention Center

INSIGHTS ON OBESITY AND DRUG ADDICTION FROM BRAIN IMAGING

Collaborative Session With the National Institute on Drug Abuse

Cp.: Joseph Frascella, Ph.D.
Co-Cp.: Nora D. Volkow, M.D.

A Modulators of Orbitofrontal Activation in Response to Food Stimuli
Deborah Yurgelun-Todd, Ph.D.

B Hunger as an Addiction
Alain Daglier, M.D.

C Application of Incentive-Sensitization Theory of Drug Addiction to Overeating
Dana M. Small, Ph.D.

D Neuroimaging Studies of Obesity and Drug Addiction
Gene-Jack Wang, M.D., Nora D. Volkow, M.D., Joanna S. Fowler, Ph.D.

Discussant: Nora D. Volkow, M.D.
THIS SESSION WILL BE AUDIOTAPE

SYMPOSIUM 6 2:00 p.m.-5:00 p.m.
Room 7 A, Upper Level, San Diego Convention Center

TREATMENTS FOR MALADAPTIVE PERSONALITY TRAITS WITH SOME EMPIRICAL SUPPORT

Cp.: James H. Reich, M.D.

A The Effect of Axis II on Outcome of Axis I Disorders
James H. Reich, M.D., Simone Kool, M.D.

B Initial Findings From the Canadian RCT of Dialectical Behavior Therapy for BPD
Paul Links, M.D., Shelley McMain, Ph.D., Robert Cardish, M.D., William Gnam, M.D., Lorne Korman, Ph.D., Adam Quastel, M.D., Jan Dawe, M.D., David Streiner, Ph.D.

C The STEPPS Model: A Cognitive Group Treatment for BPD
Donald W. Black, M.D.

D Schema Focused Therapy: An Evidence-Based Treatment for BPD
David P. Bernstein, Ph.D., Arnoud Arntz, M.D.

E Pharmacologic Treatment of Personality Disorder Traits
Erika Saunders, M.D., Kenneth R. Silk, M.D.

Discussant: Peter J. Tyrey, M.D.
THIS SESSION WILL BE AUDIOTAPE.
MONDAY

SYMPOSIUM 7  2:00 p.m.-5:00 p.m.
Room 7 B, Upper Level, San Diego Convention Center

NEUROSCIENCE AND PHENOMENOLOGY OF SCHIZOPHRENIA

Chp.: Michael A. Schwartz, M.D.
Co-Chp.: Rodrigo D. Paz, M.D.

A Integrating the Neuroscience and Phenomenology of Schizophrenia: A Challenge for the 21st Century Psychiatry
Michael A. Schwartz, M.D.

B The History of the Phenomenological Method in Clinical Psychiatry
Otto F. Doerr Zeegers, M.D.

C Neurodevelopmental Fissuration of Hippocampal-Prefrontal Cortical Synaptic Connectivity: Implications for Schizophrenia Pathophysiology
Kuei-Yuan Tseng, Ph.D.

D From the Neurobiology of Adolescence to the Neurobiology of Early Schizophrenia
Rodrigo D. Paz, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 8  2:00 p.m.-5:00 p.m.
Room 8, Upper Level, San Diego Convention Center

HOW TO PRACTICE SPORT PSYCHIATRY: A DEMONSTRATION

Chp.: Antonia L. Baum, M.D.

A The Overview of the Field of Sport Psychiatry
Ira D. Gläck, M.D.

B The ADHD Affected Athlete and Role of the Psychiatrist
David O. Conant-Norville, M.D.

C Interviewing the Athlete With a Substance Abuse Problem
Ronald L. Kamm, M.D.

D The Athlete With Depression: Understanding Etiology and Treatment Through the Interview
Antonia L. Baum, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 9  2:00 p.m.-5:00 p.m.
Room 9, Upper Level, San Diego Convention Center

CRF-ANTAGONISM FOR TREATMENT OF ALCOHOLISM AND AFFECTIVE DISORDERS

Chp.: Markus Heilig, M.D.

A Negative Affect and Excessive Alcohol Drinking
Driven by Central CRF Systems: Reversal by the Novel CRF1 Antagonist MTIP
Markus Heilig, M.D.

B The Dark Side of Alcoholism: Neuroadaptational Mechanisms With the CRF System Critical for Excessive Drinking
George F. Koob, Ph.D.

C Amygdala Protein Kinase C Epsilon Regulates Corticotropin Releasing Factor, Anxiety, and Alcohol Self-Administration
Robert O. Messing, M.D.

D Targeting the Corticotrophin Releasing Factor System for the Treatment of Alcohol Dependence
Selena Bartlett, Ph.D., Antonello Bonci, M.D.

E Genetic Association of the Human Corticotropin Releasing Hormone Receptor 1 With Binge Drinking and Alcohol Intake Patterns in Two Independent Samples
Gunter Schumann, M.D.

F Genetic Variation at the CRH Locus and Its Association With Anxiety and Alcohol Consumption-Lessons From the Macaque
Christina S. Barr, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 10  2:00 p.m.-5:00 p.m.
Room 10, Upper Level, San Diego Convention Center

THE CALIFORNIA MENTAL HEALTH SYSTEMS ACT: TRANSFORMING SYSTEMS OF CARE TO REDUCE MENTAL HEALTH DISPARITIES

Chp.: Francis G. Lu, M.D.

A Overview of California Mental Health Service Act
Rachel G. Guerrero, M.S.W.

B The Community Services and Supports Component of the MHSA: Evaluating Efforts to Address Disparities in Mental Health
Katherine Elliott, Ph.D.

C MHSA Workforce and Training: Cultural Competence and Disparities Reduction
Sergio Aguilar-Gaxiola, M.D.

D Prevention and Early Intervention in Underserved Populations: Opportunities for Change
Katherine G. Ruiz-Mellott, M.D.

Discussant: Robin Huff-Musgrove, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 11 2:00 p.m.-5:00 p.m.
Room 11 A, Upper Level, San Diego Convention Center

ETHICS, HUMAN RIGHTS AND DYNAMIC PSYCHIATRY

Chp.: Joseph P. Merlino, M.D.

A Challenge to Medical Ethics: Psychiatrists Participating in the Interrogation of Detainees
Steven S. Sharfstein, M.D.

B Ethical Implications of Big Pharma
Stephen A. Green, M.D.

C A Reorientation Towards Professionalism in Medicine: Our Ethics, Our Future
Joseph P. Merlino, M.D.

D Ethical Issues in Sexual Conversion: Reparative Therapies
Jack Drescher, M.D.

E Ethics in Residency
Lea E. de Francisci Lis, M.D.

Discussant: Spencer Eth, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 12 2:00 p.m.-5:00 p.m.
Room 11 B, Upper Level, San Diego Convention Center

EATING DISORDERS 2007: EXPANDING BIOLOGICAL AND CLINICAL PERSPECTIVES

Chp.: Joel Yager, M.D.
Co-Chp.: David B. Herzog, M.D.

A Anorexia Nervosa and Obsessive Compulsive Disorder
Walter H. Kaye, M.D.

B How Stable Are Eating Disorder Diagnoses?
David B. Herzog, M.D., Kamryn T. Eddy, Ph.D., Debra L. Franko, Ph.D., David J. Dorer, Ph.D., Kavita Tahlani, B.S.

C Impulse Control Disorders in Eating Disorder Women
Katherine A. Halmi, M.D.

D Body Image Concerns and the Desire for Plastic Surgery After Bariatric Surgery
James E. Mitchell, M.D.

E Eating Disorders in Late Life
William J. Apfeldorf, M.D., Joel Yager, M.D., C. Nathanial Roybal, M.D.

Discussant: Joel Yager, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 13 2:00 p.m.-5:00 p.m.
Room 23 A, Upper Level, San Diego Convention Center

DECONSTRUCTING PSYCHOSIS: RESEARCH PLANNING FOR DSM-V

Chp.: Carol A. Tamminga, M.D.
Co-Chp.: Jim Van Os, M.D.

A Parsing Endophenotypes Across Psychotic Disorders:
Toward a Refined Nosology of Psychoses
Matcheri Keshavan, M.D.

B Delusions in Unipolar and Bipolar Major Depression:
Recommendations for the Revision of the DSM-IV
Mario Maj, M.D.

C Deconstructing Psychosis: A Brain Imaging Perspective
Raquel E. Gur, M.D.

D Epidemiological and Psychopathological Approaches towards Psychotic Diagnoses in DSM-V
Jim Van Os, M.D.

E Pharmacology of Psychosis: Contrasting Schizophrenia
With Bipolar 1 Disorder
Carol A. Tamminga, M.D.

Discussant: William T. Carpenter, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 14 2:00 p.m.-5:00 p.m.
Room 26 A/B, Upper Level, San Diego Convention Center

BRIEF THERAPIES: AN UPDATE FOR CLINICIANS

Chp.: Mantosh J. Dewan, M.D.

A Useful Tips for Psychotherapists From Research
Roger P. Greenberg, Ph.D.

B Formulation and Intervention in Time-Limited Dynamic Psychotherapy
Hanna Levenson, Ph.D.

C Cognitive Therapy
Judith Beck, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 15 2:00 p.m.-5:00 p.m.
Room 28 D/E, Upper Level, San Diego Convention Center

WHAT IS THE DIRECTIONALITY OF THE ONSET OF COMORBID SUBSTANCE USE AND OTHER PSYCHIATRIC DISORDERS?

Collaborative Sessions With the National Institute on Drug Abuse

Chp.: Kevin P. Conway, M.D.
Co-Chp.: Ivan D. Montoya, M.D.

A Methodological Issues in Assessing the Directionality of the Onset of Substance Use and Other Comorbid Psychiatric Disorders
Helena C. Kraemer, Ph.D.

B Evidence of Directionality in Epidemiological Studies of Adults
Ronald Kessler, Ph.D.

C Genetic Factors and the Directionality of Comorbid Disorders
Michael Vanyukov, Ph.D.

(Continued next page)
D Developmental Models to Explain the Onset and Directionality of Comorbid Disorders
Monique Ernst, M.D.

E Treatment Implications of Determining the Directionality of Comorbid Disorders
Edward V. Nunes, M.D.

Discussant: Kathleen T. Brady, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 16
Room 29 A/B, Upper Level, San Diego Convention Center

CATEGORIES AND DIMENSIONS IN CLINICAL, AND RESEARCH CONTEXTS OF DIAGNOSTIC CLASSIFICATION FOR DSM-V
Collaborative Session With the National Institute on Drug Abuse

Chp.: Helena C. Kraemer, Ph.D.

A Severity is the Most Important Dimension of Depression
Michael E. Thase, M.D.

B Anxiety Disorders
M. Katherine Shear, M.D.

C Dimensional Approaches to Diagnosing Addictive Disorders
Wilson M. Compton, M.D.

D A Dimensional Prototype for BPD
Andrew L. Skodol, M.D., Robert F. Krueger, Ph.D., W. John Livesley, M.D., Patrick Shrout, Ph.D., Yueqin Huang, M.D.

E Dimensional Approach to Major Psychoses
Patricia Suppes, M.D.

Discussant: Maritza Rubio-Stripce, Sc.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 17
Room 29 C/D, Upper Level, San Diego Convention Center

THE DISRUPTIVE PHYSICIAN: REHABILITATE OR RETALIATE?

Chp.: Howard E. Book, M.D.

A Managing Disruptive Behaviour in Physicians: The Experience of Ontario’s Physician Health Program
Michael Kaufmann, M.D.

B Physician Disruptive Behavior Patterns: Assessment, Intervention and Monitoring
Larry J. Harmon, Ph.D.

C The Forensic Psychiatric Contribution to Assessing and Understanding Disruptive Physician Behaviour
Hy Bloom, M.D.

D Disruptive Docs: How Are They?
Eva C. Ritvo, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 18
Room 30 A, Upper Level, San Diego Convention Center

IMPULSIVITY: FROM NEUROPHENOMENOLOGY TO TREATMENT OPTIONS

Chp.: Stefano Pallanti, M.D.
Co-Chp.: Eric Hollander, M.D.

A Treatment of Impulsivity and Compulsivity
Eric Hollander, M.D., Daphne Simeon, Andrea Allen, Ph.D., Thomas Mick, M.D., Heather Berlin, Ph.D., Jennifer Bartz, Ph.D.

B Pharmacological Challenge in Pathological Gambling
Stefano Pallanti, M.D., Silvia Bernardi, M.D., Ilene Pampaloni, M.D., Eric Hollander, M.D.

C Searching for Endophenotypes in OCD Families: Results From Neuropsychology and Brain Imaging Studies
Naomi A. Fineberg, M.D., Lara Menzies, M.D., Ed Baltimore, M.D.

D Exploring Impulsivity and Compulsivity Using Neurocognitive Probes: Translational Approaches
Samuel Chamberlain, Ph.D., Trevor Robbins, Ph.D., Barbara Sahakian, Ph.D.

Discussant: Lorin M. Koran, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 19
Room 30 B, Upper Level, San Diego Convention Center

THE HIDDEN DIAGNOSES IN PSYCHIATRY: IMPLICATIONS FOR TRAINING, CLINICAL CARE, AND OUTCOMES

Chp.: Leighton Y. Huey, M.D.

A The Importance of Early-Onset Psychiatric Disorders and Developmental Psychopathology for the Psychiatrist
Daniel F. Conner, M.D.

B Dysmorphology, Mental Illness, and Learning Disabilities: Genetic Syndromes With Behavioral Phenotypes
Carolyn M. Drazin, M.D.

C Common Diagnostic Confusions, Addictions, Depression, and ASPD: Which Is Which?
Victor Hesselbrock, Ph.D.

D Recovering the Diagnosis of PTSD in Psychiatric Training
Julian D. Ford, Ph.D.

E Pay Attention: The Impact of ADHD in Adulthood
Leighton Y. Huey, M.D.
THIS SESSION WILL BE AUDIOTAPEP.
MONDAY

SYMPOSIUM 20  2:00 p.m.-5:00 p.m.
Room 30 C, Upper Level, San Diego Convention Center

PSYCHIATRIC PRACTICE IN THE NURSING HOME

Chp.: Subramoniam Madhusoodanan, M.D.
Co-Chp.: Ronald Brenner, M.D.

A Nursing Home Consultation
Olivera J. Bogunovic, M.D.

B Research in the Skilled Nursing Facility: It Is Different?
Sanjay Gupta, M.D.

C Behavior Management Program
Subramoniam Madhusoodanan, M.D.

Discussant: Ronald Brenner, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 21  2:00 p.m.-5:00 p.m.
Room 30 D/E, Upper Level, San Diego Convention Center

CHILDREN OF IMMIGRANTS IN THE CHANGING MOSAIC OF THE U.S.

Chp.: Consuelo C. Cagande, M.D.

A A Personal Introduction
Consuelo C. Cagande, M.D.

B Children of Immigrants: An Overview
R. Rao Gogineni, M.D.

C Balancing Act Between Two Cultural Identities
Alyssa S. Kwon, M.D.

D An Immigrant Parental Journey: Trials, Tribulations, and Triumphs
Dilip Ramehandani, M.D.

E The Second Generation: Risks and Opportunities
Andres J. Pumariega, M.D.

Discussant: Andres J. Pumariega, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 22  2:00 p.m.-5:00 p.m.
Room 31 A, Upper Level, San Diego Convention Center

UPDATE ON SUPPORTIVE PSYCHOTHERAPY

Chp.: David J. Hellerstein, M.D.

A Theory of Supportive Psychotherapy
Arnold Winston, M.D., Michael Goldstein, M.D.

B History of Supportive Psychotherapy
Stephen J. Roczewicz, Jr., M.D.

C Research on Supportive Psychotherapy in the Treatment of BPD
David J. Hellerstein, M.D., Barbara H. Stanley, M.D.,
Kimberly Kotov, Ph.D., Ron Aviram, Ph.D.

D Use of Supportive Psychotherapy in Adjustment Disorders.
Roger Peele, M.D., Vicenzo H. Perkins, M.D., Mozhdah Roozegar, M.D., Maryam Razavi, M.D.

E Teaching Supportive Psychotherapy to Psychiatric Residents
Carolyn J. Douglas, M.D.

Discussant: Peter J. Buckley, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 23  2:00 p.m.-5:00 p.m.
Room 31 B, Upper Level, San Diego Convention Center

FIRST BREAK SCHIZOPHRENIA IN FRANCOPHONE AND ANGLOPHONE COUNTRIES: TREATMENT AND NEUROIMAGING: VIVE LA DIFFERENCE
French Psychiatric Association

Chp.: John A. Talbott, M.D.
Co-Chp.: Francois C. Petitjean, M.D.

A Early Intervention in Psychosis: An Evidence-Based Reform
Patrick D. McGorry, M.D.

B Cannabis Use and Past Treatment in First Psychotic Episode
Olivier J. Canceil, Psy.D., Fayçal Mousaffak, M.D., Yannick Morvan, Psy.D., Marie-Odile Krebs, Ph.D.

C Preventing Schizophrenia: An International Initiative
Thomas H. McGlashan, M.D.

D Evaluation of Hospital-Based Care for Schizophrenia
Karen A. Ritchie, Ph.D.

E Treatment of First Episode Psychosis: Importance of Drug Selection and Early Intervention
Jeffrey A. Lieberman, M.D.

F Neuroimaging in Patients With First Psychotic Episode
Olivier Maiz, M.D., Aanick Razafimandimb, Ph.D.,
Pascale Abadie, Laurent Lecarceur, Bernard Mazoyer, M.D.,
Nathalie Tsourio-Mazoyer, M.D., Sonia Dollfus, M.D.

Discussants: Alexandra B. McLean, M.D., Robert Rosenheck, M.D.
THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 24 2:00 p.m.-5:00 p.m.
Room 31 C, Upper Level, San Diego Convention Center

CHALLENGES AND NEW DEVELOPMENTS IN THE PSYCHIATRIC EDUCATION OF MEDICAL STUDENTS

Chp.: Jonathan E. Alpert, M.D.
Co-Chp.: Eric R. Marcus, M.D.

A Psychiatric Stigma in Medical Student Education
Steven C. Schlozman, M.D., Mary Anne Badaracco, M.D.

B The Latent Curriculum and The Emotional Development of Medical Students
Eric R. Marcus, M.D.

C Ambulatory Experiences in the Psychiatry Clerkship
Tamara L. Gay, M.D.

D Interdisciplinary and Longitudinal Integration During Clinical Training
Adam M. Brenner, M.D., Derril Shtasel, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 25 2:00 p.m.-5:00 p.m.
Room 32 A, Upper Level, San Diego Convention Center

INNOVATIVE WAYS IN PSYCHOTHERAPY SUPERVISION: THE SHORT TERM DYNAMIC THERAPY EXPERIENCE

Chp.: Manuel Trujillo, M.D.
Co-Chp.: Waguih W. IsHak, M.D.

A Innovative Ways in Psychotherapy Supervision: The Short Term Dynamic Therapy Experience
Amir E. Ettikal, M.D.

Discussants: Manuel Trujillo, M.D., Waguih W. IsHak, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 26 2:00 p.m.-5:00 p.m.
Room 32 B, Upper Level, San Diego Convention Center

ALEXITHYMIA AND EMOTIONAL DYSREGULATION: FROM THEORY TO CLINICAL PRACTICE

Chp.: Maurice Corcos, M.D.
Co-Chp.: Gwenole Loas, M.D.

A Depression and Alexithymia in Eating Disorders
Maurice Corcos, M.D., Gwenole Loas, M.D., Jean-Luc Venisse, M.D., Paul Bizouard, M.D.

B Relationships Between Alexithymia, Depression, and Dependent Personality Disorder
Gwenole Loas, M.D.

C BPD and Emotional Dysregulation
Alexandra Pharm-Scotton, M.D., Marion Robin, M.D.

D Alexithymia and Self-Injurious Behavior: A Core Dimension? A Study on 692 Subjects
Ludovic Gicquel, M.D., Bruno Falissard, Ph.D., Maurice Corcos, M.D.

E Alexithymia in Infertile Women
Claire Lamas, M.D., Isabelle Nicolas, M.D., Maurice Corcos, M.D., René Frydman, M.D.

THIS SESSION WILL BE AUDIOTAPE.

ADVANCES IN TREATMENTS OF PSYCHIATRIC DISORDERS
2:00 p.m.-5:30 p.m.
Ballroom 6 A, Upper Level, San Diego Convention Center

Chp.: Glen O. Gabbard, M.D.

A Advances in Treatment of Psychiatric Disorders
Katharine A. Phillips, M.D.

B Advances in Treatment of Psychiatric Disorders, Antisocial Personality Disorders, and Psychopathy
Reid Meloy, Ph.D.

C Advances in Treatment of Psychiatric Disorders: Combined Medication and Psychotherapy for Mood Disorders
Jan Fawcett, M.D.

D Advances in Treatment of Psychiatric Disorders
Charles Marmar, M.D.

E Histrionic Personality Disorder
Glen O. Gabbard, M.D.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 3
3:00 p.m.-5:00 p.m.
Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

5:30 p.m. Sessions

CONVOCATION OF DISTINGUISHED FELLOWS
5:30 p.m.-6:30 p.m.
Ballroom 20, Upper Level,
San Diego Convention Center

All Distinguished Life Fellows, Distinguished Fellows, Life Fellows, International Fellows, Fellows, members, and registered guests are invited.

(Continued next page)
Presiding: Pedro Ruiz, M.D., President

Grand Marshals: Joseph R. Mawhinney, M.D., Marc A. Schuckit, M.D.

Marshals: Dilip V. Jeste, M.D., Kenneth L. Campos, M.D.

INTRODUCTION OF DISTINGUISHED LIFE FELLOWS
Carolyn B. Robinowitz, M.D., President-Elect

INDUCTION OF DISTINGUISHED FELLOWS
Carolyn B. Robinowitz, M.D.

INTRODUCTION OF FIFTY-YEAR DISTINGUISHED LIFE FELLOWS, FIFTY-YEAR LIFE MEMBERS, AND INTERNATIONAL FELLOWS
Pedro Ruiz, M.D.

INTRODUCTION OF FELLOWS
Pedro Ruiz, M.D.

PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS
Pedro Ruiz, M.D.

PRESENTATION OF Distinguished SERVICE AWARDS
Pedro Ruiz, M.D.

INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARD BOARD CHAIRPERSONS
Pedro Ruiz, M.D.

PRESENTATION OF AWARDS
Pedro Ruiz, M.D.
APA/Lilly Resident Research Awards
Human Rights Awards
Blanche E. Itelson Award for Research in Child Psychiatry
APIRE/Kemph Fund Awards for Research Development in Psychobiological Psychiatry
Agnes Purcell McGavin Awards
Isaac Ray Award
Jack Weinberg Memorial Award for Geriatric Psychiatry

WILLIAM C. MENNINGER MEMORIAL CONVOCATION LECTURE
Professor John F. Nash, Jr.

LECTURE 12
5:30 p.m.-6:30 p.m.
Ballroom 20 Lobby, Upper Level, San Diego Convention Center

WILLIAM C. MENNINGER MEMORIAL LECTURE
Professor John F. Nash, Jr.

Nobel laureate John Nash Jr., Ph.D., at the age of 30, descended into the debilitating blackness of severe paranoid schizophrenia. Despite the odds, however, his perseverance and genius eventually led to his winning the 1994 Nobel Prize for Economics for landmark work he had begun in the 1950s on the mathematics of game theory. His inspiring story was adapted in the movie "A Beautiful Mind," which won the best-picture Oscar for 2001. Mr. Nash was born in Bluefield, WV, in 1928. Early on he excelled at mathematics and won a scholarship to Carnegie Mellon University. He did so well that upon graduation in 1948 he was awarded a master's degree in addition to his bachelor's degree, and went on to earn a Ph.D. from Princeton University in 1950. From 1951 until his resignation in 1959, he was a faculty member at M.I.T. As an undergraduate, he began work on what is now regarded as the basic building block of the theory of games. His reputation as a mathematical genius was firmly established by his ability to solve major problems in pure mathematics using original methodology. In 1957 Nash married a woman he had met while she was a student at M.I.T. During his wife's pregnancy in 1959, he became increasingly delusional and was forcibly hospitalized on several occasions. He eventually refused to take medication and for years was a ghostly figure on the Princeton campus, believing he was engaging in research. It was in the early 1990s that acquaintances noticed that he appeared to be recovering from his illness. According to his autobiography, "When I had been long enough hospitalized... I would finally renounce my delusional hypotheses and revert to thinking of myself as a human of more conventional circumstances and return to mathematical research. In these interludes of, as it were, enforced rationality, I did succeed in doing some respectable mathematical research... But after my return to the dream-like delusional hypotheses in the later 60s, I became a person of delusionally influenced thinking but of relatively moderate behavior and thus tended to avoid hospitalization and the direct attention of psychiatrists. Thus further time passed. Then gradually I began to intellectually reject some of the delusional influenced lines of thinking which had been characteristic of my orientation. This began, most recognizably, with the rejection of politically oriented thinking as essentially a hopeless waste of intellectual effort." Despite having divorced his wife for her role in having him hospitalized, in 1970 she took him in to save him from homelessness, and they remarried in 1991. Three years later, he won the Nobel Prize. This is no fairytale ending; it provides powerful support for the growing movement within psychiatry to help patients with severe mental illness focus on recovery, not pathology.

THIS SESSION WILL BE AUDIOTAPED.
7:00 p.m. Sessions

INDUSTRY SUPPORTED SYMPOSIA 25-28

INDUSTRY SUPPORTED SYMPOSIUM 25
7:00 p.m.-10:00 p.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

IMPROVING OUTCOMES IN SCHIZOPHRENIA: PRODROME TO REMISSION
Supported by Janssen Pharmaceuticals and Research Foundation

Chp.: Christoph U. Correll, M.D.

A Early Intervention in the Psychotic Prodrome: Has Its Time Come?
Christoph U. Correll, M.D.

B The Course of Brain Abnormalities in Schizophrenia: Can We Modify Them?
Rene S. Kahn, M.D.

C Improving Rates of Response and Remission in Schizophrenia: How Do We Get Where We Need to Be?
John M. Kane, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 26
7:00 p.m.-10:00 p.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

NAVIGATING THE COMPLEX MAZE OF BIPOLAR DISORDER
Supported by Pfizer Inc.

Chp.: Prakash S. Masand, M.D.

A Diagnostic Pitfalls in Patients With Bipolar Disorder
Prakash S. Masand, M.D.

B Managing the Bipolar Patient With Medical Comorbidities
Andrea Fagiolini, M.D.

C Tailoring Antipsychotic Treatment to the Complex Patient With Bipolar Disorder
Paul E. Keck, M.D.

D Bringing Research to the Clinician: Lessons From STEP-BD
Gary S. Sachs, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 27
7:00 p.m.-10:00 p.m.
Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

WHEN ENDOCRINOLOGY AND PSYCHIATRY COLLIDE: WHAT THE CLINICIAN NEEDS TO KNOW ABOUT ANTIPSYCHOTIC-INDUCED ENDOCRINE DISTURBANCES
Supported by AstraZeneca Pharmaceuticals

Chp.: Peter F. Buckley, M.D.

A Increasing Global Burden of Cardiovascular Disease in General Populations and Patients With Schizophrenia
Charles H. Hennekens, M.D.

B Diabetes and the Metabolic Syndrome: From Soup to Nuts
Ramachandran Cooppan, M.B.Ch.B.

C Antipsychotics and Metabolic Risk: What's the Problem and What's the Solution?
John W. Newcomer, M.D.

D Prolactin Elevation and Antipsychotic Therapy: What to Tell Patients About Risks to Bones and Sexual Functioning
Meera Narasimhan, M.D.

E Guidelines for the Management of Metabolic and Endocrine Side Effects: Confusion or Consensus?
Peter F. Buckley, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 28
7:00 p.m.-10:00 p.m.
Manchester Ballroom, Second Level, Manchester Grand Hyatt

IMPROVING DEPRESSION TREATMENTS: BRIDGING THE GAP BETWEEN RESEARCH AND CLINICAL PRACTICE
Supported by Eli Lilly and Company

Chp.: Jonathan E. Alpert, M.D
Co-Chp.: Timothy Petersen, Ph.D.

A Follow-Up Care After Initiating Antidepressant Treatment: An Empirically Informed Approach
Mark Zimmerman, M.D.

B Achieving and Maintaining Optimal Therapeutic Outcomes in Old-Age Depression
Charles F. Reynolds III, M.D.

C Optimizing Care for Depression During the Menopausal Transition: The Interface Between Psychiatry and Gynecology
Hadine Joffe, M.D.

D Management of Depressed Patients With Chronic Medical Conditions
Gregory E. Simon, M.D.

E The STAR*D Study: Lessons Learned
Timothy Petersen, M.D.
TUESDAY, MAY 22, 2007

160TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 22-24

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 22, PART 2
7:00 a.m.-8:30 a.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

LIFTING THE BURDEN OF PSYCHIATRIC ILLNESS: THE MANAGEMENT OF ALLOSTATIC LOAD, METABOLIC SYNDROME, AND CO-OCCLUDING DISORDERS
Supported by Shire-Wyeth

Chp.: Mark H. Rapaport, M.D.

A Issues in the Assessment and Management of Overweight and Obesity in Psychiatric Patients
Alicia Ruelaz, M.D.

B Integrating Alternative Health Approaches Into the Care of Our Patients: Evidence About the Actions of Exercise, Massage, and Acupuncture
Mark H. Rapaport, M.D.

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 23, PART 2
7:00 a.m.-8:30 a.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

HOW DO ATYPICALS AND ANTIPSYCHOTICS WORK? FROM RECEPTORS TO REALITY
Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Managing Patients With Psychotic Disorders: From Efficacy to Effectiveness
John Lauriello, M.D.

B Pharmacologic Predictability of Antipsychotic-Related Adverse Effects: An Opportunity for Improving Outcomes
Prakash S. Masand, M.D.

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 24, PART 2
7:00 a.m.-8:30 a.m.
Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

TREATING THE SPECTRUM OF BIPOLAR DISORDERS: AN INTERACTIVE CASE DISCUSSION
Supported by AstraZeneca Pharmaceuticals

Chp.: Michael E. Thase, M.D.

A Beyond Antidepressants: Treatment Options for Bipolar Depression
Roger S. McIntyre, M.D.

B Treating and Preventing Mania
Lauren B. Marangell, M.D.

8:00 a.m. Sessions

COURSES 55-61

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 55 8:00 a.m.-12 noon
Elizabeth Ballroom F, Second Level, Manchester Grand Hyatt

ADVANCED ASSESSMENT AND TREATMENT OF ADD

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 56 8:00 a.m.-12 noon
Elizabeth Ballroom H, Second Level, Manchester Grand Hyatt

PSYCHIATRIC GENOMICS: APPLICATIONS FOR CLINICAL PRACTICE

Director: David A. Mrazek, M.D.
Faculty: Renato D. Alarcon, M.D., John L. Black, M.D.

COURSE 57 8:00 a.m.-12 noon
Edward Room A/B, Second Level, Manchester Grand Hyatt

DISASTER PSYCHIATRY: TERRORISM, TRAUMA, AND THINGS TO DO

Director: Joseph C. Napoi, M.D.
Faculty: Michael Blumenfeld, M.D.

COURSE 58 8:00 a.m.-12 noon
Madeleine Room C/D, Third Level, Manchester Grand Hyatt

RESEARCH ON A SHOESTRING BUDGET

Director: Mantosh J. Dewan, M.D.
Faculty: Stephen V. Faraone, Ph.D., Michele T. Pato, M.D.

COURSE 59 8:00 a.m.-12 noon
Mohsen Room A/B, Third Level, Manchester Grand Hyatt

TREATING MEDICAL STUDENTS AND PHYSICIANS

Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
TUESDAY

COURSE 60 8:00 a.m.-12 noon
Emma Room A/B/C, Third Level, Manchester Grand Hyatt

CHILD MURDER BY PARENTS

Director: Phillip J. Resnick, M.D.

COURSE 61 8:00 a.m.-12 noon
Randle Ballroom B, Fourth Level, Manchester Grand Hyatt

HOW TO USE YOUR PALM OS PERSONAL DIGITAL ASSISTANT IN PSYCHIATRIC PRACTICE: INTRODUCTORY COURSE

Co-Directors: Charles J. Rainey, M.D., Richard A. Montgomery, M.D.
Faculty: Carlyle H. Chan, M.D., Steven I. Altsuler, M.D., Raymond J. Kloss, M.D.

9:00 a.m. Sessions

CASE CONFERENCE 2
9:00 a.m.-12 noon
Room 23 a/b, Upper level, San Diego Convention Center

COGNITIVE THERAPY FOR DEPRESSION

Moderator: Judith Beck, Ph.D.
Presenters: Jesse H. Wright III, M.D., Donna M. Sudak, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

ADVANCES IN ASSESSMENT AND MANAGEMENT OF SUICIDE
9:00 a.m.-12:30 p.m.
Ballroom 6 A, Upper Level, San Diego Convention Center

Chp.: Robert I. Simon, M.D.

A Suicide and Gender
Liza H. Gold, M.D.

B Suicide in Children and Adolescents
Peter Ash, M.D.

C Psychiatrists’ Reactions to Patient Suicides
Michael Gitlin, M.D.

COURSES 62-69

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 62 9:00 a.m.-4:00 p.m.
Edward Room C/D, Second Level, Manchester Grand Hyatt

A PSYCHODYNAMIC APPROACH TO TREATMENT REFRACTORY MOOD DISORDERS

Director: Eric M. Plakun, M.D.
Faculty: David L. Mintz, M.D., Edward R. Shapiro, M.D.

COURSE 63 9:00 a.m.-4:00 p.m.
Gregory Room A/B, Second Level, Manchester Grand Hyatt

UNDERSTANDING THE PERSON BEHIND THE ILLNESS: AN APPROACH TO PSYCHODYNAMIC FORMULATION

Director: William H. Campbell, M.D.

COURSE 64 9:00 a.m.-4:00 p.m.
Ford Room A/B/C, Third Level, Manchester Grand Hyatt

ADVANCED INTERVIEWING TECHNIQUES

Director: Shawn C. Shea, M.D.

COURSE 65 9:00 a.m.-4:00 p.m.
Madeleine Room A/B, Third Level, Manchester Grand Hyatt

PERSONNEL MANAGEMENT FOR CLINICIAN-ADMINISTRATORS

Director: Stephen M. Sohys, M.D.
Faculty: Joseph J. Parks, M.D., Kay H. Titchenal, S.P.H.R.

COURSE 66 9:00 a.m.-4:00 p.m.
Del Mar Room A/B, Third Level, Manchester Grand Hyatt

STEPPS® TREATMENT PROGRAM FOR BORDERLINE PERSONALITY DISORDER

Co-Directors: Donald W. Black, M.D., Bruce M. Pfohl, M.D.
Faculty: Nancee Blum, M.S.W.

COURSE 67 9:00 a.m.-4:00 p.m.
Annie Room A/B, Third Level, Manchester Grand Hyatt

THE ASSESSMENT AND TREATMENT OF CHILD SEXUAL ABUSERS

Co-Directors: Gene G. Abel, M.D., John M. Bradford, F.R.C.P.C.
Faculty: Candice A. Osborn, M.D.
COURSE 68
9:00 a.m.-4:00 p.m.
Windsor Room, Third Level, Manchester Grand Hyatt

SPIRITUALITY IN PSYCHIATRY

Director: Michael D. McGee, M.D.

COURSE 69
9:00 a.m.-4:00 p.m.
Randle Ballroom A, Fourth Level, Manchester Grand Hyatt

BASIC CONCEPTS IN PALLIATIVE CARE FOR PSYCHIATRISTS

Co-Directors: Scott A. Irwin, M.D., Frank D. Ferris, M.D.
Faculty: Charles F. von Gunten, M.D., Gary T. Buckholz, M.D.,
Laurel H. Herbst, M.D., Steven Oppenheim, M.D., Kimberly A.
Bower, M.D., Sidney Zisook, M.D., Rodrigo A. Munoz, M.D.

LECTURES 13-15

LECTURE 13
9:00 a.m.-10:30 a.m.
Ballroom 6 B, Upper Level,
San Diego Convention Center

APA RESEARCH IN PSYCHIATRY
AWARD LECTURE

A. John Rush, M.D.

What Patients and Clinicians Need to Know: The Case for Patient-Focused Research

Chp.: Stuart C. Yudofsky, M.D.

Dr. A. John Rush holds two named positions at the University of Texas Southwestern Medical Center at Dallas, Professor of Psychiatry and Vice Chair in the Department of Clinical Sciences. Following his B.A. at Princeton University (1964), and his M.D. at the Columbia College of Physicians and Surgeons (1968), he completed a general medical internship at Passavant hospital, Northwestern University, and a psychiatric residency at the University of Pennsylvania (1975). His research has focused on the development and testing of innovative treatments for mood disorders including medications, medication combinations, somatic treatments and psychotherapy, as well as disease management protocols (treatment algorithms) for severe and persistent mental illnesses. He has authored more than 470 papers and chapters and 10 books and has received continuous NIH research support for 30 years. Dr. Rush's past awards include the Mood Disorders Research Award from the American College of Psychiatrists, the Paul Hoch Award from the American Psychopathological Association, the Edward J. Sachar Visiting Scholar Award from Columbia, the American Psychiatric Association Award for Research in Psychiatry, and the Gold Medal Award from the Society of Biological Psychiatry. He is past president of the Society of Biological Psychiatry and Society for Psychotherapy Research.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 14
9:00 a.m.-10:30 a.m.
Ballroom 6 C/D/E/F, Upper Level,
San Diego Convention Center

John H. Krystal, M.D.

Glutamate, the Prefrontal Cortex, and Schizophrenia: Capturing the Angel in Angel Dust

Chp.: Anu A. Matorin, M.D.

Dr. Krystal is the Robert L. McNeil, Jr., Professor of Clinical Pharmacology and Deputy Chairman for Research for the Department of Psychiatry, Yale University School of Medicine and the VA Connecticut Healthcare System. He is a graduate of the University of Chicago, Yale University School of Medicine, and the Yale Department of Psychiatry Residency Training Program. He has published over 300 papers and chapters on the neurobiology and treatment of alcoholism, schizophrenia, and post-traumatic stress disorder. In his work, he is best known for studies of the contributions of amino acid neurotransmission to behavior, cognition, psychopathology, and treatment. His research program unites psychopharmacology, neuroimaging, and molecular genetics. He is principal investigator of the NIAAA Center for the Translational Neuroscience of Alcoholism, VA Alcohol Research Center, and Clinical Neuroscience Division of the VA National Center for PTSD. Dr. Krystal received the Joel Eells Award of the American College of Neuropsychopharmacology (ACNP), the Han Jonas Weibruch Scientific Award from Bayer, the APIRE/Kempr Fund Award of the American Psychiatric Association, Most Highly Cited Investigator Award from Thomson- ISI, and other awards. He is Chairman of the NIMH Board of Scientific Counselors (2004-2007). He also serves on the NARSAD Scientific Advisory Board and the boards of directors of the ACNP and the Research Society on Alcoholism. He was a managing editor for the journal, Psychopharmacology (1999-2006) and is currently editor of Biological Psychiatry.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 15
9:00 a.m.-10:30 a.m.
Room 33 A/B/C, Upper Level,
San Diego Convention Center

Apisamai Sirisangson, M.D.

Thailand's Recent Experience: Community Mental Health and Desegitimization

Chp.: Kathryn Connor, M.D.

(Continued next page)
Apisanai Srinangson, MD, known as Dr. Birth works for
the Thai Department of Mental Health, Ministry of Public
Health and practices psychiatry at Sritanya public Psychiatric
Hospital in Nonthaburi Thailand. In addition to her work as
a psychiatrist Dr. Birth also appears as the anchor of
the national evening news and appears on several other regular
TV segment. She has used her public profile to advance the
cause of the mentally ill and has written a best selling book
Stories by Dr. Birth’s Welcome to Sritanya Psychiatric Hospital. Her
primary interests lie in the areas of community mental health
and de-stigmatization. She has also played important roles in
the development and implementation of a new community
mental health initiative, Family Link. This program is
designed to promote advocacy and education to the public.
She was Co-chair in the initiative project ’Destigmatization’ in
2002-2005. Additionally she has been a member of the
committee for the national de-stigmatization campaign that
involves the families and enlists media and political support
to reduce stigma. As a medical student she won the Award
for Excellence in Community Health for Medical Student.
In 1999 she was named Miss Thailand and represented
Thailand in the Miss Universe pageant in Trinidad and
Tobago. More recently she was awarded the Trip Tang Award
for Best Practice News Anchor and the Pew Award for
Women Role Models. Dr. Birth received her medical degree
from Khon Kaen University in 1999 and her diploma from
the Thai Board of General Psychiatry from Mahidol
University in 2002. She currently resides in Nonthaburi
Thailand, a suburb of Bangkok. In her spare time she
enjoys, writing, reading, scuba diving, studying piano,
painting and travel as well as running a coffee retail shop,
Coffee with Dr. Birth.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPE.

SMALL INTERACTIVE SESSIONS 8-9
9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come,
first-served basis.
8 Jon E. Grant, M.D., on Men’s Mental Health (Meet the Author)
Room 27 B, Upper Level, San Diego Convention Center
9 Howard E. Book, M.D., on Why Leadership Skills Benefit
Residents (Residents Only)
Room 31 C, Upper Level, San Diego Convention Center

WORKSHOPS

COMPONENTS 23-29

COMPONENT WORKSHOP 23  9:00 a.m.-10:30 a.m.
Room 3, Upper Level, San Diego Convention Center

EVALUATING COMPETENCY IN PSYCHOSOMATIC
MEDICINE
APA Council on Psychosomatic Medicine

Co-Chips.: Mary J. Massie, M.D., Thomas N. Wisc, M.D.
Participants: Lawson R. Wulsin, M.D., David F. Gitlin, M.D.,
Angel A. Caraballo, M.D.

COMPONENT WORKSHOP 24  9:00 a.m.-10:30 a.m.
Room 4, Upper Level, San Diego Convention Center

CULTURE MATTERS: A MULTICULTURAL
PERSPECTIVE ON THE IMMIGRANT EXPERIENCE
APA/AstraZeneca Minority Fellows

Co-Chips.: Alejandra Postichwai, M.D., Natasha D. Wexler, M.D.
Participants: Liwei L. Hua, M.D., Jacqueline Henschke, M.D.,
Navdeep K. Dhalival, Rascha Dughly, M.D.

COMPONENT WORKSHOP 25  9:00 a.m.-10:30 a.m.
Room 5 A, Upper Level, San Diego Convention Center

SWEET CHILD OF MINE: PREGNANCY AND
PARENTAL LEAVE DURING RESIDENCY
APA GlaxoSmithKline Fellows

Co-Chips.: Vishal Madaan, M.D., Keith R. Stowell, M.D.

COMPONENT WORKSHOP 26  9:00 a.m.-10:30 a.m.
Room 5 B, Upper Level, San Diego Convention Center

THE APA WEB SITE: POTENTIAL FUTURE
DIRECTIONS AND OPPORTUNITY FOR DIALOGUE
APA Ad Hoc Work Group on Information Systems

Chp.: Robert C. Hsiung, M.D.
Participants: William Bruce

COMPONENT WORKSHOP 27  9:00 a.m.-10:30 a.m.
Room 7 B, Upper Level, San Diego Convention Center

UPDATE ON PSYCHIATRY AND LAW
APA Council on Psychiatry and Law

Chp.: Paul S. Appelbaum, M.D.
Participants: Steven K. Hoge, M.D., Howard V. Zonana, M.D.

COMPONENT WORKSHOP 28  9:00 a.m.-10:30 a.m.
Room 7 A, Upper Level, San Diego Convention Center

LEARNING DISORDERS UPDATE FOR MENTAL
HEALTH PROFESSIONALS
APA Corresponding Committee on Mental Health and Schools

Chp.: Marcia J. Slattery, M.D.
Participants: Jodi E. Stro, M.D., Hong Shen, M.D., Lina M.
Lopez, M.D.

COMPONENT WORKSHOP 29  9:00 a.m.-10:30 a.m.
Room 30 B, Upper Level, San Diego Convention Center

THE NATIONAL HEALTH INFORMATION
NETWORK AND PSYCHIATRY: HOW WILL
ELECTRONIC HEALTH RECORDS IMPACT OUR
PATIENTS AND OUR PRACTICE?
APA Corresponding Committee on Electronic Health Records

Chp.: Farrell H. Brazel, M.D.
Participants: Peter F. Fore, M.D., Zebulon Taintor, M.D.,
Robert M. Plovnick, M.D.
ISSUE WORKSHOP 28 9:00 a.m.-10:30 a.m.
Room 11 B, Upper Level, San Diego Convention Center

PSYCHIATRY IN THE PRIMARY CARE SETTING: MAKING IT WORK FOR PATIENTS AND DOCTORS

Chp.: John C. Urbaitis, M.D.
Participants: Jonathan S. Davine, M.D., David A. Pollack, M.D., Shauna P. Reinblatt, M.D.

ISSUE WORKSHOP 29 9:00 a.m.-10:30 a.m.
Room 23 C, Upper Level, San Diego Convention Center

THE UTILITY OF COMPUTER-ASSISTED PSYCHOEDUCATION FOR RESIDENTIAL TREATMENT OF VETERANS WITH PTSD

Chp.:s Daniella David, M.D., Gary S. Kutcher, Ph.D.
Participant: Maria D. Llorente, M.D.

ISSUE WORKSHOP 30 9:00 a.m.-10:30 a.m.
Room 24 A, Upper Level, San Diego Convention Center

HOW DOES CULTURE MAKE A DIFFERENCE IN AMERICAN MENTAL HEALTH CARE? CULTURALLY-SPECIFIC CARE IN CHANGING CONTEXTS

Chp.:s Lawrence T. Park, M.D., Mary Jo Good, Ph.D.
Participants: Roberto Lewis-Fernandez, M.D., Sadeq Rahimi, Ph.D., Lisa Stevenson, Ph.D., Ken Vickery, Ph.D.

ISSUE WORKSHOP 31 9:00 a.m.-10:30 a.m.
Room 24 C, Upper Level, San Diego Convention Center

THE PROVIDER’S PURSUIT OF CULTURAL COMPETENCE: A BIOPSYCHOSOCIAL QUEST

Chp.: Richard K. Harding, M.D.
Participants: Nwoaka N. Campbell, M.D., Meeta Narasimhan, M.D., Eric R. Williams, M.D.

ISSUE WORKSHOP 32 9:00 a.m.-10:30 a.m.
Room 25 A, Upper Level, San Diego Convention Center

1:1 OBSERVATION IN A GENERAL HOSPITAL SETTING: ISSUES AND RECOMMENDATIONS.

Chp.:s Nyapati Rao, M.D., Kamal Jaghab, M.D.
Participants: Tanveer Padder, M.D., Jacob E. Sperber, M.D.

ISSUE WORKSHOP 33 9:00 a.m.-10:30 a.m.
Room 25 B, Upper Level, San Diego Convention Center

RECOGNITION AND MANAGEMENT OF NEUROLEPTIC MALIGNANT SYNDROME

Co-Chp.: Andrew J. Franks, M.D., Stephan C. Mann, M.D.
Participants: Stanley N. Croff, M.D., Sanjay Gupta, M.D., Dora D. Kohen, M.D., Perinnder Sachdev, M.D.

ISSUE WORKSHOP 34 9:00 a.m.-10:30 a.m.
Room 25 C, Upper Level, San Diego Convention Center

INVOLUNTARY HOSPITALIZATION OF MEDICAL PATIENTS WHO LACK DECISIONAL CAPACITY: AN UNRESOLVED ISSUE

Chp.: Nancy Byatt, D.O.
Participants: Debra A. Pinals, M.D., Patrick Smallwood, M.D.

ISSUE WORKSHOP 35 9:00 a.m.-10:30 a.m.
Room 28 A, Upper Level, San Diego Convention Center

HOW TO INVOLVE YOUR PATIENTS WITH BIPOLAR DISORDER IN THEIR TREATMENT PLAN: A GUIDELINE FOR CLINICIANS

Chp.: Heinz Grunze, M.D.
Participants: Frankse Colom, Ph.D., Eduard Vieta, M.D.

ISSUE WORKSHOP 36 9:00 a.m.-10:30 a.m.
Room 28 B, Upper Level, San Diego Convention Center

MAINTENANCE OF CERTIFICATION FOR DIPLOMATES OF THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY

Chp.: Larry R. Faulkner, M.D.
Participants: Victor I. Reus, M.D., Naleen N. Andrade, M.D., Christopher C. Colenda, M.D., Burton V. Reifler, M.D., Daniel K. Winstead, M.D.

ISSUE WORKSHOP 37 9:00 a.m.-10:30 a.m.
Room 29 C/D, Upper Level, San Diego Convention Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 1

Co-Chp.:s William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Martin G. Tracy, J.D., Marynell Hinton, M.A.

ISSUE WORKSHOP 38 9:00 a.m.-10:30 a.m.
Room 30 C, Upper Level, San Diego Convention Center

INTERPRETING AND DISSEMINATING FINDINGS FROM AN EVIDENCE-BASED DRUG REVIEW: ANTIEPILEPTIC DRUGS FOR MOOD DISORDERS

Chp.: John M. Oldham, M.D.
Participants: Cathay Melvin, Ph.D., William D. Evans, Ph.D., John Byrd, M.B.A.
Dr Norman Sartorius obtained his M.D. in Zagreb (Croatia). He specialized in neurology and psychiatry and subsequently obtained a Masters Degree and a Doctorate in psychology (Ph.D.). Dr Sartorius joined the World Health Organization (WHO) in 1967 and soon assumed charge of the programme of epidemiology in social psychiatry. He was also principal investigator of several major international studies on schizophrenia, on depression, and on health service delivery. In 1977, he was appointed Director of the Division of Mental Health of WHO, a position which he held until mid-1993. Dr Sartorius has served as the President of the World Psychiatric Association (WPA), President of the Association of European Psychiatrists (AEP), President of the International Association for the Promotion of Mental Health Programmes, and President of the Board of the Prize of Geneva Foundation. Dr Sartorius holds professorial appointments at the Universities of London, Prague and Zagreb and at several other universities in the USA and China. Dr Sartorius has published more than 300 articles in scientific journals, authored or co-authored several books and edited a number of others. The main areas of his interest are psychosocial aspects of health and development, public health aspects of neurology and psychiatry, cross-cultural psychiatry, scientific methodology and science policy. Dr Sartorius is an Honorary Fellow of the Royal College of Psychiatrists of the United Kingdom of Great Britain, of the Royal Australian and New Zealand College of Psychiatrists and of the American College of Psychiatry. He is a Distinguished Fellow of the American Psychiatric Association. He is a Corresponding Member of the Spanish Royal Academy of Medicine and of the Medical Academy of Mexico, Croatia and Peru. He has received the degree of Doctor of Medicine Honoris Causa of the Universities of Umea and of Prague and of Doctor of Science Honoris Causa of the University of Bath. He is an honorary fellow or member of numerous professional associations and advisory boards, both national and international.

International Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 17

11:00 a.m.-12:30 p.m.
Ballroom 6 C/D/E/F, Upper Level, San Diego Convention Center

Nora Volkow, M.D.

The Neurobiology of Free Will in Addictive Disorders

Co-Chp.: Eric C. Strain, M.D.

Nora D. Volkow, M.D., was appointed Director of the National Institute on Drug Abuse (NIDA) in May 2003. She is recognized as one of the world’s leading experts on drug addiction and brain imaging. Dr. Volkow’s work has been pivotal in demonstrating that drug addiction is a disease of the brain. She pioneered the use of brain imaging to investigate the toxic effects of drugs and the
effects of drugs responsible for their addictive properties in the human brain. In addition, she has made important contributions to the neurobiology of obesity, to the neurobiology of the behavioral changes that occur with aging, and to the treatment of ADHD. Dr. Volkow was born in Mexico, attended the Modern American School, and earned her medical degree from the National University of Mexico in Mexico City where she received the Premio Robins award for best medical student of her generation. Her psychiatric residency was at New York University where she earned the Laughlin Fellowship Award as one of the 10 Outstanding Psychiatric Residents in the USA. Dr. Volkow spent most of her professional career at the Department of Energy’s Brookhaven National Laboratory (BNL) in Upton, New York where she held several leadership positions including Director of Nuclear Medicine, Chairman of the Medical Department and Associate Director for Life Sciences. In addition, Dr. Volkow was a professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY) Stony Brook. Dr. Volkow has published more than 330 peer-reviewed articles, more than 50 book chapters and non-peer reviewed manuscripts, and also edited three books on the use of neuroimaging in studying mental and addictive disorders. Dr. Volkow has been the recipient of numerous awards for significant scientific and public service achievements, is a member of the Institute of Medicine of the National Academy of Sciences, and was named “Innovator of the Year” in 2000 by US News and World Report.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 18
11:00 a.m.-12:30 p.m.
Room 33 A/B/C, Upper Level,
San Diego Convention Center

Fred H. Gage, Ph.D.
New Neurons in the Adult Brain

Chp.: Tara Grady-Wediky, M.D.

Fred H. Gage, Ph.D. is a professor in the Laboratory of Genetics at the Salk Institute in La Jolla, CA. Gage studies degeneration and regeneration in the central nervous system, with an eye on possible future treatments for devastating neurological damages resulting from disease or injury. Gage is a leader in the neuroscience field, consistently one of its most original thinkers and productive researchers. He achieved national renown in 1998 for his groundbreaking experiments demonstrating that neurons are constantly being born in the brain, a process called neurogenesis. The study forced a paradigm shift in beliefs about how the brain functions. His data removed many barriers in neuroscience research, creating, virtually overnight, the possibility of brain repair. Gage is currently working to understand how new brain cells can be induced to become mature functioning nerve cells in the adult brain and spinal cord. He has shown that environmental enrichment and physical exercise can enhance the growth of these cells. He is studying the underlying cellular and molecular mechanisms that may be harnessed to repair the aged and damaged brain and spinal cord. Gage recently has focused his efforts on Rett Syndrome, a devastating childhood neurological disorder. In addition to substantive research, Gage has helped to define new roles in the practice of scientific research, including private funding and free market competition. In 1988 he co-founded StemCells, Inc., a small, publicly-traded company engaged in the discovery and commercialization of stem cells to treat diseases of the central nervous system, liver and pancreas. In 2000, Gage was named one of the Top 100 Innovators of the 21st Century by TIME magazine. He is a fellow of the National Academy of Sciences, American Association for the Advancement of Science, American Academy of Arts and Sciences and the Institute of Medicine and has been president of the Society for Neuroscience. Gage has received the Charles A. Dana Award for Pioneering Achievements in Health and Education, the Christopher Reeve Research Medal, the Max Planck Research Prize, and the MetLife Award for Medical Research. Dr. Gage has a B.S. degree from the University of Florida and a Ph.D. at The Johns Hopkins University.

Frontiers of Science Lecture Series
TUESDAY SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 10-18

SCIENTIFIC AND CLINICAL REPORT SESSION 10
11:00 a.m.-12:30 p.m.
Room 3, Upper Level, San Diego Convention Center

MEDICAL AND METABOLIC CONSEQUENCES OF PSYCHIATRIC TREATMENT

Chp.: Mitchel A. A. Kling, M.D.
Co-Chp.: Joel Dimsdale, M.D.

11:00 a.m.
29 Metabolic Abnormalities in Psychiatric Inpatients
John W. Goethe, M.D., Bonnie L. Szarek, R.N., Charles F. Caley, Pharm.D.

11:30 a.m.
30 Neuroleptic Malignant Syndrome Induced by Low Dose Aripiprazole in First Episode Psychosis
Harun Evcimen, M.D., Yesne Alici-Evcimen, M.D., Irakli Mania, M.D., Maju Mathews, M.D.

12 noon
31 Metabolic Abnormalities in Patients With Major Depressive Disorder
Karen Blank, M.D., Bonnie L. Szarek, R.N., John W. Goethe, M.D.

THIS SESSION WILL BE AUDIOTAPED.
TUESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 11
11:00 a.m.-12:30 p.m.
Room 4, Upper Level, San Diego Convention Center

ACCESS, AVAILABILITY, AND UTILIZATION OF PSYCHIATRIC SERVICES

Chp.: Eduardo Lopez-Gibson
Co-Chp.: Daniel P. Chapman, Ph.D.

11:00 a.m.
32 Recurrent Psychiatric Hospitalization
Christine Dunn, M.A., William H. Sledge

11:30 a.m.
33 Reducing the Medical and Financial Burden of Depressive Illness: A Plan for Improving Health Care Services
Lawrence W. Adler, M.D.

12 noon
34 Psychiatric Hospital Bed Numbers and Economic Factors in the XIX and XX Centuries: New Analyses
Alfonso Ceccherini-Nelli, M.D., Stefan Priebe, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 12
11:00 a.m.-12:30 p.m.
Room 5A, Upper Level, San Diego Convention Center

INTERNATIONAL STUDIES IN SCHIZOPHRENAIA

Chp.: Amir Kalali, M.D.
Co-Chp.: Meera Vaswani, Ph.D

11:00 a.m.
35 Brain Morphology in Schizophrenia Within the Northern Finland 1966 Birth Cohort
Matti K. Isohanni, M.D., Päiviikki Tanskanen, M.D., Jouko Miethunen, Ph.D., Graham Murray, M.D., Peter B. Jones, M.D., Ed T. Bullmore, M.D.

11:30 a.m.
36 The ADHES Project in Israel: New Insights in Adherence in Schizophrenia
Yoram Barak, M.D., Dov Aizenberg, M.D., Avi Bleich, M.D.

12 noon
37 Schizophrenia in the Offspring of Antenatally Depressed mothers and Familial Risk- Follow-Up of the Northern Finland 1966 Birth Cohort
Pirjo H. Maki, M.D., Juha M. Veijola, M.D., Jouko Miethunen, Ph.D., Jari Jokelainen, M.Sc., Paula Rantakallio, M.D., Peter B. Jones, M.D., Matti K. Isohanni, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 13
11:00 a.m.-12:30 p.m.
Ballroom 6 D, Upper Level, San Diego Convention Center

THEORETICAL AND RESEARCH APPROACHES IN THE STUDY OF VIOLENCE

Chp.: Saul Levine, M.D.
Co-Chp.: Igor Koutsenok, M.D.

11:00 a.m.
38 Beyond the Clash of Civilizations
David A. Rothstein, M.D.

11:30 a.m.
39 Phases of Trauma Recovery
Herbert L. Campbell, M.D.

12 noon
40 Predicting Unresolved PTSS in Earthquake Survivors: A Comparison Between Decision Analysis and Logistics Regression
Keng Shin Lin, Sr., D.M., Kuan-Yi Tsai, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 14
11:00 a.m.-12:30 p.m.
Room 9, Upper Level, San Diego Convention Center

DIAGNOSTIC ISSUES

Chp.: Krauz Ganadjian
Co-Chp.: Derya I. Akbijnik, M.D.

11:00 a.m.
41 Beyond Bipolar I and II: Evidence for the Validity of the "Softer" Bipolar Spectrum
Camilo J. Ruggero, Ph.D., Mark Zimmerman, M.D., Iwona Chelminski, Ph.D., Diane D. Young, Ph.D.

11:30 a.m.
42 A Proposal for a New Multi axial Model of Psychiatric Diagnosis: A Continuum Patient Model Based On Evolutionary Developmental Gene-Environment Interaction
Hoyle Leigh, M.D.

12 noon
43 Improving the Understanding of Causality in Psychiatric Research
Stephen B. Shanfield, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 15
11:00 a.m.-12:30 p.m.
Room 11B, Upper Level, San Diego Convention Center

GENETICS

Chp.: Dhatt Ajinder, M.D.
Co-Chp.: Austina Cho, M.D.

11:00 a.m.
44 CYP Genotyping in Patients Treated for Depression
Gualberto Ruano, M.D., John W. Goethe, M.D., Andreas Windemuth, Ph.D., Umme Salema Rahim, M.D.

11:30 a.m.
45 An Association Between the EPAC-1 Gene and Neuroticism and Anxiety
Christel M. Middeldorp, M.D., Xiangning Chen, Ph.D., Jacqueline M. Vink, Ph.D., Kenneth S. Kendler, M.D., Dorret I. Boomsma, Ph.D.
12 noon
46 Circadian System Polymorphisms and Bipolar Disorder
Daniel F. Kripke, M.D., Caroline M. Nievergelt, Ph.D., John R. Kelsoe, M.D., Thomas B. Barrett, M.D., Nicholas J. Schork, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 16
11:00 a.m.-12:30 p.m.
Room 24 C, Upper Level, San Diego Convention Center

CROSS CULTURAL PSYCHIATRY
Chp.: Andres Sciolla, M.D.
Co-Chp.: Jana Cook

11:00 a.m.
47 Similar Depressive Symptom Patterns in a Population Based Study of Immigrants From Turkey and Morocco and Dutch Natives
Agnes Schrier, Matty de Wit, Jack Dekker, Ralph Kupka, Aartjan Beckman

11:30 a.m.
48 Prevalence and Correlates of PMDD Among Arab Primary Care Patients in The United Arab Emirates
Ossama Tawakol Osman, M.D., Sufyan Sabri, Ph.D., Hanan Arefeesi, Amal Shamsan, M.D., Diaa Rizk, M.D.

12 noon
49 Effectiveness of Culturally Sensitive Collaborative Treatment for Treating Chinese Americans With Depression in a Primary Care Setting: A Six-Month Follow-Up Study
Albert Yeung, M.D., Lauren Fisher, B.A., Anna M. Agoston, B.A., Wan-Chen Weng, M.A., Yantao, M.D., Shamsa Sonawalla, M.D., Maurizio Fava, M.D.

12 noon
52 Mood and Anxiety Disorders in Patients With Cancer: A Case Series
Catherine L. Mancini, M.D., Andrew Cooper, B.S.C.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 18
11:00 a.m.-12:30 p.m.
Room 27 A, Upper Level, San Diego Convention Center

EVIDENCE-BASED AND GUIDELINE APPROACHES TO PSYCHIATRIC TREATMENTS
Chp.: Rajnish Mago, M.D.
Co-Chp.: Richard Buccigrossi, M.D.

11:00 a.m.
53 Preparing for Evidence-Based Medication-Related Psychiatric Practice: The Oregon Experience
Jennifer P. Wisdom, Ph.D., David A. Pollack, M.D., Ann Hamer, Pharm.D., Sarann Bielavitz

11:30 a.m.
54 Improving Adherence to Treatment Guidelines in Hospitalized Patients With Bipolar Disorder
Thomas F. Smith, M.D., Stewart B. Levine, M.D., Judith Hampel, R.N.

12 noon
55 Stepped Care for Anxiety, Depressive and Stress-Related Disorders: A Randomized Controlled Trial in Primary Care and Mental Health Care
Desiree Oosterbaan, Ph.D., Anton van Balkom, Ph.D., Marc Verbraak, Ph.D., Roelof ten Doesschate, M.D.

12 noon
50 Pilot Trial of Modafinil for Treatment of Depression Symptoms and Fatigue in Adult Patients With Brain Tumors
Thomas A. Kaleita, Ph.D., David K. Welsch, Ph.D., Timothy F. Cloughesy, M.D.

11:30 a.m.
51 Intraoperative Cerebral Oxygen Desaturation: A Significant Risk Factor for Postoperative Delirium in Cardiac Surgery Patients
Thomas S. Zaubler, M.D., James P. Slater, M.D., Rami T. Bustami, Ph.D., Theresa Guarino, R.N., Jessica Stack, Kateki Vinod, Kenneth Freundlich, Ph.D., Grant V.S. Parr, M.D.

12 noon
53 Mood and Anxiety Disorders in Patients With Cancer: A Case Series
Catherine L. Mancini, M.D., Andrew Cooper, B.S.C.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 18
11:00 a.m.-12:30 p.m.
Room 27 A, Upper Level, San Diego Convention Center

EVIDENCE-BASED AND GUIDELINE APPROACHES TO PSYCHIATRIC TREATMENTS
Chp.: Rajnish Mago, M.D.
Co-Chp.: Richard Buccigrossi, M.D.

11:00 a.m.
53 Preparing for Evidence-Based Medication-Related Psychiatric Practice: The Oregon Experience
Jennifer P. Wisdom, Ph.D., David A. Pollack, M.D., Ann Hamer, Pharm.D., Sarann Bielavitz

11:30 a.m.
54 Improving Adherence to Treatment Guidelines in Hospitalized Patients With Bipolar Disorder
Thomas F. Smith, M.D., Stewart B. Levine, M.D., Judith Hampel, R.N.

12 noon
55 Stepped Care for Anxiety, Depressive and Stress-Related Disorders: A Randomized Controlled Trial in Primary Care and Mental Health Care
Desiree Oosterbaan, Ph.D., Anton van Balkom, Ph.D., Marc Verbraak, Ph.D., Roelof ten Doesschate, M.D.

12 noon
50 Pilot Trial of Modafinil for Treatment of Depression Symptoms and Fatigue in Adult Patients With Brain Tumors
Thomas A. Kaleita, Ph.D., David K. Welsch, Ph.D., Timothy F. Cloughesy, M.D.

11:30 a.m.
51 Intraoperative Cerebral Oxygen Desaturation: A Significant Risk Factor for Postoperative Delirium in Cardiac Surgery Patients
Thomas S. Zaubler, M.D., James P. Slater, M.D., Rami T. Bustami, Ph.D., Theresa Guarino, R.N., Jessica Stack, Kateki Vinod, Kenneth Freundlich, Ph.D., Grant V.S. Parr, M.D.

12 noon
53 Mood and Anxiety Disorders in Patients With Cancer: A Case Series
Catherine L. Mancini, M.D., Andrew Cooper, B.S.C.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 18
11:00 a.m.-12:30 p.m.
Room 27 A, Upper Level, San Diego Convention Center

EVIDENCE-BASED AND GUIDELINE APPROACHES TO PSYCHIATRIC TREATMENTS
Chp.: Rajnish Mago, M.D.
Co-Chp.: Richard Buccigrossi, M.D.

11:00 a.m.
53 Preparing for Evidence-Based Medication-Related Psychiatric Practice: The Oregon Experience
Jennifer P. Wisdom, Ph.D., David A. Pollack, M.D., Ann Hamer, Pharm.D., Sarann Bielavitz

11:30 a.m.
54 Improving Adherence to Treatment Guidelines in Hospitalized Patients With Bipolar Disorder
Thomas F. Smith, M.D., Stewart B. Levine, M.D., Judith Hampel, R.N.

12 noon
55 Stepped Care for Anxiety, Depressive and Stress-Related Disorders: A Randomized Controlled Trial in Primary Care and Mental Health Care
Desiree Oosterbaan, Ph.D., Anton van Balkom, Ph.D., Marc Verbraak, Ph.D., Roelof ten Doesschate, M.D.

12 noon
50 Pilot Trial of Modafinil for Treatment of Depression Symptoms and Fatigue in Adult Patients With Brain Tumors
Thomas A. Kaleita, Ph.D., David K. Welsch, Ph.D., Timothy F. Cloughesy, M.D.

11:30 a.m.
51 Intraoperative Cerebral Oxygen Desaturation: A Significant Risk Factor for Postoperative Delirium in Cardiac Surgery Patients
Thomas S. Zaubler, M.D., James P. Slater, M.D., Rami T. Bustami, Ph.D., Theresa Guarino, R.N., Jessica Stack, Kateki Vinod, Kenneth Freundlich, Ph.D., Grant V.S. Parr, M.D.
WORKSHOPS

COMPONENTS 30-36

COMPONENT WORKSHOP 30  11:00 a.m.-12:30 p.m.
Room 5 B, Upper Level, San Diego Convention Center
PASSAGEWAYS: PSYCHOLOGICAL ROUTES TO DELINQUENCY AND THERAPEUTIC OPTIONS OUT OF THE JUVENILE JUSTICE SYSTEM
APA Corresponding Committee on Juvenile Justice Issues
Co-Chps.: Camilla Lyons, M.D., Stephen B. Billick, M.D.
Participants: Eraka Bath, M.D., Louis J. Kraus, M.D.

COMPONENT WORKSHOP 31  11:00 a.m.-12:30 p.m.
Room 7 A, Upper Level, San Diego Convention Center
DEMENTIA IN DOWN SYNDROME: RISK FACTORS, BIOMARKERS, DIAGNOSIS, AND TREATMENT
APA Council on Aging
Chp.: John M. De Figueiredo, M.D.
Participants: Ramakrishnan Shenoy, M.D., Leo O. Noragbon, M.D.

COMPONENT WORKSHOP 32  11:00 a.m.-12:30 p.m.
Room 7 B, Upper Level, San Diego Convention Center
APA Corresponding Committee on Religion, Spirituality, and Psychiatry
Chp.: William R. Miller, Ph.D.
Participant: George Vaillant, M.D.

COMPONENT WORKSHOP 33  11:00 a.m.-12:30 p.m.
Room 8, Upper Level, San Diego Convention Center
SHOULD THE COMMUNITY REPLACE THE ASYLUM IN THE 21ST CENTURY?
APA Lifers
Co-Chps.: Sheila Hafer Gray, M.D., Edward Hanin, M.D.
Participants: Alan Q. Radke, M.D., Roger Pecle, M.D., David L. Huang, M.D., Helen MacLeod Thomson

COMPONENT WORKSHOP 34  11:00 a.m.-12:30 p.m.
Room 23 C, Upper Level, San Diego Convention Center
NOVEL CAREERS IN PSYCHIATRY: WOMEN WHO HAVE MADE THEIR OWN WAY
APA Committee on Women
Chp.: Melva I. Green, M.D., Kimberley Bogan, M.D.
Participants: Gail H. Manus, M.D., Barbara S. Schneider, M.D., Gabriela Cora-Locatelli, M.D., Janet Taylor, M.D.,

COMPONENT WORKSHOP 35  11:00 a.m.-12:30 p.m.
Room 24 A, Upper Level, San Diego Convention Center
FOCUSING ON ASIA: A REVIEW OF DISASTERS, INTERVENTION AND PREVENTION PROGRAMS
APA Council on Global Psychiatry
Co-Chps.: Pedro Ruiz, M.D., Bruce S. Singh, M.D.
Participants: Pichet Udornrat, M.D., M. Parameshwaran Deva, M.D., Tsuyoshi Akiyama, M.D.

COMPONENT WORKSHOP 36  11:00 a.m.-12:30 p.m.
Room 28 A, Upper Level, San Diego Convention Center
HIV AND METABOLIC SYNDROME
APA Committee on AIDS
Chp.: Marshall Forstein, M.D.

ISSUES 40-50

ISSUE WORKSHOP 40  11:00 a.m.-12:30 p.m.
Room 25 C, Upper Level, San Diego Convention Center
SECOND OPINION CONSULTATION ON ONGOING PSYCHOTHERAPY TREATMENTS
Co-Chps.: Mardi Horowitz, M.D., Marc Jacobs, M.D.
Participants: Martina Smit, M.D., Jennifer Cummings, M.D., Jason Bemak, M.D.

ISSUE WORKSHOP 41  11:00 a.m.-12:30 p.m.
Room 28 C, Upper Level, San Diego Convention Center
PRIVACY AND CONFIDENTIALITY CONCERNS IN SHARED ELECTRONIC HEALTH RECORDS
Chp.: Benjamin Liptzin, M.D.
Participants: Ruth A. Barron, M.D., Mary A. Sullivan, M.D., Robn S. Friedman, M.D., Edward Zuzarte, M.D.

ISSUE WORKSHOP 42  11:00 a.m.-12:30 p.m.
Room 28 D/F, Upper Level, San Diego Convention Center
METHAMPHETAMINE ABUSE AND ADDICTION: PREVALENCE AND TREATMENT.
Collaborative Session With the National Institute on Drug Abuse
Co-Chps.: Ahmed M. Elkashef, M.D., Frank Voci, Jr., Ph.D.
Participants: James Collier, Ph.D., William F. Haning III, M.D., Trevor Robbins, Ph.D.

ISSUE WORKSHOP 43  11:00 a.m.-12:30 p.m.
Room 29 C/D, Upper Level, San Diego Convention Center
HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 2
Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.
12 noon Sessions

FORUMS 6-8

FORUM 6
12 noon-1:30 p.m.
Ballroom 6 E, Upper Level, San Diego Convention Center
ONGOING MENTAL HEALTH NEEDS FOLLOWING THE DEVASTATION OF HURRICANE KATRINA

Chp.: Howard Ososky, M.D.
Presenters: Joy Ososky, Ph.D., Robert S. Pynoos, M.D., Robert J. Ursano, M.D., Betty Pfefferbaum, M.D.

FORUM 7
12 noon-1:30 p.m.
Room 26 A/B, Upper Level, San Diego Convention Center
MOVING NATIONAL HEALTH INFORMATION TECHNOLOGY AGENDA FORWARD

Chp.: Robert Kolodner, M.D.

FORUM 8
12 noon-1:30 p.m.
Room 29 A/B, Upper Level, San Diego Convention Center
SHOCK: THE HEALING POWER OF ELECTROCONVULSIVE THERAPY: DOCUMENTARY AND DISCUSSION

Chp.: Larry Tye, Kitty Dukakis

NEW RESEARCH POSTER SESSION 4
12 noon-2:00 p.m.
Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research submissions, please refer to the New Research Program Book included in your registration packet.

1:00 p.m Sessions

COURSES 70-75

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 70 1:00 p.m.-5:00 p.m.
Elizabeth Ballroom F, Second Level, Manchester Grand Hyatt

DRUG THERAPY AND SCHIZOPHRENIA

Director: Philip G. Janicak, M.D.
Faculty: Morris B. Goldman, M.D., Stephen R. Marder, M.D., Rajiv Tandon, M.D.
TUESDAY

COURSE 71
Edward Room A/B, Second Level, Manchester Grand Hyatt

CBT BOOTCAMP FOR PRACTICING PSYCHIATRISTS

Director: Anton C. Trinidad, M.D.
Faculty: Stephen P. McDermott, M.D., Robert Leahy, Ph.D.

COURSE 72
Madeleine Room C/D, Third Level, Manchester Grand Hyatt

IMPROVING YOUR PRESENTATION SKILLS: A COACHING APPROACH

Director: Luis F. Ramirez, M.D.

COURSE 73
Mohsen Room A/B, Third Level, Manchester Grand Hyatt

HOW TO PRACTICE BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME METHOD

Director: Howard E. Book, M.D.

COURSE 74
Emma Room A/B/C, Third Level, Manchester Grand Hyatt

RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.

COURSE 75
Randle Ballroom B, Fourth Level, Manchester Grand Hyatt

HOW TO USE YOUR PALM OS PERSONAL DIGITAL ASSISTANT IN PSYCHIATRIC PRACTICE: ADVANCED COURSE

Co-Directors: Charles J. Rainey, M.D., John Luo, M.D.
Faculty: John D. Wynn, M.D., Steven J. Altschuler, Carlyle H. Chan, M.D., Robert C. Hsiaung, M.D., Richard A. Montgomery, M.D.

2:00 p.m Session

LECTURE 19
2:00 p.m.-3:30 p.m.
Ballroom 6 B, Upper Level,
San Diego Convention Center

APA's ADOLF MEYER AWARD LECTURE

Jeffrey A. Lieberman, M.D.

The Three Stages of Schizophrenia: Can Early Detection and Intervention Change Illness Course and Prevent Disability?

Chp.: Christine E. Marx, M.D.

Jeffrey A. Lieberman, M.D. currently is the Lawrence E. Kolb Professor and Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and Director of the New York State Psychiatric Institute. He also holds the Lieber Chair and Directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia. Dr. Lieberman received his medical degree from the George Washington School of Medicine in 1975. Following his postgraduate training in psychiatry at St. Vincent's Hospital and Medical Center of New York Medical College, he was on the faculties of the Albert Einstein College of Medicine and Mount Sinai School of Medicine, and served as Director of Research at the Hillside Hospital of Long Island Jewish Medical Center. Prior to moving to Columbia he was the Vice Chairman for Research and Scientific Affairs in the Department of Psychiatry and Director of the Mental Health and Neuroscience Center at the University of North Carolina, School of Medicine in Chapel Hill. Dr. Lieberman's research has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and pathophysiology of schizophrenia, and the pharmacology and clinical effectiveness of antipsychotic drugs. He currently serves as the Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program sponsored by the NIMH. He is also the Director of an NIMH Silvio O. Conte Center for the Neuroscience of Mental Disorders. His work has been reported in more than 400 articles in the scientific literature and he has edited or co-edited eight books. He currently chairs the APA Council of Research.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIA 3-4

PRESIDENTIAL SYMPOSIUM 3
2:00 p.m.-5:00 p.m.
Ballroom 6 D, Upper Level, San Diego Convention Center

REVIEW OF GERIATRIC PSYCHIATRY: CURRENT ISSUES

Chp.: Christopher C. Colenda, M.D.
Co-Chp.: Pedro Ruiz, M.D.

A Late Life Addiction: Rapidly Changing Needs
David D. Oslin, M.D.

B Health Services Research in Geriatric Psychiatry
Mark Snowden, M.D.

C Training and Workforce Issues in geriatric Psychiatry
Paul D. Kirwin, M.D.

D Diversity Issues in Geriatric Psychiatry
Warachal E. Faison, M.D.

E Ethical Issues in Geriatric Psychiatry Research
Scott Y. Kim, M.D.

THIS SESSION WILL BE AUDIOTAPED.
PRESIDENTIAL SYMPOSIUM 4
2:00 p.m.-5:00 p.m.
Ballroom 6 E, Upper Level, San Diego Convention Center

CURRENT RESEARCH ADVANCES:
APA/NIMH/NIDA/NIAAA/NAMI PERSPECTIVES
APA Council on Global Psychiatry

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Darrel A. Regier, M.D.

Discussants: Nora D. Volkow, M.D., Thomas R. Insel, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIA 27-51

SYMPOSIUM 27 2:00 p.m.-5:00 p.m.
Room 2, Upper Level, San Diego Convention Center

BULLYING IN THE WORKPLACE: ASSOCIATED HEALTH PROBLEMS

Chp.: Jorge C. Srabstein, M.D.
Co-Chp.: Liza H. Gold, M.D.

A Bullying, Basic Assumptions, and Symptoms of PTSD
Eva Mikkelsen, Ph.D., Ståle Einarsen, Ph.D.

B Morbidity Associated With Workplace Bullying Among Hospital Staff
Marianna Virtanen, Ph.D., Jussi Vahtera, Ph.D., Marko Elovainio, Ph.D., Mika Kivimäki, Ph.D.

C Patterns of Workplace Bullying and Psychopathology
Jose L. González de Rivera, M.D., Manuel J. Rodríguez-Abuin, Ph.D.

D Psychosocial Rehabilitation of Victims of Bullying and Emotional Abuse at Work
Eva Mikkelsen, Ph.D., Ståle Einarsen, Ph.D.

E Regulatory Responses to Workplace Bullying: A Global Law and Public Policy Perspective
David Yamada, J.D.

Discussant: Liza H. Gold, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 28 2:00 p.m.-5:00 p.m.
Room 3, Upper Level, San Diego Convention Center

NEW PERSPECTIVES IN PSYCHODYNAMIC TREATMENTS FOR BPD

Chp.: Lois W. Choi-Kain, M.D.
Co-Chp.: John G. Gunderson, M.D.

A Mentalization: A Review of the Origins and Applications of the Concept in the Treatment of BPD
Lois W. Choi-Kain, M.D.

B Is Mentalization Based Therapy More Effective Than Structured Supportive Psychotherapy for BPD: A Randomized Controlled Trial
Anthony Bateman, M.D., Peter Fonagy, M.D.

C Transference Focused Psychotherapy
Otto F. Kernberg, M.D.

D The Role of Reflective Functioning in Affect Regulation and Psychotherapy
John F. Clarkin, Ph.D.

E A Psychotherapy Case Study on Alternative Perspectives
John G. Gunderson, M.D.

Discussant: Glen O. Gabbard, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 29 2:00 p.m.-5:00 p.m.
Room 4, Upper Level, San Diego Convention Center

AGGRESSIVE BEHAVIORAL DISTURBANCES IN GEROPSYCHIATRIC PATIENTS

Chp.: Helen H. Kyomen, M.D.

A Neurobiology of Aggression
Randy J. Nelson, Ph.D.

B Gene-Environment Interactions and Aggression
Brian C. Trainor, Ph.D.

C Epidemiology of Aggressive Behaviors in Geropsychiatric Patients
Nhi-Ha T. Trinh, M.D.

D Evaluation and Management of Aggressive Behaviors in Geropsychiatric Patients
Helen H. Kyomen, M.D., Theodore H. Whitfield, Sc.D

Discussant: Barry D. Lebowitz, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 30 2:00 p.m.-5:00 p.m.
Room 5 A, Upper Level, San Diego Convention Center

FORMATION OF MODERN LESBIAN AND GAY IDENTITIES: PERSONAL, HISTORICAL, AND MENTAL HEALTH PERSPECTIVES

Chp.: Gene A. Nakajima, M.D.
Co-Chp.: Carolyn B. Robinowitz, M.D.

A Gertrude Stein’s Medical Education, Her Evolving Feminism, and Lesbian Identity
Gene A. Nakajima, M.D.

B Superior Guinea Pig: Bryher and Psychoanalysis
Maggie Magiec, Psy.D.

C I Didn’t Want to Be Queer: Virgil Thomson’s Adaptation to His Homosexual Identity
Anthony Tommasini, D.M.A.

D From the Closet to the Table: A 40 Year History of Gays and the APA
David R. Kessler, M.D.

Discussants: Clayton M. Bullock, M.D., Robert P. Cabaj, M.D.
THIS SESSION WILL BE AUDIOTAPED.
TUESDAY

SYMPOSIUM 31  2:00 p.m.-5:00 p.m.
Room 5 B, Upper Level, San Diego Convention Center

RESEARCH UPDATE ON ADOLESCENTS WITH SCHIZOPHRENIA: IMPLICATIONS FOR PRODROMAL RESEARCH

Chp.: Sanjiv Kumra, M.D.

A Early-Stage Neurocognitive Functioning in Adolescent Psychosis: An Examination of Illness Course and Implications for Intervention
Jeffrey R. Wozniak, Ph.D.

B Clozapine and Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison
Harvey Kranzler, M.D.

C Efficacy and Tolerability of Atypical Antipsychotics in Adolescents with Psychosis
Joel Oberstar, M.D.

D Anomalies in White Matter Microstructure in Occipital-Temporal Pathways in Adolescents With Schizophrenia
Sanjiv Kumra, M.D.

THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 32  2:00 p.m.-5:00 p.m.
Room 7 A, Upper Level, San Diego Convention Center

MIRROR NEURONS, EMPATHY, INTUITION AND INTERPRETATION: UNDERSTANDING THE MINDS OF OTHERS

Chp.: Regina Pally, M.D.

A From Mirror Neurons to Empathy
Christian Keysers, Ph.D.

B How is the Mirror Neuron Discovery Relevant to Psychoanalysis and Psychotherapy?
Morris N. Eagle, Ph.D.

THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 33  2:00 p.m.-5:00 p.m.
Room 7 B, Upper Level, San Diego Convention Center

PTSD, BPD, AND MOTHERHOOD: EARLY RELATIONS, RECOGNITION, AND INTERVENTION

Chp.: Gisele Apter, M.D.

A Personal and Other Terrorism Toward Women Worldwide
Leah J. Dickstein, M.D.

B Violence Turned Against the Victim
Nada L. Stromland, M.D.

C Early Interactions Between Borderline Mothers and Their Infants: Why More Intervention Could Mean Less Repetition Trauma and Distortion
Gisele Apter, M.D.

D The Therapeutic Use of Videotape in Working With Parents of Children With Psychiatric Disorders
Alexandra M. Harrison, M.D.

Discussant: Carol C. Nadelson, M.D.

THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 34  2:00 p.m.-5:00 p.m.
Room 8, Upper Level, San Diego Convention Center

UNEASY PARTNERS: THE PHARMACEUTICAL INDUSTRY AND THE PSYCHIATRIC PROFESSION

Chp.: Nassir Ghaemi, M.D.
Co-Chp.: David N. Osser, M.D.

A The Pharmaceutical Industry, Evidence-Based Medicine, and Psychiatric Practice
Howard I. Kushner, Ph.D.

B Disease Mongering
David Healy, M.D.

C Cleaning up Evidence-Based Medicine
David N. Osser, M.D.

D Data, Dollars, and Drugs: The Dilemmas of Practice and Research
Nassir Ghaemi, M.D.

E Conflict of Interest in Psychiatry: How Much Disclosure Is Enough?
Daniel J. Carlat, M.D.

Discussant: Frederick K. Goodwin, M.D.

THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 35  2:00 p.m.-5:00 p.m.
Room 9, Upper Level, San Diego Convention Center

STALKING OFFENDERS AND VICTIMS

Chp.: Gail E. Robinson, M.D.

A Stalking: An Overview of the Problem
Gail E. Robinson, M.D.

B Stalking Victims: A Comprehensive Treatment Approach
Karen M. Abrams, M.D.

C The Recon Typology of Stalking
J. Reid Meloy, Ph.D.

D Stalking: Threat Management by Professional Cooperation
Werner Tschern, M.D.

E Stalking: Threat Assessment and Management
Jeff Dunn

THIS SESSION WILL BE AUDIOTAPEED.
SYMposium 36  2:00 p.m.-5:00 p.m.
Room 10, Upper Level, San Diego Convention Center

Humane Aspects of Private Practice

Chp.: Rodrigo A. Munoz, M.D.
Co-Chp.: Roger Peele, M.D.

A Comprehensive Psychiatry in Private Practice, 2007
Brian Crowley, M.D.

B Private Practice: The Very Model of Humane Care
Ronald Abramson, M.D.

C Comprehensive Psychiatry in a Community Hospital
and Medical Center Provides Ready Access for Least
Restrictive Treatment
John C. Urbaitis

Discussant: Donna M. Norris, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMposium 37  2:00 p.m.-5:00 p.m.
Room 11 A, Upper Level, San Diego Convention Center

Eating Disorders Update

Chp.: Hans W. Hoek, M.D.
Co-Chp.: Walter H. Kaye, M.D.

A Alterations of Neurocircuits and Symptoms in Anorexia
and Bulimia Nervosa
Walter H. Kaye, M.D., Ursula F. Baier, M.D., Guilio K.
Frank, M.D., Angela Wagner, M.D.

B Epidemiology of Eating Disorders
Hans W. Hoek, M.D.

C Psychological Treatments of Eating Disorders: Status
Quo and New Developments
Ulrike Schmidt, M.D.

D Pharmacological Treatment of Eating Disorders
B. Timothy Walsh, M.D.

E Children and Adolescents With Eating Disorders
Annemarie A. van Elburg, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMposium 38  2:00 p.m.-5:00 p.m.
Room 11 B, Upper Level, San Diego Convention Center

Lumping versus Splitting in Psychiatric Nosology

Chp.: Ahmed M. Okasha, M.D.
Co-Chp.: Rodrigo A. Munoz, M.D.

A The Controversy Over Lumping vs. Splitting in
Psychiatric Nosology
Ahmed Okasha, M.D.

B Lumping vs. Splitting: Psychopathology and the Rest
of Medicine
G. Scott Waterman, M.D.

C Splitting in Order to Better Lump
Hagop Akiskal, M.D.

D Lumping in Order to Better Split
Juan J. Lopez-Ibor Jr., Ph.D.

E The Need for an Eclectic Approach to the Classification
of Mental Disorders
Norman H. Sartorius, M.D.

Discussant: Darrel A. Regier, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMposium 39  2:00 p.m.-5:00 p.m.
Room 26 A/B, Upper Level, San Diego Convention Center

Choosing the Right Treatment for Substance Abuse

Chp.: Herbert D. Kleber M.D.

A Cocaine Dependence: Choosing the Right Treatment
Adam Bisaga, M.D.

B Choosing the Best Treatment: Marijuana and Club
Drugs
David M. McDowell, M.D.

C Treatment of Comorbid Conditions
Frances R. Levin, M.D.

D Integrating Psychosocial Interventions With Medications
in the Treatment of Substance Dependence
Edward V. Nunes Jr., M.D.

E Choosing the Right Treatment for Opioid Dependence
Herbert D. Kleber, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMposium 40  2:00 p.m.-5:00 p.m.
Room 28 C, Upper Level, San Diego Convention Center

Ethical Issues in Psychiatric Genetics

Chp.: Paul S. Appelbaum, M.D.
Co-Chp.: Laura B. Dunn, M.D.

A What Can Psychiatric Genetics Tell The Clinician?
John R. Kelsoe, M.D., Thomas B. Barrett, M.D., Xianjin
Zhou, Ph.D., Nicholas Schork, Ph.D.

(Continued next page)
B Ethical Issues Involved in Decision Making About Genetic Testing, Disclosure, and Reproductive Choices Among Individuals at Risk for Huntington’s Disease
Robert L. Klitzman, M.D.

C Disclosure of Genetic Information: Patients, Third Parties, Employers, and Insurers
Paul S. Appelbaum, M.D.

D Presenter Ethical Issues Related to the Use of Genetic Information in the Workplace: APA Symposium on Ethics of Psychiatric Genetics
Laura W. Roberts, M.D.

E Training Psychiatrists in Psychiatric Genetics: Views of Program Directors and Residents
Laura B. Dunn, M.D., Jinger G. Hoop, M.D., Sidney Zisook, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 41
2:00 p.m.-5:00 p.m.
Room 28 D/E, Upper Level, San Diego Convention Center
WOMEN AND PSYCHIATRY AROUND THE WORLD: THE IMPORTANCE OF GENDER AND CULTURE
Chp.: Nigel Bark, M.D.
Co-Chp.: Hamid Ghodse, M.D.

A Gender Issues in Psychiatry in Pakistan
Haroon R. Chaudhry, M.D., Saima Niaz, M.D., Mirrat G. Butt, Nadia Arshad, Amara Shabir, Khalid A. Mufi

B The African Woman in Health and Disease: Cultural Issues in the Mental Health of Women
Frank G. Njenga, M.B.Ch.B.

C Stress and Mental Disorder Among Mexican Females
Maria Asuncion Lara, Ph.D., Maria E. Medina-Mora, M.D.

D Women and Psychiatry Around the World: The Impact of Gender and Culture in the Middle Eastern Culture
Nasser F. Loza, Nacl M. Hasan, M.B.Ch.B.

E Changing Patterns of Self Harm Behaviour Among Women in Trinidad and Tobago: The Emergence of Self Mutilation
Gerard Hutchinson, M.D.

G Gender Differences in Psychiatry: A Biopsychosocial Approach From Australia
Jayashri Kulkarni, M.B.B.S.

Discusant: Sheila C. Hollins, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 42
2:00 p.m.-5:00 p.m.
Room 29 A/B, Upper Level, San Diego Convention Center
PSILOCYBIN AND PSYCHIATRY: RECENT RESEARCH
Chp.: Thomas M. Brod, M.D.

A Psilocybin in Late-Stage Cancer Anxiety
Charles S. Grob, M.D.

B Safety and Efficacy of Psilocybin in OCD
Francisco A. Moreno, M.D.

C Psilocybin can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance: 14-Month Follow-Up
Roland R. Griffiths, Ph.D., William A. Richards, Una D. McCann, M.D., Robert Jesse

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 43
2:00 p.m.-5:00 p.m.
Room 29 C/D, Upper Level, San Diego Convention Center
HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 3
Chp.: William E. Callahan, Jr., M.D.
Co-Chp.: Keith W. Young, M.D.

A Personal Factors Leading to a Successful Private Practice
William E. Callahan, Jr., M.D.

B Office Location and Design for Efficiency and Success
William E. Callahan, Jr., M.D.

C Streamlining Overhead and Managing Your Business in Private Practice
Keith W. Young, M.D.

D Marketing Your Unique Private Practice
William F. Callahan, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 44
2:00 p.m.-5:00 p.m.
Room 30 B, Upper Level, San Diego Convention Center
THE HIV AND AIDS PANDEMIC: CHANGES IN POPULATIONS, PERCEPTIONS, PRACTICES, AND PROMISES
Chp.: Francisco Fernández, M.D.

A New Clinical Developments and Opportunities in Combating HIV
Milton L. Wainberg

B The Changing Face of AIDS and HIV Disease
Francine Courtes, M.D.

C The Role of the Psychiatrist: Changing With the Epidemic
Marshall Forstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 45
2:00 p.m.-5:00 p.m.
Room 30 B, Upper Level, San Diego Convention Center
DSM-V: OBSESSIVE-COMPULSIVE RELATED DISORDERS
Chp.: Eric Hollander, M.D.
Co-Chp.: Joseph Zohar, M.D.
A  Overview and Autism
   Eric Hollander, M.D., Ting Wang, Ph.D., Daphne Simeon, 
   Evdokia Anagnostou, M.D., Jennifer Bartz, Ph.D., Latha 
   Soorya, Ph.D., Andrea Allen, Ph.D.

B  OCD and the Link With Schizophrenia
   Joseph Zohar, M.D., Michael Poyurovsky

C  Are the Impulse Control Disorders Related to OCD?
   Lorrin M. Koran, M.D.

D  Genetics of OCD
   Gerald Nestadt, M.D., Jack F. Samuels, Ph.D., Mark A.
   Riddle, M.D., Marco Grados, M.D., Bernadette Cullen, M.D.,
   O. Joseph Bienvenu, M.D., Yin Shugart, Ph.D., Ying Wang

E  Neuroimaging in Obsessive-Compulsive Related Disorders
   Sanjaya Saxena, M.D.

   Discussant: Katharine A. Phillips, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 46  2:00 p.m.-5:00 p.m.
Room 30 C, Upper Level, San Diego Convention Center

LEADERSHIP DISCOURSE: AGENTS OF CHANGE IN MENTAL HEALTH
   American Association of Psychiatric Administrators

Chp.: Yad M. Jabbarpour, M.D.

A  Overview of Agents of Change in Mental Health Transformation
   Yad M. Jabbarpour, M.D.

B  Law as an Agent of Change in the Mental Health System
   Paul S. Appelbaum, M.D.

C  Federal Perspective: Government as an Agent of Change
   Anita S. Everett, M.D.

D  How to Lose Friends and Influence People: Challenges in Transforming a State Mental Health Agency
   James S. Reinhard, M.D.

E  Research, Evidence, Practice, and Policy: New Frontiers in Re-alignments?
   Junius J. Gonzales, M.D.

   Discussant: Steven S. Sharfstein, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 47  2:00 p.m.-5:00 p.m.
Room 30 D/E, Upper Level, San Diego Convention Center

DEPRESSION AND ANXIETY, CONTINUOUS OR CATEGORICAL? A VIEW FROM DIFFERENT ANGLES
Chp.: Robert Schoevers

A  Epidemiology of Mood and Anxiety Disorders in a Multicultural European City
   Wilco Tuinbreijer, M.D., Matty de Wit, Ph.D.

B  Is Comorbidity Between Anxiety and Depression Caused by Shared Genes? A Genome Wide Linkage Analysis
   Christel M. Middeldorp, Jouke-Jan Hottenga, Eline Slagboom, Patrick F. Sullivan, Leo Beem, Gonnieke Willemsen, Dorret I. Boomsma

C  Differential Neural Patterns in Major Epressive Disorder and Obsessive-Compulsive Disorder: An Affective Activation Neuroimaging Experiment
   Peter L. Remijnsse, M.D.

D  Optimizing Treatment Strategies in Depressed Patients With Comorbid Anxiety Symptoms
   Henricus Van, M.D.

E  The Relationship Between Generalized Anxiety Disorder, Depression, and Mortality in Old Age
   Tjalling Jan Holwerda III, M.D., Robert A. Schoevers, Sr., Ph.D.

F  Managing the Patient With Comorbid Depression and an Anxiety Disorder
   Robert Schoevers, Ph.D., Henricus Van, Simone Kool, M.D.,
   Jack J. Dekker, Ph.D.

   Discussant: Aartjan T.F. Beekman, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 48  2:00 p.m.-5:00 p.m.
Room 31 A, Upper Level, San Diego Convention Center

FROM CLINICAL TRIALS TO REAL WORLD OUTCOMES

Chp.: Naveed Iqbal, M.D.
Co-Chp.: Zafar Sharif, M.D.

A  Schizophrenia With Comorbid Conditions in Clinical Trials: Clinical Applicability
   Michael Y. Hwang, M.D.

B  Gaining a Better Understanding of Clinical Trial Applicability Through the Use of Outcome Measures and Adverse Event Rating Scales
   Gabie Goldfeider, M.A.

C  Clinical Implications of Randomized Clinical Trial Designs
   Naveed Iqbal, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 49  2:00 p.m.-5:00 p.m.
Room 31 B, Upper Level, San Diego Convention Center

INVENTORY OF STIGMATIZING EXPERIENCES

Chp.: Roumen V. Milev, M.D.

A  Stigma of Mental Illness: From Theory to Practice
   Julio E. Arboleda-Florez, Ph.D.

B  The Inventory of Stigma Experiences: Development and Reliability
   Michelle Koller, M.A. Heather Stuart, Ph.D., Roumen V.
   Milev, M.D.

C  Stigma and Discrimination in Patients With Depression and Bipolar Disorders as Captured by the Inventory of Stigmatizing Experiences
   Roumen V. Milev, M.D., Heather Stuart, Ph.D.

(Continued next page)
TUESDAY

D Stigma and Recovery
Heather Stuart, Ph.D., Rounen V. Miley, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 50 2:00 p.m.-5:00 p.m.
Room 31 C, Upper Level, San Diego Convention Center

CONSUMER PROVIDER TRAINING:
INTEGRATING INDIVIDUALS IN RECOVERY INTO THE BEHAVIORAL WORKFORCE

Chp.: Lori Ashcraft, Ph.D.

A The University of Kansas Consumers as Providers Program: Overview of the National Award Winning Training, Internship, and Research Program Utilizing Best Practices
Diane McDiarmid

B The Implementation and Benefits of Incorporating Self Identified Client Employees in the South Carolina Department of Mental Health
Katherine M. Roberts, M.P.H.

C Developing Needed Competencies to Meet Workforce Demands: The Role of Training, Supervision, and Mentoring
Cheryl Gagne, Sc.D

D Adding People in Recovery to the Behavioral Health Workforce
Lori Ashcraft, Psy.D.

E CPSA’s Recovery Support Specialist Initiative: Evaluation Results of a Consumer Provider Training Program
Jason Malpuit, M.A.

THIS SESSION WILL BE AUDIOTAPED.

ADVANCES IN NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
2:00 p.m.-5:30 p.m.
Ballroom 6 A, Upper Level, San Diego Convention Center
Chp.: Stuart C. Yudofsky, M.D.

A Update on Functional Brain Imaging in Neuropsychiatry
Robin Hurley

B Update on Diagnostic Testing in Neuropsychiatry
Florence Kim

C Update on the Neuropsychiatry of Delirium
Paula Trepacz, M.D.

D Update on the Neuropsychiatry of Mood Disorders
Helen S. Mayberg, M.D.

E Update on the Neuropsychiatry of Stroke
Robert G. Robinson, M.D.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 5
3:00 p.m.-5:00 p.m.
Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

7:00 p.m. Sessions

INDUSTRY SUPPORTED SYMPOSIA 29-32

INDUSTRY SUPPORTED SYMPOSIUM 29
7:00 p.m.-10:00 p.m.
Ballroom 20, Upper Level, San Diego Convention Center

CIGARETTE SMOKING, SMOKING CESSION, AND PSYCHIATRIC ILLNESS
Supported by Pfizer Inc.

Chp.: Alexander H. Glassman, M.D.

A Reward Systems Underlying Motivation and Addiction
Peter W. Kalivas, M.D.

B Animal Modeling and Integrative Neurocircuitry of Addiction Vulnerability in Mental Illness
R. Andrew Chambers, M.D.

C What Makes Smoking Cessation Unique in Patients With a History of Depression
Alexander H. Glassman, M.D.
Pharmacological Treatment of Nicotine Dependence in Schizophrenia: The Devil Is in the Details
Tony P. George, M.D.

Pharmacotherapies for Smoking Cessation
Cheryl A. Oncken, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 30
7:00 p.m.-10:00 p.m.
Marina Ballroom, South Tower, Level Three, Marriott

AM I A PSYCHIATRIST... OR AN ENDOCRINOLOGIST?
COPING WITH METABOLIC DISTURBANCES DURING THE TREATMENT OF SCHIZOPHRENA
Supported by Pfizer & Sclay-Wyeth
Chp.: Peter F. Buckley, M.D.

A The Increasing Global Burden of Cardiovascular Disease in General Populations and in Patients With Schizophrenia
Charles H. Hennekens, M.D.

B Antipsychotics and Metabolic Risk: A Clinical Issue at the Forefront of Contemporary Psychiatry
Dan Haupt, M.D.

C Antipsychotic-Induced Hyperprolactinemia: A Neglected Issue in Psychiatry
Robert Conley, M.D.

D Guidelines for the Management of Metabolic and Endocrine Side Effects: Confusion or Consensus
Peter F. Buckley, M.D.

E Consumer Perspective on Tolerability and Safety of Antipsychotic Medications
Frederick J. Frese, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 31
7:00 p.m.-10:00 p.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

MONOAMINE OXIDIZE INHIBITORS TODAY: A 21ST CENTURY VIEW ON THE TREATMENT OF DEPRESSION
Supported by Bristol-Myers Squibb Company and Otsuka
Chp.: Philip R. Muskin, M.D.

A Everything You Always Wanted to Know About Evidence-Based Psychiatry: But Were Afraid to Ask
Sharon A. Mozian, M.D.

B MAOI's Revisited: The Facts and The Myths
Philip R. Muskin, M.D.

C Diet and MAOI's: Where We Went Wrong and Where We Need to Go?
Kenneth I. Shulman, M.D.

D Treatment of Mood Disorders in the 21st Century: The Best of Applied Neuroscience
Charles B. Nemeroff, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 32
7:00 p.m.-10:00 p.m.
Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

UNDERSTANDING THE COMPLEXITY OF BIPOLAR MIXED EPISODES
Supported by Eli Lilly and Company
Chp.: Susan L. McElroy, M.D.

A Diagnostic Dilemmas of Mixed States in Bipolar Disorder
Mark A. Frye, M.D.

B Comorbidity and Consequences of Bipolar Mixed Episodes
Joseph F. Goldberg, M.D.

C The Acute Treatment of the Patient With Mixed Bipolar Episodes
Roger S. McIntyre, M.D.

D Improving Long-Term Outcomes in Patients With Bipolar Mixed Episodes
Susan L. McElroy, M.D.
Wednesday sessions are over …now what are you going to do?

Join the San Diego Psychiatric Society for a tour of the U.S.S. Midway aircraft carrier.

APA members and their guests can take guided tours of the ship during the reception, to be held on the ship’s flight deck, which spans four acres. The reception will feature hors d'oeuvres and a cash bar. APA members are also invited to attend a dinner aboard ship, in Hangar Bay 1, for the installation of new district branch officers and an awards ceremony to salute members of the media, legislators, and advocacy groups.

The reception and tours of the Midway will be held from 5 p.m. to 7:30 p.m., followed by dinner from 7:30 p.m. to 9:30 p.m. Tickets for the reception are $10 per APA member and spouse or one guest and $15 for non-APA members. Tickets for the reception and dinner are $65 per APA member and spouse or one guest and $75 for non-APA members. The charge for children aged 12 and under is $35 for the reception and dinner.

The U.S.S. Midway San Diego Aircraft Carrier Museum is about a mile from the San Diego Convention Center at 910 North Harbor Drive.

More information is available from Paula Margules, executive director of the San Diego Psychiatric Society, by phone at (858) 279-4586. Reservations can also be made through Margules. Information about the U.S.S. Midway is posted at www.midway.org.
WEDNESDAY, MAY 23, 2007
160TH ANNUAL MEETING

8:00 a.m. Sessions

COURSES 76-82

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 76
8:00 a.m.-12 noon
Elizabeth Ballroom H, Second Level, Manchester Grand Hyatt

MULTIDISCIPLINARY TREATMENT OF LOW SEXUAL DESIRE IN WOMEN

Director: Nancy C. Raymond, M.D.
Faculty: Jamie Feldman, M.D., Karin Larsen, Ph.D., Beatrice E. Robinson, Ph.D., Meg I. Striepe, Ph.D.

COURSE 77
8:00 a.m.-12 noon
Edward Room A/B, Second Level, Manchester Grand Hyatt

PSYCHIATRIC ROLES IN ASSESSING AND TREATING ADULT AND ADOLESCENT SEX OFFENDERS

Co-Directors: Bradley R. Johnson, M.D., Judith V. Becker, Ph.D.

COURSE 78
8:00 a.m.-12 noon
Edward Room C/D, Second Level, Manchester Grand Hyatt

PSYCHIATRIC CARE OF THE HEPATITIS C PATIENT

Co-Directors: Muhammad Aly Rifai, M.D., Peter Hauser, M.D.
Faculty: David Indest, M.D.

COURSE 79
8:00 a.m.-12 noon
Madeleine Room A/B, Third Level, Manchester Grand Hyatt

HOW TO USE YOUR POCKET PC PERSONAL DIGITAL ASSISTANT IN PSYCHIATRIC PRACTICE

Co-Directors: Robert J. Boland, M.D., Joshua L. Straus, M.D.
Faculty: Roger L. McRoberts, M.D., Elizabeth V. Getter, M.D.

COURSE 80
8:00 a.m.-12 noon
Madeleine Room C/D, Third Level, Manchester Grand Hyatt

REEL PSYCHIATRY

Co-Directors: Luis F. Ramirez, M.D., David J. Robinson, M.D.,

COURSE 81
8:00 a.m.-12 noon
Emma Room A/B/C, Third Level, Manchester Grand Hyatt

INSANITY DEFENSE EVALUATIONS

Director: Phillip J. Resnick, M.D.

COURSE 82
8:00 a.m.-12 noon
Windsor Room, Third Level, Manchester Grand Hyatt

SHORT-TERM PSYCHODYNAMIC SUPPORTIVE PSYCHOTHERAPY FOR DEPRESSION

Director: Henricus Van, M.D.
Faculty: Robert Schoevers, Ph.D., Gerda van Aalst, M.D., Simone Kool, M.D.

9:00 a.m. Sessions

ADVANCES IN GERIATRIC PSYCHIATRY
9:00 a.m.-12:30 p.m.
Ballroom 6 A, Upper Level, San Diego Convention Center

Chp.: Dan Blazer, M.D.

A Depression in Late Life: Complicating Factors and the Role of Medical Illness
Harold W. Goforth, M.D.

B Anxiety Disorders in Late Life
John L. Beyer, M.D.

C Psychotic Disorders in Late Life
Dilip V. Jeste, M.D.

D Psychopharmacological Treatment of Late Life Psychiatric Disorders
Bruce G. Pollock, M.D.

CASE CONFERENCE 3
9:00 a.m. – 12:00 p.m.
Room 23 A/B, Upper Level, San Diego Convention Center

FROM MATERNAL BLISS TO MATERNAL BLUES: A CASE OF INFANTICIDE

Moderator: Nicole F. Wolfe, M.D.
Presenters: John J. Worthington, M.D., Alyson Kuros-Kutzin, M.D., Jeffrey Childers, M.D.

COURSES 83-87

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 83
9:00 a.m.-4:00 p.m.
Elizabeth Ballroom F, Second Level, Manchester Grand Hyatt

PSYCHOTHERAPY FOR BORDERLINE PERSONALITY

Co-Directors: Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.
Faculty: John F. Clarkin, Ph.D., Eve Caligor, M.D.
COURSE 84  9:00 a.m.-4:00 p.m.  
Gregory Room A/B, Second Level, Manchester Grand Hyatt

NAVIGATING THE MINEFIELDS OF MANAGED CARE CONTRACTING: WHAT PSYCHIATRISTS NEED TO KNOW

Director: William H. Campbell, M.D.

COURSE 85  9:00 a.m.-4:00 p.m.  
Ford Room A/B/C, Third Level, Manchester Grand Hyatt

EEG FEEDBACK IN PSYCHIATRY: CLINICAL APPLICATIONS

Director: Thomas M. Brod, M.D.  
Faculty: Gary J. Schummer, Ph.D., Harold L. Burke, Ph.D.,  
William C. Scott, B.S.W., Stephen E. Buie, M.D.

COURSE 86  9:00 a.m.-4:00 p.m.  
Annie Room A/B, Third Level, Manchester Grand Hyatt

INTERPERSONAL AND SOCIAL RHYTHM THERAPY FOR BIPOLAR DISORDER

Co-Directors: Ellen Frank, Ph.D., Holly A. Swartz, M.D.

COURSE 87  9:00 a.m.-4:00 p.m.  
Randle Ballroom A, Fourth Level, Manchester Grand Hyatt

MOOD AND ANXIETY DISORDERS IN LATER LIFE

Co-Directors: James M. Ellison, M.D., Brent P. Forester, M.D.  
Faculty: F. Yusuf Sivrioglu, M.D., Donald A. Davidoff, Ph.D.,  
Francesca C. Antognini Ph.D., M. Cornelia Cremens, M.D.

LECTURE 20

LECTURE 20  
9:00 a.m.-10:30 a.m.  
Ballroom 6 C/D/E/F, Upper Level,  
San Diego Convention Center

APA'S JOHN FRYER AWARD LECTURE  
Lawrence Hartmann, M.D.

HOMOSEXUALITY AND IGNORANCE  
Chp.: Serena Y. Volpp, M.D.  
Co-Chp.: Dan H. Karasic, M.D.

Lawrence Hartmann, M.D., is a Past President of the American Psychiatric Association; a psychoanalytic and pragmatic child, adolescent, and adult psychiatrist in Cambridge, Massachusetts; and a long-term member of the Harvard Medical School faculty (in his words "a rather minor clinical professor of psychiatry"). Born in Vienna, he grew up in New York City, went to Harvard College and then Oxford University as a Rhodes Scholar. He returned to Harvard for Medical School, went to the University of California at San Francisco for a pediatric internship, and returned to Harvard again (Massachusetts Mental Health Center) for a residency in psychiatry and a fellowship in child and adolescent psychiatry. He went on to teach child, adolescent, and adult psychiatry at Harvard for over 35 years. He ran a prominent child and adolescent psychiatry clinic and a school consultation and treatment program, and wrote on psychotherapy, play, language, human rights, homosexuality, torture, apartheid, humane values and biopsychosocial integration. Dr. Hartmann's interest in dynamic and social psychiatry, in biopsychosocial integration, in women, children, minorities, homosexuality, and human rights led him to much activity and several leadership positions in both child and adult psychiatric organizations. This included serving on or leading several AACP Task Forces and Committees and serving on or leading many APA committees and components. He helped to reform the APA in the 1970's, helped the APA remove homosexuality from its Diagnostic Manual in 1973, and has been part of many subsequent APA studies, decisions, and position statements. He served as President of the New England Council on Child and Adolescent Psychiatry, and recently as President of the American Association for Social Psychiatry, in addition to serving in APA over the years as Speaker of the Assembly, Area I Trustee, and Vice President before being elected APA President. He helped organize and lead several APA Human Rights missions (Chile, South Africa, the Soviet Union) and led a post-iron-curtain Travelling University of Psychiatry to Poland, Czechoslovakia, and Hungary. He continues actively to attend APA Board of Trustees meetings, and to teach, and he enjoys seeing patients of all ages in Cambridge, Massachusetts.

THIS SESSION WILL BE AUDIOTAPED.

SMALL INTERACTIVE SESSIONS 12-13  
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

12 Eric Hollander, M.D., on New Treatment Developments For Autism and Impulse Control Disorders (Meet the Author)  
Room 28 C, Upper Level, San Diego Convention Center

13 Michael Schwartz, on The Recovery Movement in Mental Health: 2007 and Beyond  
Room 28 D, Upper Level, San Diego Convention Center
WORKSHOPS

COMPONENTS 37-45

COMPONENT WORKSHOP 37 9:00 a.m.-10:30 a.m.
Room 3, Upper Level, San Diego Convention Center

CAREER ADVANCEMENT IN ADMINISTRATIVE
PSYCHIATRY FOR EARLY CAREER PSYCHIATRISTS
APA Assembly Committee of Early Career Psychiatrists

Chp.: Dimitri D. Markov, M.D.
Participants: Arthur L. Lazarus, M.D., Thomas S. Newmark, M.D.,
Shivkumar Hatti, M.D., Joanette A. Sorkin, M.D.

COMPONENT WORKSHOP 38 9:00 a.m.-10:30 a.m.
Room 5 A, Upper Level, San Diego Convention Center

THE SACRED HERB AND ADDICTION SCIENCE: A
STUDY OF NICOTINE DEPENDENCE AND AXIS I
COMORBIDITIES AMONG AMERICAN INDIANS
APA Committee of American Indian, Alaska Native, and Native
Hawaiian Psychiatrists

Chp.: Daniel L. Dickerson, D.O.
Participants: Joseph J. Westermeyer IV, M.D., David A. Gilder, M.D.

COMPONENT WORKSHOP 39 9:00 a.m.-10:30 a.m.
Room 5 B, Upper Level, San Diego Convention Center

TRANSCULTURAL ARAB PSYCHIATRY WITH A
FOCUS ON WOMEN'S MENTAL HEALTH
APA Arab American Psychiatric Association

Co-Chp.: Ossama T. Osman, M.D., Mahmoud S. Taman, M.D.
Participants: Mona H. Al-Sawai, M.D., Naser F. Loza, M.D.,

COMPONENT WORKSHOP 40 9:00 a.m.-10:30 a.m.
Room 7 A, Upper Level, San Diego Convention Center

SUICIDE ICON: THE GOLDEN GATE BRIDGE
APA Northern California Psychiatric Society

Chp.: Mel Blaustein, M.D.
Participant: Anne Fleming, M.D.

COMPONENT WORKSHOP 41 9:00 a.m.-10:30 a.m.
Room 7 B, Upper Level, San Diego Convention Center

LESSONS LEARNED FROM BUSINESS PRACTICES:
HOW CAN PSYCHIATRISTS INCREASE THEIR
PRACTICE OPPORTUNITIES BY IMPLEMENTING
SUCCESSFUL BUSINESS STRATEGIES
APA Committee on APA/Business Relations

Chp.: Gabriela Cora-Locarelli, M.D.
Participants: Dauda A. Griffin, M.D., Alan Langlieb, M.D.,
Kenneth C. Nash, M.D.

COMPONENT WORKSHOP 42 9:00 a.m.-10:30 a.m.
Room 8, Upper Level, San Diego Convention Center

SOCIAL DIMENSIONS OF DISASTERS AND
COMMUNITY RECOVERY
APA Committee on Psychiatric Dimensions of Disasters

Co-Chps.: Jacqueline Henschke, M.D., Sonali Sharma, M.D.

COMPONENT WORKSHOP 43 9:00 a.m.-10:30 a.m.
Room 31 A, Upper Level, San Diego Convention Center

THE ISMS: HOW RACISM, SEXISM, CLASSISM, AND
HETEROSEXISM AFFECT MENTAL HEALTH CARE
APA/SAMHSA Minority Fellows

Co-Chps.: K. Ron-Li Liaw, M.D., Nisba F. Husain, M.D.
Participants: Alphonso E. Nichols III, M.D., Tracee
Burroughs, M.D., Eugene Lee, M.D., Jennifer D. Pender, M.D.

COMPONENT WORKSHOP 44 9:00 a.m.-10:30 a.m.
Room 31 B, Upper Level, San Diego Convention Center

MANAGED CARE, PSYCHIATRISTS, AND
EMPLOYERS: COLLABORATING EFFECTIVELY TO
ENSURE PATIENT CARE
APA Committee on Managed Care

Chp.: Paul H. Wick, M.D.
Participants: David K. Nace, M.D., Alan Axelson, M.D.,
George D. Santos, M.D., Joel P. Johnson, M.D.

COMPONENT WORKSHOP 45 9:00 a.m.-10:30 a.m.
Room 32 A, Upper Level, San Diego Convention Center

RACISM, RACIAL DISCRIMINATION, AND
XENOPHOBIA: HOW PSYCHIATRY CAN REDUCE
THEIR ADVERSE EFFECTS ON MENTAL HEALTH
APA Council on Minority Mental Health and Health Disparities

Chp.: Francis G. Lu, M.D.
Participants: Sandra C. Walker, M.D., Michele Reid, M.D.,
Andres J. Pumariega, M.D., Rahn K. Bailey, M.D., Napoleon B.
Higgins Jr., M.D.

ISSUES 51-65

ISSUE WORKSHOP 51 9:00 a.m.-10:30 a.m.
Room 11 B, Upper Level, San Diego Convention Center

BIOPSYCHOSOCIAL AND SPIRITUAL ASPECTS OF
TREATING OUR PHYSICIAN COLLEAGUES

Co-Chps.: Syed S. A. Naqvi, M.D., Monisha R. Vasa, M.D.
Participants: Michael F. Myers, M.D., Amir Estekal, M.D., Tara
Klein, M.D.
ISSUE WORKSHOP 52  9:00 a.m.-10:30 a.m.
Room 23 C, Upper Level, San Diego Convention Center

RESPONDING TO THE IMPACT OF SUICIDE ON CLINICIANS

Chp.: Eric M. Plakun, M.D.
Participants: Edward R. Shapiro, M.D., Jane G. Tillman, Ph.D.

ISSUE WORKSHOP 53  9:00 a.m.-10:30 a.m.
Room 24 A, Upper Level, San Diego Convention Center

DEVELOPING RESEARCH TRAINING OPPORTUNITIES WITHIN A PSYCHIATRIC RESIDENCY TRAINING PROGRAM: GOALS, MOTIVATIONS, BARRIERS, AND SOLUTIONS

Chp.: Robert J. Love, D.O.
Participants: Vanessa Wong, M.D., Julianne Flynn, M.D., Thomas L. Matthews, M.D., Pedro L. Delgado, M.D.

ISSUE WORKSHOP 54  9:00 a.m.-10:30 a.m.
Room 24 B, Upper Level, San Diego Convention Center

THE ADHD/PEDIATRIC BIPOLAR INTERFACE: SAILING THROUGH TROUBLED WATERS?

Co-Chps.: Vishal Madaan, M.D., Kiki D. Chang, M.D.

ISSUE WORKSHOP 55  9:00 a.m.-10:30 a.m.
Room 24 C, Upper Level, San Diego Convention Center

ORAL BOARDS BOOT CAMP: 2007

Co-Chps.: Elyse D. Weiner, M.D., Eric D. Peselow, M.D.

ISSUE WORKSHOP 56  9:00 a.m.-10:30 a.m.
Room 25 A, Upper Level, San Diego Convention Center

NEUROIMAGING RESEARCH: IMPLICATIONS FOR THE TREATMENT OF SUBSTANCE ABUSE

Collaborative Session With the National Institute on Drug Abuse

Chp.: Steven J. Grant, Ph.D.
Participants: Anna R. Childress, Ph.D., Martin P. Paulus, M.D., Clinton D. Kilts, Ph.D., Christopher deCharms, Ph.D., Cameron Carter, M.D.

ISSUE WORKSHOP 57  9:00 a.m.-10:30 a.m.
Room 25 B, Upper Level, San Diego Convention Center

PROJECT MATCH: A RESIDENT CURRICULUM OF MENTORSHIP, ADVOCACY, TEACHING, CAREER ISSUES, AND HEALTH

Co-Chps.: Heather I. Flett, M.D., Jillian Sussman, M.D.
Participant: Bruce Ballon, M.D.

ISSUE WORKSHOP 58  9:00 a.m.-10:30 a.m.
Room 25 C, Upper Level, San Diego Convention Center

THE RESIDENT EXPERIENCES A PATIENT SUICIDE: STRATEGIES THAT CAN HELP

Co-Chps.: Joan M. Anzis, M.D., Surinder S. Nand, M.D.
Participants: Janet L. Kemp, Arsheep S. Jawandha, M.D.

ISSUE WORKSHOP 59  9:00 a.m.-10:30 a.m.
Room 26 A/B, Upper Level, San Diego Convention Center

TELEPSYCHIATRY IN ACTION: IMPLEMENTING AND SUSTAINING A SUCCESSFUL TELEPSYCHIATRY PROGRAM

Chp.: Susan Stabinsky, M.D.
Participants: Richard A. Silverman, M.D., Maria L.A. Tiamson-Kassab, M.D., James Varrell, M.D.

ISSUE WORKSHOP 60  9:00 a.m.-10:30 a.m.
Room 27 A, Upper Level, San Diego Convention Center

RESEARCH TRAINING FOR ALL PSYCHIATRIC RESIDENTS: A PROBLEMATIC ENDEAVOR

Chp.: Milton Kramer, M.D.
Participants: Jerald Kay, M.D., Mantosh J. Dewan, M.D., Michele T. Pato, M.D.

ISSUE WORKSHOP 61  9:00 a.m.-10:30 a.m.
Room 27 B, Upper Level, San Diego Convention Center

DETECTING BIPOLAR DISORDER

Co-Chps.: Gary E. Millet,, M.D., Richard L. Noel, M.D.

ISSUE WORKSHOP 62  9:00 a.m.-10:30 a.m.
Room 30 A, Upper Level, San Diego Convention Center

CAN WE DO BETTER AT PREVENTING THE CHRONIC COURSE OF MOOD DISORDERS?

Co-Chps.: Alina Marin, M.D., Irene Patelis-Siotis, M.D.

ISSUE WORKSHOP 63  9:00 a.m.-10:30 a.m.
Room 30 B, Upper Level, San Diego Convention Center

SAFETY TRAINING FOR MEDICAL STUDENTS DURING THEIR PSYCHIATRY CLERKSHIP

Chp.: Erica Z. Shoemaker, M.D.

ISSUE WORKSHOP 64  9:00 a.m.-10:30 a.m.
Room 30 C, Upper Level, San Diego Convention Center

THE ROLE OF DSM-IV RATING SCALES IN PSYCHIATRY

Co-Chps.: Joyce Sprafkin, Ph.D., Kenneth D. Gadow, Ph.D.
Participant: Margaret D. Weiss, M.D.
ISSUE WORKSHOP 65  9:00 a.m.-10:30 a.m.
Room 32 B, Upper Level, San Diego Convention Center

COMPLEXITIES OF POST TERMINATION RELATIONSHIPS

Chp.: Malkah T. Norman, M.D.
Participants: Elissa P. Benedek, M.D., Carl P. Malmquist, M.D., Linda M. Jorgenson, J.D.

LECTURES 21-22

LECTURE 21
11:00 a.m.-12:30 p.m.
Ballroom 6 B, Upper Level, San Diego Convention Center

APA'S JUDD MARMOR AWARD LECTURE

Nancy C. Andreasen, M.D.

The Creating Brain: The Neuroscience of Genius

Chp.: Stuart C. Yudofsky, M.D.

Dr. Andreasen holds positions as Chair of Psychiatry, University of Iowa, Director of the Iowa Neuroimaging Center, and Director of the Mental Health Clinical Research Center, University of Iowa; since 2001 she has also assumed the position of Adjunct Professor of Psychiatry and Neurology, University of New Mexico MIND Institute, a new imaging center dedicated to understanding mental illness. Although Dr. Andreasen is best known to APA as the Editor in Chief, American Journal of Psychiatry, she is an internationally renowned neuropsychiatrist, researcher, educator, and mentor. One of the world's foremost authorities on schizophrenia, Dr. Andreasen was an early pioneer in applying neuroimaging techniques to study the neural basis of major mental illness. Her work was among the first to suggest that schizophrenia was linked to abnormal brain development and that a decrease in the size of the brain's frontal lobe was associated with the negative symptoms of the disorder, including impaired cognitive function. Dr. Andreasen's research has also provided significant insight into the brain mechanisms underlying language, emotion, and the creative process. She led the first extensive empirical study of creativity and was the first to recognize the association between creativity and manic-depressive illness. In 2006 Dr. Andreasen was selected as the recipient of the first "Vanderbilt Prize in Biomedical Science," an award established by Vanderbilt University School of Medicine to honor women who have made significant advances in the biological and biomedical sciences and have contributed positively to the mentorship of other women in science. This major new award carries a $25,000 prize and establishes a scholarship in the name of the awardee; the scholarship supports a M.D./Ph.D. candidate at Vanderbilt University School of Medicine. Dr. Andreasen was elected a member of the Institute of Medicine (National Academy of Sciences) and of the American Academy of Arts and Sciences. In 2000 she was awarded the National Medal of Science by President Clinton.

THIS SESSION WILL BE AUDIOTAPED.
LECTURE 22
11:00 a.m.-12:30 p.m.
Ballroom 6 C/D/E/F, Upper Level,
San Diego Convention Center

William T. Carpenter, Jr., M.D.

A Paradigm Shift for Schizophrenia Discovery

Chp.: Christine E. Marx, M.D.

William T. Carpenter, Jr., M.D., is a Professor of the University of Maryland School of Medicine and the Director of the Maryland Psychiatric Research Center. He obtained his medical degree from the Wake Forest University School of Medicine. After an internship at the North Carolina Baptist Hospital, he undertook postgraduate training at the University of Rochester Medical Center. He began his research career with the National Institute of Mental Health Intramural Program in 1966, using neuroendocrine strategies to study the psychobiology of affective disorders. He has also been a collaborating investigator with the World Health Organization’s International Pilot Study of Schizophrenia. Dr. Carpenter is the Editor-in-Chief for *Schizophrenia Bulletin*, has served on the several editorial boards, along with authoring over 300 publications. Dr. Carpenter is President of the American College of Neuropsychopharmacology and his major professional interest has been severe mental illness, especially schizophrenia, including phenomenology of the psychoses, the etiology, pathophysiology, anatomy, and treatment of schizophrenia. He has made original and fundamental contributions in psychopathology, assessment methodology, testing of new treatments, and research ethics. His special professional assignments include service on the NIMH Intramural Research Program Board of Scientific Counselors and as a consultant and reviewer for NIMH and National Institutes of Health on many topics. He chaired the NIMH Research Scientist Career Development Committee and the NIMH National Plan Committee on Treatment Research. Dr. Carpenter is the only scientist to direct both an NIMH-funded Clinical Research Center (now Advanced Centers for Interventions and Services Research) and an NIMH-funded Center for Neuroscience and Schizophrenia. He provided expert testimony in the cases of the United States Government v. John Hinckley and in 1989 was a member of the State Department delegation to inspect the political use of psychiatry in the Soviet Union. He has been the recipient of national and international research awards. Dr. Carpenter was elected to the Institute of Medicine of the National Academy of Sciences in 1998.

Distinguished Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 19-27

SCIENTIFIC AND CLINICAL REPORT SESSION 19
11:00 a.m.-12:30 p.m.
Room 3, Upper Level, San Diego Convention Center

PSYCHOPHARMACOLOGY AND SCHIZOPHRENIA

Chp.: Harry Sekhon
Co-Chp.: Meera Vaswani, Ph.D

11:00 a.m.
56 Number Needed to Treat and Number Needed to Harm: Making Sense of CATIE
Leslie L. Citrome, M.D., T. Scott Stroup, M.D.

11:30 a.m.
57 Switching From Long-Acting Typical Antipsychotic Drugs to the Second Generation Antipsychotics: Olanzapine and Risperidone in the Treatment of Patients With Chronic Schizophrenia
Martina Swartz-Vanetik, M.D., Ella Lavun, M.D., Yehuda Baruch, M.D., Yoram Barak, M.D.

12 noon
58 Zolpidem in Treatment Resistant Catatonia: Two-Case Reports and Literature Review
Cristinel M. Coconcea, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 20
11:00 a.m.-12:30 p.m.
Room 4, Upper Level, San Diego Convention Center

MANAGING VIOLENCE

Chp.: Britta Ostermeyer, M.D.
Co-Chp.: Jason R. Kornberg, M.D.

11:00 a.m.
59 Variables Affecting Violence That Required Physical Restraint Among Psychiatric Inpatients During The First Week Of Hospitalization
Pinkhas Sirota, M.D., Yuri Markman, Nuc.E., Rachel R. Rosenberg, M.A.

11:30 a.m.
60 Decreasing the Use of Restraint and Seclusion Among Psychiatric Inpatients
David J. Hellerstein, M.D., Amy B. Staub, M.B.A., Elizabeth LeQuese, M.D.

12 noon
61 CES Reduces Aggression in Violent Neuropsychiatric Patients
Allen Childs, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 21
11:00 a.m.-12:30 p.m.
Room 5 A, Upper Level, San Diego Convention Center

CONTINUATION AND DISCONTINUATION OF SSRRS

Chp.: Rajnish Mago, M.D.
Co-Chp.: Aysegul Yildiz-Yesiloglu, M.D.

11:00 a.m.
62 Comparison of the Prophylactic Efficacy of Antidepressants-Factors Associated With Better Outcome
Sabrina J. Khan, M.D., Eric D. Peselow, M.D., Barbara Orlowski, Ph.D.

11:30 a.m.
63 How Often Do SSRIs Lose Their Effect During Continuation Treatment?: Evidence Suggesting the Rate is True Tachyphylaxis During Continuation Treatment is Low
Mark Zimmerman, M.D.

12 noon
64 Discontinuation of SSRI's After Five Years Stability
Tara M. Pundiak, M.D., Eric D. Peselow, M.D., Loretta Mulcare, Brady G. Case, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 22
11:00 a.m.-12:30 p.m.
Ballroom 6 D, Upper Level, San Diego Convention Center

SEX, ATTRACTION, AND INTIMACY

Chp.: Waguih W. Ishak, M.D.
Co-Chp.: Daniel Sewell, M.D.

11:00 a.m.
65 An Eight-Week Randomized, Double-Blind, Placebo-Controlled Trial of PDE5 Sildenafil Treatment of SRI-Antidepressant-Associated Sexual Dysfunction in Women With MDD in Remission: Identifying a Hormone Endophenotype Associated With Treatment
H. George Nurnberg, Paula L. Hensley

11:30 a.m.
66 Breakthrough Intimacy: Treating Personality
Yukio Ishizuka

12 noon
67 A Link Between Oxytocin and Anxiety of Romantic Attachment
Donatella Marazziti, M.D., Mario Catena, M.D., Stefano Baroni, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 23
11:00 a.m.-12:30 p.m.
Room 9, Upper Level, San Diego Convention Center

PSYCHOPHARMACOLOGY AND BIPOLAR DISORDER

Chp.: Vivek Singh, M.D.
Co-Chp.: Igor Elman, M.D.

11:00 a.m.
68 Effect of Comorbid Anxiety on Antidepressant Use in a Community Sample of Bipolar Subjects
Ayala Schaffer, M.D., John Cairney, Ph.D., Scott Veldhuijzen, Amy H. Cheung, M.D., Anthony J. Levitt, M.D.

11:30 a.m.
69 Difficult to Treat Patients: The Role of Quetiapine in the Management of Acute Bipolar Depression With a Focus on Bipolar II Patients
Michael E. Thase, M.D.

12 noon
70 Indirect Comparison of the Safety and Tolerability of Antipsychotics in Patients With Bipolar Disorder and Schizophrenia
Keming Gao, M.D., Stephen J. Ganoczy, Ph.D., Joseph R. Calabrese, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 24
11:00 a.m.-12:30 p.m.
Room 11 B, Upper Level, San Diego Convention Center

TREATMENT ISSUES IN COLLEGE AND MEDICAL STUDENTS

Chp.: Joel Dimsdale, M.D.
Co-Chp.: Suzanna Parker, M.D.

11:00 a.m.
71 Subjective Sleep Quality and Suicidal Ideation Among College Students
Shamsah B. Sonawalla, M.D., Amy H. Farabaugh, Ph.D., Maribeth Pender, Ph.D., Timothy J. Petersen, Ph.D., Albert Yeung, M.D., Jonathan E. Alpert, M.D., Maurizio Fava, M.D.

11:30 a.m.
72 Prevalence and Attitudes Concerning ADHD Diagnosis and Use of Stimulant Medications in Medical Students
Jeffrey Tuttle, M.D., Neil Scheurich, M.D., John Ranseen, Ph.D.

12 noon
73 Prevalence and Symptom Patterns of Depression Among College Students: Findings From a Cross-Cultural Study Across Boston and Bombay
Rajesh M. Parikh, M.D., Shamsah Sonawalla, M.D., Santvana Sharma, M.D., Amy H. Farabaugh, Ph.D., Albert Yeung, M.D., Steve Salten, Ph.D., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 25
11:00 a.m.-12:30 p.m.
Room 24 C, Upper Level, San Diego Convention Center

FUNCTIONING AND DISEASE BURDENS IN MOOD DISORDERS

Chp.: Kenneth Silk, M.D.
Co-Chp.: Jennifer Heath, M.D.

11:00 a.m.
74 Disease Burden of Bipolar and Schizoaffective Disorder in an Australian Cohort
Jayashi Kulikarni, M.B.B.S., Michael Berk, Paul Fitzgerald, Anthony de Castella, Sectal Dodd, Meg Smith, William Montgomery

11:30 a.m.
75 Days Missed from Work in Patients With MDD With or Without a Personality Disorder
Daniela A. Borescu, M.D., Mark Zimmerman, M.D., Iwona Chelminski, Ph.D.

12 noon
76 The Relationship Between Global Functioning, Depression, and Painful Somatic Symptoms in Patients With MDD
Thomas N. Wise, Adam L. Meyers, Durisala Dasaiah, Craig H. Mallineckrodt, Michael J. Robinson, Daniel Kajdasz

THIS SESSION WILL BE AUDIOTAPE

SCIENTIFIC AND CLINICAL REPORT SESSION 26
11:00 a.m.-12:30 p.m.
Room 25 A, Upper Level, San Diego Convention Center

STIGMA AND DISCRIMINATION

Chp.: Sonja Randle, M.D.
Co-Chp.: Jana Cook

11:00 a.m.
77 How Dangerous is Stigma? Perceived Stigma and HIV Risk Among Women With Severe Mental Illness
Pamela Y. Collins, Patricia Zybert, Ph.D., Annika Sweetland, M.S.W.

11:30 a.m.
78 Comparison of Public's Stigma Attitude Between Mental Illness and Physical Handicap
Chih-Wei Yang, M.D., Chih-Yu Yang, Ph.D., Pi-Fern Hsu, Ph.D., Li-Min Su, M.S.

12 noon
79 Obsessions About Homosexuality and the Y-BOCS Lessons From an Anti-Discrimination Case in Sweden
Christian Rück, M.D.

THIS SESSION WILL BE AUDIOTAPE

SCIENTIFIC AND CLINICAL REPORT SESSION 27
11:00 a.m.-12:30 p.m.
Room 27 A, Upper Level, San Diego Convention Center

SUICIDE AND SELF DESTRUCTION

Chp.: Austina Cho, M.D.
Co-Chp.: Derya I. Akbiyik, M.D.

11:00 a.m.
80 The 10-Year Course of Physically Self-destructive Acts of Patients With Borderline Personality Disorder
Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D., D. Bradford Reich, M.D.

11:30 a.m.
81 Indicators of Treatment Refractory Illness and Risk of Suicide
Bonnie S. Szarkc, R.N., John W. Goethe, M.D., Stephen B. Woolley, D.Sc

12 noon
82 Personality Traits as Prospective Predictors of Suicide Attempts: Negative Affectivity/Temperament and Disinhibition in a Personality Disorder Sample
M. Tracie Shea, Ph.D., Shirley Yen, Ph.D., Charles A. Sanislow, Ph.D., Andrew E. Skodol II, M.D., Carlos M. Grilo, Ph.D., Robert L. Stout, Ph.D.

THIS SESSION WILL BE AUDIOTAPE.

SMALL INTERACTIVE SESSION 14
11:00 a.m.-12:30 p.m.

Susan L. McElroy, M.D., on Metabolic Syndrome
(Meet the Author)
Room 27 B, Upper Level, San Diego Convention Center

WORKSHOPS

COMPONENTS 46-54

COMPONENT WORKSHOP 46 11:00 a.m.-12:30 p.m.
Room 5 B, Upper Level, San Diego Convention Center

LEADERSHIP CHALLENGES: BREAKING BARRIERS TO SUCCESS
APA Committee on International Medical Graduates

Co-Chps.: Antony Fernandez, M.D., Annette B. Pimm, M.D.
Participants: Francis M. Sanchez, M.D., Emilio F. Romero, M.D., Marie-Claude Rigaud, M.D., Aleksandra Postelwaite, M.D.

COMPONENT WORKSHOP 47 11:00 a.m.-12:30 p.m.
Room 7 A, Upper Level, San Diego Convention Center

PUBLIC POLICY, HIV AND MENTAL HEALTH: POLITICS, IDEOLOGY OR SCIENCE
APA New York County District Branch's AIDS Committee

Chp.: Mary Ann Cohen, M.D.

COMPONENT WORKSHOP 48 11:00 a.m.-12:30 p.m.
Room 7 B, Upper Level, San Diego Convention Center

CPT CODING AND DOCUMENTATION UPDATE
APA Committee on RBRVS, Codes, and Reimbursements

Co-Chps.: Ronald M. Bury, M.D., David Nace, M.D.
Participants: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D., Allan A. Anderson, M.D., Edward Gordon, M.D.
COMPONENT WORKSHOP 49 11:00 a.m.-12:30 p.m.
Room 8, Upper Level, San Diego Convention Center

ETHICS AND ETIQUETTE: KEEPING OUT OF TROUBLE
APA Ethics Committee

Chp.: Wade C. Myers
Participants: William Arroyo, M.D., Richard D. Milone, M.D., Burton V. Reifler, M.D., Harriet C. Stern, M.D., Lawrence Hartmann, M.D.

COMPONENT WORKSHOP 50 11:00 a.m.-12:30 p.m.
Room 23 C, Upper Level, San Diego Convention Center

MANAGING OPIATE DETOXIFICATION WITH BUPRENORPHINE/NALOXONE
APA Council on Addiction Psychiatry

Chp.: John A. Renner, Jr., M.D.
Participants: Eric C. Strain, M.D., Herbert D. Kleber, M.D., Ray C. Hsiao, M.D.

COMPONENT WORKSHOP 51 11:00 a.m.-12:30 p.m.
Room 24 A, Upper Level, San Diego Convention Center

NEW APA PRACTICE GUIDELINES ON DEMENTIA, PANIC DISORDER, AND OCD
APA Steering Committee on Practice Guidelines

Chp.: Jack S. McIntyre, M.D.
Participants: Lon S. Schneider, M.D., Murray B. Stein, M.D., Lorrin M. Koran, M.D., Laura J. Fochtmann, M.D.

COMPONENT WORKSHOP 52 11:00 a.m.-12:30 p.m.
Room 25 C, Upper Level, San Diego Convention Center

MISSION POSSIBLE: RECLAIMING AMERICA'S STATE HOSPITAL BEDS
APA Council on Social Issues and Public Psychiatry

Co-Chps.: Jagannathan Srinivasaraghavan, M.D., Jeffrey L. Geller, M.D.
Participants: Tracee Burroughs, M.D., Terri L. Randall, M.D., Ruth S. Shim, M.D.

COMPONENT WORKSHOP 53 11:00 a.m.-12:30 p.m.
Room 28 A, Upper Level, San Diego Convention Center

EARLY COGNITIVE DEVELOPMENT AND PSYCHIATRIC PRESENTATION: IMPLICATIONS FOR ETIOLOGIC UNDERSTANDING AND INTERVENTION
APA Corresponding Committee on Infant and Early Childhood

Co-Chps.: Jean M. Thomas, M.D., Irene Chatooor, M.D.
Participant: Penny Glass, Ph.D.

COMPONENT WORKSHOP 54 11:00 a.m.-12:30 p.m.
Room 32 B, Upper Level, San Diego Convention Center

MENTORING OF WOMEN IN ACADEMIC PSYCHIATRY
APA Central California Psychiatric Society

Chp.: Linda L.M. Worley, M.D.
Participants: Tracy H. McCarthy, M.D., Andrea L. Scitano, M.D., Donald M. Hilty, M.D.

ISSUE 66-76

ISSUE WORKSHOP 66 11:00 a.m.-12:30 p.m.
Room 24 B, Upper Level, San Diego Convention Center

ETHNICITY, CULTURE, AND PSYCHOPHARMACOLOGY: RECENT ADVANCE

Chp.: Pedro Ruiz, M.D.
Participants: William B. Lawson, M.D., Ph.D., Edmond H. Pi, M.D., Tarek A. Okasha, M.D.

ISSUE WORKSHOP 67 11:00 a.m.-12:30 p.m.
Room 28 B, Upper Level, San Diego Convention Center

COGNITIVE BEHAVIOUR THERAPY FOR PSYCHOSIS IN PRACTICE: BASIC TECHNIQUES FOR PSYCHIATRISTS

Chp.: Shanaya Rathod, M.D.
Participants: David G. Kingdon, M.D., Douglas Turkington, M.D.

ISSUE WORKSHOP 68 11:00 a.m.-12:30 p.m.
Room 28 C, Upper Level, San Diego Convention Center

PROMISING MEDICATIONS FOR THE TREATMENT OF COCAINE ADDICTION
Collaborative Session With the National Institute on Drug Abuse

Chp.: Ahmed Elkashif, M.D., Frank Vocci, Jr., Ph.D.
Participants: Kyle M. Kampean, M.D., Bankole Johnson, M.D., George F. Koob, Ph.D.

ISSUE WORKSHOP 69 11:00 a.m.-12:30 p.m.
Room 28 D, Upper Level, San Diego Convention Center

PSYCHIATRISTS WHO HAVE BEEN IN TREATMENT. AN INTERACTIVE DISCUSSION

Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Elizabeth A. Baxter, M.D., Francine Cournos, M.D., Raymond M. Reyes, M.D., Suzanne E. Vogel-Scibilia, M.D.
WEDNESDAY

ISSUE WORKSHOP 70  11:00 a.m.-12:30 p.m.
Room 30 A, Upper Level, San Diego Convention Center

ELECTRIFYING DISCOURSES: PRESENTATION AND COMMUNICATION SKILLS FOR PSYCHIATRISTS AND TRAINEES

Chp.: Shyam K. Bhat, M.D.
Participants: David S. Resch, M.D., Thomas O. Osinowo, M.D., Anjan Bhattacharyya, M.D.

ISSUE WORKSHOP 71  11:00 a.m.-12:30 p.m.
Room 30 B, Upper Level, San Diego Convention Center

AIR FORCE SUICIDE PREVENTION PROGRAM: A COMMUNITY AND ORGANIZATIONAL APPROACH TO PREVENTION

Chp.: Steven E. Pfanz, M.D.

ISSUE WORKSHOP 72  11:00 a.m.-12:30 p.m.
Room 30 C, Upper Level, San Diego Convention Center

DAY-TO-DAY VARIABILITY IN BIPOLAR DISORDER

Co-Chps.: Jan L. Scott, M.D., Michael Bauer, M.D.
Participants: Mark S. Bauer, M.D., Tasha Glenn, Ph.D.

ISSUE WORKSHOP 73  11:00 a.m.-12:30 p.m.
Room 30 D/E, Upper Level, San Diego Convention Center

FROM THE MISSISSIPPI TO THE GANGES: UNDERSTANDING THE CROSS CULTURAL CONTEXT OF TREATMENT FROM THE PERSPECTIVE OF THE SOUTH ASIAN PSYCHIATRIST IN AMERICA

Indo-American Psychiatric Association

Co-Chps.: Asha S. Mishra, M.D., Südeepa Varma, M.D.
Participants: Surinder Nand, M.D., Nalini Juthani, M.D.

ISSUE WORKSHOP 74  11:00 a.m.-12:30 p.m.
Room 31 A, Upper Level, San Diego Convention Center

RELIGIOUS AND SPIRITUAL ASSESSMENT IN CLINICAL PRACTICE

Co-Chps.: Francis G. Lu, M.D., James L. Griffith, M.D.
Participant: Christina M. Puchalski, M.D.

ISSUE WORKSHOP 75  11:00 a.m.-12:30 p.m.
Room 31 B, Upper Level, San Diego Convention Center

FROM EVIDENCE TO CLINICAL METHODS IN INTEGRATIVE MENTAL HEALTH CARE

Chp.: James Lake, M.D.

ISSUE WORKSHOP 76  11:00 a.m.-12:30 p.m.
Room 32 A, Upper Level, San Diego Convention Center

GAY MEN AND CRYSTAL METHAMPHETAMINE: A REVIEW

Co-Chp.: Eugene Lee, M.D., Waguih W. Ishak, M.D.
Participants: Douglas Braun-Harvey, Jeffrey N. Wilkins, M.D.

12 noon Sessions

FORUMS 9-10

FORUM 9
12 noon-1:30 p.m.
Ballroom 6 E, Upper Level, San Diego Convention Center

CATASTROPHE MANAGEMENT: PSYCHIATRY RESPONSE TO HURRICANES KATRINA AND RITA IN LOUISIANA

Chp.: David E. Post, M.D.
Presenters: Kathleen A. Crapanzano, M.D., Rochelle Head-Dunham, M.D., Jacquelyn A. Robinson, M.D.

FORUM 10
12 noon-1:30 p.m.
Room 26 A/B, Upper Level, San Diego Convention Center

WALLY: A FILM BY BOB FINK, M.D.

Chp.: Robert Fink, M.D.

NEW RESEARCH POSTER SESSION 6
12 noon-2:00 p.m.
Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research submissions, please refer to the New Research Program Book included in your registration packet.
1:00 p.m. Sessions

COURSES 88-91

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 88 1:00 p.m.-5:00 p.m.
Elizabeth Ballroom H, Second Level, Manchester Grand Hyatt

THE WAY OF YOGA AND HERBS IN TREATMENT OF STRESS, DEPRESSION, AGGRASSION, AND MASS TRAUMA

Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbarg M.D.

COURSE 89 1:00 p.m.-5:00 p.m.
Madeleine Room A/B, Third Level, Manchester Grand Hyatt

MOTIVATIONAL THERAPY FOR PATIENTS WITH CONCURRENT DISORDERS

Director: Shimi Kang, M.D.
Faculty: Steve Mathias, M.D., Jennifer Toomey, R.P.N., Tristin Wayte, Ph.D.

COURSE 90 1:00 p.m.-5:00 p.m.
Madeleine Room C/D, Third Level, Manchester Grand Hyatt

PERSONALITY DISORDERS: COMBINING RELATIONAL THERAPY AND PSYCHOPHARMACOLOGY

Director: Roy O. Resnikoff, M.D.

COURSE 91 1:00 p.m.-5:00 p.m.
Emma Room A/B/C, Third Level, Manchester Grand Hyatt

CORRECTIONAL PSYCHIATRY: A SKILLS BUILDING COURSE

Director: Melissa P. Piasceki, M.D.
Faculty: Keith Courtney, M.D., Steven J. Zuchowski, M.D., Ole J. Thienhaus, M.D.

2:00 p.m. Sessions

ADVANCES IN ADVANCES IN C-L PSYCHIATRY AND PSYCHOSOMATIC MEDICINE

2:00 p.m.-5:30 p.m.
Ballroom 6 A, Upper Level, San Diego Convention Center

Chp.: James L. Levenson, M.D.

A Legal Issues at the Interface of Psychiatry and Medicine
James L. Levenson, M.D.

B Somatization and Somatoform Disorders
Steven A. Epstein, M.D.

C Depression in the Medically Ill
Gary Rodin, M.D.

D Psychosis in the Medically Ill
Prakash S. Masand, M.D.

E Deception Syndromes
Charles V. Ford, M.D.

LECTURES 23-24

LECTURE 23
2:00 p.m.-3:30 p.m.
Ballroom 5 B, Upper Level,
San Diego Convention Center

Tanya Luhrmann, Ph.D.

Psychosis on the Streets: An Ethnography of Chicago's Netherworld

Chp.: Deborah Spitz, M.D.

Tanya Luhrmann is the Max Palevsky Professor in the Committee on Human Development. She trained at the University of Cambridge (PhD 1986), taught for many years at the University of California San Diego, and joined the University of Chicago faculty in 2000. Her work focuses on the social construction of psychological experience, and the way that social practice alters psychological mechanism, particularly in the domain of what some would call the "irrational". Her first project is a detailed study of the way apparently reasonable people come to believe apparently unreasonable beliefs (Persuasions of the Witch's Craft, Harvard, 1989). Her second project explored the apparently irrational self-criticism of a postcolonial India elite, the result of colonial identification with the colonizers (The Good Farsi, Harvard 1996). Her third book identified two cultures within the American profession of psychiatry and examined the way these different cultures encouraged different experiences of empathy and different understandings of mental illness (Of Two Minds, Knopf, 2000). Her current work looks at the experience of voices and visions both in the new style of American religion and among psychiatric clients, and the way the interpretation of these phenomena may affect the experience of God (on the one hand) and the identification, experience and outcome of psychiatric illness (on the other). She is a director of the Clinical Ethnography project in the Committee on Human Development.

Frontiers of Science Award Lecture Series
THIS SESSION WILL BE AUDIOTAPED.
LECTURE 24

2:00 p.m.-3:30 p.m.
Ballroom 6 C/D/E/F, Upper Level,
San Diego Convention Center

Leah Dickstein, M.D.

Keys to Effective Mentoring for All in Psychiatry
Chp.: Kathryn Connor, M.D.
Co-Chp.: Christine E. Marx, M.D.

Leah J. Dickstein, M.D., earned her undergraduate and master’s degrees in elementary education at Brooklyn College, taught in an inner city school for almost seven years and earned her M.D. from the University of Louisville. She joined the faculty in 1975 to found the University Student Mental Health Section of the University Student Health Service, and became School of Medicine Associate Dean for Student Affairs in 1981, then Associate Dean for Faculty and Student Advocacy in 1989, was associate chair for academic affairs, and became Professor Emerita in 2002. She established a number of medical school health promotion programs. Dr. Dickstein has edited/co-edited a number of books and has served in various positions of leadership with numerous associations. In addition she initiated the first APA named lecture for a woman: Alexandra Symonds, M.D., the Nancy C.A. Roeske, M.D. Teaching Award at every medical school, The AWP Man of Good Conscience Award (Martin Symonds, M.D.), the AWP Marian Butterfield, M.D. Early Career Leadership Award, and proposed the Irma Bland Award. She created the medical student physicians and the arts elective (and awards). Her research has focused on health promotion among medical students and residents, interviews of over 200 Catholic and Jewish Women & Men Nazi Concentration Camp Survivors related to gender, spiritual, and coping differences. Her publications exceed 100, she is a reviewer for several journals, and has given over 500 national and international lectures. Currently, Dr. Dickstein is Professor Emerita, and continues to lecture, write, and mentor students, trainees, and young faculty nationwide.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIA 5-7

PRESIDENTIAL SYMPOSIUM 5
2:00 p.m.-5:00 p.m.
Ballroom 6 D, Upper Level, San Diego Convention Center

HEALTH INEQUALITIES FOR PERSONS WITH MENTAL HEALTH PROBLEMS AND DEVELOPMENTAL DISABILITIES
Royal College of Psychiatrists

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Sheila Hollins, M.D.

A Health Care Delivery Systems in the United Kingdom
Dinesh Bughra, M.D.

B The Role of Organized Medicine and Psychiatry in the United Kingdom
Sue Bailey, M.D.

C The Provision of Care for Persons With Intellectual Disabilities in the United Kingdom
Helen Miller, M.B.

D Health Care Delivery Systems in the U.S.
Roger Pecce, M.D.

E The Role of the Professional Society (Organized Psychiatry) in Addressing Health Care in the U.S.
James H. Scully Jr., M.D.

F The Provision of Care for Persons With Intellectual Disabilities in the U.S.
Stephen Ruedrich

Discussants: Greg Richardson, M.D., Sidney Weissman, M.D.

PRESIDENTIAL SYMPOSIUM 6
2:00 p.m.-5:00 p.m.
Ballroom 6 E, Upper Level, San Diego Convention Center

FOCUSING ON EUROPEAN PSYCHIATRY
APA Council on Global Psychiatry

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Cyril Hoschl, M.D.

A European Psychiatry: Between Neuroscience and Medical Humanities
Michael Musalek, M.D.

B Current European Perspectives on the Concept of Schizophrenia
Mario Maj, M.D.

C Green Paper and Limits of Psychiatry as a Medical Discipline
Cyril Hoschl, M.D.

Discussant: Norman H. Sartorius, M.D.
PRESIDENTIAL SYMPOSIUM 7
2:00 p.m.-5:00 p.m.
Room 33 A/B/C, Upper Level, San Diego Convention Center

GLOBALIZATION AND MENTAL HEALTH: ROLE OF SPANISH-SPEAKING PSYCHIATRY

Chp.: Renato D. Alarcon, M.D.
Co-Chp.: Cesar M. Mejias

A Globalization and its Discontents: The Spanish-Speaking Perspective
Renato D. Alarcon, M.D.

B Psychiatry in Ibero-America: Historical Perspective
Pedro Ruiz, M.D.

C Globalization and Psychiatry in Latin America: A Role for Professional Prudence
Fernando Lolas, M.D.

D A Global Psychiatry for a Globalized World
Jose Lazarro

Discussant: Manuel Trujillo, M.D.

SYMPOSIA 52-74

SYMPOSIUM 52
2:00 p.m.-5:00 p.m.
Room 2, Upper Level, San Diego Convention Center

BEHAVIORAL AND SUBSTANCE ADDICTIONS IN MINORITY POPULATIONS

Chp.: Jon E. Grant, M.D.

A Implications of Black/African American Race, Ethnicity, and Culture for Addiction
Marc N. Potenza, M.D., Marvin Steinberg, Ph.D., Ran Wu, M.S., Declan Barry, Ph.D.

B Native American and Hispanic Veterans With Addictive Disorders: Comorbidity With Internalizing and Externalizing Disorders
Joseph J. Westermeyer, M.D.

C Asian-Americans, Addictions, and Barriers to Treatment
Timothy W. Fong, M.D.

D Addictions Within the Gay and Lesbian Community
Jon E. Grant, M.D.

E Clinical Challenges to Addiction Treatment Within the Latino Community
Carlos Blanco-Jerez

SYMPOSIUM 53
2:00 p.m.-5:00 p.m.
Room 3, Upper Level, San Diego Convention Center

TREATMENT OF DEPRESSION IN THE MEDICALLY ILL: AN UPDATE FROM RECENT CLINICAL TRIALS

Chp.: François Lespérance, M.D.

A The Create Trial: Background and Design of a 2 by 2 Factorial Randomized Trial of Citalopram and IPT for Major Depression in Patients with Coronary Artery Disease
Nancy Frasure-Smith, François Lespérance, M.D., Diana Koszycki, Ph.D., John R. Swenson, M.D., Brian Baker, M.B.Ch.B., Louis T. van Zyl, M.D., Marc-André Laliberté, M.D., Beth L. Abramson, M.D., Marie-Claude Guertin

B The Create Trial: Results of a 2 by 2 Factorial Randomized Trial of Citalopram and IPT for Major Depression in Patients With Coronary Artery Disease
François Lespérance, M.D., Nancy Frasure-Smith, Ph.D., Diana Koszycki, Marc-André Laliberté, M.D., Louis T. vanZyl, M.D., Brian Baker, M.D., John R.Swenson, M.D., Kayhan Ghatavi, M.D., Beth L. Abramson, M.D.

C Randomized Controlled Trial of Treatments for Depression After Coronary Bypass Surgery
Kenneth E. Freedland, Ph.D.

D Cost-Effectiveness or Improving Depression Outcomes in Patients With Diabetes and Depression
Wayne J. Katon, M.D., Gregory E. Simon, M.D., Jurgen Unutzer, M.D., Ming-Yu Fan, Ph.D., Michael Schoenbaum, Ph.D., Michael Von Korff, Sc.D, John W. Williams, Jr., M.D., Carolyn Rutter, Ph.D., Paul S. Ciechanowski, M.D.

E Efficacy of Sertraline for Prevention of Depression Recurrence in Older Versus Younger Adults With Diabetes
Patrick J. Lustman, Ph.D., Ray E. Clouse, M.D., Billy D. Nix, Monique M. Williams, M.D.

Discussant: Craig B. Taylor, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 54
2:00 p.m.-5:00 p.m.
Room 4, Upper Level, San Diego Convention Center

DRUG ABUSE TREATMENT WITHIN THE CRIMINAL JUSTICE SYSTEM: ADDRESSING OUR NATION'S PUBLIC HEALTH NEEDS

Collaborative Session With the National Institute on Drug Abuse

Chp.: Timothy Condon Ph.D.
Co-Chp.: Re Donna K. Chandler Ph.D.

A Findings From a National Survey of Correctional Agencies on Substance Abuse Treatment and Health Services: Who Can Get Served?
Faye S. Taxman, Ph.D.

(Continued next page)
B The Long-Term Effectiveness of Corrections-Based Treatment for Drug-Involved Offenders
James A. Inciardi, Ph.D.

C Mental Health and Co-occurring Treatment Needs of Individuals in the Criminal Justice System
Roger H. Peters, Ph.D.

D Meeting the Medical Needs of Offenders
Peter D. Fritzmann, M.D., Jennifer G. Clarke, M.D., Lynn E. Taylor, M.D., Michael Posthkus, M.D., Josiah D. Rich, M.D.

E Pharmacotherapy in Correctional Settings for Addictive and Other Mental Disorders
Robert P. Schwartz, M.D.

Discussant: Redonna K. Chandler, Ph.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 55  2:00 p.m.-5:00 p.m.
Room 5 A, Upper Level, San Diego Convention Center

IMPROVING CROSS-CULTURAL COMPETENCY IN PSYCHIATRIC PRACTICE

Chp.: Maria Lujan, M.D.

A South Asian Psychiatrist-Providing Culturally Sensitive Treatment
R. Rao Gogineni, M.D.

B Cultural Competency in Psychiatry and African-Americans
Altha J. Stewart, M.D.

C Filipino Families and Mental Health: Understanding Their Perspectives
Consuelo Cagande, M.D.

D Latinos in the United States, Cross-Cultural Issues
Maria Velazquez, M.D.

Discussant: Andres Pumariega, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 56  2:00 p.m.-5:00 p.m.
Room 5 B, Upper Level, San Diego Convention Center

EATING BEHAVIOR IN SCHIZOPHRENIA: BIOLOGICAL AND CLINICAL IMPLICATIONS

Chp.: Michael Y. Hwang
Co-Chp.: Katherine A. Halmi, M.D.

A Obesity and Metabolic Disorders in Schizophrenia
Naveed Iqbal, M.D.

B Eating Disorders in Schizophrenia: Conceptual and Clinical Issues
Michael Y. Hwang, M.D.

C Phenomenological and Clinical Profiles of Eating Behavior in Schizophrenia
Sun Y. Yum, M.D., Michael Y. Hwang, M.D.

D Effect of Atypical Antipsychotics on Obesity and Metabolism in Schizophrenia
Palmiero Monteleone, M.D., Michele Fabrazzo, M.D., Alfonso Tortorella, M.D., Mario Maj, M.D.

Discussant: Katherine A. Halmi, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 57  2:00 p.m.-5:00 p.m.
Room 7 A, Upper Level, San Diego Convention Center

SIMPLE TECHNOLOGIES TO IMPROVE PSYCHOTHERAPY

Chp.: Mantosh J. Dewan, M.D.

A Web-Based Learning in Psychotherapy: A Demonstration
Priyanthy Weerasakera, M.D.

B Seeing Is Believing: Web-Cams in Psychotherapy Supervision
John Mannig, M.D.

C Evidence for Measuring, Monitoring, and Feeding Back Progress Information to Providers: Technology in the Service of Improving Patient Outcome
Michael J. Lambertz, Ph.D.

D Using Technology in Cognitive Therapy
Judith Beck, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 58  2:00 p.m.-5:00 p.m.
Room 7 B, Upper Level, San Diego Convention Center

PSYCHIATRIC TRAINING ACROSS THE CONTINENTS: INTERNATIONAL YOUNG PSYCHIATRIST PERSPECTIVES

Chp.: Julian Beezhold, M.B.Ch.B.
Co-Chp.: Allan Tasman, M.D.

A From the Old to the New: Changes to Postgraduate Psychiatric Training in the UK
Amit Malik, M.B.B.S.

B Psychiatric Training in Kenya: An African Perspective
Violet A. Okech, M.Med.

C The Specialist Training in Psychiatry in Bolivia and Latin America
Guillermo C. Rivera Arroyo, Sr., Ph.D.

D Psychiatric Training Program in Japan
Atsu Nakagawa, M.D., Ryoko Sato, M.D.

E The Interface Between East and West: Psychiatric Training in Turkey
Ozgur Ozturk, M.D.

F A Review of Psychiatric Training in the United States
Abigail L. Donovan, M.D.

THIS SESSION WILL BE AUDIOTAPE.
SYMPOSIUM 59  2:00 p.m.-5:00 p.m.
Room 8, Upper Level, San Diego Convention Center

AMERICAN PSYCHIATRY VIEWED FROM THE OUTSIDE: A GLOBAL PERSPECTIVE ON THE DSM5 AND PSYCHOPHARMACOLOGY

Chp.: Nassir Ghaemi, M.D.
Co-Chp.: Eduardo A. Correa, M.D.

A  A View from South America: A Chilean Perspective
   Eduardo A. Correa, M.D.

B  U.S. Influence on the Evolution of European Psychiatry
   Athanasios Koukopoulos

C  The View From the Middle East
   Kemal Sayar, M.D.

D  The Rise and Fall of American Psychiatry
   Nassir Ghaemi, M.D.

Discussant: P.R. McHugh
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 60  2:00 p.m.-5:00 p.m.
Room 9, Upper Level, San Diego Convention Center

THE END, MIDDLE, AND BEGINNING OF THE AFFAIR: INFIDELITY IN FILM AND TELEVISION

Chp.: Robert J. Boland, M.D.
Co-Chp.: Anton C. Trinidad, M.D.

A  Do Married People Have Affairs Because They Can't Help It? Lessons From the History of Marriage
   Anton C. Trinidad, M.D.

B  Why We Think People Cheat
   Robert J. Boland, M.D.

Discussant: Joseph A. Cheong, M.D., S.D. Haltzman
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 61  2:00 p.m.-5:00 p.m.
Room 11 A, Upper Level, San Diego Convention Center

CONNECTIONS TO MEDICAL INFORMATION

Chp.: John Luo, M.D.
Co-Chp.: Carlyle H. Chan, M.D.

A  Medical Information Devices: The Technology to Connect
   John Luo, M.D.

B  Connectivity and Interactivity
   Britton A. Arey, M.D.

C  Information Resources
   Carlyle H. Chan, M.D.

D  Connections: The Present and the Future
   Robert Kennedy, M.D., Britton A. Arey, M.D., Carlyle H. Chan, M.D., John Luo, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 62  2:00 p.m.-5:00 p.m.
Room 11 B, Upper Level, San Diego Convention Center

PRESCRIBING PATTERNS, PREDICTORS, AND COSTS FOR ANTIDEPRESSANT MEDICATIONS:

Chp.: Ronald J. Diamond, M.D.
Co-Chp.: Marion A. Becker, Ph.D.

A  Changes in Prescribing When Antidepressants Become Generic
   Ronald J. Diamond, M.D., Michael Mergener, Pharm.D., Theodore M. Collins, Pharm.D.

B  Patterns of Pharmacotherapy for MDD
   Marion A. Becker, Ph.D.

C  Retrospective Analysis of Public Payer Healthcare Costs Associated With Specific Types of Antidepressant Treatment for MDD
   Paul Stiles, Ph.D.

D  Recent Patterns and Predictors of Antidepressant Medication Regimens Used to Treat MDD
   M. Scott Young, Ph.D., Marion A. Becker, Ph.D., Lodi Rohrer, M.P.H.

Discussant: James W. Jefferson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 63  2:00 p.m.-5:00 p.m.
Room 26 A/B, Upper Level, San Diego Convention Center

NEUROBIOLOGY OF THE UNCONSCIOUS: IMPLICATIONS FOR PSYCHOTHERAPEUTIC UNDERSTANDING AND TECHNIQUE

Chp.: Barton J. Blinder, M.D.

A  Historical Overview of the Concept Unconscious
   Barton J. Blinder, M.D.

B  Mapping the Unconscious in the Brain
   George I. Viamontes, M.D.

C  The Mirror Neuron System
   Marco Iacoboni, M.D.

D  Unconscious Enactments in Psychotherapy
   Glen O. Gabbard, M.D.

E  Metacommunication, Psychotherapy and the Brain
   Bernard D. Beitman, M.D., Jessica R. Nittlcr, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 64  2:00 p.m.-5:00 p.m.
Room 28 C, Upper Level, San Diego Convention Center

UPDATE ON THE BIOLOGY OF PERSONALITY DISORDERS

Chp.: Kenneth R. Silk, M.D.
Co-Chp.: Larry J. Siever, M.D.

(Continued next page)
**WEDNESDAY**

A New Developments in Neurocircuits and Neurotransmitters in the Personality Disorders  
Larry J. Siever, M.D.

B Biology and Treatment of Impulsive Aggression in Personality Disorder  
Emil F. Coccaro, M.D.

C NMDA Neurotransmission and the Neurobiology of BPD  
Bernadette M. Grosjean, M.D.

D Pain Processing in BPD  
Christian Schmahl, Anja Jochims, M.A., Petra Ludueñescher, M.A., Martin Bohus, M.D.

E 5HT2a Receptor Binding in BPD  
Paul H. Soloff, M.D., Julie C. Price, Ph.D., Carolyn C. Meltzer, M.D., Anthony Fabio, Ph.D., Guido Frank, M.D., Walter H. Kaye, M.D.

F A Neurodevelopmental Model of BPD  
Kenneth R. Silk, M.D., Katherine Putnam, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 65**  
2:00 p.m.-5:00 p.m.  
Room 29 A/B, Upper Level, San Diego Convention Center

**A PICTURE OF THE DEVELOPMENT OF THE ADOLESCENT BRAIN: A STRUCTURAL AND FUNCTIONAL ASSESSMENT**  
Collaborative Session With the National Institute on Drug Abuse

Chp.: David Shurtleff, Ph.D.,  
Co-Chp.: Laurence R. Stanford, Ph.D.

A Mapping Adolescent Brain Maturation with Structural Magnetic Resonance Imaging  
Elizabeth R. Sowell, Ph.D.

B The Usefulness of Diffusion Tensor Imaging for the Study of Brain Development in Children  
Michael J. Rivkin, M.D.

C Magnetic Resonance Spectroscopy Studies of Human Brain Development  
Perry F. Renshaw, M.D., Young Hoon H. Sung, M.D.

D Risk Taking and the Adolescent Brain: Who Is at Risk?  
B.J. Casey, Ph.D.

Discusssant: Linda C. Mayes, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 66**  
2:00 p.m.-5:00 p.m.  
Room 29 C/D, Upper Level, San Diego Convention Center

**AN UPDATE ON CROSS-CULTURAL, ETHNIC, AND ETHNOPSYPHARMACOLOGICAL ASPECTS OF MOOD DISORDERS**

Chp.: Shamsah B. Sonawalla, M.D.  
Co-Chp.: Rajesh M. Parikh, M.D.

**SYMPOSIUM 67**  
2:00 p.m.-5:00 p.m.  
Room 30 A, Upper Level, San Diego Convention Center

**ETHICS OF TREATING SUBSYNDROMAL PSYCHIATRIC DISORDERS**

Chp.: Ahmed M. Okasha, M.D.

A Should We Treat Subsyndromal Psychiatric Disorders?  
Ahmed M. Okasha, M.D.

B Subthreshold Mood States Are Not Subclinical  
Hagop S. Akiskal, M.D.

C Treating Subsyndromal Schizophrenia: Why the Uproar?  
Thomas H. McGlashan, M.D.

D Defining the Threshold for the Diagnosis of Mental Disorder: Some Current Approaches  
Mario Maj, M.D.

Discusssant: Pedro Ruiz, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 68**  
2:00 p.m.-5:00 p.m.  
Room 30 B, Upper Level, San Diego Convention Center

**INNOVATIONS IN THE TREATMENT OF ADOLESCENT SUBSTANCE USE DISORDERS**  
Collaborative Session With the National Institute on Drug Abuse

Chp.: Marc Galanter, M.D.  
Co-Chp.: Yifrah Kaminer, M.D.

A Fluoxetine in Adolescents With Comorbid Major Depressive Disorder and an Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial  
Jack R. Cornelius, M.D.
B  Evidence for Adolescent Participation in Alcoholics Anonymous and Narcotics Anonymous: Further Steps Needed
   John F. Kelly, Ph.D.

C  Does Smoking Cessation Intervention Influence Adolescent Alcohol and Other Drug Abuse Treatment Outcome?
   Mark G. Myers, Ph.D.

D  Aftercare for Adolescent Alcohol Use Disorders
   Yifrash Kaminer, M.D.

   Discussants: Frances R. Levin, M.D., Wilson M. Compton, M.D.
   THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 69  2:00 p.m.-5:00 p.m.
Room 30 C, Upper Level, San Diego Convention Center

SEXUALITY IN LONG-TERM CARE FACILITY RESIDENTS

Chp.: Helen H. Kyomen, M.D.

A  Normal Aging and Sexuality in Later Life
   Shanda McGahee, M.D.

B  The Impact of Psychiatric Illness on Sexual Function in Elderly Long Term Care Facility Residents
   Robert K. Dolgoff, M.D.

C  Assessment and Management of Inappropriate Sexual Behavior in the Long Term Care Setting
   David D. Myran, M.Ed.

D  Sexuality and Rights of Residents in Long-Term Care Facilities
   Ken Schwartz, M.D.

   Discussant: Helen H. Kyomen, M.D.
   THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 70  2:00 p.m.-5:00 p.m.
Room 30 D/E, Upper Level, San Diego Convention Center

THE SEXUALLY VIOLENT OFFENDER

Chp.: Jean-Pierre Lindenmayer, M.D.
Co-Chp.: Samuel J. Langer, M.D.

A  Civil Commitment of Sex Offenders
   Howard V. Zonana, M.D.

B  The Civil Facility Experience With a Program for SVPs
   Samuel J. Langer

C  Risk Assessment and Treatment Issues Related to Paraphilic Sex Offenders
   Fabian M. Salch

D  The Role of Treatment Outcome in the SVP Courtroom
   Howard E. Barbaree, Ph.D.

E  Treatment of Sex Offenders in a Prison Setting
   Lawrence A. Siegel, M.D.

   Discussant: Ruichard B. Krueger, M.D.
   THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 71  2:00 p.m.-5:00 p.m.
Room 31 A, Upper Level, San Diego Convention Center

PRENATAL NICOTINE EXPOSURE: HOW DOES IT RELATE TO DEVELOPMENTAL VULNERABILITIES?
Collaborative Session With the National Institute on Drug Abuse

Chp.: Nicollete Borel, Ph.D.
Co-Chp.: Allison Chausma, Ph.D.

A  Beyond Diagnosis: Unpacking the Association of Prenatal Smoking and Exposure Across Developmental Periods
   Kimberly A. Espy, Ph.D., Bennett L. Leventhal, M.D.,
   Gretchen Biseckock, Ph.D., Kate Pickett, Ph.D., Daniel
   Pine, M.D.

B  Neuroimaging Evidence of Altered Medial Temporal Lobe Function in Adolescent Tobacco Smokers With Prenatal Exposure to Maternal Smoking
   Leslie K. Jacobsen, M.D., Theodore A. Slotkin, Ph.D.,
   Michael Westerveld, Ph.D., W. Einar Mencl, Ph.D.,
   Kenneth R. Pugh, Ph.D.

C  Gestational Nicotine Alters Brain Nicotinic Cholinergic Receptor Expression in Dopaminergic Regions of Adolescents and Adults
   Burt Sharp, M.D., H. Chen, S.L. Parker, J.M. McIntosh,
   S G. Matta

D  Prenatal Nicotine Exposure Induces Sex-Dependent Changes in Dopamine Pathways in Adolescent Brain
   Frances Leslie, Ph.D., Ryan Frank, Anita Lakatos, Ph.D.,
   James D. Belluzzi, Ph.D.

   Discussant: Bennett L. Leventhal, M.D.
   THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 72  2:00 p.m.-5:00 p.m.
Room 31 B, Upper Level, San Diego Convention Center

THE IOM INFORMS, NAMI Storms, and AACP Transforms: How to Make the Grade in Response to the U.S. Mental Health's Bad Report Card

Chp.: David A. Pollack, M.D.
Co-Chp.: Neal H. Adams MD

A  Can Community Psychiatry Cross the Quality Chasm?
   The Institute of Medicine Report on Improving Care for Mental and Substance-Use Conditions
   Harold A. Pincus, M.D.

B  What Families and Consumers See and Want in Americas Mental Health Service System
   Kenneth S. Duckworth, M.D.

C  Leadership and Collaboration: Transforming Community Psychiatry
   Wesley E. Sowers, M.D.

(Continued next page)
3:00 p.m. Session

NEW RESEARCH POSTER SESSION 7
3:00 p.m.-5:00 p.m.
Sails Pavilion, Upper Level, San Diego Convention Center

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

7:00 p.m. Session

INDUSTRY SUPPORTED SYMPOSIUM 33
7:00 p.m.-10:00 p.m.
Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

FIBROMYALGIA: NEW INSIGHTS INTO THE PATHOPHYSIOLOGY AND TREATMENT
Supported by Pfizer Inc.

Chp.: Lesley M. Arnold, M.D.

A The Pathophysiology of Pain in Fibromyalgia and Related Syndromes
   Daniel J. Clauw, M.D.

B The Role of Disordered Sleep in Fibromyalgia
   Lesley M. Arnold, M.D.

C New Developments in the Pharmacological Treatment of Fibromyalgia
   Leslie J. Crofford, M.D.

D Exercise as a Treatment for Fibromyalgia
   Dina Dadabhoy, M.D.

DID and DID-Like Cases of Dissociative Disorder Not Otherwise Specified
   Paul F. Dell, Ph.D.

C Depersonalization Disorder and Dissociative Amnesia
   Daphne Simeon, M.D.

D Conversion Disorder, Dissociative Psychosis, and Childhood Dissociative Disorder
   Vedat Sar, M.D.

Discussant: Michael B. First, M.D.

THIS SESSION WILL BE AUDIOTAPED.

HIV UPDATE FOR PSYCHIATRIC CARE

Chp.: Marshall Forstein, M.D.

A HIV Medical Update: What Every Psychiatrists Needs to Know
   Diane Pennesi

B Evidence-Based Treatments in HIV Psychiatric Care
   Stephen Ferrando, M.D.

C HIV as a Lifelong Illness
   Karl Goodkin

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 73

Room 32 A, Upper Level, San Diego Convention Center

2:00 p.m.-5:00 p.m.

SYMPOSIUM 74

Room 32 B, Upper Level, San Diego Convention Center

2:00 p.m.-5:00 p.m.

WEDNESDAY
THURSDAY, MAY 24, 2007

160TH ANNUAL MEETING

8:00 a.m. Sessions

COURSES 92-94

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 92 8:00 a.m.-12 noon
Elizabeth Ballroom F, Second Level, Manchester Grand Hyatt

CONNECTIONS

Co-Directors: Robert S. Kennedy, M.D., John Luo, M.D.
Faculty: Carlyle H. Chan, M.D.

COURSE 93 8:00 a.m.-12 noon
Elizabeth Ballroom H, Second Level, Manchester Grand Hyatt

JUDGING JUDGMENT: PSYCHIATRIST'S GUIDE TO DECISION MAKING

Co-Directors: Ansar M. Haroun, M.D., Paul J. Zak, Ph.D.
Faculty: Martin P. Paulus, M.D.

COURSE 94 8:00 a.m.-12 noon
Windsor Room, Third Level, Manchester Grand Hyatt

DECONSTRUCTING SOCIAL PHOBIA: FOCUS ON SHAME AND NEUROTICISM

Director: Paul B. Bohn, M.D.

WORKSHOPS

ISSUES 77-94

ISSUE WORKSHOP 77 9:00 a.m.-10:30 a.m.
Room 24 A, Upper Level, San Diego Convention Center
USING AUDIOVISUAL TECHNOLOGY TO TEACH BEHAVIORAL SCIENCES
Chp.: Jonathan S. Davine, M.D.

ISSUE WORKSHOP 78 9:00 a.m.-10:30 a.m.
Room 24 B, Upper Level, San Diego Convention Center
THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILM
Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 79 9:00 a.m.-10:30 a.m.
Room 24 C, Upper Level, San Diego Convention Center
INNOVATIVE CHILD PROGRAMS DESIGNED TO INCREASE ACCESS TO CARE IN DIVERSE SETTINGS
Chp.: Radmil Bogdanich, M.A.
Participants: Mary I. Dobbins, M.D., Deborah E. Seale, M.A.

ISSUE WORKSHOP 80 9:00 a.m.-10:30 a.m.
Room 25 A, Upper Level, San Diego Convention Center
CONFIDENTIALITY IN OVERSEAS SETTINGS: THE PRIORITIZATION OF THE INDIVIDUAL VERSUS THE INSTITUTION VERSUS THE COMMUNITY
Chp.: Herbert L. Campbell, M.D.

ISSUE WORKSHOP 81 9:00 a.m.-10:30 a.m.
Room 25 B, Upper Level, San Diego Convention Center
SPIRITUALLY AUGMENTED WELL-BEING COGNITIVE-BEHAVIOR THERAPY
American Psychiatric Association and the World Psychiatric Association
Co-Chps.: Russell F. D'Souza, M.D., Jack S. McIntyre, M.D.

ISSUE WORKSHOP 82 9:00 a.m.-10:30 a.m.
Room 25 C, Upper Level, San Diego Convention Center
PSYCHIATRIC ISSUES IN ARGENTINA
Co-Chps.: Rodolfo D. Fahrer, Sr., M.D., Michelle B. Riba, M.D.
Participants: Salvador M. Guinjoan, M.D., Alfredo O. Fragola, Sr., M.D., Alicia B. Vitrone, M.D.

9:00 a.m. Sessions

CASE CONFERENCE 4
9:00 a.m.-12 noon
Room 23 A/B, Upper Level, San Diego Convention Center

TRANSFERENCE FOCUSED PSYCHOTHERAPY FOR BORDERLINE PATIENTS

Moderator: Otto F. Kernberg, M.D.
Presenters: Glen O. Gabbard, M.D., John M. Oldham, M.D., Frank E. Yeomans, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.
THURSDAY

ISSUE WORKSHOP 83  9:00 a.m.-10:30 a.m.
Room 27 B, Upper Level, San Diego Convention Center

BUDDHIST TEACHINGS AND TECHNIQUES
APPLIED TO DISASTER RELIEF: A 2 YEAR FOLLOW-UP ON SRI LANKAN TSUNAMI VICTIMS

Chp.: Syed S.A. Naqvi, M.D.
Participants: Viet Bui, M.D., Amy R. Dewar, M.D., Norana Caivano, M.D.

ISSUE WORKSHOP 84  9:00 a.m.-10:30 a.m.
Room 28 A, Upper Level, San Diego Convention Center

MINORITY MENTAL HEALTH POLICY TRAINING:
DEVELOPING PSYCHIATRIC LEADERS FOR
CAREERS ABOUT CULTURAL COMPETENCE AND
DISPARITIES REDUCTION

Chp.: Francis G. Lu, M.D.
Participants: Joan Y. Reccle, M.D., Octavio N. Martinez, Jr.,
M.D., Richard J. Nunes, M.D., Katherine G. Ruiz-Mellott, M.D.

ISSUE WORKSHOP 85  9:00 a.m.-10:30 a.m.
Room 28 B, Upper Level, San Diego Convention Center

RESEARCH ON PROCEDURAL MEMORY:
PRACTICAL APPLICATIONS IN DEMENTIA CARE

Co-Chps: Sheila M. Lobopnabhu, M.D., Theron C. Bowers, Jr., M.D.
Participants: Ellen F. Barr, L.C.S.W., Victor A. Molinar, Ph.D.

ISSUE WORKSHOP 86  9:00 a.m.-10:30 a.m.
Room 28 C, Upper Level, San Diego Convention Center

VIETNAM VETERANS AND THE IRAQ WAR: IS THE
PAST EVER THE PAST?

Co-Chps.: Laura C. Kordon, M.D., Eric Glessner, L.C.S.W.

ISSUE WORKSHOP 87  9:00 a.m.-10:30 a.m.
Room 30 A, Upper Level, San Diego Convention Center

A ROLE FOR SELF-AWARENESS, MINDFULNESS,
AND MEDITATION IN PSYCHIATRIC EDUCATION

Chp.: Robert S. Marin, M.D.

ISSUE WORKSHOP 88  9:00 a.m.-10:30 a.m.
Room 30 B, Upper Level, San Diego Convention Center

FRONTIER PSYCHIATRY: WORKING WITH
STREET-INVOLVED YOUTH

Co-Chps.: Seena S. Grewal, M.D., John H. Langley, M.D.

ISSUE WORKSHOP 89  9:00 a.m.-10:30 a.m.
Room 30 C, Upper Level, San Diego Convention Center

FIBROMYALGIA: CURRENT UNDERSTANDING
AND FUTURE DIRECTIONS

Co-Chps.: Alan Z.A. Manevitz, M.D., James P. Halper, M.D.

ISSUE WORKSHOP 90  9:00 a.m.-10:30 a.m.
Room 31 A, Upper Level, San Diego Convention Center

PERCEPTION AND COLOR IN AFFECTIVE STATES

Co-Chps.: Lina I. Augius, M.D., Suzanne Silverstein, M.A.
Participant: Nima A. Fahnian, M.D.

ISSUE WORKSHOP 91  9:00 a.m.-10:30 a.m.
Room 31 B, Upper Level, San Diego Convention Center

MEDICAL BOARD OF CALIFORNIA MEDICAL
EXPERT WITNESS TRAINING

Chp.: Matthew F. Carroll, M.D.

ISSUE WORKSHOP 92  9:00 a.m.-10:30 a.m.
Room 31 C, Upper Level, San Diego Convention Center

RACIST REALITY: AN ASSESSMENT OF
REPRESENTATIONS OF MINORITIES IN REALITY
TELEVISION PROGRAMMING

Chp.: Cutley L. Bonds II, M.D.
Participants: Austina Cho, M.D., Evc Marcment, M.D.

ISSUE WORKSHOP 93  9:00 a.m.-10:30 a.m.
Room 32 A, Upper Level, San Diego Convention Center

THE FOUR A'S OF COLLABORATIVE MENTAL
HEALTH CARE: ACCESSIBLE, ACCOUNTABLE,
APPROPRIATE, AND AFFEABLE

Chp.: John M. Haggarty, M.D.
Participants: Jennifer Leho, R.N., James Goertzen, M.D.,
Randy B. Goosen, F.R.C.P.C., Tammy E. McKinnon, M.S.W.,
Jatinder Takhar, M.D.

ISSUE WORKSHOP 94  9:00 a.m.-10:30 a.m.
Room 32 B, Upper Level, San Diego Convention Center

REFRACTORY SCHIZOPHRENIA:
TREATMENT ISSUES

American Association of Practicing Psychiatrists

Co-Chps: Michael Y. Hwang, M.D., Miklos F. Losonczy, M.D.
Participants: Jean-Pierre Lindenmayer, M.D., Naveed Iqbal, M.D.
THURSDAY

11:00 a.m. Sessions

ADVANCES IN MEDICINE 4

11:00 a.m.-12:30 p.m.
Room 2, Upper Level, San Diego Convention Center

CONGESTIVE HEART FAILURE: ADVANCES IN DIAGNOSIS AND MANAGEMENT

Chp.: Julio Licinio, M.D.
Presenter: Alan S. Maisel, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 28-35

SCIENTIFIC AND CLINICAL REPORT SESSION 28
11:00 a.m.-12:30 p.m.
Room 3, Upper Level, San Diego Convention Center

PHARMACOTHERAPY AND PERSONALITY DISORDERS

Chp.: Kenneth Silk, M.D.
Co-Chp.: Jennifer Heath, M.D.

11:00 a.m.
83 Personality Traits and Prophylactic Treatment With Selective Serotonin Reuptake Inhibitors
Sabrina J. Khan, M.D., Eric D. Peselow, M.D., Barbara Orlowski, Ph.D.

11:30 a.m.
84 Olanzapine for the Treatment of BPD: A Flexible-Dose 12-Week Randomized Double-Blind Placebo-Controlled Study
S. Charles Schulz, M.D., Mary C. Zanarini, Ed.D., Holland C. Detke, Ph.D., Quynh Trzaskoma, M.S., Daniel Lin, Ph.D., Walter Deberdt, M.D., Sara Corya, M.D.

12 noon
85 A Dose Comparison of Olanzapine for the Treatment of BPD: A 12-Week Randomized Double-Blind Placebo-Controlled Study
Mary C. Zanarini, Ed.D., S. Charles Schulz, M.D., Holland C. Detke, Ph.D., Yoko Tanaka, Ph.D., Fangyi Zhao, Ph.D., Walter Deberdt, M.D., Sara Corya, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 29
11:00 a.m.-12:30 p.m.
Room 4, Upper Level, San Diego Convention Center

LONG-TERM OUTCOMES OF SCHIZOPHRENIA

Chp.: Brian P. Miller, M.D.
Co-Chp.: Austina Cho, M.D.

11:00 a.m.
86 Relationship Between Neurocognitive Performance and Instrumental Work Functioning in Schizophrenia and Other Disorders: A 20-Year Prospective Longitudinal Study
Linda S. Grossman, Ph.D., Martin Harrow, Cherise Rosen, Ph.D., Henry W. Dove, M.D., Robert Faull, B.S.

11:30 a.m.
87 A 20-Year Multi-Followup Study of Persecutory Delusions in Schizophrenia
Martin Harrow, Ph.D., Thomas H. Jobe, M.D., Linda S. Grossman, Ph.D., Dennis D. Beedle, M.D., Joseph F. Goldberg, M.D.

12 noon
88 Neurocognition, Coralex Social Cognition, and Functional Outcome in Schizophrenia
Joseph Ventura, Ph.D., Michael F. Green, Ph.D., Mark J. Sergi, Ph.D., Kimmy S. Kee, Ph.D., Sarah A. Wilson, M.A., Keith H. Nuechterlein, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 30
11:00 a.m.-12:30 p.m.
Room 5 A, Upper Level, San Diego Convention Center

NOVEL APPROACHES TO WELLNESS

Chp.: Julio Licinio, M.D.
Co-Chp.: Richard Buccigross, M.D.

11:00 a.m.
89 A New Kind of Psychiatry: Information Theory in the 21st Century
David A. Rothstein, M.D.

11:30 a.m.
90 Spirituality and Recovery From Panic Attacks
Caroline B. Williams, M.D., Eric D. Peselow, M.D., Barbara Orlowski, Ph.D.

12 noon
91 Fostering Spiritual Values and Well-Being: The Need in Psychiatry
Russell F. D'Souza, M.D., Pedro Ruiz, M.D., Jack S. McIntyre, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 31
11:00 a.m.-12:30 p.m.
Ballroom 6 D, Upper Level, San Diego Convention Center

METHODOLOGICAL ISSUES IN PSYCHIATRIC DISORDERS

Chp.: Rajnish Mago, M.D.
Co-Chp.: Donna Mancuso, M.D.

11:00 a.m.
92 Joint Crisis Plans for People With Psychosis: Economic Evaluation of an RCT
  Claire Henderson, M.D., Sarah Byford, Ph.D., Chris Flood, M.S.C., Morven Leese, Ph.D., Graham Thornicroft, M.B.B.S., George Szumukier, M.B.B.S.

11:30 a.m.
93 LOCF (Last Observation Carried Forward) and Distortion of Findings in a Psychotopic Drug Clinical Study
  Alex A. Cardoni, M.S., Stephen B. Woolley, D.Sc, John W. Goethe, M.D.

12 noon
94 Comparison of Depression and Personality Ratings by a Patient and Informant Regarding the Patient’s Psychopathology
  Gavi Hollander, D.O., Eric D. Peselow, Barbara Orlowski, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 32
11:00 a.m.-12:30 p.m.
Room 9, Upper Level, San Diego Convention Center

TRAUMA, AGGRESSION, AND PSYCHOPATHOLOGY

Chp.: Britta Osterneyer, M.D.
Co-Chp.: Igor Elman, M.D.

11:00 a.m.
95 Clinical Differences Between Patients With PTSD With and Without Psychotic Symptoms
  Brian P. Mika, M.D., Anu Asnaani, Ivona Chelminkski, Ph.D., Diane Young, Ph.D., Mark Zimmerman, M.D.

11:30 a.m.
96 A Controlled Comparison Study of a Yoga Breath-Based Program and a Client-Centered Exposure Therapy for PTSD and Depression in Survivors of Tsunami Disaster
  Patricia L. Gerbarg, M.D., Richard P. Brown, M.D., Teresa Descilo, M.S.W., A. Vedamurthachar, Ph.D., R. Damodaran, Ph.D., B.N. Gangadhar, M.D.

12 noon
97 Exploratory Factor Analysis of Borderline Personality Disorder Criteria in Hispanic Men and Women With Substance Use Disorders

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 35  
11:00 a.m.-12:30 p.m.  
Room 25 A, Upper Level, San Diego Convention Center

ANTIDEPRESSANTS AND MOOD DISORDERS: OUTCOME STUDIES

Chp.: Waguhi W. IsHak, M.D.  
Co-Chp.: Nitin Gupta, M.D.

11:00 a.m.  
104 Impact of Study Design on the Results of Continuation Studies of Antidepressants  
Mark Zimmerman, M.D., Michael A. Posternak, M.D.,  
Camilo J. Ruggero, Ph.D.

11:30 a.m.  
105 The Effectiveness of Venlafaxine and its Metabolite in Refractory Depressed Patients  
Patrick S. Mbaya, Faouzi Alam, M.D., Aung Tint, M.D.,  
Edgar Specer, Ph.D.

12 noon  
106 Discontinuation of Antidepressant Prophylaxis: Are There Predictors  
Tara M. Punjabi, M.D., Eric D. Peselow, M.D., Loretta Mulcare, B.S., Brady G. Case, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

ISSUES 95-107

ISSUE WORKSHOP 98  
11:00 a.m.-12:30 p.m.  
Room 28 A, Upper Level, San Diego Convention Center

ADAPTING THE ACT MODEL FOR THE NEEDS OF DIFFERENT COMMUNITIES: A COMPARATIVE CASE STUDY OF TWO JAPANESE AND CANADIAN ACT TEAMS

Co-Chps.: Wendy S. Chow, M.S.W., Molyn Leszcz, M.D.  
Participants: Joel Sadavoy, M.H.S.C, Miyuki Shikha, M.S.W.

ISSUE WORKSHOP 99  
11:00 a.m.-12:30 p.m.  
Room 28 B, Upper Level, San Diego Convention Center

CLINICAL PATHWAYS FOR MOOD AND ANXIETY DISORDERS

Chp.: Waguhi W. IsHak, M.D.

ISSUE WORKSHOP 100  
11:00 a.m.-12:30 p.m.  
Room 30 A, Upper Level, San Diego Convention Center

FINDING BALANCE; THE APPLICATION OF YOGA TO MENTAL HEALTH

Co-Chps.: Syed S.A. Naqvi, M.D., Tara A. Klein, M.D.  
Participants: Monisha Vasa, M.D., Carla Mandili, M.D.

ISSUE WORKSHOP 101  
11:00 a.m.-12:30 p.m.  
Room 30 B, Upper Level, San Diego Convention Center

AKATHISIA: AN ELUSIVE PHENOMENON

Co-Chps.: Naveed Iqbal, M.D., Peter Weiden, M.D.  
Participant: Gabe Goldfeeder, M.A.

ISSUE WORKSHOP 102  
11:00 a.m.-12:30 p.m.  
Room 30 C, Upper Level, San Diego Convention Center

A MALPRACTICE LAWSUIT PRIMER

Co-Chps: Eugene Lowenkopf, M.D., Abe M. Rychik, J.D.

ISSUE WORKSHOP 103  
11:00 a.m.-12:30 p.m.  
Room 31 A, Upper Level, San Diego Convention Center

MULTIDISCIPLINARY TREATMENT OF CHRONIC PAIN

Chp.: Vladimir Bokarius, MD, Ph.D.  
Participants: Steven Richeimer, M.D., Ali Nemat, M.D., Lisa Victor, Ph.D., Yogi Matharu, D.P.T., Mary Kay Wolfe, O.T.D.
THURSDAY

ISSUE WORKSHOP 104  11:00 a.m.-12:30 p.m.
Room 31 B, Upper Level, San Diego Convention Center

ADDRESSING THE NEEDS OF COMMUNITY DWELLING OLDER SCHIZOPHRENIC PERSONS

Chp.: Carl I. Cohen, M.D.
Participants: Colin Depp, Ph.D., Ipsit Vahia, M.D., Azziza O. Bankole, M.D., Shilpa P. Diwan, M.D., Pia N. Reyes, M.D., John Kasckow, M.D.

ISSUE WORKSHOP 105  11:00 a.m.-12:30 p.m.
Room 31 G, Upper Level, San Diego Convention Center

FROM LAB TO CLINICAL PRACTICE: BIOLOGY AND TREATMENT OF DEPRESSION AND PTSD

Co-Chps.: Meera Narasimhan, M.D., Marlene A. Wilson, Ph.D.
Participants: Travis O. Bruce, M.D., Lawrence P. Reagan, Ph.D.

ISSUE WORKSHOP 106  11:00 a.m.-12:30 p.m.
Room 32 A, Upper Level, San Diego Convention Center

THE ULTIMATE GOAL: A MODULAR APPROACH TO PSYCHOSIS?

Chp.: Wolfgang Gaebel, M.D.
Participants: Juergen Zielasek, M.D., Franz Muller-Spahn, M.D.

ISSUE WORKSHOP 107  11:00 a.m.-12:30 p.m.
Room 32 B, Upper Level, San Diego Convention Center

CASE STUDIES USING VIDEO PLAYBACK IN COUPLES THERAPY

Chp.: Anita Menfi, R.N.
Participant: Ian F. Alger, M.D.

2:00 p.m. Sessions

SYMPOSIUM 75-89

SYMPOSIUM 75  2:00 p.m.-5:00 p.m.
Ballroom 6 D, Upper Level, San Diego Convention Center

CULTURE AS A RATIONALIZATION FOR VIOLENCE AGAINST WOMEN

Chp.: Gail E. Robinson, M.D.

A Finding a Firm Base in a Sea of Cultural Relativism
Sarah E. Romans, M.D.

B Culture as a Rationalization for Violence Against Women-Pakistani Perspective
Unaiza Niaz, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 76  2:00 p.m.-5:00 p.m.
Room 2, Upper Level, San Diego Convention Center

The COMBINE Trial: Treatment of Alcohol Dependence From Bench to Bedside

Chp.: Mark L. Willenbring, M.D.

A Adapting the COMBINE Trial Findings for Clinical Practice: The 2006 NIAAA Clinicians Guide
Mark L. Willenbring, M.D.

B Primary Results From Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study
Raymond F. Anton, M.D.

C Relationship Between Patient Adherence and Treatments Outcomes in the COMBINE Study
Allen Zweben, D.S.W.

D Cost and Cost-Effectiveness of the COMBINE Study
Gary Zarkin, Ph.D.

E Predicting Drinking Outcomes in the COMBINE Study
Dennis M. Donovan, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 77  2:00 p.m.-5:00 p.m.
Room 3, Upper Level, San Diego Convention Center

DEPRESSION AS INDICATOR AND FOCUS OF TREATMENT IN PRIMARY CARE CLINICS

Chp.: Rodrigo A. Munoz, M.D.
Co-Chp.: Nancy Bryant-Wallis, D.P.H.

A From Dreaming to Doing: Essential Infrastructure Supports for Successful Mental Health/Primary Care Integration
Nancy Bryant-Wallis, D.P.H.

B Addressing the Behavioral Health Needs of the Medically Underserved: Integrating Mental Health Services Into the Primary Care Setting
Nora Cole, M.Ed.

C Depression Treatment from a Primary Care Physician Perspective
Paul E. Hubley MD

D A Psychiatry Perspective on Mental Health/Primary Care Integration
Claudio O. Cabrejos, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 78  2:00 p.m.-5:00 p.m.
Room 4, Upper Level, San Diego Convention Center

THE PSYCHOPATHOLOGY OF PERSONALITY: PERSPECTIVES FROM THE COLLABORATIVE LONGITUDINAL PERSONALITY DISORDERS STUDY

Chp.: Andrew F. Skodol, M.D.
Co-Chp.: Donna S. Bender, Ph.D.

A Longitudinal Course and Validity of Schizotypal Personality Disorder
Thomas H. Mc Glashan, M.D.
B  Life Events and Relapse in Personality Disorders  
M. Tracie Shea, R.Ph., John G. Gunderson, M.D., Shirley Yen, Psy.D., Robert L. Stout, Ph.D.

C  Clinical Course and Impact of Avoidant Personality Disorder  
Andrew E. Skodol, M.D., Donna S. Bender, Ph.D., Maria E. Pagano, Ph.D.

D  A Multidimensional Model of Obsessive-Compulsive Personality Disorder  
Anthony Pinto, Ph.D., Emily Ansell, Ph.D., Carlos M. Grilo, Ph.D., M. Tracie Shea, Ph.D.

E  New Episodes and New Onsets of Major Depression in Borderline and Other Personality Disorders  
John G. Gunderson, M.D.

Discussant: Paul S. Links, M.D.  
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 79  
2:00 p.m.-5:00 p.m.
Room 5 A, Upper Level, San Diego Convention Center

EXPANDING NEW YORK STATE PRISON PSYCHIATRY

Chp.: Zebulon C. Taintor, M.D.
Co-Chp.: Henry C. Weinstein, M.Div.

A  Prison Psychiatric Care: Access, Parity, and Humane Care  
Zebulon C. Taintor, M.D.

B  Forensic Mental Health Triage & Admission Services: The Operations of the NYS-OMH Forensic Diagnostic Unit Within a Maximum Security Correctional Environment  
Mike Hill, M.S. Ed.

C  Therapy, Advocacy, and Staff Burnout  
Al Shimkunas, Ph.D.

D  Inmates With Serious Mental Illness and Significant Disciplinary Issues  
Bruce B. Way, Ph.D.

E  The Evolution of New York State's Civil Commitment for Sex Offenders  
Bezalel Wurzberger, M.D.

Discussant: Steven S. Sharfstein, M.D.  
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 80  
2:00 p.m.-5:00 p.m.
Room 5 B, Upper Level, San Diego Convention Center

NEURAL CORRELATES OF PSYCHODYNAMIC CONSTRUCTS

Chp.: Harold W. Koenigsberg, M.D.

A  Neural Correlates of Psychodynamic Constructs  
Georg Northoff, M.D.

B  Neural Correlates of Cognitive Reappraisal in BPD  
Harold W. Koenigsberg, M.D., Jin Fan, Ph.D., Kevin Ochsner, Ph.D., Scott Pizzarello, Antonia S. New, M.Div., Marianne S. Goodman, M.D., Larry J. Siever, M.D.

C  Brain-Behavior Relationship in the Process of Establishing a Trusting Relationship in Individuals With a Diagnosis of BPD  
Peter Fonagy, Ph.D., Brooks King-Casas, Ph.D., Carla Sharp, Ph.D., Laura Lomax, Ph.D., Read P. Montague, Jr., Ph.D.

D  Neuroimaging of the Role of the Self and Identification in Emotion Regulation  
Philippe Fossati, M.D.

Discussant: Larry J. Siever, M.D.  
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 81  
2:00 p.m.-5:00 p.m.
Room 8, Upper Level, San Diego Convention Center

ADDRESSING PATIENT'S NEEDS: PATIENT CENTERED DIAGNOSIS

Chp.: Rodrigo A. Munoz, M.D.
Co-Chp.: G. Scott Waterman, M.D.

A  Recording Multiple Psychiatric Diagnoses in an Individual Patient: Does It Lead to a More Comprehensive and Targeted Approach to Treatment?  
Marió Maj, M.D.

B  Biopsychosocial Thinking: Friend or Foe?  
G. Scott Waterman, M.D.

C  Therapeutic Diagnosing  
Roger Pecie, M.D.

D  Patient Centered Practice Guidelines: The Challenge  
Jack S. McInerney, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 82  
2:00 p.m.-5:00 p.m.
Room 11 A, Upper Level, San Diego Convention Center

OPTIMUM TREATMENT DURATION IN EARLY PSYCHOSIS

Chp.: Wolfgang Gaebel, M.D.
Co-Chp.: Patrick D. McGorry, M.D.

A  Early Intervention in the Initial Prodromal Phase: Results From the German Research Network on Schizophrenia  
Joachim Klosterkötter, M.D., Andreas Bechdolf, M.D., Stephan Ruhrmann, M.D.

B  Intervention in Ultra-High Risk Patients: The Pace Experience  
Patrick D. McGorry, M.D.

C  Are Antidepressants an Alternative for the Early Treatment of the Schizophrenia Prodrome?  
Barbara A. Cornblatt, Ph.D.

(Continued next page)
THURSDAY

SYMPOSIUM 83 2:00 p.m.-5:00 p.m.
Room 11 B, Upper Level, San Diego Convention Center

MODEL PSYCHIATRY RESIDENCY PROGRAMS ON RELIGION AND SPIRITUALITY
Chp.: Francis G. Lu, M.D.

A Baylor College of Medicine Educational Programs in Psychiatry and Spirituality
   Linda B. Andrews, M.D.

B The George Washington University Curriculum in Psychiatry and Spirituality
   James L. Griffith, M.D.

C The University of California, Irvine, Psychiatry and Spirituality Curriculum for Resident Training
   Aaron Khenany, M.D.

Discussants: Allan M. Josephson, M.D., Christina M. Puchalski, M.D.

THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 86 2:00 p.m.-5:00 p.m.
Room 30 A, Upper Level, San Diego Convention Center

CHILDREN AND WAR: EMOTIONAL AND PSYCHIATRIC CONSEQUENCES OF WAR AND TERROR ON CHILDREN AND ADOLESCENTS
   Council for Global Psychiatry
Chp.: Siham Muntasser, M.D.
Co-Chp.: Rodrigo A. Muñoz, M.D.

A Overview: The Impact of War and Terror on Middle Eastern Children and Adolescents
   Siham Muntasser, M.D.

B Treatment of Children in War
   Elie G. Karam, M.D., John Fayyad, M.D., Aimee N. Karam, Ph.D., Caroline C. Tabet, M.A., Zeina Mneimneh, M.P.H., Hani Dimassi, Ph.D., Nadine Melhem, Ph.D.

C Dealing With Children's Anxiety and Fears During Wartime
   Alan Apter, M.D.

D War Trauma and Child Mental Health in Iraqi Kurdistan
   Abdulbaghi Ahmad, Ph.D.

E Considerations in Developing Therapeutic Services for Children Traumatized by War
   Dennis J. Hunt, Ph.D.

Discussant: Anthony T. Ng, M.D.

THIS SESSION WILL BE AUDIOTAPEd.
SYMPOSIUM 87  2:00 p.m.-5:00 p.m.
Room 30 B, Upper Level, San Diego Convention Center

THE PSYCHOCULTURAL FOUNDATIONS OF CONTEMPORARY TERRORISM

Chp.: Jerrold M. Post, M.D.
Co-Chp.: Stevan M. Weine, Ph.D.

A Killing for a Cause: An Integrated Social Science and Social Psychological Approach
Dipak K. Gupta, Ph.D.

B Understanding the Girls' Madrasas in Pakistan
Fatnana Ali, M.A.

C Why we Are Losing the War on Terrorism
George Everly, Ph.D.

D Crimes of Obedience
Jerrold M. Post, M.D.

E Migrant Youth and the Risk for Terrorism
Stevan M. Weine, M.D.

Discussant: David A. Rothstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 88  2:00 p.m.-5:00 p.m.
Room 30 C, Upper Level, San Diego Convention Center

WORK OUTCOME IN SCHIZOPHRENIA: ADVANCES IN PREDICTION AND INTERVENTION

Chp.: Keith H. Nuechterlein, Ph.D.
Co-Chp.: Joseph Ventura, Ph.D.

A Functional Capacity and Work Outcomes: Are There any Specific Relationships?
Philip D. Harvey, Ph.D.

B Improving Work Outcome in Recent-Onset Schizophrenia: Supported Employment and Education, Workplace Skills Training, and Neurocognition
Keith H. Nuechterlein, Ph.D., Kenneth L. Subotnik, Ph.D., Joseph Ventura, Ph.D., Michael J. Gitlin, Denise Gretchen-Doodley, Ph.D., Michael Green, Charles J. Wallace, Ph.D., Deborah R. Becker, M.A., Robert P. Liberman, M.D.

C Work Outcome in Schizophrenia: Advances in Prediction and Intervention
Jean-Pierre Lindenmayer, M.D.

D Neurocognitive Enhancement Therapy and Work Therapy: Productivity Outcomes at 6- and 12- Months
Joanna Fiszdon, Ph.D., Morris D. Bell, Ph.D., Bruce E. Wexler, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 89  2:00 p.m.-5:00 p.m.
Room 30 D/E, Upper Level, San Diego Convention Center

PASSAGES: PERSPECTIVES OF WOMEN PSYCHIATRISTS NEGOTIATING CAREER TRANSITIONS

Chp.: Asha S. Mishra, M.D.
Co-Chp.: Stephanie S. Duruthy, M.D.

A Retirement as a Life Passage
Leah J. Dickstein, M.D.

B The Juggling Act: Balancing the Scales at Mid-Career
Carol A. Bernstein, M.D.

C Career Transitions for Women in Psychiatry
Joan A. Lang, M.D.

D Pursuing Different Paths in Academic Psychiatry
Laura W. Roberts, M.D.

E To Thine Own Self Be True
Melva I. Green, M.D.

F Passages: Navigating Career Changes Within the Health Care Industry
Kathy M. Vincent, M.D.

G Passages: The Perspective of a Female MIT Navigating Through the Medical School and Residency Years
Navdeep K. Dhaliwal, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 90  2:00 p.m.-5:00 p.m.
Room 31 A, Upper Level, San Diego Convention Center

STUCK IN THE BLACK BOX: PRESCRIBING ANTIDEPRESSANTS: A PATIENT SAFETY APPROACH

Chp.: Geetha Jayaram, M.D.
Co-Chp.: Alfred Herzog, M.D.

A Assessing Suicide Risk in Prescribing Antidepressant Medications
Geetha Jayaram, M.D.

B From Obstetrics to Pediatrics to Geriatrics: Safe Antidepressant Prescribing Across the Years
Yad M. Jabbarpour, M.D.

C Making It to Morning: A Resident's Perspective
Jason G. Roof, M.D.

D Educating Residents in Patient Safety
Carl B. Greiner, M.D.

E Stuck in the Black Box: Safe Prescribing of Antidepressants Using A Patient-Safety Approach
Alfred Herzog, M.D.

THIS SESSION WILL BE AUDIOTAPED.
American Psychiatric Association
161st Annual Meeting • May 3-8, 2008 • Washington, D.C.

CALL FOR PAPERS

PRESIDENT'S THEME:
Our Voice in Action: Advancing Science, Care, and the Profession

Carolyn B. Robinowitz, M.D.
President

Robert W. Guynn, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry-Supported Symposia</td>
<td>August 9, 2007</td>
</tr>
<tr>
<td>Courses</td>
<td></td>
</tr>
<tr>
<td>Scientific &amp; Clinical Reports</td>
<td></td>
</tr>
<tr>
<td>Symposia</td>
<td></td>
</tr>
<tr>
<td>Workshops (Issue &amp; Media)</td>
<td></td>
</tr>
<tr>
<td>Component Workshops</td>
<td>September 20, 2007</td>
</tr>
<tr>
<td>New Research Posters</td>
<td>December 6, 2007</td>
</tr>
</tbody>
</table>

Submissions are accepted ONLINE ONLY!

For format descriptions, instructions, guidelines, and to submit your program or poster proposal, consult the 2008 Annual Meeting information available on the APA home page (www.psych.org).

Paper submissions, as well as incomplete submissions, will not be accepted or considered.

If you would like to volunteer to chair a session, please send a letter to the attention of Dr. Guynn, at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.
2007 ANNUAL MEETING
TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

Addiction Psychiatry
AIDS and HIV-Related Disorders
Alcohol and Drug-Related Disorders
Anxiety Disorders
Attention Spectrum Disorders
Behavior and Cognitive Therapies
Biological Psychiatry and Neuroscience
Brain Imaging
Child and Adolescent Psychiatry and Disorders
Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)
Community and Social Psychiatry
Computers
Consultation/Liaison Psychiatry
Couple and Family Therapies
Creativity and the Arts
Cross-Cultural and Minority Issues
Diagnostic Issues
Dissociative Disorders
Eating Disorders
Electronic Medical Records
Emergency Psychiatry
Epidemiology
Ethics and Human Right
Forensic Psychiatry
Gender Issues
Genetics
Geriatric Psychiatry
Group Therapy
Health Services Research
Historical Issues
Individual Psychotherapies
Information Technology
Internet
Lesbian/Gay/Bisexual/Transgender Issues
Managed Care and Health Care Funding
Men’s Issues
Mental Retardation (Child/Adolescent/Adult)
Mood Disorders
National Institute on Drug Abuse
Neuropsychiatry
Other Somatic Therapies
Pain Management
Patient Safety
Personal Digital Assistants (PDAs)
Personality Disorders
Pharmacotherapy and Psychotherapy
Political Questions
Premenstrual Dysphoric Disorder
Presidential Theme: “Addressing Patient Needs: Access, Parity, and Humane Care”
Professional and Personal Issues
Psychiatric Administration and Services: Public, Private, and University
Psychiatric Education
Psychiatric Rehabilitation
Psychoanalysis
Psychoimmunology
Psychopharmacology
Religion, Spirituality, and Psychiatry
Research Issues
Resident and Medical Student Issues
Schizophrenia and Other Psychotic Disorders
Sexual and Gender Identity Disorders
Sleep Disorders
Somatoform Disorders
Stigma/Advocacy
Stress
Suicide
Telepsychiatry
Treatment Techniques and Outcome Studies
Violence, Trauma, and Victimization
Virtual Reality
Women’s Health Issues

GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. Under each topic listed above, you will find a list of formats (types of sessions) listed alphabetically underneath. Within each format, you will find the title of the individual session listed by number. The listing will also show the page number that the session appears on. You should refer to the page number in this Program Book to obtain further details about the session.
ADDICTION PSYCHIATRY

COURSES
41 Office-Based Buprenorphine Treatment of Opioid-Dependent Patients 18
51 Street Drugs and Mental Disorder: Overview and Treatment 30

INDUSTRY SUPPORTED SYMPOSIA
9 Still Sleepy After All These Cures: Hypersomnia in Psychiatry 10
29 Cigarette Smoking, Smoking Cessation, and Psychiatric Illness 58

COMPONENT WORKSHOP
36 The Sacred Herb and Addiction Science: A Study of Nicotine Dependence and Axis I Comorbidities Among American Indians 63

ISSUE WORKSHOP
11 Practical Pharmacotherapy for the Treatment of Alcohol Dependence 23

MEDIA WORKSHOP
4 “Thirteen”: Parenting and Treating the Addicted Teenager 46

AIDS AND HIV-RELATED DISORDERS

SCIENTIFIC AND CLINICAL REPORT
77 How Dangerous is Sigma? Perceived Sigma and HIV Risk among Women With Severe Mental Illness 68

COMPONENT WORKSHOPS
36 HIV and Metabolic Syndrome 50
47 Public Policy, HIV, and Mental Health: Politics, Ideology, or Science 68

ALCOHOL AND DRUG-RELATED DISORDERS

SCIENTIFIC AND CLINICAL REPORT
6 Paternal Alcoholism Predicts Alcohol Dependence But Not Recovery After 40 Years 25

SYMPOSIA
9 CRF-Antagonism for Treatment of Alcoholism and Affective Disorders 34
76 The COMBINE Trial: Treatment of Alcohol Dependence From Bench to Bedside 84

MEDIA WORKSHOP
5 “Rock Bottom”: Understanding the Methamphetamine Experience: and the Struggle for Sobriety 65

ANXIETY DISORDERS

ADVANCES IN
Advances in Treatment of Psychiatric Disorders 38

COURSE
94 Deconstructing Social phobia: Focus on Shame and Neuroticism 79

SCIENTIFIC AND CLINICAL REPORTS
8 Capsulotomy in Refractory OCD: Long-Term Outcome in 25 Patients 26
9 Trichotillomania in Youth: A Naturalistic Outcome Study 26
17 Treatment Outcome of Panic Disorder and Agoraphobia in a Naturalistic Clinical Setting 26
18 Panic Disorder With Social Anxiety Disorder Comorbidity: Difference of Response to Low Versus High Doses of Clonazepam 26
19 the Relationship Between Functional Outcomes and Treatment of Anxious and Painful Somatic Symptoms in Patients With Generalized Anxiety Disorder 26
52 Mood and Anxiety Disorders in Patients With Cancer: A Case Series 49
99 Clinical Differences Between Patients With PTSD With and Without Psychotic Symptoms 82

SYMPOSIUM
47 Depression and Anxiety, Continuous or Categorical? A View From Different Angles 57

COMPONENT WORKSHOP
51 New APA Practice Guidelines on Dementia, Panic Disorder, and OCD 69

ATTENTION SPECTRUM DISORDERS

COURSES
14 ADD in Adults 5
55 Advanced Assessment and treatment of ADD 41

INDUSTRY SUPPORTED SYMPOSIA
1 Clinical Management of ADHD 2
10 Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management 6
18 How Comorbid is ADHD? Results from Epidemiological and Clinical Studies 9

SCIENTIFIC AND CLINICAL REPORTS
21 Is Comorbid Adult ADHD Prevalent in Psychiatric Outpatients? 27
22 Extended Duration of Action of SPM465, a 16-Hour Mixed Amphetamine Salts Formulation, in the Treatment of Adults With ADHD 27

BEHAVIOR AND COGNITIVE THERAPIES

CASE CONFERENCE
1 Cognitive Therapy for Chronic Depression 46

SCIENTIFIC AND CLINICAL REPORT
66 Breakthrough Intimacy: Treating Personality 67

BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE

COURSES
3 The Evaluation, Identification, and Treatment of the Major Dementias 1
9 Neuroanatomy of Emotions: From Brain to Clinical Practice 1
27 EEG in Clinical Practice: Indications and Limitations 7
37 Behavioral Neuroanatomy: An Introduction 18
42 Advances in Neuropsychiatry 18
44 Traumatic Brain Injury: Neuropsychiatric Assessment 18

SCIENTIFIC AND CLINICAL REPORT
66 CES Reduces Aggression in Violent Neuropsychiatric Patients 66

SYMPOSIA
18 Impulsivity: From Neuropsychology to Treatment Options 36
42 Psilocybin and Psychiatry: Recent Research 56
63 Neurobiology of the Unconscious: Implications for Psychotherapeutic Understanding and Technique 75
<table>
<thead>
<tr>
<th>Topic Index</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISSUE WORKSHOPS</td>
<td>Page #</td>
</tr>
<tr>
<td>105 From Lab to Clinical Practice: Biology and Treatment of Depression and PTSD</td>
<td>84</td>
</tr>
<tr>
<td>BRAIN IMAGING</td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>11 Introduction to Transcranial Magnetic Stimulation</td>
<td>2</td>
</tr>
<tr>
<td>28 Vagus Nerve Stimulation</td>
<td>7</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>80 Neural Correlates of Psychodynamic Constructs</td>
<td>85</td>
</tr>
<tr>
<td>ISSUE WORKSHOP</td>
<td></td>
</tr>
<tr>
<td>90 Perception and Color in Affective States</td>
<td>80</td>
</tr>
<tr>
<td>CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS</td>
<td></td>
</tr>
<tr>
<td>COURSE</td>
<td></td>
</tr>
<tr>
<td>33 ADD in Children and Adolescents</td>
<td>17</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
</tr>
<tr>
<td>23 Quality of Care for Children and Adolescents: Access to Psychotherapy</td>
<td>27</td>
</tr>
<tr>
<td>24 Adolescent Depression and Its Relationship to School Dropouts and Accidents on University Campus</td>
<td>27</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>86 Children and War: Emotional and Psychiatric Consequences of War and Terror on Children and Adolescents</td>
<td>86</td>
</tr>
<tr>
<td>COMPONENT WORKSHOPS</td>
<td></td>
</tr>
<tr>
<td>28 Learning Disorders Update for Mental Health Professionals</td>
<td>44</td>
</tr>
<tr>
<td>30 Passageways: Psychological Routes to Delinquency and Therapeutic Options out of the Juvenile Justice System</td>
<td>50</td>
</tr>
<tr>
<td>53 Early Cognitive Development and Psychiatric Presentation: Implications for Etiologic Understanding and Intervention</td>
<td>69</td>
</tr>
<tr>
<td>ISSUE WORKSHOP</td>
<td></td>
</tr>
<tr>
<td>54 The ADHD/Pediatric Bipolar Interface: Sailing Through Troubled Waters?</td>
<td>64</td>
</tr>
<tr>
<td>COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)</td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>13 Cognitive Therapy for Severe Mental Disorders</td>
<td>3</td>
</tr>
<tr>
<td>25 Introduction to Cognitive-Behavioral Therapy</td>
<td>7</td>
</tr>
<tr>
<td>31 Cognitive Therapy for Schizophrenia</td>
<td>8</td>
</tr>
<tr>
<td>46 Cognitive Therapy on the Fly</td>
<td>18</td>
</tr>
<tr>
<td>71 CBT Bootcamp for Practicing Psychiatrists</td>
<td>52</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORT</td>
<td></td>
</tr>
<tr>
<td>51 Intraoperative Cerebral Oxygen Desaturation: A Significant Risk Factor for Postoperative Delirium in Cardiac Surgery Patients</td>
<td>49</td>
</tr>
<tr>
<td>COMMUNITY AND SOCIAL PSYCHIATRY</td>
<td></td>
</tr>
<tr>
<td>COMPONENT WORKSHOPS</td>
<td></td>
</tr>
<tr>
<td>2 Reentry After Prison: Rejoining the Community</td>
<td>21</td>
</tr>
<tr>
<td>42 Social Dimensions of Disasters and Community Recovery</td>
<td>63</td>
</tr>
<tr>
<td>52 Mission Possible: Reclaiming America's State Hospital Beds</td>
<td>69</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
<td>Page #</td>
</tr>
<tr>
<td>79 Innovative Child Programs Designed to Increase Access to Care in Diverse Settings.</td>
<td>79</td>
</tr>
<tr>
<td>88 Frontier Psychiatry: Working With Street-Involved Youth</td>
<td>80</td>
</tr>
<tr>
<td>MEDIA WORKSHOP</td>
<td></td>
</tr>
<tr>
<td>3 &quot;When the Levees Broke: A Requiem in Four Acts by Spike Lee&quot;: The Psychiatric Dimension of Hurricane Katrina</td>
<td>46</td>
</tr>
<tr>
<td>CONSULTATION/LIAISON PSYCHIATRY</td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>1 Dynamic Psychotherapy for Cancer Patients and Their Spouses</td>
<td>1</td>
</tr>
<tr>
<td>40 Families Coping With Medical Illness: A Treatment Approach for Psychiatry</td>
<td>18</td>
</tr>
<tr>
<td>69 Basic Concepts in Palliative Care for Psychiatrists</td>
<td>43</td>
</tr>
<tr>
<td>78 Psychiatric Care of the Hepatitis C Patient</td>
<td>61</td>
</tr>
<tr>
<td>INDUSTRY SUPPORTED SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>33 Fibromyalgia: New Insights Into the Pathophysiology and Treatment</td>
<td>78</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORT</td>
<td></td>
</tr>
<tr>
<td>50 Pilot Trial of Modafinil Treatment of Depression Symptoms and Fatigue in Adult Patients With Brain Tumors</td>
<td>49</td>
</tr>
<tr>
<td>SYMPOSIAS</td>
<td></td>
</tr>
<tr>
<td>8 How to Practice Sport Psychiatry: A Demonstration</td>
<td>34</td>
</tr>
<tr>
<td>53 Treatment of Depression in the Medically Ill: An Update From Recent Clinical Trials</td>
<td>73</td>
</tr>
<tr>
<td>COMPONENT WORKSHOPS</td>
<td></td>
</tr>
<tr>
<td>23 Evaluating Competency in Psychosomatic Medicine</td>
<td>44</td>
</tr>
<tr>
<td>41 Lessons Learned From Business Practices: How can Psychiatrists Increase their Practice Opportunities by Implementing Successful Business Strategies</td>
<td>63</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
<td></td>
</tr>
<tr>
<td>1 Assessment of Capacity: A Multimedia Approach to Enhancing Clinical Skills In Different Cultural and Legal Settings</td>
<td>23</td>
</tr>
<tr>
<td>28 Psychiatry in the Primary Care Setting: Making It Work for Patients and Doctors</td>
<td>45</td>
</tr>
<tr>
<td>32 1:1 Observation in A General Hospital Setting; Issues and Recommendations</td>
<td>45</td>
</tr>
<tr>
<td>34 Involuntary Hospitalization of Medical Patients Who Lack Decisional Capacity: An Unresolved Issue</td>
<td>45</td>
</tr>
<tr>
<td>39 Planned Care for Depression: A Program for the Management of Depression In Primary Care.</td>
<td>46</td>
</tr>
<tr>
<td>93 The 4 A's of Collaborative Mental Health Care: Accessible, Accountable, Appropriate and Affable</td>
<td>80</td>
</tr>
<tr>
<td>COUPLE AND FAMILY THERAPIES</td>
<td></td>
</tr>
<tr>
<td>COURSE</td>
<td></td>
</tr>
<tr>
<td>35 Family Skills for the General Psychiatrist</td>
<td>18</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
<td></td>
</tr>
<tr>
<td>95 Caregivers In Bipolar Families: Patients and Partners In Treatment</td>
<td>83</td>
</tr>
<tr>
<td>107 Case Studies Using Video Feedback in Couples' Therapy</td>
<td>84</td>
</tr>
<tr>
<td>CREATIVITY AND THE ARTS</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>60 The End, Middle, and Beginning of the Affair: Infidelity in Film and Television</td>
<td>75</td>
</tr>
</tbody>
</table>
### Issue Workshops

<table>
<thead>
<tr>
<th>Issue Workshops</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychiatry and the Medical Humanities</td>
<td>5</td>
</tr>
<tr>
<td>The Portrayal of Psychiatry in Recent American Film</td>
<td>78</td>
</tr>
</tbody>
</table>

### Media Workshop

<table>
<thead>
<tr>
<th>Media Workshop</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal Transformation Through an Encounter With Death: Akira Kurosawa’s “Ikiru”</td>
<td>1</td>
</tr>
</tbody>
</table>

### Cross-Cultural and Minority Issues

### Course

<table>
<thead>
<tr>
<th>Course</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSM-IV/TR Cultural Formulations: Diagnosis and Treatment</td>
<td>2</td>
</tr>
</tbody>
</table>

### Scientific and Clinical Reports

<table>
<thead>
<tr>
<th>Scientific and Clinical Reports</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dealing With Disaster Mental Health</td>
<td>4</td>
</tr>
<tr>
<td>Similar Depressive Symptom Patterns in a Population-Based Study of Immigrants from Turkey and Morocco and Dutch Natives</td>
<td>47</td>
</tr>
<tr>
<td>Effectiveness of Culturally Sensitive Collaborative Treatment for Treating Chinese Americans With Depression in a Primary Care Setting: A Six-Month Follow-Up Study</td>
<td>49</td>
</tr>
</tbody>
</table>

### Symposia

<table>
<thead>
<tr>
<th>Symposia</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suicide Across the Life Cycle: A Spanish Language Update (Manejo y Tratamiento del Paciente Suicida en las Distintas Etapas de la Vida)</td>
<td>4</td>
</tr>
<tr>
<td>The California Mental Health Systems Act: Transforming Systems of Care to Reduce Mental Health Disparities</td>
<td>10</td>
</tr>
<tr>
<td>Children of Immigrants in the Changing Mosaic of the U.S.</td>
<td>21</td>
</tr>
<tr>
<td>First: Break Schizophrenia in Francophone and Anglophone Countries: Treatments and Neuroimaging: Vive la Difference</td>
<td>23</td>
</tr>
<tr>
<td>Women and Psychiatry Around the World: The Importance of Gender and Culture</td>
<td>41</td>
</tr>
<tr>
<td>Behavioral and Substance Addictions in Minority Populations</td>
<td>52</td>
</tr>
<tr>
<td>Improving Cross-Cultural Competency in Psychiatric Practice</td>
<td>55</td>
</tr>
<tr>
<td>American Psychiatry Viewed from the Outside: a Global Perspective on the DSM-IV and Psychopharmacology</td>
<td>59</td>
</tr>
<tr>
<td>An Update on Cross-Cultural, Ethnic, and Ethnomethodological Aspects of Mood Disorders</td>
<td>66</td>
</tr>
</tbody>
</table>

### Component Workshops

<table>
<thead>
<tr>
<th>Component Workshops</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncovering the Secret: Intimate Partner Violence Among Asian-Americans</td>
<td>14</td>
</tr>
<tr>
<td>How to Teach Cultural Competence in Geriatric Psychiatry: Addressing Unmet Patient Needs</td>
<td>17</td>
</tr>
<tr>
<td>The Impact of Violence in Latino Communities</td>
<td>20</td>
</tr>
<tr>
<td>Culture Matters: A Multicultural Perspective on the Immigrant Experience</td>
<td>24</td>
</tr>
<tr>
<td>Transcultural Arab Psychiatry With a Focus on Women’s Mental Health</td>
<td>39</td>
</tr>
<tr>
<td>The Imsa: How Racism, Sexism, Classism, and Heterosexism Affect Mental Health Care</td>
<td>43</td>
</tr>
<tr>
<td>Racism, Racial Discrimination, and Xenophobic: How Psychiatry can Reduce Their Adverse Effects on Mental Health</td>
<td>45</td>
</tr>
<tr>
<td>Leadership Challenges: Breaking Barriers to Success</td>
<td>46</td>
</tr>
</tbody>
</table>

### Issue Workshops

<table>
<thead>
<tr>
<th>Issue Workshops</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>How Does Culture Make a Difference in American Mental Health Care? Culturally-Specific Care in Changing Contexts</td>
<td>30</td>
</tr>
<tr>
<td>The Provider’s Pursuit of Cultural Competence: A Biopsychosocial Quest</td>
<td>31</td>
</tr>
<tr>
<td>Ethnicity, Culture, and Psychopharmacology: Recent Advances</td>
<td>66</td>
</tr>
<tr>
<td>From the Mississippi to the Ganges: Understanding the Cross Cultural Context of Treatment From the Perspective of the South Asian Psychiatrist in America</td>
<td>73</td>
</tr>
<tr>
<td>Psychiatric Issues in Argentina</td>
<td>82</td>
</tr>
<tr>
<td>Minority Mental Health Policy Training: Developing Psychiatric Leaders for Careers About Cultural Competence and Disparities Reduction</td>
<td>84</td>
</tr>
<tr>
<td>Racial Reality: An Assessment of Representations of Minorities in Reality Television Programming</td>
<td>92</td>
</tr>
</tbody>
</table>

### Diagnostic Issues

### Courses

<table>
<thead>
<tr>
<th>Course</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Practical Approach to Risk Assessment</td>
<td>5</td>
</tr>
<tr>
<td>Web-Based CADD, Behavioral Healthcare, and CMHCs</td>
<td>32</td>
</tr>
<tr>
<td>FEER Feedback in Psychiatry: Clinical Applications</td>
<td>85</td>
</tr>
<tr>
<td>Judging Judgment: Psychiatrist’s Guide to Decision Making</td>
<td>93</td>
</tr>
</tbody>
</table>

### Scientific and Clinical Reports

<table>
<thead>
<tr>
<th>Scientific and Clinical Reports</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCD in Psychiatric Outpatients: Prevalence, Comorbidity, and Demographic and Clinical Characteristics</td>
<td>10</td>
</tr>
<tr>
<td>Beyond Bipolar I and II: Evidence for the Validity of the Softer Bipolar Spectrum</td>
<td>41</td>
</tr>
<tr>
<td>A Proposal for a New Multiaxial Model of Psychiatric Diagnosis: A Continuum Patient Model Based On Evolutionary Developmental Gene-Environment Interaction</td>
<td>42</td>
</tr>
<tr>
<td>Comparison of Depression and Personality Ratings by a Patient and Informant Regarding the Patient’s Psychopathology</td>
<td>94</td>
</tr>
</tbody>
</table>

### Symposia

<table>
<thead>
<tr>
<th>Symposia</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>The &quot;Hidden&quot; Diagnoses in Psychiatry: Implications for Training, Clinical Care, and Outcomes</td>
<td>19</td>
</tr>
<tr>
<td>Lumping Versus Splitting in Psychiatric Nomenclature</td>
<td>38</td>
</tr>
<tr>
<td>DSM-V: Obsessive-Compulsive Related Disorders</td>
<td>45</td>
</tr>
</tbody>
</table>

### Issue Workshop

<table>
<thead>
<tr>
<th>Issue Workshop</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Role of DSM-IV Rating Scales in Psychiatry</td>
<td>64</td>
</tr>
</tbody>
</table>

### Dissociative Disorders

### Symposium

<table>
<thead>
<tr>
<th>Symposium</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dissociative Disorders: Meeting the Challenges of the DSM-IV</td>
<td>74</td>
</tr>
</tbody>
</table>

### Eating Disorders

### Course

<table>
<thead>
<tr>
<th>Course</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutic Interventions in Eating Disorders: Basic Principles</td>
<td>21</td>
</tr>
</tbody>
</table>

### Scientific and Clinical Report

<table>
<thead>
<tr>
<th>Scientific and Clinical Report</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self-Loathing and Perfectionism: Linking Eating Disorders and Compulsive Exercise</td>
<td>7</td>
</tr>
</tbody>
</table>

### Symposia

<table>
<thead>
<tr>
<th>Symposia</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eating Disorders 2007: Expanding Biological and Clinical Perspectives</td>
<td>12</td>
</tr>
<tr>
<td>Eating Disorders Update</td>
<td>37</td>
</tr>
</tbody>
</table>

### Component Workshop

<table>
<thead>
<tr>
<th>Component Workshop</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity in our Youth: the Weight of Mental Illness</td>
<td>5</td>
</tr>
</tbody>
</table>

### Electronic Medical Records

### Issue Workshops

<table>
<thead>
<tr>
<th>Issue Workshops</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>The National Health Information Network and Psychiatry: How Will Electronic Health Records Impact Our Patients and Our Practice?</td>
<td>29</td>
</tr>
<tr>
<td>Privacy and Confidentiality Concerns In Shared Electronic Health Records</td>
<td>41</td>
</tr>
</tbody>
</table>
## EPIDEMIOLOGY

### SCIENTIFIC AND CLINICAL REPORT
- 40 Predicting Unresolved PTSD in Earthquake Survivors: A Comparison Between Decision Analysis and Logistics Regression

## ETHICS AND HUMAN RIGHT

### COURSES
- 30 Bioethics 2007
- 38 The Evaluation and Treatment of Physicians Involved in Sexual Misconduct and/or Sexual Harassment

### PRESIDENTIAL SYMPOSIUM
- 1 The Role of Ethics in World Psychiatry

## SYMPOSIA
- 3 Physical Illness in People With Severe Mental Disorders
- 11 Ethics, Human Rights and Dynamic Psychiatry
- 40 Ethical Issues in Psychiatric Genetics
- 67 Ethics of Treating Subsyndromal Psychiatric Disorders

## COMPONENT WORKSHOPS
- 16 Multi-National Perspectives of Psychiatric Ethics
- 49 Ethics and Etiquette: Keeping out of Trouble

## ISSUE WORKSHOP
- 65 Complexities of Post Termination Relationships

## FORENSIC PSYCHIATRY

### COURSES
- 39 The Detection of Malingered Mental Illness
- 54 The Psychiatrist as Expert Witness
- 60 Child Murder by Parents
- 77 Psychiatric Roles in Assessing and Treating Adult and Adolescent Sex Offenders
- 81 Insanity Defense Evaluations
- 91 Correctional Psychiatry: A Skills Building Course

### SCIENTIFIC AND CLINICAL REPORTS
- 14 Understanding Feticide
- 16 Correctional Mental Health Care in a Large, Urban Jail: Challenges and Opportunities

### SYMPOSIUM
- 79 Expanding New York State Prison Psychiatry

## COMPONENT WORKSHOPS
- 3 Committing Occupational Suicide: A Psychiatric Emergency
- 18 Providing Services to Mentally Ill Inmates Returning to the Community
- 27 Update on Psychiatry and Law

## ISSUE WORKSHOPS
- 14 Internet Child Pornography and Mental Illness: the Psychiatrist’s Role
- 26 Detection of Malingering
- 46 Psychiatric Expert Testimony: Increased Scrutiny, Increased Liability
- 48 Are Sex Offenders Criminally Responsible?
- 91 Medical Board of California Medical Expert Witness Training
- 96 Gender Benders in Forensic Psychiatry
- 102 A Malpractice Lawsuit Primer

## GENDER ISSUES

### SCIENTIFIC AND CLINICAL REPORT
- 100 Comparison of Longitudinal Course of Illness Between Women and Men: A 25-Year Multi-Followup Study of Schizophrenia, Other Psychotic Disorders, and Nonpsychotic Depression

### COMPONENT WORKSHOP
- 10 Gender and Culture in Academic Leadership: Improving the Current State for Women

### ISSUE WORKSHOP
- 17 The Dilemma of Women’s Professional Garments and Professionalism

## GENETICS

### COURSE
- 56 Psychiatric Genomics: Applications for Clinical Practice

### FOCUS LIVE
- 1 Genetics and Psychiatry

### SCIENTIFIC AND CLINICAL REPORTS
- 44 Gene Genotyping in Patins Treated for Depression
- 45 An Association Between the EPAC1 Gene and Neuroticism and Anxiety
- 46 Circadian System Polymorphisms and Bipolar Disorder

## GERIATRIC PSYCHIATRY

### ADVANCES IN
- 61 Geriatric Psychiatry

### COURSES
- 6 Updates in Geriatric Psychiatry 2007
- 17 Psychiatric Consultation in Long-Term Care: Basic
- 53 Psychiatric Consultation in Long-Term Care: Advanced
- 87 Mood and Anxiety Disorders in Later Life

### INDUSTRY SUPPORTED SYMPOSIUM
- 2 Expert Dialogue on Alzheimer’s Disease: Diagnostic and Referral Issues, Treatment of the Cognitive Deficits, Managing the Behavior Complications, and Comprehensive Multidisciplinary Care

### PRESIDENTIAL SYMPOSIUM
- 3 Review of Geriatric Psychiatry: Current Issues

## SMALL INTERACTIVE SESSION
- 4 Issues in Geriatric Psychiatry

### SYMPOSIUM
- 20 Psychiatric Practice in the Nursing Home
- 29 Aggressive Behavioral Disturbances in Geropsychiatric Patients
- 69 Sexuality in Long-Term Care Facility Residents

### COMPONENT WORKSHOPS
- 15 Controversies in the Management of Behavioral Disturbance in Dementia
- 31 Dementia in Down Syndrome: Risk Factors, Biomarkers, Diagnosis, and Treatment

### ISSUE WORKSHOPS
- 9 Prevention of Burden and Burnout in Caregivers at Home and Healthcare Workers in Long-Term Care Settings
- 85 Research on Procedural Memory: Practical Applications in Dementia Care
- 104 Addressing the Needs of Community Dwelling Older Schizophrenic Persons

---
**TOPIC INDEX**

**GROUP THERAPY**

**COURSE**
66 STEPPS Treatment Program for BPD 42

**LECTURE**
13 What Patients and Clinicians Need to Know: The Case for Patient-Focused Research 43

**HEALTH SERVICES RESEARCH**

**SCIENTIFIC AND CLINICAL REPORTS**
33 Reducing the Medical and Financial Burden of Depressive Illness: A Plan for Improving Health Care Services 48
53 Preparing for Evidence-Based Medication-Related Psychiatric Practice: The Oregon Experience 49
54 Improving Adherence to Treatment Guidelines in Hospitalized Patients With Bipolar Disorder 49
55 Stepped Care for Anxiety, Depressive and Stress-Related Disorders: A Randomized Controlled Trial in Primary Care and Mental Health Care 49
62 Comparison of the Prophylactic Efficacy of Antidepressants-Factors Associated With Better outcome 67
92 Joint Crisis Plans for People With Psychosis: Economic Evaluation of an RCT 82
106 Discontinuation of antidepressant prophylaxis: Are There Predictors 83

**HISTORICAL ISSUES**

**SCIENTIFIC AND CLINICAL REPORTS**
15 Testimonies of APA and ANA Presidents in the Harry Thaw Brain Storm Defense: Temporary Insanity One Hundred Years Ago in 1907 26
34 Psychiatric Hospital Bed Numbers and Economic Factors in the XIX and XX Centuries: New Analyses 48

**INDIVIDUAL PSYCHOTHERAPIES**

**CASE CONFERENCE**
4 Transference Focused Psychotherapy for Borderline Patients 79

**COURSES**
15 Using Boundary Crossings as Creative therapy Instead of Slippery Slopes 5
18 Interpersonal Psychotherapy 5
23 Achieving Psychotherapy Effectiveness: Practical Approaches for Clinicians 7
34 Engaging Resistant and Difficult-to-Treat Patients in Collaborative Treatment 17
47 Davanzo's Intensive Short-Term Dynamic Psychotherapy in Clinical Practice 19
59 Treating Medical Students and Physicians 41
62 A Psychodynamic Approach to Treatment of Refractory Mood Disorders 42
64 Advanced Interviewing Techniques 42
73 How to Practice Brief Psychodynamic Psychotherapy: The Core Conflictual Relationship Theme Method 52
82 Short-Term Psychodynamic Supportive Psychotherapy for Depression 59
86 Interpersonal and Social Rhythm therapy for Bipolar Disorder 61
89 Motivational therapy for Patients With Concurrent Disorders 71
90 Personality Disorders: Combining Relational therapy and Psychopharmacology 71

**SYMPOSIA**
14 Brief Therapies: An Update for Clinicians 35
22 Update on Supportive Psychotherapy 37
57 Simple Technologies to Improve Psychotherapy 74

**ISSUE WORKSHOP**
18 Dynamic Therapy With Self-Destructive Borderlines 29

**INFORMATION TECHNOLOGY**

**COURSES**
61 How to Use Your Palm OS Personal Digital Assistant in Psychiatric Practice: Introductory Course 42
75 How to Use Your Palm OS Personal Digital Assistant in Psychiatric Practice: Advanced Course 52
79 How to Use Your Pocket PC Personal Digital Assistant in Psychiatric Practice 61
92 Connections 79

**SCIENTIFIC AND CLINICAL REPORT**
89 A New Kind of Psychiatry: Information Theory in the 21st Century 81

**INTERNET**

**COMPONENT WORKSHOP**
26 The APA Web Site: Potential Future Directions and Opportunity for Dialogue 44

**LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES**

**LECTURE**
20 Homosexuality and Ignorance 62

**SCIENTIFIC AND CLINICAL REPORT**
79 Obsessions about homosexuality and the Y-BOCS: Lessons From A Anti-Discrimination Case in Sweden 68

**SYMPOSIUM**
30 Formation of Modern Lesbian and Gay Identities: Personal, Historical, and Mental Health Perspectives 53

**COMPONENT WORKSHOP**
9 Mental Health and Men Who Have Sex With Men in the African-American Community: Controversies About the Down Low 22

**MEDIA WORKSHOPS**
2 "Brokeback Mountain": The Myth, the Reality, and the Controversy 23
6 "We Are Dad": HIV-Positive Children and Lesbian, Gay, Bisexual, or Transgender Parenting 65

**MANAGED CARE AND HEALTH CARE FUNDING**

**COURSES**
50 Current CPT Coding and Documentation Requirements 30
84 Navigating the Minefields of Managed Care Contracting: What Psychiatrists Need to Know 62

**SYMPOSIUM**
62 Prescribing Patterns, Predictors, and Costs for Antidepressant Medications: 75
<table>
<thead>
<tr>
<th>Component Workshops</th>
<th>Page#</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>COMPONENT WORKSHOPS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21 Conceptualizing Access to Psychiatric Care</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>44 Managed Care, Psychiatrists, and Employers: Collaborating Effectively to Ensure Patient Care</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>48 CPT Coding and Documentation Update</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>MEN'S ISSUES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28 The Effect of Sildenafil on Erectile Function and Depression: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies in Men With ED and Treated or Untreated Depression</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>SMALL INTERACTIVE SESSION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 Men's Mental Health</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>MENTAL RETARDATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(CHILD/adolescent/adult)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COMPONENT WORKSHOP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Providing Optimum Care for Patients With Mental Retardation and Developmental Disabilities in the Psychiatric Emergency Room</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>MOOD DISORDERS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INDUSTRY SUPPORTED SYMPOSIA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Insights from STAR*D: Are Our Patients' Needs Being Met?</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>7 The Prevaling Predominant Role of Bipolar Depression</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>16 Rethinking Bipolar Disorder: Implications of Comorbidities</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>17 Caring for our Most Challenging Patients: Depression: An Interactive Forum on Novel Treatments</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>21 STAR*D Findings: Implications for Patients, Clinicians, and Other Stakeholders</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>24 Treating the Spectrum of Bipolar Disorders: An Interactive Case Discussion; Part 1</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>24 Treating the Spectrum of Bipolar Disorders: An Interactive Case Discussion; Part 2</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td>28 Improving Depression Treatment: Bridging the Gap Between Clinical Trials and Community Practice</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>LECTURE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 A Neurotrophic Hypothesis of Depressions and Antidepressant Response</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>OTHER SOMATIC THERAPIES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADVANCES IN MEDICINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 New Integrative Treatments for PTSD and Chronic Fatigue, Disorders of Autonomic Function</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>2 Medicine in Review: A Journal Roundup for 2006</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31 Metabolic Abnormalities in Patients With Major Depressive Disorder</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>63 How Often Do SSRIs Lose Their Effect During Continuation Treatment: Evidence Suggesting the Rate is True Tachyphylaxis</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>68 Effect of Comorbid Anxiety on Antidepressant Use in a Community Sample of Bipolar Subjects</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>69 Difficult to Treat Patients: the Role of Quetiapine in the Management of Acute Bipolar Depression (With a Focus on Bipolar Ii Patients)</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>70 Indirect Comparison of the Safety and Tolerability of Antipsychotics in Patients With Bipolar Disorder and Schizophrenia</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>71 Subjective Sleep Quality and Suicidal Ideation Among College Students</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>73 Prevalence and Symptom Patterns of Depression Among College Students: Findings From A Cross-Cultural Study Across Boston and Bombay</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>74 Disease burden of bipolar and schizoaffective disorder in an Australian cohort</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>76 the Relationship Between Global Functioning, Depression and Painful Somatic Symptoms in Patients With Major Depressive Disorder</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>102 Information Processing in Bipolar Disorder During Remission</td>
<td>82</td>
<td></td>
</tr>
<tr>
<td>103 Mitochondrial Function in the Anterior Cingulate and Treatment Response In MDD</td>
<td>82</td>
<td></td>
</tr>
<tr>
<td>104 Impact of Study Design on the Results of Continuation Studies of Antidepressants</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td>105 The Effectiveness of Venlafaxine and its Metabolite in Refractory Depressed Patients</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Biological Foundations of Bipolar Disorder: New Insights and Prospects for Treatment</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>COMPONENT WORKSHOP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Optimizing Depression Treatment: Clinical Applications of Measurement-Based Care</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19 First Episode Mood Disorders: What Have We Learned and Where Do We Go From Here?</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>35 How to Involve Your Patients With Bipolar Disorder In their Treatment Plan: A Guideline for Clinicians</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>47 Quality of Life of Patients With Major Depression in A Natural Clinical Setting</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>61 Detecting Bipolar Disorder</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>62 Can We Do Better At Preventing the Chronic Course of Mood Disorders?</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>72 Day-to-Day Variability In Bipolar Disorder</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>75 From Evidence to Clinical Methods in Integrative Mental Health Care</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>NATIONAL INSTITUTE ON DRUG ABUSE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FORUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Substance Abuse in Your Patients: Beyond What is Taught in Your Residency</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>LECTURE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 The Road to Equity: Marching Towards a Just Treatment of Mental Illness and Addiction in America</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>6 Spiritus Contra Spiritum: The Strange Case of Spirituality and Addiction</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>8 Stress Reactivity, Gene Variants, and the Persistence of Addictions</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>17 The Neurobiology of Free Will in Addictive Disorders</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>PRESIDENTIAL SYMPOSIUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Current Research Advances: APA/NIMH/NIDA/NIAAA/NAMI Perspectives</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Association of Cannabis Use With Prodromal Features of Psychosis and Behavioral Problems in Adolescents</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Insights on Obesity and Drug Addiction From Brain Imaging</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>15 What Is the Directionality of the Onset of Comorbid Substance Use and Other Psychiatric Disorders?</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>16 Categories and Dimensions in Clinical and Research Contexts of Diagnostic Classification for DSM-V</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>39 Choosing the Right Treatment for Substance Abuse</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>95</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topic</td>
<td>Page</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td><strong>TOPIC INDEX</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>51 Drug Abuse Treatment Within the Criminal Justice System: Addressing Our Nation’s Public Health Needs</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>52 A Picture of the Development of the Adolescent Brain: A Structural and Functional Assessment</td>
<td>76</td>
<td></td>
</tr>
<tr>
<td>68 Innovations in the Treatment of Adolescent Substance Use Disorders</td>
<td>76</td>
<td></td>
</tr>
<tr>
<td>71 Prenatal Nicotine Exposure: How Does It Relate to Developmental Vulnerabilities?</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50 Managing Opiate Detoxification With Buprenorphine/Naloxone</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Grantwriting Workshop: Research Funding Opportunities From the National Institute on Drug Abuse</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>7 Gene-Environment-Development Interactions: Implications for Psychiatric and Substance Abuse Disorders</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>42 Methamphetamine Abuse and Addiction: Prevalence and Treatment</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>56 Neuroimaging Research: Implications for the Treatment of Substance Abuse</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>68 Promising Medications for the Treatment of Cocaine Addiction</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>76 Gay Men and Crystal Methamphetamine: A Review</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td><strong>NEUROPSYCHIATRY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ADVANCES IN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuropsychiatry and Clinical Neurosciences</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td><strong>INDUSTRY SUPPORTED SYMPOSIAS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 Dark Horizons: Depression and Cognitive Impairment</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>23 How do Atypicals and Antipsychotics Work? From Receptors to Reality: Part 1</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>23 How do Antipsychotics and Antidepressants Work? From Receptors to Reality: Part 2</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td>26 Navigating the Complex Maze of Bipolar Disorder</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>27 When Endocrinology and Psychiatry Collide: What the Clinician Needs to Know About Antipsychotic-induced Endocrine Disturbances</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 Neuroscience and Phenomenology of Schizophrenia</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td><strong>PAIN MANAGEMENT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>103 Multidisciplinary Treatment of Chronic Pain</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td><strong>PATIENT SAFETY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29 Metabolic Abnormalities in Psychiatric Inpatients</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>60 Decreasing the Use of Restraining and Seclusion Among Psychiatric Inpatients</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>84 Suicide: Practical Patient Safety for the Doctor From Risk Assessment to Risk Reduction</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td><strong>PERSONALITY DISORDERS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COURSE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>83 Psychotherapy for Borderline Personality</td>
<td>96</td>
<td></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75 Days Missed from Work in Patients With Major Depressive Disorder With or Without a Personality Disorder</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>80 The 10-Year Course of Physically Self-destructive Acts of Patients With BPD</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>83 Personality Traits and Psychopharmacological Treatment With Selective Serotonin Reuptake Inhibitors</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>84 Olanzapine for the Treatment of BPD: A Flexible-Dose 12-Week Randomized Double-Blind Placebo-Controlled Study</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>85 A Dose Comparison of Olanzapine for the Treatment of BPD: A 12-Week Randomized Double-Blind Placebo-Controlled Study</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>97 Exploratory Factor Analysis of BPD Criteria in Hispanic Men and Women With Substance Use Disorders</td>
<td>82</td>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Treatments for Maladaptive Personality Traits With Some Empirical Support</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>28 New Perspectives in Psychodynamic Treatments for Borderline Personality Disorder</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>64 Update on the Biology of Personality Disorders</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>78 The Psychopathology of Personality: Perspectives From the Collaborative Longitudinal Personality Disorders Study (CLPS)</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td><strong>PHARMACOTHERAPY AND PSYCHOTHERAPY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>85 Combined Treatment With Psychotherapy and Medications: Research and Clinical Issues</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 Achieving Medication Adherence by Understanding Recovery</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td><strong>POLITICAL QUESTIONS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>41</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COURSE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>43 Personality and Political Behavior</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td><strong>PREMENSTRUAL DYSPHORIC DISORDER</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>48 Prevalence and Correlates of PMDD Among Arab Primary Care Patients in the United Arab Emirates</td>
<td>49</td>
<td></td>
</tr>
<tr>
<td><strong>PRESIDENTIAL THEME: “ADDRESSING PATIENT NEEDS: ACCESS, PARITY, AND HUMANE CARE”</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 The Future of Psychiatry: International Perspectives</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td><strong>PRESIDENTIAL SYMPOSIAS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Health Inequalities for Persons With Mental Problems and Intellectual Disabilities</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>7 Globalization and Mental Health: Role of Spanish-Speaking Psychiatry</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 The Discourse of Health Care Economics</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>32 Recurrent Psychiatric Hospitalization</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>36 The ADHS Project in Israel: New Insights in Adherence in Schizophrenia</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>TOPIC INDEX</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36 Humane Aspects of Private Practice</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>72 The IOM Informs, NAMI Storms, and AACP Transforms: How to Make the Grade in Response to the U.S. Mental Health’s Bad Report Card</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>77 Depression as Indicator and Focus of Treatment in Primary Care Clinics</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>81 Addressing Patient’s Needs: Patient Centered Diagnosis</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35 Focusing on Asia: A Review of Disasters, Intervention and Prevention Programs</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>44 Psychiatry In the Americas: Update From the World Psychiatric Association</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>80 Confidentiality in Overseas Settings: The Prioritization of the Individual Versus the Institution Versus the Community</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td><strong>PROFESSIONAL AND PERSONAL ISSUES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PRESIDENTIAL SYMPOSIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Women Leaders in the APA and Beyond</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17 The Disruptive Physician: Rehabilitate or Retaliate?</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>34 Uneasy Partners: The Pharmaceutical Industry and the Psychiatric Profession</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>43 How to Launch a Successful Private Practice: Part 3</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>89 Passages: Perspectives of Women Psychiatrists Negotiating Career Transitions</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOPS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 Reaching Out: Approaches to Suicide Amongst the Physician Population</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>22 Peals and Pitfalls in Negotiating Your First Job</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>34 Novel Careers in Psychiatry: Women who Have Made Their Own Way</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>54 Mentoring of Women in Academic Psychiatry</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Risk Management Issues in Psychiatric Practice</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>4 Children of Psychiatrists</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>21 American Board of Psychiatry and Neurology Update: Certification and Maintenance of Certification In Psychiatry and Its Subspecialties</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>36 Maintenance of Certification for Diplomats of the American Board of Psychiatry and Neurology</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>37 How to Launch a Successful Private Practice: Part 1</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>43 How to Launch a Successful Private Practice: Part 2</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>51 Biopsychosocial and Spiritual Aspects of Treating our Physician Colleagues</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>69 Psychiatrists Who Have Been In Treatment. An Interactive Discussion</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td><strong>PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 Basic Concepts in Administrative Psychiatry I: Theory, Human Resources, and Fiscal Management</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>24 Basic Concepts in Administrative Psychiatry II</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>65 Personnel Management for Clinician-Administrators</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td><strong>PRESIDENTIAL SYMPOSIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 Current European perspectives on the concept of schizophrenia</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>46 Leadership Discourse: Agents of Change in Mental Health</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOPS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 Mental Health Transformation: Is It for Real?</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>33 Should the Community Replace the Asylum in the 21st Century?</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>37 Career Advancement In Administrative Psychiatry for Early Career Psychiatrists</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td><strong>PSYCHIATRIC EDUCATION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ADVANCES IN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatments of Psychiatric Disorders</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 the Conceptual Basis of Psychiatry</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>16 How to Give a More Effective Lecture: Punch, Passion, and Polish</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>20 Seeing the Forest and the Trees: A Biopsychosocial Approach to the Oral Board Examination</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>36 Teaching Psychiatry? Let Hollywood Help!</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>63 Understanding the Person Behind the Illness: An Approach to Psychodynamic Formulation</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>72 Improving Your Presentation Skills: A Coaching Approach</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>80 Reel Psychiatry</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 The American Board of Psychiatry and Neurology: Impact on Psychiatric Education: Past, Present, and Future</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>72 Prevalence and Attitudes Concerning ADHD Diagnosis and Use of Stimulant Medications in Medical Students</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 Challenges and New Developments in the Psychiatric Education of Medical Students</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>25 Innovative Ways in Psychotherapy Supervision: The Short Term Dynamic Therapy Experience</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>58 Psychiatric Training Across the Continents: International Young Psychiatrist Perspectives</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOPS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 A Model Curriculum for Teaching the Working Alliance as a Core Process Across Psychotherapies</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>6 How to Become a More Creative Teacher: Winning Strategies for Residents and Faculty</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Headspace Theatre: An Innovative Method for Experiential Learning of Psychiatric Symptomatology Using Modified Role-Playing and Improvisational Theatre Techniques Association for Academic Psychiatry</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>6 Lessons From Teaching Interviewing to International Residents: Integrating Cultural Competency From the Start of Training</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>20 Teaching Cognitive Behavior Therapy to Child and Adult Residents</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>57 Project Match: A Resident Curriculum of Mentorship, Advocacy, Teaching, Career Issues, and Health</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>58 The Resident Experiences a Patient Suicide: Strategies That can Help</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>63 Safety Training for Medical Students During Their Psychiatry Clerkship</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>70 Electrifying Discourses: Presentation and Communication Skills for Psychiatrists and Trainees</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>77 Using Audiolinal Technology to Teach Behavioral Sciences</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td>87 A Role for Self Awareness, Mindfulness, and Meditation in Psychiatric Education</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>97 A Sigma of Much Substance: Educational Skills to Enhance Trainees Attitudes and Approaches to Substance Use and Concurrent Disorders</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td>TOPIC INDEX</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>MEDIA WORKSHOP</td>
<td>7 Psychiatric Residents' Perspective of Couples and Family Therapy Training</td>
<td>65</td>
</tr>
<tr>
<td>PSYCHIATRIC REHABILITATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COURSE</td>
<td>19 Improving Clinical Outcomes: A Practical Guide to Evidence-Based Employment and Recovery Practices</td>
<td>5</td>
</tr>
<tr>
<td>SMALL INTERACTIVE SESSION</td>
<td>5 American Psychoanalysis Today</td>
<td>27</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>50 Consumer Provider Training: Incorporating Individuals in Recovery Into the Behavioral Workforce</td>
<td>40</td>
</tr>
<tr>
<td>ISSUE WORKSHOP</td>
<td>29 The Utility of Computer-Assisted Psychoeducation for Residential Treatment of Veterans With PTSD</td>
<td>45</td>
</tr>
<tr>
<td>PSYCHOANALYSIS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>32 Mirror Neurons, Empathy, Intuition, and Interpretation: Understanding the Minds of Others</td>
<td>58</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
<td>10 Going to the Heart of the Master in Patient Interviews: A Further Exploration</td>
<td>23</td>
</tr>
<tr>
<td>PSYCHOPHARMACOLOGY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td>70 Drug Therapy and Schizophrenia</td>
<td>51</td>
</tr>
<tr>
<td>INDUSTRY SUPPORTED SYMPOSIUM</td>
<td>31 Monoamine Oxidase Inhibitors Today: A 21st Century View on the Treatment of Depression</td>
<td>59</td>
</tr>
<tr>
<td>LECTURE</td>
<td>19 The Three Stages of Schizophrenia: Can Early Detection and Intervention Change Illness Course and Prevent Disability?</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>11 Second-Generation Antipsychotics and Diabetes Mellitus: Risk, Number Needed to Harm, and Clinical Impact</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>30 Neuroleptic Malignant Syndrome Induced by Low Dose Aripiprazole in First Episode Psychosis</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>64 Discontinuation of SSRI's after 5 years stability</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>93 LOCF and Distortion of Findings in a Psychotropic Drug Clinical Study</td>
<td>82</td>
</tr>
<tr>
<td>SMALL INTERACTIVE SESSIONS</td>
<td>6 Treatment of Dementia with Behavioral Disturbance: If Not an Antipsychotic, Then What?</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>12 New Treatment Developments For Autism and Impulse Control Disorders</td>
<td>62</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
<td>33 Recognition and Management of Neuroleptic Malignant Syndrome</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>38 Interpreting and Disseminating Findings From An Evidence-based Drug Review: Antiepileptic Drugs for Mood Disorders</td>
<td>45</td>
</tr>
<tr>
<td>RELIGION, SPIRITUALITY, AND PSYCHIATRY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td>22 Kundalini Yoga Meditation Techniques for Mental Health</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>49 Spirituality and Worldview in Clinical Practice</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>68 Spirituality in Psychiatry</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>88 The Way of Yoga and Herbs in Treatment of Stress, Depression, Aggression, and Mass Trauma</td>
<td>71</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td>90 Spirituality and Recovery From Panic Attacks</td>
<td>81</td>
</tr>
<tr>
<td></td>
<td>91 Fostering Spiritual Values and Well being: the need in psychiatry</td>
<td>81</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>83 Model Psychiatry Residency Programs on Religion and Spirituality</td>
<td>86</td>
</tr>
<tr>
<td>COMPONENT WORKSHOP</td>
<td>32 Spiritus Contra Spiritum: The Strange Case of Spirituality and Addiction: Discussion of the 2007 Oskar Pfister Award Lecture</td>
<td>50</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
<td>74 Religious and Spiritual Assessment In Clinical Practice</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>81 Spiritually Augmented Well-Being Cognitive-Behavior Therapy</td>
<td>79</td>
</tr>
<tr>
<td></td>
<td>83 Buddhist Teachings and Techniques Applied to Disaster Relief, A 2 Year Follow-up On Sri Lankan Tsunami Victims</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>100 Finding Balance; the Application of Yoga to Mental Health</td>
<td>83</td>
</tr>
<tr>
<td>RESEARCH ISSUES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COURSES</td>
<td>29 Clinician Administered Rating Scales for Mood and Anxiety Disorders</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>58 Research on a Shoestring Budget</td>
<td>41</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td>43 Improving the Understanding of Causality in Psychiatric Research</td>
<td>48</td>
</tr>
<tr>
<td></td>
<td>67 A link between oxytocin and anxiety of romantic attachment</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>101 Brain-Derived Neurotrophic Factor Levels in Depressed Patients during Antidepressant Treatments</td>
<td>82</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>46 From Clinical Trials to Real World Outcomes</td>
<td>38</td>
</tr>
<tr>
<td>RESIDENT AND MEDICAL STUDENT ISSUES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMALL INTERACTIVE SESSION</td>
<td>9 Why Leadership Skills Benefit Residents [Residents Only]</td>
<td>44</td>
</tr>
<tr>
<td>COMPONENT WORKSHOP</td>
<td>25 Sweet Child of Mine: Pregnancy and Parental Leave During Residency</td>
<td>44</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
<td>24 Women Residents' Needs During Psychiatric Training</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>53 Developing Research Training Opportunities Within a Psychiatric Residency Training Program: Goals, Motivations, Barriers, and Solutions</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td>55 Oral Boards Boot Camp: 2007</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td>60 Research Training for all Psychiatric Residents: A Problematic Endeavor</td>
<td>64</td>
</tr>
</tbody>
</table>
### SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS

**COURSES**

- 52 Assessing Positive and Negative Symptoms With the Positive and Negative Syndrome Scale
  - Page: 30

**INDUSTRY SUPPORTED SYMPOSIUM**

- 6 Clinical Skills to Clinical Scales: Practical Tools in the Management of Patients with Schizophrenia
- 8 The Ongoing Debate Surrounding Atypicals: Are the Benefits Worth the Risks?
- 11 Long-term Treatment Approaches for Schizophrenia: Comparing Maintenance and Recovery Models
- 13 Planning for Success in Schizophrenia Management
- 20 Weighing the Risks and Benefits of Atypical Antipsychotics: Can We Have Our Cake and Eat It Too?
- 25 Improving Outcomes in Schizophrenia: Prostrance to Remission
- 32 Understanding the Complexity of Bipolar Mixed Episodes
  - Page: 59

**LECTURES**

- 14 Glutamate, the Prefrontal Cortex, and Schizophrenia: Capturing the Angel in “Angel Dust”
- 22 A Paradigm Shift for Schizophrenia Discovery
- 23 Psychosis on the Streets: An Ethnography of Chicago’s Netherworld
  - Page: 71

**SCIENTIFIC AND CLINICAL REPORTS**

- 12 Metabolic Risks of Psychosis in Sweden
- 13 Effect of Body Weight and Metabolic Complications on Health Related Quality of Life in Swedish Outpatients With Schizophrenia
- 25 Insulin Resistance in Adolescent Subjects at Risk for Psychosis
- 35 Brain Morphology in Schizophrenia Within the Northern Finland 1966 Birth Cohort
- 56 Number Needed to Treat and Number Needed to Harm: Making Sense of CATIE
- 58 Zolpidem in Treatment Resistant Catatonia: Two Case Reports and Literature Review
- 86 Relationship Between Neuropsychological Performance and Instrumental Work Functioning In Schizophrenia and Other Disorders: A 20-Year Prospective Longitudinal Study
- 87 A 20-Year Multi-Followup Study of Persecutory Delusions in Schizophrenia
- 88 Neurocognition, Complex Social Cognition, and Functional Outcome in Schizophrenia
- 99 Diagnostic and Gender Differences in Schizophrenia and Other Psychotic Disorders in First Episode Psychosis
  - Page: 82

### SEXUAL AND GENDER DISORDERS

**COURSE**

- 48 Love, Desire, Intimacy, and Infidelity
  - Page: 19

### SLEEP DISORDERS

**COURSES**

- 12 Melatonin and Light Treatment of SAD, Sleep, and Other Body Clock Disorders
- 26 Sleep Medication Review and Update for Psychiatrists
  - Page: 7

**INDUSTRY SUPPORTED SYMPOSIUM**

- 3 Recognition and Management of Restless Legs Syndrome in Psychiatric Practice
- 5 Insomnia: Primary Diagnosis or Secondary Symptoms?
- 9 Stolp Sleep After All These Cues: Hypersomnia in Psychiatry
- 14 Making Every Sleep Count: Evidence-Based Approaches to Treating Insomnia
  - Page: 8

**SCIENTIFIC AND CLINICAL REPORTS**

- 20 Circadian Rhythm Disturbances in ADHD
- 27 Modafinil Improves Behavioral Alertness in Patients With Residual Excessive Sleepiness Following Nasal Continuous Positive Airway Pressure (nCPAP): Treated Obstructive Sleep Apnea
  - Page: 27

**ISSUE WORKSHOP**

- 22 Assessing Capacity to Drive A Practical Approach to the Psychiatrist’s Role and Responsibilities
  - Page: 29

### SOMATOFORM DISORDERS

**SYMPOSIUM**

- 26 Alexithymia and Emotional Dysregulation: From Theory to Clinical Practice
  - Page: 38

**ISSUE WORKSHOP**

- 89 Fibromyalgia: Current Understanding and Future Directions
  - Page: 80

### STIGMA/ADVOCACY

**LECTURES**

- 11 The Healing Power of Electroconvulsive Therapy
- 15 Thailand’s Recent Experience: Community Mental Health and De-Stigmatization
  - Page: 43

**SCIENTIFIC AND CLINICAL REPORT**

- 78 Comparison of Public’s Stigma Attitude Between Mental Illness and Physical Handicap
  - Page: 68

**SYMPOSIUM**

- 49 Inventory of Stigmatizing Experiences
  - Page: 57

**COMPONENT WORKSHOP**

- 13 Advocacy Training for Early Career Psychiatrists With a Focus on Party Legislation
  - Page: 28

### STRESS

**SYMPOSIUM**

- 27 Bullying in the Workplace: Associated Health Problems
  - Page: 53

**ISSUE WORKSHOP**

- 25 The Earliest Environment: Prenatal Stress, Anxiety, and Depression and Child Outcome
  - Page: 29

- Page: 99
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUICIDE</td>
<td></td>
</tr>
<tr>
<td><strong>ADVANCES IN</strong></td>
<td></td>
</tr>
<tr>
<td>Assessment and Management of Suicide</td>
<td>42</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>26 Severe Headaches and the Risk of Subsequent Suicidal Thoughts or Behaviors</td>
<td>27</td>
</tr>
<tr>
<td>81 Indicators of Refractory Illness and Risk of Suicide</td>
<td>68</td>
</tr>
<tr>
<td>82 Personality Traits as Prospective Predictors of Suicide Attempts: Negative Affectivity/Temperament and Disinhibition in a Personality Disorder Sample</td>
<td>68</td>
</tr>
<tr>
<td>98 Suicide Among Female Veterans in the General U.S. Population</td>
<td>82</td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>40 Suicide Icon: The Golden Gate Bridge</td>
<td>63</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>49 Impact of Patient Suicide on Psychiatry Residents: A Workshop Discussion</td>
<td>51</td>
</tr>
<tr>
<td>52 Responding to the Impact of Suicide on Clinicians</td>
<td>64</td>
</tr>
<tr>
<td>71 Air Force Suicide Prevention Program: A Community and Organizational Approach to Prevention</td>
<td>70</td>
</tr>
<tr>
<td><strong>TELEPSYCHIATRY</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOP</strong></td>
<td></td>
</tr>
<tr>
<td>7 Beyond Powerpoint: How Technology can Improve Mental Health Training</td>
<td>21</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>15 Challenging the Status Quo: Centralized Assessments in Psychiatric Clinical Trials</td>
<td>23</td>
</tr>
<tr>
<td>23 Implementing a Telepsychiatry Program in the Kern County Mental Health System in Rural California</td>
<td>29</td>
</tr>
<tr>
<td>59 Telepsychiatry in Action: Implementing and Sustaining a Successful Telepsychiatry Program</td>
<td>64</td>
</tr>
<tr>
<td><strong>TREATMENT TECHNIQUES AND OUTCOME STUDIES</strong></td>
<td></td>
</tr>
<tr>
<td><strong>ADVANCES IN</strong></td>
<td></td>
</tr>
<tr>
<td>Treatments of Psychiatric Disorders</td>
<td>38</td>
</tr>
<tr>
<td><strong>ADVANCES IN MEDICINE</strong></td>
<td></td>
</tr>
<tr>
<td>3 Advances in the Cause, Treatment, and Psychology of Hypertension</td>
<td>65</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
<td></td>
</tr>
<tr>
<td>57 Switching From Long-Acting Typical Antipsychotic Drugs to the Second Generation Antipsychotics: Olanzapine and Risperidone in the Treatment of Patients With Chronic Schizophrenia</td>
<td>66</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>40 Second Opinion Consultation on Ongoing Psychotherapy Treatments</td>
<td>50</td>
</tr>
<tr>
<td>99 Clinical Pathways for Mood and Anxiety Disorders</td>
<td>83</td>
</tr>
<tr>
<td><strong>VIOLENCE, TRAUMA, AND VICTIMIZATION</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
<td></td>
</tr>
<tr>
<td>4 Psychiatric Interventions in Disaster and Public Health Emergencies: Theory &amp; Practice</td>
<td>1</td>
</tr>
<tr>
<td>57 Disaster Psychiatry: Terrorism, Trauma, and Things to Do</td>
<td>41</td>
</tr>
<tr>
<td>67 The Assessment and Treatment of Child Sexual Abusers</td>
<td>42</td>
</tr>
<tr>
<td>74 Risk Assessment for Violence</td>
<td>52</td>
</tr>
<tr>
<td><strong>FORUM</strong></td>
<td></td>
</tr>
<tr>
<td>3 On the Frontline in America: Treating Violent Patients and the Ethics of Providing Care</td>
<td>30</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>38 Beyond the Clash of Civilizations</td>
<td>48</td>
</tr>
<tr>
<td>39 Phases of Trauma Recovery</td>
<td>48</td>
</tr>
<tr>
<td>59 Variables Affecting Violence That Required Physical Restraint Among Psychiatric Inpatients During the First Week of Hospitalization</td>
<td>66</td>
</tr>
<tr>
<td>96 A Controlled Comparison Study of a Yoga Breath-Based Program and a Client-Centered Exposure Therapy for PTSD and Depression in Survivors of Trauma Disaster</td>
<td>82</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>35 Stalking Offenders and Victims</td>
<td>54</td>
</tr>
<tr>
<td>70 The Sexually Violent Offender</td>
<td>77</td>
</tr>
<tr>
<td>87 The Psychocultural Foundations of Contemporary Terrorism</td>
<td>87</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>12 the Triumph of War: Understanding Interventions In A Developmental Context</td>
<td>23</td>
</tr>
<tr>
<td>27 Music As A Means of Survival: The Significance of Music In Surviving the Holocaust</td>
<td>29</td>
</tr>
<tr>
<td>45 Assessing Violence Risk Among Persons With Mental Illnesses</td>
<td>51</td>
</tr>
<tr>
<td>50 Physical Trauma as a Result of War or Natural Disaster: Psychiatric Interventions</td>
<td>51</td>
</tr>
<tr>
<td>86 Vietnam Veterans and the Iraqi War: Is the Past Ever the Past?</td>
<td>80</td>
</tr>
<tr>
<td><strong>WOMEN'S HEALTH ISSUES</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
<td></td>
</tr>
<tr>
<td>10 Management of Psychiatric Disorders in Pregnant and Postpartum Women</td>
<td>2</td>
</tr>
<tr>
<td>76 Multidisciplinary Treatment of Low Sexual Desire in Women</td>
<td>60</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>37 Schizophrenia in the Offspring of Antisocially Depressed mothers and Familial Risk Follow-Up of the Northern Finland 1966 Birth Cohort 48</td>
<td>67</td>
</tr>
<tr>
<td>65 An 8-Week Randomized, Double-blind, Placebo-controlled Trial of PDE5I Sildenafil Treatment of SRI-Associated Sexual Dysfunction in Women With Major Depression Disorder in Remission: Identifying a Hormone Endophenotype Associated With Treatment</td>
<td>67</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>33 PTSD, Borderline Personality Disorder and Motherhood: Early Relations, Recognition and Intervention</td>
<td>54</td>
</tr>
<tr>
<td>75 Culture as a Rationalization for Violence Against Women</td>
<td>84</td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>19 Boot Camp for Burnout</td>
<td>28</td>
</tr>
</tbody>
</table>
PARTICIPANT INDEX

APA 160TH ANNUAL MEETING

A

Abadie, Pascale ................................................... 37
Abdel, Amin ...................................................... 26
Afri, Gene G ..................................................... 18, 42
Abrams, Karen M ........................................... 54
Abramson, Beth L ............................................. 73
Abramson, Ronald ............................................ 55
Adams, Neal H ............................................... 77, 78
Adams, Dominic .............................................. 26
Adler, Lawrence W ........................................... 48
Adler, Lenard A ............................................... 27
Agoston, Anna M ............................................. 76
Aguiar-Grilloh, Sergio ....................................... 34
Ahmad, Abdurrahman ................................. 87, 88
Ahmed, Iqbal .................................................... 21
Aizenberg, Dec .......................... .......................... 48
Ajinder, Dharti .................................................. 48
Akai, Hasag S .................................................. 55, 76
Akira, Hiroshi .................................................... 50
Albenson, Soren ................................................ 26
Alam, Faizuddin ................................................ 83
Alavera, Renato D ........................................... 41, 73
Alger, Ian E ...................................................... 65, 84
Ali, Farhana .................................................... 87
Ali-Evtschenko, Yeolo ................................. 42, 52
Anagnostou, Evstokia ........................................ 57
Anderson, Allan A ........................................... 8, 50
Andrade, Nael N .............................................. 45, 47
Andresen, Nancy C ......................................... 68
Andrews, Linda B ............................................ 86
Andrus, Jason ................................................... 25
Anz, Lizz M ...................................................... 82
Ansell, Emily .................................................... 85
Antognini, Francesca C ................................. 62, 84
Anton, Raymond F .......................................... 84
Arizzi, Maria M .............................................. 21, 64
Apfelbaum, William J ........................................ 35
Appelbaum, Paul S ........................................... 30, 44, 51, 55, 56, 57
Apter, Alan ....................................................... 87
Apter, Giselle .................................................... 34
Arboleda-Florea, Jolene L ............................... 51, 57
Arey, Jettison A ................................................ 75
Arias, Albert J ................................................... 10
Arkoff, Lesley M ............................................... 78
Arms, Arnold .................................................... 33
Aron, Sanjay ..................................................... 33
Arroyo, William ............................................... 71, 78, 89
Azned, Nadia .................................................... 36
Azeb, Peter ...................................................... 82
Azevedo, Robert W ......................................... 87
Augustus, Lisa L .............................................. 80
Avrin, Ron ....................................................... 37
Axelson, Alan .................................................. 63

B

Badaracco, Mary Anne ................................. 38
Baier, Ursula F ............................................... 55
Bailey, Ralph K ................................................ 63
Bailey, Sue ...................................................... 72
Bak, Mirza ......................................................... 28
Bakker, Brian ................................................... 73
Balkom, Anton V ............................................. 49
Balt, Bruce ....................................................... 22, 64
Banks, Aneesa O ............................................. 84
Barak, Yoram ................................................... 48, 66
Barbee, Howard P ........................................... 77
Barile, Nicholas .............................................. 56
Barr, Christina S ............................................. 34
Barr, Tim .......................................................... 80
Barrett, Thomas B ........................................... 49, 55
Bartron, Ruth A ............................................... 50
Barry, Declan ................................................... 73
Barth, Selena .................................................... 34
Bart, Jennifer ................................................... 36, 57
Bascou, Monica R ........................................... 3
Bateman, Anthony ........................................... 53
Bates, Dorothy ................................................ 30
Beck, Elizabeth .............................................. 50
Becker, Mark S ................................................ 70
Beuerer, Michael ............................................. 34
Bollinger, Ehud ................................................ 69
Borden, Andreas ............................................. 86
Beck, Judith S ................................................... 29, 35, 42, 74
Becker, Daniel F ............................................. 62
Becker, Deborah R ........................................... 87
Becker, Judith V ............................................. 61
Becker, Alan R ................................................ 19
Beckman, Aarons ............................................. 49, 57
Beckman, Aaran .............................................. 47
Beckman, Richard ........................................... 49, 81
Beckman, Alec ................................................ 28
Buckholz, Gary T ............................................ 43
Buckley, Peter E ............................................ 11, 37, 40, 58, 59
Baghdzhiev, Dinesh ........................................ 72
Bus, Viet ......................................................... 80
Bue, Stephen F ................................................. 62
Bullock, Clayton M ......................................... 54
Bulmash, E.A ................................................... 36, 48
Burden, Ronald M ........................................... 30, 68
Burke, Harald L .............................................. 62
Burrroughs, Tracee .......................................... 63, 69
Burt, Martin H ................................................ 23, 36
Bush, George .................................................... 6
Bush, Ramzi M ................................................... 49
Butler, Jeremy R ............................................... 18
Bryce, Daniel T ............................................... 5, 8
Bryce, John ...................................................... 45
Bryce, Barbara ................................................. 62

C

Cabaj, Robert P ............................................... 54
Cabreiros, Claudio O ....................................... 84
Caicedo, Consuelo C ..................................... 37, 74
Cairney, John .................................................. 67
Carras, Norah A ............................................. 80
Callan, Eunice ................................................. 61
Callahan, William E ........................................ 45, 50, 56
Camacho, Alvaro ............................................ 46
Camarena, Enrique R ...................................... 51
Campbell, Herbert L ....................................... 48, 79
Campbell, Nicola N ......................................... 45
Campbell, William H ...................................... 1, 6, 28, 42, 62
Caruso, Anna R ............................................. 21
Cecil, Olivier J ................................................ 37
### PARTICIPANT INDEX

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Porter, William Z.</td>
<td>23</td>
</tr>
<tr>
<td>Powsner, Seth</td>
<td>21</td>
</tr>
<tr>
<td>Poyurovsky, Michael</td>
<td>9</td>
</tr>
<tr>
<td>Pradaia, Aparna</td>
<td>26</td>
</tr>
<tr>
<td>Preud’Homme, Xavier A.</td>
<td>3</td>
</tr>
<tr>
<td>Price, Julie C.</td>
<td>76</td>
</tr>
<tr>
<td>Price, Marilyn</td>
<td>21</td>
</tr>
<tr>
<td>Pribe, Stefan</td>
<td>48</td>
</tr>
<tr>
<td>Prieto, Amelie</td>
<td>46</td>
</tr>
<tr>
<td>Price, Luis F.</td>
<td>12, 68</td>
</tr>
<tr>
<td>Prince, Jefferson B.</td>
<td>5, 17, 41</td>
</tr>
<tr>
<td>Puchalski, Christina M.</td>
<td>70</td>
</tr>
<tr>
<td>Pudlowski, Derek</td>
<td>22</td>
</tr>
<tr>
<td>Pugh, Kenneth R.</td>
<td>77</td>
</tr>
<tr>
<td>Pumareaga, Andres J.</td>
<td>3, 28, 37, 63, 74</td>
</tr>
<tr>
<td>Punzel, Tara M.</td>
<td>67, 83</td>
</tr>
<tr>
<td>Purnell, Katherine</td>
<td>76</td>
</tr>
<tr>
<td>Pyneer, Robert S.</td>
<td>51</td>
</tr>
<tr>
<td>Quastel, Adam</td>
<td>33</td>
</tr>
<tr>
<td>Radke, Alan Q.</td>
<td>50</td>
</tr>
<tr>
<td>Rae, Donald S.</td>
<td>25, 27</td>
</tr>
<tr>
<td>Rahim, Umme Salema</td>
<td>48</td>
</tr>
<tr>
<td>Rahimi, Sadeq</td>
<td>45</td>
</tr>
<tr>
<td>Rainey, Charles J.</td>
<td>42, 52</td>
</tr>
<tr>
<td>Ramchandani, Dilip</td>
<td>37</td>
</tr>
<tr>
<td>Ranger, Luis F.</td>
<td>12, 68</td>
</tr>
<tr>
<td>Randall, Terri L.</td>
<td>69</td>
</tr>
<tr>
<td>Randle, Sonja</td>
<td>68</td>
</tr>
<tr>
<td>Ransev, John</td>
<td>9</td>
</tr>
<tr>
<td>Rantakallo, Paula</td>
<td>48</td>
</tr>
<tr>
<td>Rao, Niyapati</td>
<td>22, 45, 49</td>
</tr>
<tr>
<td>Raya, Maski R.</td>
<td>17, 19, 24, 31, 41, 51</td>
</tr>
<tr>
<td>Rathou, Shanaya</td>
<td>6, 69</td>
</tr>
<tr>
<td>Rathore, Varinder</td>
<td>46</td>
</tr>
<tr>
<td>Ravitz, Paula</td>
<td>7</td>
</tr>
<tr>
<td>Raymond, Nancy C.</td>
<td>61</td>
</tr>
<tr>
<td>Raufi, Mehmood Ahmad</td>
<td>37</td>
</tr>
<tr>
<td>Razavi, Maryam</td>
<td>37</td>
</tr>
<tr>
<td>Reagan, Lawrence P.</td>
<td>84</td>
</tr>
<tr>
<td>Recupero, Parricia R.</td>
<td>9</td>
</tr>
<tr>
<td>Reede, Joan</td>
<td>80</td>
</tr>
<tr>
<td>Regler, Darad A.</td>
<td>4, 8, 25, 27, 29, 32, 35, 55</td>
</tr>
<tr>
<td>Reich, D. Bradford</td>
<td>68</td>
</tr>
<tr>
<td>Reich, James H.</td>
<td>33</td>
</tr>
<tr>
<td>Reichman, William E.</td>
<td>2</td>
</tr>
<tr>
<td>Riehl, Michael</td>
<td>19, 63</td>
</tr>
<tr>
<td>Rieil, William H.</td>
<td>7</td>
</tr>
<tr>
<td>Riffater, Bartom</td>
<td>29, 45, 69</td>
</tr>
<tr>
<td>Rinblatt, Shana P.</td>
<td>45</td>
</tr>
<tr>
<td>Rinhard, James S.</td>
<td>57</td>
</tr>
<tr>
<td>Richford, Azarou</td>
<td>51</td>
</tr>
<tr>
<td>Rimjus, Peter L.</td>
<td>82</td>
</tr>
<tr>
<td>Renner, John H.</td>
<td>69</td>
</tr>
<tr>
<td>Renshaw, Perry F.</td>
<td>76, 82</td>
</tr>
<tr>
<td>Rezendez, Cynthia I.</td>
<td>28</td>
</tr>
<tr>
<td>Resnick, Phillip J.</td>
<td>5, 18, 30, 42, 52, 61</td>
</tr>
<tr>
<td>Resnick, Roy O.</td>
<td>71</td>
</tr>
<tr>
<td>Reus, Victor I.</td>
<td>45</td>
</tr>
<tr>
<td>Reyes, Raymond M.</td>
<td>69</td>
</tr>
<tr>
<td>Reynoldson, Sigery</td>
<td>26</td>
</tr>
<tr>
<td>Reynolds, Charles F.</td>
<td>40</td>
</tr>
<tr>
<td>Reznik, Vivian</td>
<td>42</td>
</tr>
<tr>
<td>Reza, Kasia D.</td>
<td>18</td>
</tr>
<tr>
<td>Rilu, Michelle B.</td>
<td>22, 33, 51, 79</td>
</tr>
<tr>
<td>Rich, Josiah D.</td>
<td>74</td>
</tr>
<tr>
<td>Richards, William A.</td>
<td>36</td>
</tr>
<tr>
<td>Richardson, Greg</td>
<td>72</td>
</tr>
<tr>
<td>Richeimer, Steven</td>
<td>83</td>
</tr>
<tr>
<td>Riddle, Mark A.</td>
<td>57</td>
</tr>
<tr>
<td>Ritz, Michael D.</td>
<td>76</td>
</tr>
<tr>
<td>Rizzi, Giuseppe</td>
<td>37</td>
</tr>
<tr>
<td>Rizzo, Flavia</td>
<td>26</td>
</tr>
<tr>
<td>Rissi, Arlene O.</td>
<td>46</td>
</tr>
<tr>
<td>Ritchie, Karen A.</td>
<td>37</td>
</tr>
<tr>
<td>Ritvo, Eva C.</td>
<td>36</td>
</tr>
<tr>
<td>Rivera Arroyo, Guillermo C.</td>
<td>74</td>
</tr>
<tr>
<td>Rivas, Michael J.</td>
<td>76</td>
</tr>
<tr>
<td>Rizk, Diaa</td>
<td>49</td>
</tr>
<tr>
<td>Robins, Trevor</td>
<td>36, 50</td>
</tr>
<tr>
<td>Roberts, Katherine M.</td>
<td>58</td>
</tr>
<tr>
<td>Roberts, Laura W.</td>
<td>56, 87</td>
</tr>
<tr>
<td>Rober, Marlin</td>
<td>38</td>
</tr>
<tr>
<td>Robinow, Carolyn B.</td>
<td>9, 17, 39, 53</td>
</tr>
<tr>
<td>Robins, Beatrix F.</td>
<td>61</td>
</tr>
<tr>
<td>Robins, David J.</td>
<td>61</td>
</tr>
<tr>
<td>Robins, Gail E.</td>
<td>5, 28, 54, 84</td>
</tr>
<tr>
<td>Robinson, Jacob A.</td>
<td>70</td>
</tr>
<tr>
<td>Robinson, Michael J.</td>
<td>26, 68</td>
</tr>
<tr>
<td>Robinson, Robert G.</td>
<td>58</td>
</tr>
<tr>
<td>Rocker, Charlotte A.</td>
<td>26</td>
</tr>
<tr>
<td>Rodin, Gary</td>
<td>71</td>
</tr>
<tr>
<td>Rodgers, Mercedes M.</td>
<td>28</td>
</tr>
<tr>
<td>Rodriguez-Alban, Manuel J.</td>
<td>53</td>
</tr>
<tr>
<td>Rogge, Stephen J.</td>
<td>37</td>
</tr>
<tr>
<td>Rolland, John S.</td>
<td>18</td>
</tr>
<tr>
<td>Romans, Sarah F.</td>
<td>84</td>
</tr>
<tr>
<td>Romero, Emilio E.</td>
<td>68</td>
</tr>
<tr>
<td>Roose, Steven P.</td>
<td>6, 86</td>
</tr>
<tr>
<td>Rossig, Mozudeh</td>
<td>37</td>
</tr>
<tr>
<td>Rouen, Cerisse</td>
<td>82</td>
</tr>
<tr>
<td>Rothenbach, Robert</td>
<td>37</td>
</tr>
<tr>
<td>Rokos, Erik</td>
<td>21</td>
</tr>
<tr>
<td>Rohman, Marc F.</td>
<td>29</td>
</tr>
<tr>
<td>Rohlstein, David A.</td>
<td>25, 48, 81</td>
</tr>
<tr>
<td>Roy, Alec</td>
<td>32</td>
</tr>
<tr>
<td>Roobal, C. Nathaniel</td>
<td>35</td>
</tr>
<tr>
<td>Ruan, Guillerbo</td>
<td>48</td>
</tr>
<tr>
<td>Rufio-Stipes, Martina</td>
<td>36</td>
</tr>
<tr>
<td>Rücker, Christian</td>
<td>26, 68</td>
</tr>
<tr>
<td>Ruder, Stepen</td>
<td>72</td>
</tr>
<tr>
<td>Ruadli, Alexia</td>
<td>41</td>
</tr>
<tr>
<td>Ruggiero, Camilo J.</td>
<td>48, 82, 83</td>
</tr>
<tr>
<td>Rüdermann, Stephan</td>
<td>86</td>
</tr>
<tr>
<td>Ruiz, Amanda</td>
<td>29</td>
</tr>
<tr>
<td>Ruiz, Pedro</td>
<td>7, 9, 25, 39, 50, 52, 53, 69, 72, 73, 76, 78, 81</td>
</tr>
<tr>
<td>Ruzzol, Jo-Ellen M.</td>
<td>32</td>
</tr>
<tr>
<td>Ryan, Deidre M.</td>
<td>29</td>
</tr>
<tr>
<td>Ryhik, Abe M.</td>
<td>83</td>
</tr>
<tr>
<td>Sabri, Sufyan</td>
<td>49</td>
</tr>
<tr>
<td>Saculea, Perinodor</td>
<td>45</td>
</tr>
<tr>
<td>Sacus, Gary S.</td>
<td>8, 40</td>
</tr>
<tr>
<td>Sadavoy, Joel</td>
<td>83</td>
</tr>
<tr>
<td>Saeed, Ay.</td>
<td>10, 43</td>
</tr>
<tr>
<td>Rusakoff, L. Mark</td>
<td>1, 22</td>
</tr>
<tr>
<td>Russell, James</td>
<td>26</td>
</tr>
<tr>
<td>Rutherford, Bert R.</td>
<td>22, 86</td>
</tr>
<tr>
<td>Rutner, Carolyn</td>
<td>73</td>
</tr>
<tr>
<td>Ryall, Jo-Lynn M.</td>
<td>32</td>
</tr>
<tr>
<td>Ryan, Jetta M.</td>
<td>29</td>
</tr>
<tr>
<td>Ryshik, Abe M.</td>
<td>83</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sabri, Sufyan</td>
<td>49</td>
</tr>
<tr>
<td>Saculea, Perinodor</td>
<td>45</td>
</tr>
<tr>
<td>Sacus, Gary S.</td>
<td>8, 40</td>
</tr>
<tr>
<td>Sadavoy, Joel</td>
<td>83</td>
</tr>
<tr>
<td>Saeed, Ay.</td>
<td>10, 43</td>
</tr>
<tr>
<td>Rusakoff, L. Mark</td>
<td>1, 22</td>
</tr>
<tr>
<td>Russell, James</td>
<td>26</td>
</tr>
<tr>
<td>Rutherford, Bert R.</td>
<td>22, 86</td>
</tr>
<tr>
<td>Rutner, Carolyn</td>
<td>73</td>
</tr>
<tr>
<td>Ryall, Jo-Lynn M.</td>
<td>32</td>
</tr>
<tr>
<td>Ryan, Jetta M.</td>
<td>29</td>
</tr>
<tr>
<td>Ryshik, Abe M.</td>
<td>83</td>
</tr>
</tbody>
</table>
## PARTICIPANT INDEX

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tsouros-Mazoyer, Nathalie</td>
<td>37</td>
</tr>
</tbody>
</table>

### U

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Udenmann, Pichet</td>
<td>14, 50</td>
</tr>
<tr>
<td>Urbatis, John C.</td>
<td>45, 55</td>
</tr>
<tr>
<td>Ursano, Robert J.</td>
<td>51</td>
</tr>
<tr>
<td>Uswakwe, Richard</td>
<td>33</td>
</tr>
</tbody>
</table>

### V

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vakia, Ipir</td>
<td>84</td>
</tr>
<tr>
<td>Vahtera, Justi</td>
<td>53</td>
</tr>
<tr>
<td>Valiant, George</td>
<td>50</td>
</tr>
<tr>
<td>Valença, Alexandre M.</td>
<td>26</td>
</tr>
<tr>
<td>Vailles, Rene J.</td>
<td>28</td>
</tr>
<tr>
<td>van Asbrt, Gert</td>
<td>61</td>
</tr>
<tr>
<td>van Arsingen, Michael A.</td>
<td>26</td>
</tr>
<tr>
<td>van Elburg, Annamaria A.</td>
<td>55</td>
</tr>
<tr>
<td>Van Os, Jim</td>
<td>35</td>
</tr>
<tr>
<td>van Zyl, Louis T.</td>
<td>73</td>
</tr>
<tr>
<td>Van, Henricus</td>
<td>57, 61</td>
</tr>
<tr>
<td>Van Duijvenvoorde, Donna</td>
<td>22, 51</td>
</tr>
<tr>
<td>Van Montfort, Michael</td>
<td>35</td>
</tr>
<tr>
<td>van Zyl, Louis T.</td>
<td>73</td>
</tr>
<tr>
<td>Varma, Sudheeta</td>
<td>70</td>
</tr>
<tr>
<td>Varrell, James</td>
<td>64</td>
</tr>
<tr>
<td>Vasa, Monisha R.</td>
<td>63, 83</td>
</tr>
<tr>
<td>Vasswani, Meera</td>
<td>25, 48, 66, 82</td>
</tr>
<tr>
<td>Vasswani, Sanjay M.</td>
<td>23, 27</td>
</tr>
<tr>
<td>Vedamurthachar, A.</td>
<td>82</td>
</tr>
<tr>
<td>Vichola, Julio M.</td>
<td>25, 27, 48</td>
</tr>
<tr>
<td>Vela, Riccardo M.</td>
<td>1</td>
</tr>
<tr>
<td>Velhoezer, Maria</td>
<td>74</td>
</tr>
<tr>
<td>Veldhuizen, Scott</td>
<td>67</td>
</tr>
<tr>
<td>Velgiman, Dawn I.</td>
<td>8</td>
</tr>
<tr>
<td>Velvis, Yitas</td>
<td>7</td>
</tr>
<tr>
<td>Verisse, Jean-Luc</td>
<td>38</td>
</tr>
<tr>
<td>Ventura, Joseph</td>
<td>81, 87</td>
</tr>
<tr>
<td>Verbraak, Marc</td>
<td>49</td>
</tr>
<tr>
<td>Verduin, Marcia J.</td>
<td>8</td>
</tr>
<tr>
<td>Viamontes, George J.</td>
<td>75</td>
</tr>
<tr>
<td>Vickers, Ken</td>
<td>45</td>
</tr>
<tr>
<td>Vicet, Lisa</td>
<td>83</td>
</tr>
<tr>
<td>Vieira, Eduardo</td>
<td>33, 45</td>
</tr>
<tr>
<td>Vincent, Kathy M.</td>
<td>87</td>
</tr>
<tr>
<td>Vink, Jacqueline M.</td>
<td>48</td>
</tr>
<tr>
<td>Vissel, Karin</td>
<td>49</td>
</tr>
<tr>
<td>Vitracoo, Mariana</td>
<td>53</td>
</tr>
<tr>
<td>Vitorino, Cilcida B.</td>
<td>79</td>
</tr>
<tr>
<td>Voci, Frank</td>
<td>50, 69</td>
</tr>
<tr>
<td>Vogel-Schillia, Suzanne F.</td>
<td>69</td>
</tr>
<tr>
<td>Volkow, Nora D.</td>
<td>13, 20, 30, 33, 46, 53</td>
</tr>
<tr>
<td>Volpe, Serena Y.</td>
<td>62</td>
</tr>
<tr>
<td>von Guten, Charles F.</td>
<td>43</td>
</tr>
<tr>
<td>Von Korff, Michael</td>
<td>73</td>
</tr>
</tbody>
</table>

### W

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wadhwa, Partik D.</td>
<td>29</td>
</tr>
<tr>
<td>Wagner, Angela</td>
<td>53</td>
</tr>
<tr>
<td>Wahlstrom, Carl M.</td>
<td>29</td>
</tr>
<tr>
<td>Wall, Harold</td>
<td>51</td>
</tr>
<tr>
<td>Wainberg, Milton L.</td>
<td>56</td>
</tr>
<tr>
<td>Waldenbach, Marjorie F.</td>
<td>46</td>
</tr>
<tr>
<td>Walcker, Sandra C.</td>
<td>22, 63</td>
</tr>
<tr>
<td>Walker, Schmoecker, William E.</td>
<td>21</td>
</tr>
<tr>
<td>Wall, Chuck</td>
<td>23</td>
</tr>
<tr>
<td>Wallace, Charles J.</td>
<td>87</td>
</tr>
<tr>
<td>Walsh, B. Timothy</td>
<td>55</td>
</tr>
<tr>
<td>Wang, Gene-Jack</td>
<td>33</td>
</tr>
<tr>
<td>Wang, Ting</td>
<td>57</td>
</tr>
<tr>
<td>Waterman, G. Scott</td>
<td>55, 85</td>
</tr>
<tr>
<td>Watson, John</td>
<td>29</td>
</tr>
<tr>
<td>Way, Bruce B.</td>
<td>85</td>
</tr>
<tr>
<td>Wayne, Tristan</td>
<td>71</td>
</tr>
<tr>
<td>Weider, Natalie D.</td>
<td>28, 44</td>
</tr>
<tr>
<td>Weerakoropa, Priyazh</td>
<td>74</td>
</tr>
<tr>
<td>Weiden, Peter J.</td>
<td>6, 8, 83</td>
</tr>
<tr>
<td>Weisz, Colin A.</td>
<td>65</td>
</tr>
<tr>
<td>Weine, Sievan M.</td>
<td>23, 87</td>
</tr>
<tr>
<td>Weiner, Elsy D.</td>
<td>64</td>
</tr>
<tr>
<td>Weiner, Richard</td>
<td>32</td>
</tr>
<tr>
<td>Weinstein, Henry C.</td>
<td>21, 85</td>
</tr>
<tr>
<td>Wensel, Richard H.</td>
<td>27</td>
</tr>
<tr>
<td>Weiss, Margee D.</td>
<td>64</td>
</tr>
<tr>
<td>Weiss, Roger D.</td>
<td>10, 23</td>
</tr>
<tr>
<td>Weisser, Lydia F.</td>
<td>22</td>
</tr>
<tr>
<td>Weissman, Sidney</td>
<td>72</td>
</tr>
<tr>
<td>Wellisch, David K.</td>
<td>49</td>
</tr>
<tr>
<td>Weng, Wan-Chen</td>
<td>49, 76</td>
</tr>
<tr>
<td>West, Joyce A.</td>
<td>23, 87</td>
</tr>
<tr>
<td>West, Susan G.</td>
<td>26</td>
</tr>
<tr>
<td>Westermeier, Joseph J.</td>
<td>63, 73</td>
</tr>
<tr>
<td>Westerstjeld, Michael</td>
<td>77</td>
</tr>
<tr>
<td>Wexler, Bruce F.</td>
<td>87</td>
</tr>
<tr>
<td>Wittinger, Theodore H.</td>
<td>53</td>
</tr>
<tr>
<td>Wieczor, Duje</td>
<td>86</td>
</tr>
<tr>
<td>Willins, Timothy P.</td>
<td>2, 6</td>
</tr>
<tr>
<td>Willwerth, Denise</td>
<td>6</td>
</tr>
<tr>
<td>Wilk, Joshua F.</td>
<td>25</td>
</tr>
<tr>
<td>Wilkins, Jeffrey N.</td>
<td>70</td>
</tr>
<tr>
<td>Wilkins, Kirsten M.</td>
<td>1</td>
</tr>
<tr>
<td>Willerding, Mark L.</td>
<td>48</td>
</tr>
<tr>
<td>Williams, Caroline B.</td>
<td>81</td>
</tr>
<tr>
<td>Williams, Eric R.</td>
<td>45</td>
</tr>
<tr>
<td>Williams, Janet B.W.</td>
<td>23</td>
</tr>
<tr>
<td>Williams, John</td>
<td>73</td>
</tr>
<tr>
<td>Williams, Monique M.</td>
<td>73</td>
</tr>
<tr>
<td>Williams, Solomon</td>
<td>1</td>
</tr>
<tr>
<td>Wilson, Markene A.</td>
<td>84</td>
</tr>
<tr>
<td>Wilson, Sarah A.</td>
<td>81</td>
</tr>
<tr>
<td>Wilson, Stephen N.</td>
<td>23</td>
</tr>
<tr>
<td>Winkelman, John W.</td>
<td>2</td>
</tr>
<tr>
<td>Winkler, Dietmar</td>
<td>32</td>
</tr>
<tr>
<td>Winstead, Daniel K.</td>
<td>29, 45</td>
</tr>
<tr>
<td>Winston, Arnold</td>
<td>57</td>
</tr>
<tr>
<td>Wisdom, Jennifer P.</td>
<td>49</td>
</tr>
<tr>
<td>Wic, Thomas N.</td>
<td>44, 68</td>
</tr>
</tbody>
</table>

### Y

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yahr, Mary Kay</td>
<td>83</td>
</tr>
<tr>
<td>Wald, Nicole F.</td>
<td>61</td>
</tr>
<tr>
<td>Wang, Vanessa</td>
<td>64</td>
</tr>
<tr>
<td>Waite, Stephen B.</td>
<td>27, 82</td>
</tr>
<tr>
<td>Wolf, Jessica L.</td>
<td>22</td>
</tr>
<tr>
<td>Wolley, Linda M.</td>
<td>69</td>
</tr>
<tr>
<td>Worthington, John J.</td>
<td>61</td>
</tr>
<tr>
<td>Wozniak, Jeffrey R.</td>
<td>54</td>
</tr>
<tr>
<td>Wright, H. Jesse H.</td>
<td>29, 42</td>
</tr>
<tr>
<td>Wright, Jesse H.</td>
<td>3, 8, 29, 42</td>
</tr>
<tr>
<td>Wulsin, Lawton R.</td>
<td>44</td>
</tr>
<tr>
<td>Wunderlich, Lexi</td>
<td>86</td>
</tr>
<tr>
<td>Wurbecker, Beazley</td>
<td>85</td>
</tr>
<tr>
<td>Wynne, John D.</td>
<td>52</td>
</tr>
</tbody>
</table>

### Z

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zai, Paul</td>
<td>79</td>
</tr>
<tr>
<td>Zanarini, Mary C.</td>
<td>68, 81</td>
</tr>
<tr>
<td>Zaetschy, Anna F.</td>
<td>18</td>
</tr>
<tr>
<td>Zarkin, Gary</td>
<td>84</td>
</tr>
<tr>
<td>Zaubler, Thomas S.</td>
<td>49</td>
</tr>
<tr>
<td>Zhao, Pangli</td>
<td>81</td>
</tr>
<tr>
<td>Ziegler, Michael G.</td>
<td>65</td>
</tr>
<tr>
<td>Ziegler, Penelope P</td>
<td>22</td>
</tr>
<tr>
<td>Zieks, Jancacek</td>
<td>44, 7</td>
</tr>
<tr>
<td>Zimmerman, Mark</td>
<td>26, 40, 48, 67, 68, 82, 83</td>
</tr>
<tr>
<td>Zivick, Sidney</td>
<td>43</td>
</tr>
<tr>
<td>Zuck, Stephanie</td>
<td>22</td>
</tr>
<tr>
<td>Zahir, Joseph</td>
<td>56, 57</td>
</tr>
<tr>
<td>Zaleski, Beatriz A.</td>
<td>23</td>
</tr>
<tr>
<td>Zidane, Howard V.</td>
<td>44, 7</td>
</tr>
<tr>
<td>Zubowski, Steven J.</td>
<td>71</td>
</tr>
<tr>
<td>Zuzarte, Edward</td>
<td>50</td>
</tr>
<tr>
<td>Zuremben, Allen</td>
<td>23, 84</td>
</tr>
<tr>
<td>Zylber, Patricia</td>
<td>68</td>
</tr>
</tbody>
</table>
2007 Annual Meeting Online
Your One-Stop Educational Resource library

"APA Annual Meeting Online" is an e-resource for psychiatrists to learn and earn CME credits through the 2007 Annual Meeting Online library - providing audio-visual programs that offer a dynamic learning experience 24/7.

- Special pre-meeting and on-site pricing to access the library
- 70+ hours of new 2007 meeting content
- Vast online, searchable database
- Review presentations from world renowned faculty
- Participate online and earn CME credit
- Free admission for Industry-Supported Symposia and previous meetings content
- DVD-ROMs also available

More information will be available post-meeting. Look for more details to follow.

Visit the APA Annual Meeting Online
www.psych.org/amlibrary

The American Psychiatric Association is accredited by the ACCME to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 1-3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
THE FIRST AND LAST

Visit the APPI BOOKSTORE at the 2007 APA ANNUAL MEETING IN SAN DIEGO!

Psychiatry's premiere publisher brings the cutting-edge titles you've been waiting for directly to you! Come check out APPI's latest groundbreaking selection, from the newest textbooks, review series, and journals, to electronic products for your handheld or online—including PsychiatryOnline.com.

The APPI Bookstore is the one place you can go to gather all the resources you'll need in the next year. Update subscriptions, complete your series collections, browse through hard to find titles, and even develop your course adoptions—all in one stop. Don't miss Author Book Signings or discounts for APA Members—see you there!

Gabbard's Treatments of Psychiatric Disorders, Fourth Edition
Edited by Glen O. Gabbard, M.D.
2007 • 986 pages • ISBN 978-1-59562-216-0 • Hardcover $195.00 • Item #62216

Manual of Clinical Psychopharmacology, Sixth Edition
Alan F. Schatzberg, M.D., Jonathan O. Cole, M.D., and Charles Dehutti, D.M.H., M.D.
2007 • 720 pages • ISBN 978-1-59562-317-4 • Paperback $79.00 • Item #62317

Introductory Textbook of Psychiatry, Fourth Edition
Nancy C. Andreasen, M.D., Ph.D., and Donald W. Black, M.D.
2006 • 668 pages • ISBN 978-1-59562-223-8 • Hardcover $78.00 • Item #62223

2006 • 668 pages • ISBN 978-1-59562-227-4 • Paperback $58.00 • Item #62227

Essentials of Psychosomatic Medicine
Edited by James L. Levenson, M.D.
2007 • 604 pages • ISBN 978-1-59562-246-7 • Paperback $85.00 • Item #62246

2007 • 496 pages • ISBN 978-1-59562-237-5 • Paperback $75.00 • Item #62237

The American Psychiatric Publishing Board Prep and Review Guide for Psychiatry
Edited by James A. Bourgeois, O.D., M.D., Robert E. Hales, M.D., M.B.A., and Stuart C. Yudofsky, M.D.

Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems
A Resource Book of Medication Information Handouts, Third Edition
Edited by Mina K. Dulcan, M.D.
2007 • 759 pages • ISBN 978-1-59562-253-5 • Paperback $79.00 • Item #62253

DSM-IV-TR® Casebook, Volume 2
Experts Tell How They Treated Their Own Patients
Edited by Robert L. Spitzer, M.D., Michael B. First, M.D., Janet B. W. Williams, D.S.W., and Miriam Gibbon, M.S.W.
2006 • 483 pages • ISBN 978-1-59562-219-1 • Hardcover $62.00 • Item #62219

2006 • 483 pages • ISBN 978-1-59562-220-7 • Paperback $42.00 • Item #62220

Essentials of Geriatric Psychiatry
Edited by Dan G. Blazer, M.D., Ph.D., David C. Steffens, M.D., M.H.Sc., and Ewald W. Busse, M.D.
2007 • 499 pages • ISBN 978-1-59562-247-4 • Paperback $75.00 • Item #62247

The First and Last Word in Psychiatry
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209-3901

Phone: 703-907-7322 or 1-800-368-5777 • Mon.-Fri., 9 am to 5:30 pm, ET
Fax: 703-907-1091 Email: appi@psych.org Web: www.appi.org

Please reference priority code AH739 when ordering
<table>
<thead>
<tr>
<th>JANUARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Managing Metabolic Abnormalities in the Psychiatrically Ill</td>
</tr>
<tr>
<td>A Clinical Guide for Psychiatrists</td>
</tr>
<tr>
<td>Edited by Richard A. Bernuidex, M.D., Paul E. Keck, Jr., M.D., and Susan L. McIntyre, M.D.</td>
</tr>
<tr>
<td>Paperback • $49.00 • Item #62241</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FEBRUARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Manual of Geriatric Psychopharmacology</td>
</tr>
<tr>
<td>Sandra A. Jacobson, M.D., Ronald W. Piers, M.D., and Ira R. Katz, M.D., Ph.D.</td>
</tr>
<tr>
<td>2007 • 829 pages • ISBN 978-1-58562-252-8</td>
</tr>
<tr>
<td>Hardcover • $74.00 • Item #62252</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MARCH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transcranial Magnetic Stimulation in Clinical Psychiatry</td>
</tr>
<tr>
<td>Edited by Mark S. George, M.D., and Robert H. Belmaker, M.D.</td>
</tr>
<tr>
<td>Paperback • $55.00 • Item #62197</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>APRIL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gabbard’s Treatments of Psychiatric Disorders, Fourth Edition</td>
</tr>
<tr>
<td>Edited by Glen O. Gabbard, M.D.</td>
</tr>
<tr>
<td>2007 • 986 pages • ISBN 978-1-58562-216-0</td>
</tr>
<tr>
<td>Hardcover • $195.00 • Item #62216</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MARCH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Handbook of Dynamic Psychotherapy for Higher Level Personality Pathology</td>
</tr>
<tr>
<td>Eve Caligor, M.D., Otto F. Kernberg, M.D., and John F. Clarkin, Ph.D.</td>
</tr>
<tr>
<td>Hardcover • $60.00 • Item #62212</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MAY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Guide to Clinical Psychopharmacology</td>
</tr>
<tr>
<td>Kelly L. Cozza, M.D., Scott C. Armstrong, M.D., Jessica Overstreet, M.D., and Neil B. Sandson, M.D.</td>
</tr>
<tr>
<td>2007 • 304 pages • ISBN 978-1-58562-301-3</td>
</tr>
<tr>
<td>Paperback • $37.95 • Item #62301</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MAY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Traumatic Dissociation Neurobiology and Treatment</td>
</tr>
<tr>
<td>Edited by Eric Vernet, M.D., Ph.D., Martin J. Dorsey, Ph.D., and David Spiegel M.D.</td>
</tr>
<tr>
<td>Paperback • $52.00 • Item #62196</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MAY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic Issues in Dementia</td>
</tr>
<tr>
<td>Advancing the Research Agenda for DSM-V</td>
</tr>
<tr>
<td>Edited by Ture Sandland, M.D., Dilip V. Jeste, M.D., Olusogun Bavyeju, M.D., Paul J. Strovas, M.S., and Daniel A. Regier, M.D., M.P.H.</td>
</tr>
<tr>
<td>2007 • 192 pages • ISBN 978-0-89049-298-4</td>
</tr>
<tr>
<td>Paperback • $45.00 • Item #2298</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MAY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Manual of Eating Disorders</td>
</tr>
<tr>
<td>Edited by Joel Yager, M.D., and Pauline S. Powers, M.D.</td>
</tr>
<tr>
<td>Paperback • $49.00 • Item #62270</td>
</tr>
</tbody>
</table>
2007 Annual Benefit "Celebrate San Diego!"
Saturday, May 19, 2007
7-10 p.m.
San Diego Wine & Culinary Center
200 Harbor Drive
San Diego, California

You are invited to an exciting special evening featuring a California wine tasting, regional cuisine, live music and the presentation of the Awards for Advancing Minority Mental Health. Event proceeds support the foundation’s grants, programs, research funding and awards that advance public understanding that mental illnesses are real and treatable.

Tickets:
$125 per person. To order tickets on Friday May 18, call (703) 907-8512. For tickets on Saturday May 19, please visit the foundation booth in the Member Center.

"Conversations" featuring Brooke Shields
Tuesday, May 22, 2007
5:30-6:30 p.m.
San Diego Marriott, San Diego Ballroom B/C, Lobby Level
Free to all annual meeting attendees

Don’t miss our sixth annual "Conversations" event, an interactive series that offers psychiatrists an opportunity to hear unique perspectives on mental illness. Actress and former model Brooke Shields will share her personal story of postpartum depression and recovery and the ensuing media frenzy.

Take Me Out to the Ball Game
Field level tickets ($38 ticket value):
Tuesday, May 22 or Wednesday, May 23, 2007 at 7 p.m. - $35 per ticket
Thursday, May 24, 2007 - 7 p.m. - $24 per ticket

Upper level tickets:
Tuesday, May 22 or Wednesday, May 23, 2007 at 7 p.m. - $12 per ticket
Thursday, May 24, 2007 - 7 p.m. - $11 per ticket

Enjoy a spring evening at PETCO Park while supporting the work of the foundation. The San Diego Padres will play the Chicago Cubs in an exciting three-game series. For every ticket sold, $5 will be contributed to the foundation. To order tickets, log on to www.padres.com/groups. The username is APA and the password is PADRES.

Golfers of the APA 2007 Annual Golf Tournament
Monday, May 21, 2007
8 a.m. with a shotgun start
Maderas Golf Club

Enjoy a round of golf at the Maderas Golf Club. Your $210 registration fee includes transportation to the course, greens fees, carts, lunch, amenities and prizes. Golf cart rental is offered by the course for $70. Event proceeds will benefit the foundation. For more information on the course, visit www.maderasgolf.com. To enter, please contact Stan Jennings, M.D., at mbeards@comcast.net or (804) 329-7881.
Clinical Management of ADHD
ATTENTION SPECTRUM DISORDERS

LEARNING OBJECTIVES
After taking part in this educational activity, participants should be able to:
• Implement a multifaceted approach to diagnosing children and adults with ADHD, comparing and contrasting the advantages and disadvantages of various diagnostic tools and rating scales
• Describe the special considerations required in the diagnosis and management of preschool children, children, adults, and other special groups with ADHD
• Understand the role that psychosocial interventions play in the management and treatment of ADHD
• Identify comorbid conditions related to ADHD and make appropriate recommendations for pharmacotherapy
• Understand, evaluate, and appropriately manage the cardiovascular risks associated with the use of medications for ADHD
• Describe the bidirectional overlap between ADHD and substance use disorders that has been observed both statistically and clinically.

May 19, 2007
LUNCHE: 12:00PM-1:30PM
SYMPOSIUM: 12:30PM-3:30PM
SAN DIEGO MARRIOTT HOTEL AND MARINA
Marina Ballroom South Tower

INDUSTRY-SUPPORTED SYMPOSIUM 2
Saturday, May 19, 2007, 12:30 p.m.-3:30 p.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

A CME LUNCH SYMPOSIUM
Expert Dialogue on Alzheimer’s Disease
Diagnostic and Referral Issues, Treatment of Cognitive Deficits, Ameliorating the Behavioral Complications, and Comprehensive Multidisciplinary Care

AGENDA
12:00 LUNCH
12:30 INTRODUCTION
George J. Grossberg, MD (Chair)
Saint Louis University School of Medicine
12:45 DIAGNOSTIC AND REFERRAL ISSUES
William G. Reichman, MD
Professor of Psychiatry and Neurology
Robert Wood Johnson Medical School
1:05 TREATING COGNITIVE DEFICITS IN PATIENTS WITH ALZHEIMER’S DISEASE
Pierroz J. Tarazi, MD
Research Professor of Psychiatry
University of Arizona College of Medicine
1:25 AMELIORATING THE BEHAVIORAL COMPLICATIONS IN PATIENTS WITH ALZHEIMER’S DISEASE
Incide R. M. Martin, MD
Professor of Psychiatry, Neurology, Physiology, and Neuroscience
Medical University of South Carolina
2:15 COMPREHENSIVE MULTIDISCIPLINARY CARE
Warad E. Faisal, MD
Assistant Professor of Psychiatry
Medical University of South Carolina
2:45 QUESTION AND ANSWER SESSION
George T. Grossberg, MD (Chair)

113

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for a maximum of 3AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Sponsored by: Shire

Sponsored by: the American Psychiatric Association

Supported by an educational grant from Forest Pharmaceuticals, Inc.
RECOGNITION AND MANAGEMENT OF RESTLESS LEGS SYNDROME (RLS) IN PSYCHIATRIC PRACTICE

2007 APA ANNUAL MEETING

AGENDA

12:00 PM - 12:20 PM LUNCH

12:20 PM - 12:40 PM OPENING REMARKS

John W. Winkelman, M.D., PhD

12:40 PM - 12:45 PM INTRODUCTION AND PRESENTATION

John W. Winkelman, M.D., PhD

12:45 PM - 1:15 PM UNDERSTANDING RLS: EPIDEMIOLOGY AND CLINICAL FEATURES

Barbara A. Phillips, M.D.

1:15 PM - 1:35 PM RLS-ASSOCIATED PSYCHIATRIC SYMPTOMS: MARKING THE LINKS

M. Regenstrief, M.D.

1:35 PM - 1:45 PM Q & A

1:45 PM - 2:15 PM TREATMENT OPTIONS FOR RLS: IMPROVEMENTS TO THERAPEUTIC STRATEGIES

Michel A. Bliwise, M.D.

2:15 PM - 2:30 PM THE PSYCHOLOGIST’S ROLE IN MANAGEMENT: JUDITH A. BAYLE, M.D.

2:30 PM - 2:35 PM CLINICAL PATHWAYS: AN INTERACTIVE CASE STUDY

J. W. Winkelman, M.D., PhD

2:35 PM - 2:50 PM CLOSING REMARKS

John W. Winkelman, M.D., PhD

INDUSTRY-SUPPORTED SYMPOSIUM 4

SATURDAY, MAY 19, 2007, 6:00 p.m.-9:00 p.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

APA 2007 ANNUAL MEETING IN SAN DIEGO

INSIGHTS FROM STAR*D: ARE OUR PATIENTS’ NEEDS BEING MET?

LEARNING OBJECTIVES

At the conclusion of this symposium, participants should be able to:

1. Identify the unmet needs of patients who are unlikely to achieve remission with any one treatment.
2. Evaluate strategies for partial or non-responders that include switching, augmentation, and combination strategies.
3. Design a treatment plan that utilizes non-pharmacologic and pharmacologic strategies to achieve remission.

Supported by an educational grant from Cephalon, Wyeth

PROGRAM AGENDA

5:30-6:00 PM Dinner

6:00-6:10 PM Introduction

Brian A. Marzka, MD (Chair)

Massachusetts General Hospital

Howard Medical School

6:10-6:35 PM Do Antidepressants Work in the Real World and for Whom?

• Ros H. Perlis, MD

Harvard Medical School

Massachusetts General Hospital

6:35-7:00 PM Polyparmacy to Increase the Chances of Remission

• Maurizio Fava, MD

University of Pennsylvania

Harvard Medical School

7:00-7:25 PM Switching Antidepressants: The STAR*D Experience

• Michael E. Thase, MD

University of Pennsylvania

7:25-7:50 PM Augmentation and Combination Strategies in Treatment-Resistant Depression

• Alan F. Schatzberg, MD

Stanford University School of Medicine

7:50-8:15 PM The Role of Psychotherapy as Adjunctive Treatment in Depression

• Amy Farbough, PhD

Northwestern University

8:15-9:00 PM Panel Discussion/Q&A

Sponsored by The American Psychiatric Association

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

The APA designates this educational activity for a maximum of 3 AAPI PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

REGISTRATION

Attendance must be confirmed for the APA Annual Meeting to attend this symposium. Seating is limited and will be held on a first-come, first-served basis. For more information about this event, please visit the APA website at www.psych.org or contact the APA toll-free at 312-455-7000 (within the U.S.) or 703-907-7000.
INDUSTRY-SUPPORTED SYMPOSIUM 5
Saturday, May 19, 2007, 6:00 p.m.-9:00 p.m.
Marina Ballroom, South Tower, Level Three, Marriott

INSOMNIA
Primary diagnosis or secondary symptom?
Held during the American Psychiatric Association 160th Annual Meeting
Saturday, May 19th, 2007
5:30 PM - 9:00 PM at the San Diego Marriott (Marina Ballroom)

At the conclusion of this symposium, the participant should be able to:
• Review the prevalence of insomnia and its link to the consequences of morbidity and mortality in the affected population
• Recognize early presentations of primary and secondary insomnia and understand the cause and relationships of the psychological factors
• Identify the abnormal sleep conditions in older adults and discuss how the identification of action at current pharmaceutical agents enhances the current armamentarium for patient sleep cycles
• Discuss future research directions and clinical trials of TAPs, medications, and how they influence our understanding of the sleep mechanism

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 2 Category 1 credits toward the APA’s Recognition Program and for the SAMPE requirement of the APA. The maximum number of credits available for this program is 1.5. The American Psychiatric Association does not accept últimos.

INDUSTRY-SUPPORTED SYMPOSIUM 6
Saturday, May 19, 2007, 6:00 p.m.-9:00 p.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

YOU ARE INVITED to Attend a Complimentary Dinner Symposium at the APA 2007 Annual Meeting

CLINICAL SKILLS & CLINICAL SCALES:
Practical Tools in the Management of Patients with Schizophrenia

PRESENTED BY
John M. Kane, MD
The Zucker Hillside Hospital

FACULTY
Michael H. Allen, MD
Colorado Psychiatric Hospital
Rona Hu, MD
Stanford University School of Medicine
Stephen R. Marder, MD
Scripps Clinic and Research Foundation

OBJECTIVES
Upon completion of this activity, participants should be able to:
1) Identify and implement clinical assessment tools to measure patient health, psychopathology, adverse effects, and functioning
2) Increase awareness of underlying medical comorbidities that may impact patient outcomes
3) Recognize real-world challenges patients face that impact functioning and long-term outcomes

AGENDA
5:30 PM - Dinner
6:00 PM - Welcome and Introduction
6:15 PM - Monitoring Physical Health - Stephen R. Marder, MD
6:50 PM - Measuring and Managing Agitation - Michael H. Allen, MD
8:00 PM - Measurement-Based Clinical Decision-Making in Patients with Schizophrenia - John M. Kane, MD
8:35 PM - Panel Discussion/Q&A
9:00 PM - Symposium Adjournment

WHO SHOULD ATTEND
This program will benefit all clinicians who want to increase their knowledge of the assessment and treatment of patients with schizophrenia. This includes psychiatrists, neurologists, family practitioners, internists, and other healthcare professionals.

CONTINUING EDUCATION CREDITS
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.
## THE PREVAILING PREDOMINANT POLE OF BIPOLAR DEPRESSION

**PROGRAM AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30-6:00</td>
<td>Dinner</td>
</tr>
</tbody>
</table>
| 6:00-6:10  | Introduction
Mark R. Frye, MD (Chair)
Mayo Clinic
Mayo College of Medicine |
| 6:10-6:35  | Neurobiology of Bipolar Depression: Implications for Treatment
Robert M. Post, MD
Penn State University College of Medicine
Biological Collaborative Network |
| 6:35-7:00  | New Treatment Options for Bipolar Depression
Marcia L. Verdul, MD
Medical University of South Carolina |
| 7:00-7:25  | Clinical Correlates Associated with Treatment-Emergent Mania
Mark R. Frye, MD
Mayo Clinic
Mayo College of Medicine |
| 7:25-7:50  | The Clinical Interface Between Obesity and Bipolar Depression
Susan L. McElroy, MD
University of Cincinnati |
| 7:50-8:15  | Clinical Challenges of Diagnosing and Treating Adolescents with Bipolar Depression
Yao Ji Zhang, MD
Stanford University School of Medicine |
| 8:15-9:00  | Panel Discussion/Q&A |

**LEARNING OBJECTIVES**

At the conclusion of this symposium, the participant should be able to:
1. Describe the neurobiology of bipolar depression.
2. Discuss current evidence-based medicine for the treatment of bipolar depression.
3. Realize the impact of obesity and bipolar depression, and the challenges of diagnosing and treating bipolar depression in adolescence.
4. Integrate these data into clinical practice.

**CREDIT DESIGNATION**

The APA designates this educational activity for a maximum of 3 AMA-PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**ACCREDITATION STATEMENT**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**REGISTRATION**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-567-7924 (within the U.S. or Canada) or 703-957-7300.

---

## THE ONGOING DEBATE SURROUNDING ATYPICALS

**AGENDA AND FACULTY**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30AM</td>
<td>Breakfast</td>
</tr>
</tbody>
</table>
| 8:00AM | Introductory Remarks/Welcome
Stephen R. Marder, MD (Chair)
Sarnoff Institute for Neuroscience and Human Behavior, UCLA |
| 8:10AM | Balancing Efficacy and Side Effects
Samuel J. Keilin, MD
University of New Mexico |
| 8:50AM | The Effect of Atypicals on Health Outcomes in Proactive Depression
Henry A. Nasrallah, MD
University of Cincinnati Medical Center |
| 9:20AM | The Risk/Benefit Ratio of Atypical Antipsychotics in Early Phase Schizophrenia
Elizabeth Bramley, MD
University of California, Los Angeles |
| 10:10AM | New Mechanisms and Innovative Pharmacologic Strategies
Stephen R. Marder, MD |
| 10:50AM | Concluding Remarks
Stephen R. Marder, MD |

**EDUCATIONAL OBJECTIVES**

At the conclusion of this symposium, the participant should be able to:
1. Compare and contrast the effectiveness of atypical antipsychotics in terms of symptom control and cognitive functioning in schizophrenia.
2. Consider multiple factors that contribute to overall functional outcomes in patients with schizophrenia, including health considerations, medication tolerability, and adherence.
3. Discuss the rationale for drug selection to achieve optimal mental and physical outcomes.
4. Review the risk/benefit ratio of atypicals in early-phase schizophrenia.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 AMA-PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-567-7924 (within the U.S. or Canada) or 703-957-7300.
INDUSTRY-SUPPORTED SYMPOSIUM 9
Sunday, May 20, 2007, 8:00 a.m.-11:00 a.m.
Marina Ballroom, South Tower, Level Three, Marriott

STILL SLEEPY AFTER ALL THESE CURES
HYPERSOMNIA IN PSYCHIATRY

May 20, 2007 • Breakfast • 7:30-8:00 a.m. • Symposium • 8:00-11:00 a.m.
Marina Ballroom, South Tower, Level Three • San Diego Marriott Hotel & Marina

AGENDA
7:30-8:00 a.m. Breakfast
8:00-8:15 a.m. Welcome and Introduction
    Stephen M. Stahl, MD, Ph.D., Chairman
    Adjunct Professor, Department of Psychiatry,
    University of California, San Diego School of Medicine

8:15-8:40 a.m. The Neurobiology of Hypersomnia
    Stephen M. Stahl, MD, Ph.D., Chairman
    Adjunct Professor, Department of Psychiatry,
    University of California, San Diego School of Medicine

8:40-9:05 a.m. The Clinical Spectrum of Hypersomnia
    Daniel J. Nyssen, M.D.
    Psychiatry, University of Pittsburgh School of Medicine

9:05-9:25 a.m. Measurement of Hypersomnia
    Meeta Singh, M.D.
    Sleep Disorders Center, Henry Ford Hospital

9:25-9:50 a.m. Strategies for the Management of Hypersomnia
    Leslie P. Lundt, M.D.
    Faculty of Idaho State University
    Director, Foothills Foundation Boise, Idaho

9:50-10:15 a.m. Prevalence and Consequences of Hypersomnia
    Christopher L. Drake, Ph.D.
    Senior Staff Scientist, Hospital Sleep Center
    Assistant Professor
    Psychiatry and Behavioral Neurosciences
    Wayne State University

10:15-11:00 a.m. Faculty Panel Question-and-Answer Session

OBJECTIVES
At the conclusion of this symposium, the participant should be able to:
- Discuss the prevalence and most common types of hypersomnia
- Describe the most common symptoms and signs of hypersomnia
- Choose the best test for the hypersomnia
- Recognize the most current evidence-based treatment strategies for hypersomnia

Attendees must register for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 within the US or Canada or 703-907-7900.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Sponsored by the American Psychiatric Association

Support by an educational grant from

INDUSTRY-SUPPORTED SYMPOSIUM 10
Sunday, May 20, 2007, 8:00 a.m.-11:00 a.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

Deconstructing Attention and Cognition in ADHD:
New Understandings for Improved Management

2007 APA Annual Meeting • San Diego, CA • Sunday, May 20, 2007 • Manchester Grand Hyatt • Douglas Pavilion C/D, Ground Floor

Learning Objectives
At the conclusion of this symposium, the participant should be able to:
1. Describe the neuroanatomy and clinical presentation of ADHD.
2. Discuss the treatment of the brain and neurotransmitter imbalance in ADHD.
3. Explain the various pharmacological treatment options and their effects on the improvement of attention.
4. Recognize the neuropsychological underpinnings of ADHD.
5. Examine ADHD's impact on cognition and executive functioning.

Program Chair
Thomas J. Spencer, MD
Associate Chief
Clinic and Research Program in
Pediatric Psychopharmacology
Massachusetts General Hospital
Associate Professor, Psychiatry
Harvard Medical School
Boston, Massachusetts

Distinguished Faculty
George Bush, MD, MPH
Director, Children's Clinic Research Laboratory
Assistant Professor of Psychiatry
University of California, San Diego
San Diego, California

Rebecca Fried, EdD
Neuropsychologist
Orchid Program Development
Department of Psychiatry
Massachusetts General Hospital
Boston, Massachusetts

Sponsored by the American Psychiatric Association

Supported by an educational grant from

Steven E. Sather, PhD
Director, Behavioral Pediatrics
Thomas Program
Depression and Bipolar Disorder
Massachusetts General Hospital
Associate Professor, Psychiatry
Harvard Medical School
Boston, Massachusetts

Thomas E. Wilson, MD
Shetler, Behavioral Science Services
Pediatric Psychopharmacology Unit
Massachusetts General Hospital
Associate Professor, Psychiatry
Harvard Medical School
Boston, Massachusetts
Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management

2007 APA Annual Meeting • San Diego, CA • Sunday, May 20, 2007 • Manchester Grand Hyatt • Douglas Pavilion C/D, Ground Floor

Learning Objectives:
1. To review the current state of the science regarding diagnosis and treatment of ADHD.
2. To review the latest evidence regarding the impact of attention and cognition on behavior and academic performance.
3. To explore the role of pharmacological and non-pharmacological treatments in managing ADHD.
4. To discuss the importance of early intervention and the role of multidisciplinary teams in managing ADHD.

Program Chair: Steven A. Safren, Ph.D.
Co-Chair: Thomas J. Spencer, M.D.
Program Team: E. Allen Schachter, Ph.D., Judith R. Rapoport, M.D., Adam M. Gitlin, M.D., Mark A. Heline, M.D., John F. Murphy, M.D., Ph.D., Sarah E. F湻elsen, M.D., M.A., Ph.D., and Steven A. Safren, Ph.D.

Supported by the American Psychiatric Association

Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management

2007 APA Annual Meeting • San Diego, CA • Sunday, May 20, 2007 • Manchester Grand Hyatt • Douglas Pavilion C/D, Ground Floor

Learning Objectives:
1. To review the current state of the science regarding diagnosis and treatment of ADHD.
2. To review the latest evidence regarding the impact of attention and cognition on behavior and academic performance.
3. To explore the role of pharmacological and non-pharmacological treatments in managing ADHD.
4. To discuss the importance of early intervention and the role of multidisciplinary teams in managing ADHD.

Program Chair: Steven A. Safren, Ph.D.
Co-Chair: Thomas J. Spencer, M.D.
Program Team: E. Allen Schachter, Ph.D., Judith R. Rapoport, M.D., Adam M. Gitlin, M.D., Mark A. Heline, M.D., John F. Murphy, M.D., Ph.D., Sarah E. F湻elsen, M.D., M.A., Ph.D., and Steven A. Safren, Ph.D.

Supported by the American Psychiatric Association

Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management

2007 APA Annual Meeting • San Diego, CA • Sunday, May 20, 2007 • Manchester Grand Hyatt • Douglas Pavilion C/D, Ground Floor

Learning Objectives:
1. To review the current state of the science regarding diagnosis and treatment of ADHD.
2. To review the latest evidence regarding the impact of attention and cognition on behavior and academic performance.
3. To explore the role of pharmacological and non-pharmacological treatments in managing ADHD.
4. To discuss the importance of early intervention and the role of multidisciplinary teams in managing ADHD.

Program Chair: Steven A. Safren, Ph.D.
Co-Chair: Thomas J. Spencer, M.D.
Program Team: E. Allen Schachter, Ph.D., Judith R. Rapoport, M.D., Adam M. Gitlin, M.D., Mark A. Heline, M.D., John F. Murphy, M.D., Ph.D., Sarah E. F湻elsen, M.D., M.A., Ph.D., and Steven A. Safren, Ph.D.

Supported by the American Psychiatric Association

Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management

2007 APA Annual Meeting • San Diego, CA • Sunday, May 20, 2007 • Manchester Grand Hyatt • Douglas Pavilion C/D, Ground Floor

Learning Objectives:
1. To review the current state of the science regarding diagnosis and treatment of ADHD.
2. To review the latest evidence regarding the impact of attention and cognition on behavior and academic performance.
3. To explore the role of pharmacological and non-pharmacological treatments in managing ADHD.
4. To discuss the importance of early intervention and the role of multidisciplinary teams in managing ADHD.

Program Chair: Steven A. Safren, Ph.D.
Co-Chair: Thomas J. Spencer, M.D.
Program Team: E. Allen Schachter, Ph.D., Judith R. Rapoport, M.D., Adam M. Gitlin, M.D., Mark A. Heline, M.D., John F. Murphy, M.D., Ph.D., Sarah E. F湻elsen, M.D., M.A., Ph.D., and Steven A. Safren, Ph.D.

Supported by the American Psychiatric Association

Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management

2007 APA Annual Meeting • San Diego, CA • Sunday, May 20, 2007 • Manchester Grand Hyatt • Douglas Pavilion C/D, Ground Floor

Learning Objectives:
1. To review the current state of the science regarding diagnosis and treatment of ADHD.
2. To review the latest evidence regarding the impact of attention and cognition on behavior and academic performance.
3. To explore the role of pharmacological and non-pharmacological treatments in managing ADHD.
4. To discuss the importance of early intervention and the role of multidisciplinary teams in managing ADHD.

Program Chair: Steven A. Safren, Ph.D.
Co-Chair: Thomas J. Spencer, M.D.
Program Team: E. Allen Schachter, Ph.D., Judith R. Rapoport, M.D., Adam M. Gitlin, M.D., Mark A. Heline, M.D., John F. Murphy, M.D., Ph.D., Sarah E. F湻elsen, M.D., M.A., Ph.D., and Steven A. Safren, Ph.D.

Supported by the American Psychiatric Association

Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management

2007 APA Annual Meeting • San Diego, CA • Sunday, May 20, 2007 • Manchester Grand Hyatt • Douglas Pavilion C/D, Ground Floor

Learning Objectives:
1. To review the current state of the science regarding diagnosis and treatment of ADHD.
2. To review the latest evidence regarding the impact of attention and cognition on behavior and academic performance.
3. To explore the role of pharmacological and non-pharmacological treatments in managing ADHD.
4. To discuss the importance of early intervention and the role of multidisciplinary teams in managing ADHD.

Program Chair: Steven A. Safren, Ph.D.
Co-Chair: Thomas J. Spencer, M.D.
Program Team: E. Allen Schachter, Ph.D., Judith R. Rapoport, M.D., Adam M. Gitlin, M.D., Mark A. Heline, M.D., John F. Murphy, M.D., Ph.D., Sarah E. F湻elsen, M.D., M.A., Ph.D., and Steven A. Safren, Ph.D.

Supported by the American Psychiatric Association

Deconstructing Attention and Cognition in ADHD: New Understandings for Improved Management

2007 APA Annual Meeting • San Diego, CA • Sunday, May 20, 2007 • Manchester Grand Hyatt • Douglas Pavilion C/D, Ground Floor

Learning Objectives:
1. To review the current state of the science regarding diagnosis and treatment of ADHD.
2. To review the latest evidence regarding the impact of attention and cognition on behavior and academic performance.
3. To explore the role of pharmacological and non-pharmacological treatments in managing ADHD.
4. To discuss the importance of early intervention and the role of multidisciplinary teams in managing ADHD.

Program Chair: Steven A. Safren, Ph.D.
Co-Chair: Thomas J. Spencer, M.D.
Program Team: E. Allen Schachter, Ph.D., Judith R. Rapoport, M.D., Adam M. Gitlin, M.D., Mark A. Heline, M.D., John F. Murphy, M.D., Ph.D., Sarah E. F湻elsen, M.D., M.A., Ph.D., and Steven A. Safren, Ph.D.

Supported by the American Psychiatric Association
INDUSTRY-SUPPORTED SYMPOSIUM 13
Sunday, May 20, 2007, 1:30 p.m.-4:30 p.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

Planning for Success in Schizophrenia Management

A Symposium held at the APA ’60th Annual Meeting

Sunday May 20, 2007
1:30pm-4:30pm
San Diego Marriott Hotel and Marina
Marriott Halls 1-4
North Tower (lower level)
Complimentary lunch from 1:00pm-1:30pm

- Introduction (1:30pm-1:35pm)
  Dilip V. Jeste, MD (Chair); Estelle and Edgar Levi Chair in Aging; Director, Sam and Rose Stein Institute for Research on Aging; Distinguished Professor of Psychiatry & Neurosciences, University of California, San Diego, California

- Why Do Patients With Schizophrenia Take Their Medication? Adherence Models for First-Episode Patients (1:30pm-2:30pm)
  Peter J. Weintraub, MD; Professor of Psychiatry, SUNY Downstate Medical Center, Brooklyn, New York

- Strategies for Assessing and Managing Adherence (2:30pm-2:45pm)
  Dilip V. Jeste, MD; Estelle and Edgar Levi Chair in Aging; Director, Sam and Rose Stein Institute for Research on Aging; Distinguished Professor of Psychiatry & Neurosciences, University of California, San Diego, California

- Schizophrenia Treatment Planning: Guidelines, Medication Algorithms, Psychosocial Strategies (2:45pm-3:25pm)
  Dawn L. Velligan, PhD; Professor and Co-Director, Division of Schizophrenia and Related Disorders, University of Texas Health Science Center, San Antonio, Texas

- Case Presentations of Adherence Dilemmas (3:25pm-3:55pm)
  David P. Folks, MD; Assistant Clinical Professor of Family and Preventive Medicine, University of California, San Diego, California

- General Discussion (3:55pm-4:30pm)
Panel

At the end of this session, participants will be able to

- Improve their ability to assess a patient’s likelihood of treatment adherence
- Apply major models of adherence to strategies for remaining on antipsychotic medications for schizophrenia
- Incorporate adherence prevention and treatment factor data from studies of patients at various stages of disease, including first-episode and refractory, to the development of practical management strategies for improving treatment adherence among people with schizophrenia in a variety of treatment settings
- Develop individualized management plans, including psychosocial interventions, augmentation strategies, depot or long-acting injectable stimulants, and side-effect management strategies, to improve patient outcomes

Attendance must be registered for the APA Annual Meeting to attend this Symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7920.

This symposium is supported by an educational grant from Ortho-McNeil Janssen Scientific Affairs, LLC, and is sponsored by the American Psychiatric Association.

Accreditation Statement
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity as a maximum of 5.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 14
Sunday, May 20, 2007, 1:30 p.m.-4:30 p.m.
Marina Ballroom, South Tower, Level Three, Marriott

Making Every Sheep Count: Evidence-Based Approaches to Treating Insomnia

Educational Objectives
At the end of this educational activity participants should be able to

1. Summarize the neural circuitry and physiological regulation of sleep, wakefulness, and circadian rhythms in humans. Relate the neurobiology of sleep to insomnia and its daytime consequences
2. Describe the emerging evidence regarding interactions between sleep, circadian rhythms, and psychiatric disorders
3. Discuss the role of sleep in neurocognitive and psychiatric disorders, and apply the basic science of these treatments to clinical practice
4. Discuss new developments and new treatment targets for pharmacological management of insomnia

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity as a maximum of 5.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7920.

Sponsored by the American Psychiatric Association
Supported by an educational grant from Takata Pharmaceuticals North America
RETHINKING BIPOLAR DISORDER:
IMPLICATIONS OF COMORBIDITIES

SUNDAY, MAY 20, 2007 • Lunch: 1:00–1:30 PM • Symposium: 1:30–4:30 PM
Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

This program will be conducted on May 20, 2007, during the APA 2007 Annual Meeting.

AGENDA:
1:00–1:30 PM Lunch
1:30–2:00 PM Welcome and Introduction
   GARY S. SACHS, MD
   Massachusetts General Hospital
2:00–2:10 PM Medical Comorbidities in
   Bipolar Disorder
   GARY S. SACHS, MD
2:10–2:40 PM Comorbid Substance Abuse in
   Bipolar Disorder
   MICHAEL L. OSTAHER, MD, MPH
   Massachusetts General Hospital
2:40–3:10 PM suicidality as a component of
   bipolar disorder
   LAUREN B. MARANGEL, MD
   Baylor College of Medicine

3:10–3:40 PM Posttraumatic Stress Disorder and
   Bipolar Disorder: Critical Overlapping
   Factors in Pathology and Treatment
   LORI L. DAVIS, MD
   VA Medical Center
3:40–4:10 PM Neuropsychology of Dual Diagnosis
   STEPHEN M. STRAKOWSKI, MD
   University of Cincinnati
   College of Medicine
4:10–4:30 PM Case Discussion
   ALL FACULTY

Each presentation will conclude with a question-and-answer discussion.

LEARNING OBJECTIVES:
After attending this symposium, participants should be able to:
• Understand the general medical comorbidities associated with bipolar disorder, in particular the association of inflammatory markers in bipolar disorder
• Understand the significance of high rates of comorbidity between bipolar disorder and alcohol and substance abuse and emerging data on treatment strategies
• Be aware of the assessment techniques for evaluation of suicide in bipolar disorder and evidence-based treatment options
• Recognize the potential relationships between trauma and bipolar disorder and the prognosis of posttraumatic stress disorder in bipolar patients
• Examine the findings in brain regions of interest related to bipolar disorder and comorbidity

CASE STATEMENT
This case will be conducted on May 20, 2007, during the APA 2007 Annual Meeting.

INDUSTRY-SUPPORTED SYMPOSIUM 17
Sunday, May 20, 2007, 1:30 p.m.–4:30 p.m.
Manchester Ballroom, Second Level, Manchester Grand Hyatt

CARING for OUR MOST CHALLENGING PATIENTS with DEPRESSION: An Interactive Forum on Novel Treatments

PRESENTED AT THE APA 2007 ANNUAL MEETING IN SAN DIEGO, CA

PROGRAM AGENDA
1:00 p.m. Lunch
1:30 p.m. Introduction
   Charles N. Nemeroff, MD, PhD (Chair)
   Emory University School of Medicine
1:45 p.m. Mechanism of Action of Vagus Nerve Stimulation (VNS)
   Charles N. Nemeroff, MD, PhD
   Emory University School of Medicine
2:15 p.m. Assessing the Efficacy of VNS in Patients with TRD
   Paul Porchet, MD
   Emory University School of Medicine
2:45 p.m. Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) and Magnetic Seizure Therapy (MST)
   Thomas R. Wainwright, MD
   University of Iowa
   John Hopkins Medical School
3:15 p.m. Mechanisms of Action and Efficacy of Deep Brain Stimulation
   Helen Mayberg, MD
   Emory University School of Medicine
3:45 p.m. Panel Discussion/Q&A
4:30 p.m. Conclusion

LEARNING OBJECTIVES:
At the conclusion of this symposium, the participant should be able to:
1. Identify criteria used to recognize depressed patients who are treatment-resistant.
2. Compare and contrast somatic interventions for treatment-resistant depression (TRD).
3. Recognize the neurobiological substrates of investigational treatments for refractory depression.

REGISTRATION
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at: www.psych.org. To contact the APA toll-free at 1-888-552-5724 (within the U.S. or Canada) or 1-937-323-4000.

CREDIT DESIGNATION
The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. The credit(s) should only claim credit commensurate with the extent of participation in the activity.

ACREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
INDUSTRY-SUPPORTED SYMPOSIUM 18
Sunday, May 20, 2007, 7:00 p.m.-10:00 p.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

Sponsored by the American Psychiatric Association
Supported by an educational grant from Shire Pharmaceuticals Inc.

How Comorbid is ADHD?
Results from Epidemiological and Clinical Studies:

11:30 AM - 12:00 PM
WELCOME AND INTRODUCTIONS

12:00 PM - 12:30 PM
Pattern of Comorbidity: An Epidemiological Sample of Boys and Girls with ADHD

12:30 PM - 1:00 PM
Pattern of Comorbidity: Clinical Samples of Adults with ADHD

1:00 PM - 1:30 PM
Pattern of Comorbidity and Community Sample of Adults with ADHD: Results from the National Comorbidity Survey

1:30 PM - 2:00 PM
Most Common Disorders Found in Adults with ADHD and Attention Deficit Hyperactivity Disorder

2:00 PM - 2:30 PM
SPONSORED BREAK

2:30 PM - 3:00 PM
Distribution of Comorbidities in Children With ADHD and Attention Deficit Hyperactivity Disorder

9:30 AM - 10:00 AM
Question and Answer Session

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. More information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-753-7521 (within the U.S. or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 19
Sunday, May 20, 2007, 7:00 p.m.-10:00 p.m.
Marina Ballroom, South Tower, Level Three, Marriott

2007 APA Annual Meeting
THE ALCOHOL-DEPENDENT PATIENT | IMPROVING OUTCOMES THROUGH ADHERENCE
SUNDAY, MAY 20, 2007 | 6:30 PM - 10:00 PM
Marina Ballroom 1 San Diego Marriott North and Marina 1 San Diego, California

Activity Chairperson: ROBERT SWIFT, MD, PhD

AGENDA

6:30 PM - 7:00 PM
OPENING

7:00 PM - 7:05 PM
OPENING REMARKS
Robert Swift, MD, PhD

7:05 PM - 7:35 PM
PATIENT ADHERENCE IN THE TREATMENT OF ALCOHOL DEPENDENCE: THE JOURNEY OF RECOVERY
Roger D. Weiss, MD

7:35 PM - 8:05 PM
PHARMACOTHERAPEUTIC OPTIONS FOR THE MANAGEMENT OF ALCOHOL DEPENDENCE: IMPROVING ADHERENCE
Robert Swift, MD, PhD

8:05 PM - 8:35 PM
PATIENT READINESS: IMPLICATIONS FOR ADHERENCE AND MANAGEMENT OF ALCOHOL DEPENDENCE
Carlo D. DiClemente, PhD

8:35 PM - 9:05 PM
IMPLEMENTING ADHERENCE-ENHANCING STRATEGIES IN CLINICAL PRACTICE: NEGOTIATING WITHIN THE THERAPEUTIC ALLIANCE
Albina J. Adams, MD

9:05 PM - 9:30 PM
PANEL DISCUSSION
Robert Swift, MD, PhD

9:50 PM - 10:00 PM
CLOSING REMARKS
Robert Swift, MD, PhD

PROGRAM OVERVIEW
Alcohol dependence is a chronic disorder associated with significant morbidity and mortality. Although available pharmacologic and psychosocial treatments have demonstrated improved outcomes in alcohol-dependent patients, the effectiveness of evidence-based therapies is often limited by patient nonadherence. Alcohol-dependent patients are more likely to have poorer treatment outcomes when they exhibit resistance and motivation to initiate behavioral change. Psychosocial components, such as training motivation for abstinence, developing psychotherapeutic relationships, learning coping skills, improving interpersonal functioning, and enhancing social supports, can be used in combination with pharmacotherapy. Strategies for increasing patient adherence to treatment include using contingency management components of psychological interventions in combination with pharmacotherapy. There are various routes and pharmacologic agents available to treat alcohol dependence, such as disulfiram, acamprosate, and naltrexone, which require daily administration. Furthermore, there is evidence for furthering patient adherence. This symposium will address the factors that hinder treatment adherence in patients with alcohol dependence, describe the stages of behavioral change, and discuss the role of psychosocial and pharmacologic therapies in achieving desired outcomes.

LEARNING OBJECTIVES
After attending this symposium, participants should be able to:

- Discuss the impact of treatment nonadherence on outcomes in patients with alcohol dependence.
- Review factors that facilitate or hinder treatment adherence and assess patient readiness for changing behavior related to alcohol consumption.
- Describe pharmacologic and psychological interventions that may promote adherence to treatment and improve patient outcomes.
- Describe evidence-based treatment matching strategies for alcohol dependence and approaches to measuring adherence.

Accreditation Statement
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The APA designates this educational activity as a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
INDUSTRY-SUPPORTED SYMPOSIUM 20
Sunday, May 20, 2007, 7:00 p.m.-10:00 p.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

APA 2007 Annual Meeting Sponsored by the American Psychiatric Association

WEIGHING THE RISKS AND BENEFITS OF ATYPICAL ANTI精神病ICS:
Can We Have Our Cake and Eat It Too?

SUNDAY, MAY 20, 2007

Dinner: 6:30–7:00 pm
Symposium: 7:00–10:00 pm
Manchester Grand Hyatt, San Diego
Douglas Pavilion C/D
One Market Place
San Diego, California

AGENDA

0210 Opening Remarks
S. Anand, MD; CBP; University of Mississippi Medical Center

0315 High Mandalay and Cadillac in Schizophrenia and Bipolar Disorders: What, Why, if Any?
Quinn E. Murphy, MD*; University of Cincinnati College of Medicine

0415Metabolic Complications in the Context of Antipsychotic Effectiveness: Lessons from the CATIE Schizophrenia Trial
Donald C. Goff, MD*; Harvard Medical School

0515 The Dual Health Importance in Schizophrenia: High Prevalence of Metabolic Disorders and Low Access to Medical Treatment
Hanun A. Nemeroff, MD

0600 Lessons from ATMP III, the APA, and the APA Workgroup on Antipsychotics and Metabolic Risk
John W. Nasrallah, MD*; Washington University School of Medicine

0700 Patients, Providers, and System Approaches to Reducing Risk of Poor Health in Patients Receiving Antipsychotics
Lisa B. Davis, MD, MPH*; University of Maryland School of Medicine
U.S. Capital Health Care Network, MS/CC

0800 Question and Answer

0900 Closing Remarks

*Each presentation will include 5 minutes for audience questions.

EDUCATIONAL OBJECTIVES

Attendees of the educational activity will be able to:
1. Review the current state of knowledge regarding the use of atypical antipsychotics in reducing the incidence of relapse in schizophrenia and bipolar I disorder.
2. Describe the link between antipsychotic medication and metabolic risk, including strategies to manage metabolic risk.
3. Discuss the role of the patient in managing their own health and compliance with medication regimens.

ACREDITATION/SUPPORT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity as a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Accreditation credits are available for physicians, psychologists, and nurses.

Program Agenda

SUNDAY, MAY 20, 2007
7:00–10:00 pm
Manchester Ballroom, Second Level

Presented at the APA 2007 Annual Meeting in San Diego, California

LEARNING OBJECTIVES

At the conclusion of this symposium, the participant should be able to:
1. Apply data from large-scale research studies to clinical practice.
2. Translate switching, augmentation, and combination data from STAR*D and apply to clinical practice.
3. Identify augmentation strategies in MHD that may improve patient outcomes.
4. Evaluate emerging therapies that may help patients achieve remission and improve long-term outcomes.

CREDIT DESIGNATION

The APA approves this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

REGISTRATION

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org. Contact the APA at 1-888-357-7091. In Illinois, call 703-907-7200.

Supported by an educational grant, with credit by Forest Pharmaceuticals, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 21
Sunday, May 20, 2007, 7:00 p.m.-10:00 p.m.
Manchester Ballroom, Second Level, Manchester Grand Hyatt

STAR*D Findings

Implications for Patients, Clinicians, and Other Stakeholders

PROGRAM AGENDA

SUNDAY, MAY 20, 2007
7:00–10:00 pm
Manchester Grand Hyatt
Manchester Ballroom, Second Level

6:30–7:00 pm
Dinner

7:00–7:15 pm
Introduction
Grayson N. Nagust, MD, MSPH (Chir)
University of Mississippi Medical Center

7:15–7:35 pm
Clinical Methods and Procedures to Enhance Acute and Long-Term Outcomes
Judy J. Gonzales, MD, MBA
Abt Associates, Inc.

7:35–7:45 pm
Interactive Panel Discussion

7:45–8:05 pm
Selecting Among First- and Second-Step Acute Treatments: Level 1 and Level 2
Marlene Freeman, MD
University of Arizona Health Sciences Center

8:05–8:15 pm
Interactive Panel Discussion

8:15–8:35 pm
Interactive Panel Discussion

8:35–8:45 pm
Interactive Panel Discussion

8:45–9:05 pm
The Role of Other Treatment Options in the Management of Depression
K. R. King, MD, MPH
Duke University Medical Center

9:05–9:15 pm
Panel Discussion/Q&A

122
INDUSTRY-SUPPORTED SYMPOSIUM 22
Monday, May 21, 2007, 7:00 a.m.-8:30 a.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

LIFTING THE BURDEN OF PSYCHIATRIC ILLNESS
The Management of Allergic Load, Metabolic Syndrome, and Co-occurring Disorders

Part I: MONDAY, MAY 21
6:30 a.m. Breakfast
7:00 a.m. Introduction/Welcome
Mark H. Rapoport, MD
Cedars-Sinai Medical Center
7:05 a.m. The Heart of the Matter: Allergic Load, Psychiatric Illness R. Brody, PhD, MD
Medical University of South Carolina
7:25 a.m. Diabetes: The Complex Interplay Between Psychiatric Syndromes, Substance Use, and Health
Kathleen T. Brody, PhD, MD
Medical University of South Carolina
7:45 a.m. Psychosocial Medicine, Psychiatric Illness, and Weight Gain
Dina G. Genguli, MD
University of Pennsylvania School of Medicine
8:05 a.m. Q&A
8:25 a.m. Concluding Remarks

Part II: TUESDAY, MAY 22
6:30 a.m. Breakfast
7:00 a.m. Welcome/Recap of Part I
Mark H. Rapoport, MD
Cedars-Sinai Medical Center
7:05 a.m. Issues in the Assessment and Management of Overweight and Obesity in Psychiatric Patients
Alicia Reilly, MD
Cedars-Sinai Center for Weight Loss
7:35 a.m. Integrating Alternative Health Approaches into the Care of Our Patients: Evidence of the Actions of Exercise, Massage, and Acupuncture
Mark H. Rapoport, MD
8:05 a.m. Q&A
8:25 a.m. Concluding Remarks

EDUCATIONAL OBJECTIVES
After taking part in this educational activity, participants should be able to:
1. Describe the pathological bi-directional relationships between allergic load and psychiatric illness
2. Recognize the complex interactions that occur between psychiatric medications, weight regulation, and the challenges of metabolic syndrome
3. Discuss the health and mental health implications of the presence of comorbid substance use disorders including tobacco, psychiatric symptoms, and physical health (including HIV risk)
4. Identify treatment interventions possible to help mitigate the effects of allergic load, medication-induced health complications, and co-occurring disorders

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity as a maximum of 1.8 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendance must be recorded by the APA Annual Meeting to receive CME credit. See the Daily Agenda for details.

INDUSTRY-SUPPORTED SYMPOSIUM 23
Monday, May 21, 2007, 7:00 a.m.-8:30 a.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

2007 APA ANNUAL MEETING HOW DO AUTOMATIC PSYCHIATRIC ILLNESS PSYCHIATRIC DISORDERS FROM RECEPTORS TO REALITY WORK?

AGENDA
MONDAY, MAY 21, 2007 – PART A
6:30 AM – 7:00 AM Breakfast
7:00 AM – 7:05 AM Opening Remarks
Robert E. Vane, MD, MBA
Stuart C. Yekowsky, MD
7:05 AM – 7:30 AM Mechanisms of Antipsychotic Efficacy: Linking Pharmacology to Pharmacodynamics
Dai Xu, MD, PhD, FRCP
Neurobiology of Schizophrenia: From Basic Sciences to Clinical Practice
Samir B. Sane, MD
Panel Discussion
Robert E. Vane, MD, MBA
7:30 AM – 8:25 AM Panel Discussions
8:25 AM – 8:30 AM Closing Remarks
Robert E. Vane, MD, MBA

TUESDAY, MAY 22, 2007 – PART B
6:30 AM – 7:00 AM Breakfast
7:00 AM – 7:05 AM Opening Remarks
Robert E. Vane, MD, MBA
Stuart C. Yekowsky, MD
7:10 AM – 7:30 AM Managing Patients with Psychiatric Disorders: From Efficacy to Effectiveness
Stuart E. Yekowsky, MD
Pharmacologic Predictability of Antipsychotic-Related Adverse Effects: An Opportunity for Improving Outcomes
Preethi S. Mounard, MD
Panel Discussions
Robert E. Vane, MD, MBA
Stuart E. Yekowsky, MD
8:45 AM – 9:00 AM Closing Remarks
Robert E. Vane, MD, MBA
Stuart E. Yekowsky, MD

The APA Annual Meeting is a registered service mark of the American Psychiatric Association. The APA logo is a registered service mark and the APA Annual Meeting logo is a service mark of the American Psychiatric Association. All other trademarks are the property of their respective owners.
TREATING THE SPECTRUM OF BIPOLAR DISORDERS: AN INTERACTIVE CASE DISCUSSION

INDUSTRY-SUPPORTED SYMPOSIUM 24
Monday, May 21, 2007, 7:00 a.m.-8:30 a.m.
Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

AGENDA:
MONDAY, MAY 21, 2007
6:30-7:00 AM
Breakfast
7:00-7:05 AM
Welcome and Introductions
MICHAELE T. THASE, MD (CHAIRPERSON)
University of Pittsburgh
7:05-7:20 AM
Psychosurgery and Bipolar Disorder
HOLLY A. SWARTZ, MD
University of Pittsburgh
7:20-7:35 AM
Case Scenario Discussion with Audience Interaction
ALL FACULTY
7:35-7:50 AM
Antidepressants in Bipolar Depression: A Two-Sided Story
MICHAELE T. THASE, MD
7:50-8:05 AM
Case Scenario Discussion with Audience Interaction
ALL FACULTY
8:05-8:20 AM
Question and Answer Session
ALL FACULTY
8:30 AM
Adjourn

TUESDAY, MAY 22, 2007
6:30-7:05 AM
Breakfast
7:00-7:05 AM
Welcome and Introductions
MICHAELE T. THASE, MD (CHAIRPERSON)
7:05-7:20 AM
Beyond Antidepressants: Treatment Options for Bipolar Depression
ROGER R. MONTGOMERY
University of Toronto
7:20-7:35 AM
Case Scenario Discussion with Audience Interaction
ALL FACULTY
7:35-7:50 AM
Treating and Preventing Mania
LAUREN B. MARANGELL, MD
College of Medicine
7:50-8:05 AM
Case Scenario Discussion with Audience Interaction
ALL FACULTY
8:05-8:20 AM
Question and Answer Session
ALL FACULTY
8:30 AM
Adjourn

LEARNING OBJECTIVES:
After attending this symposium, participants should be able to:
• Examine the role of psychosurgery in the management of patients with bipolar disorder with an emphasis on empirical data demonstrating its efficacy in adjunctive treatment for bipolar depression
• Review the implications of antidepressants in bipolar depression and the importance of differential diagnosis in patients with bipolar disorder with regard to treatment
• Identify and evaluate current and future treatment options and the optimal approaches to the pharmacotherapy of patients with bipolar disorder
• Formulate management strategies for the treatment of mania and discuss successful methods of intervention aimed at preventing mania

CME STATEMENT
This symposium will be followed by a CME evaluation on May 22, 2007, during the APA Annual Meeting. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Each physician should claim credit commensurate with the extent of participation in the activity.

IMPROVING OUTCOMES IN SCHIZOPHRENIA—From Prodrome to Remission

INDUSTRY-SUPPORTED SYMPOSIUM 25
Monday, May 21, 2007, 7:00 p.m.-10:00 p.m.
Marriott Halls 1-4, North Tower, Lower Level, Marriott

AGENDA
6:30 PM – 6:50 PM
Dinner
7:00 PM – 7:05 PM
Opening Remarks
CHRISTOPHER T. CORRELL, MD
7:05 PM – 7:45 PM
Early Intervention in the Psychotic Prodrome: Has Its Time Come?
CHRISTOPHER T. CORRELL, MD
7:45 PM – 8:25 PM
The Course of Brain Abnormalities in Schizophrenia: Can We Slow Disease Progression?
RENÉ K. KAHN, MD, PhD

REGISTRATION STATEMENT
Registration for the APA Annual Meeting is required to attend this symposium. The registration fee is $350. For more information about the meeting, please visit www.apa.org or contact the APA secretariat at 1-888-567-7074 (in the US and Canada) or 703-973-7300.

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

LEARNING OBJECTIVES
After completing this symposium, participants should be able to:
• Identify prodromal symptom criteria and strategies in patients who are considered at high risk for developing schizophrenia
• Discuss the current status of early intervention for schizophrenia and efficacy to modify the course of psychiatric symptoms and to reduce the burden of chronic schizophrenia

PROGRAM OVERVIEW
The course of schizophrenia, whether it occurs in late onset or is marked with deteriorative signs in patients, can be managed. During the prodromal phase, the severity of symptoms may be mild, the clinical features of behavioral deterioration may be minimal, and symptoms are often not perceived as disorder related by either the patient or his or her family. Patients may not recognize their illness or express their illness or perceive it as a problem. Patients may seek care initially or are brought to the attention of medical personnel by their family. Patients may not receive early intervention because of the early detection of schizophrenia. The early detection of schizophrenia is often delayed because of changes in the signs or symptoms of the disease and the personal characteristics of the patient. Early detection of schizophrenia is critical for the management of the disease, and early intervention can be effective in reducing the burden of chronic schizophrenia.
APRIL 2007 ANNUAL MEETING SPONSORED BY THE AMERICAN PSYCHIATRY ASSOCIATION

NAVIGATING THE COMPLEX MAZE OF BIPOLAR DISORDER

Monday, May 21, 2007
6:30 – 7:00 pm Dinner
7:00 – 10:00 pm Symposium
Manchester Grand Hyatt San Diego
Douglass Pavilion C/D
One Market Place
San Diego, California

AGENDA
7:00 – 7:10 pm
Opening Remarks
Pakash Arduss, MD – Chairman
Duke University Medical Center
7:10 – 7:40 pm
Diagnostic Pitfalls in Patients with Bipolar Disorder
Pakash Arduss, MD
7:40 – 8:10 pm
Managing the Bipolar Patient with Medical Comorbidities
Andrew Freyman, MD
University of Pittsburgh School of Medicine
8:10 – 8:40 pm
Tailoring Antipsychotic Treatment to the Complex Patient with Bipolar Disorder
Paul E. Kirk, Jr, MD
University of Cincinnati College of Medicine
8:40 – 9:10 pm
Bringing Research to the Clinician: Lessons from STEP-BD
Gary Sachs, MD
Massachusetts General Hospital
9:10 – 9:55 pm
Panel Discussion
Faculty Panel

EDUCATIONAL OBJECTIVES
At the end of this educational activity participants should be able to:
1. List major obstacles to the diagnosis of bipolar disorder and describe strategies for distinguishing bipolar disorder from depression and agitation.
2. Describe common psychiatric and medical comorbidities in bipolar patients, and their implications for treatment.
3. Outline major findings from STEP-B and their implications for clinical practice.

ACCREDITATION
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3.00 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Attitudes must be registered for the 2007 APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll-free at 1-888-557-7524 (within the US or Canada) or 703-974-7300. Registered conference participants and registrants may attend an industry-supported symposium at the APA meeting.

Sponsored by the American Psychiatric Association.

INDUSTRY-SUPPORTED SYMPOSIUM 27
Monday, May 21, 2007, 7:00 p.m.-10:00 p.m.
Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

WHEN ENDOCRINOLOGY AND PSYCHIATRY COLLIDE: WHAT THE CLINICIAN NEEDS TO KNOW ABOUT ANTIPSYCHOTIC-INDUCED ENDOCRINE DISTURBANCES

MONDAY, MAY 21, 2007 • Dinner: 6:30–7:00 pm • Symposium: 7:00–10:00 pm
Elizabeth Ballroom A/E, Second Level • Manchester Grand Hyatt San Diego • SAN DIEGO, CALIFORNIA

AGENDA:
6:30–7:00 pm
Dinner
7:00–7:10 pm
Welcome and Introductions
PETER F. BUCKLEY, MD
Chairperson
Medical College of Georgia
7:10–7:15 pm
Increasing Global Burden of Cardiovascular Disease in General Populations and Patients with Schizophrenia
CHARLES M. HENNEKENS, MD, PhD, MPH, MS
Faulk Medical Education
7:15–8:00 pm
Endocrinology and the Metabolic Syndrome: From Soup to Nuts
RAMACHANDRAN
COGHAN, MD, FRCP, FACE
Harvard Medical School
8:00–8:25 pm
Antipsychotics, Diabetes, and the Metabolic Syndrome: What Is the Strength of These Relationships?
JOHN W. NEWCOMER, MD
Washington University School of Medicine
8:25–8:50 pm
Protein Elevation and Antipsychotic Therapy: What to Tell Patients About Risks to Bones and Sexual Functioning
MEERA NARASIMHAN, MD
University of South Carolina School of Medicine
8:50–9:15 pm
Guidelines for the Management of Metabolic and Endocrine Side Effects: Confusion or Consensus?
PETER F. BUCKLEY, MD
9:15–10:00 pm
Panel Discussion
ALL FACULTY
10:00 pm
Adjourn

LEARNING OBJECTIVES:
After attending this symposium participants should be able to:
1. Discuss the epidemiologic relationship between cardiovascular disease and schizophrenia, and the importance of the aggressive management of cardiovascular disease risk factors in this population.
2. Employ the current state of medical knowledge about diabetes mellitus and the metabolic syndrome.
3. Complete risk analysis for diabetes and the metabolic syndrome during antipsychotic therapy.
4. Describe the clinical impact of antipsychotic, both upon sexual functioning and also the longer term risk for osteoporosis during antipsychotic therapy.
5. Describe management strategies as well as emergent, new lifestyle behavioral approaches to minimize the risk of antipsychotic-induced endocrine adverse effects and to deal with these effectively when they emerge during treatment.

CME STATEMENT
This symposium will be conducted on May 21, 2007, during the APA 2007 Annual Meeting. Participation in this symposium qualifies for CME credit. The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Psychiatric Association designates this educational activity for a maximum of 3.00 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in this activity.

The APA is not responsible for any problems or consequences arising from any educational material or advice which is given or implied by any speaker. The APA will not issue CME credits for self-directed education activities.

End of activities on May 11, 2007, is subject to continued review.
INDUSTRY-SUPPORTED SYMPOSIUM 28
Monday, May 21, 2007, 7:00 p.m.-10:00 p.m.
Manchester Ballroom, Second Level, Manchester Grand Hyatt

IMPROVING DEPRESSION TREATMENTS: BRIDGING THE GAP BETWEEN RESEARCH AND CLINICAL PRACTICE
Monday, May 21, 2007
6:30 pm – 7:00 pm Dinner | 7:00 pm – 10:00 pm Scientific Session
Manchester Grand Hyatt • Manchester Ballroom • One Market Place • San Diego, California • USA

Supported by an educational grant from Eli Lilly and Company.
Sponsored by the American Psychiatric Association

OVERALL EDUCATIONAL OBJECTIVES:
At the conclusion of this symposium, the participant should be able to:
• recognize factors that limit the generalizability of traditional clinical trials.
• demonstrate knowledge of effective treatment approaches for depressed patient populations commonly found in community-based practices.

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION
The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

REGISTRATION
Attendees must register for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 29
Tuesday, May 22, 2007, 7:00 p.m.-10:00 p.m.
Ballroom 20, Upper Level, San Diego Convention Center

PRESENTED AT THE APA 2007 ANNUAL MEETING IN SAN DIEGO, CA
Cigarette Smoking, Smoking Cessation, and Psychiatric Illness
Tuesday, May 22, 2007 • 7:00 – 10:00 pm • San Diego Convention Center, Ballroom 20, Upper Level

PROGRAM AGENDA
6:30-7:00 pm Dinner
7:00-7:10 pm Introduction
Alexander F. Glassman, MD (Chair)  
Columbia University College of Physicians and Surgeons
New York State Psychiatric Institute
7:10-7:35 pm
Reward Systems Underlying Motivation and Addiction
Peter M. Kalivas, PhD  
Medical University of South Carolina
7:35-8:00 pm
Animal Modeling and Integrative Neuropsychology of Addiction: Vulnerability in Mental Illness
R. Andrew Chambers, MD  
Indiana University School of Medicine
8:00-8:25 pm
What Makes Smoking Cessation Unique in Patients with a History of Depression?
Alexander H. Glassman, MD  
Columbia University College of Physicians and Surgeons
New York State Psychiatric Institute
8:25-8:50 pm
Pharmacological Treatment of Nicotine Dependence in Schizophrenia: The Devil Is in the Details
Tony P. George, MD, FRCP  
University of Connecticut
Centre for Addiction and Mental Health
4:30-4:55 pm
Pharmacotherapies for Smoking Cessation
Cheryl Conant, MD, MPH  
University of Connecticut Health Center

LEARNING OBJECTIVES
At the conclusion of this symposium, the participant should be able to:
• Recognize the unique risks of cigarette smoking for patients with psychiatric illness.
• Discuss common neurobiology underlying addiction.
• Compare and contrast smoking addiction with depression and schizophrenia.
• Outline tools and treatments for smoking cessation in patients with and without psychiatric illness.

CREDIT DESIGNATION
The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

REGISTRATION
Attendees must register for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.
INDUSTRY-SUPPORTED SYMPOSIUM 30
Tuesday, May 22, 2007, 7:00 p.m.-10:00 p.m.
Marina Ballroom, South Tower, Level Three, Marriott

2007 APA Annual Meeting

AM I A PSYCHIATRIST... OR AN ENDOCRINOLOGIST?
Coping With Metabolic Disturbances During the Treatment of Schizophrenia

Activity Chairperson | Peter F. Buckley, MD
TUESDAY, MAY 22, 2007 | 6:30 PM – 10:00 PM
Marina Ballroom | San Diego Marriott Hotel and Marina
SAN DIEGO, CALIFORNIA

AGENDA
4:00 pm – 5:00 pm Opening Remarks
Peter F. Buckley, MD
5:00 pm – 5:30 pm The Increasing Global Burden of Cardiovascular Disease in General Population and in Patients with Mental Illness
Carlos Rodriguez-Torres, MD
5:30 pm – 6:00 pm Antipsychotics and Hyperglycemia
A Clinical Issue at the Forefront of Research: The Promise and the Peril
Den Maughan, MD
6:00 pm – 6:30 pm Antipsychotics and Hyperglycemia: A Neglected Issue in Psychiatric Practice
Peter F. Buckley, MD

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESTRUCTION STATEMENT
The APA designates this educational activity for a maximum of 3 APA PRA Category I Credits. Physicians should only credit commensurate with the extent of their participation in the activity.

Sponsored by

INDUSTRY-SUPPORTED SYMPOSIUM 31
Tuesday, May 22, 2007, 7:00 p.m.-10:00 p.m.
Douglas Pavilion C/D, Ground Floor, Manchester Grand Hyatt

2007 APA ANNUAL MEETING
MONOAMINO OXIDASE INHIBITORS TODAY
A 21st Century View on the Treatment of Depression

Program Overview
Many psychiatrists consider monoamine oxidase inhibitors (MAOIs) an effective class of antidepressants. Although MAOIs have substantial efficacy in the treatment of depression and other disorders, they are often prescribed because of efficacy concerns. One of the safety concerns with MAOIs is the potential for patients to develop hypertensive crises, which may be precipitated by food containing tyramine. Initially, the hypotensive or atypical MAOIs were developed to minimize the potential for these hypertensive crises to occur. However, research shows that many patients originally treated with hypotensive selective agents may experience serious side effects, particularly those associated with food or drug interactions.

PROGRAM AGENDA
TUESDAY, MAY 22, 2007
6:30 pm – 7:00 pm Dinner
7:00 pm – 7:05 pm Opening Remarks
Philip R. Muskin, MD
7:05 pm – 7:35 pm Virtually Everyone Always Wanted to Know about Consumer-Biased Studies (But Were Afraid to Ask)
Sharon A. Morgenstern, MD
7:35 pm – 8:05 pm MAO Revisited: Facts and Myths
Philip R. Muskin, MD
8:05 pm – 8:35 pm Out and About: Where We Aren’t Working and Where We Need to Go
Karen C. Schulman, MD
8:35 pm – 9:05 pm Treatment of Depression in the 21st Century: The Best of Applied Neurosciences
9:05 pm – 9:55 pm Panel Discussion
9:55 pm – 10:00 pm Closing Remarks

Sponsored by

Program Sponsors
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Program Sponsors
The APA designates the educational activity for a maximum of 3 APA PRA Category I Credits. Physicians should only credit commensurate with the extent of their participation in the activity.

Registration Statement
This symposium will be registered for the 2007 APA Annual Meeting to attend the symposium, please register in advance and select the APA West slots of 2007 registration at 1-800-354-7580 (within the U.S. or Canada) or 703-908-7300.
INDUSTRY-SUPPORTED SYMPOSIUM 32
Tuesday, May 22, 2007, 7:00 p.m.-10:00 p.m.
Elizabeth Ballroom A/B/C/D/E, Second Level,
Manchester Grand Hyatt

Understanding the Complexity of Bipolar Mixed Episodes
Tuesday, May 22, 2007
Manchester Grand Hyatt
Second Level, Elizabeth Ballroom A-E
San Diego, California

Learning Objectives
- Define bipolar mixed episodes
- Discuss new treatment options for patients with mixed episodes
- Describe cognitive behavioral strategies for preventing future episodes

AGENDA
4:30PM
Don't Miss This Important CME Activity!

6:30PM
Dinner

7:00PM
Welcome and Introduction
Sponsor: Pfizer, Inc.

7:15PM
Disorder of Consciousness in Mixed States
Departmental: MO

7:45PM
Comorbidity and Consequences of Bipolar Mixed Episodic States
James J. Goorden, MD

8:15PM
The Acute Treatment of the Patient with Bipolar Mixed Episodes
Roger F. McIntyre, MD, FRCP(C)

8:45PM
Improving Long-Term Outcomes in Patients with Bipolar Mixed Episodes
Robert A. McAllister, MD

9:15PM
Q&A

INDUSTRY-SUPPORTED SYMPOSIUM 33
Wednesday, May 23, 2007, 7:00 p.m.-10:00 p.m.
Elizabeth Ballroom A/B/C/D/E, Second Level, Manchester Grand Hyatt

Fibromyalgia: New Insights into the Pathophysiology and Treatment

Wednesday, May 23 6:30PM
Manchester Grand Hyatt, Elizabeth Ballroom A-E
San Diego, CA

Chairperson
Lesley M. Arnold
University of Cincinnati

Faculty
Daniel J. Clauw
University of Michigan
Leslie J. Crawford
University of Kentucky
Dina Dadabhoy
University of Michigan

Who Should Attend
This program will benefit all clinicians who want to increase their knowledge of the treatment of patients with fibromyalgia. This includes psychiatrists, neurologists, family practitioners, internists and other healthcare professionals.

Continuing Education Credit
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Sponsored by the American Psychiatric Association.
Supported by an educational grant from Pfizer Inc.